No retraction, correction or concern found when last checked on Oct 17, 2026.
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
Martin A Katzman, Pierre Bleau, Pierre Blier and 4 more (opens in a new tab)
BMC Psychiatry · 2014 · Review
doi:10.32920/14638581 (opens in a new tab)
Abstract
BACKGROUND: Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated. METHODS: These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980-2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines. RESULTS: These guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions. CONCLUSIONS: Anxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments.
Shown for reading. Its publisher allows quoting it, not republishing it.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.
Introduction
Anxiety and related disorders are among the most common of mental disorders. Lifetime prevalence of anxiety disorders is reportedly as high as 31%; higher than the lifetime prevalence of mood disorders and substance use disorders (SUDs). Unfortunately, anxiety disorders are under-diagnosed and under-treated.
These guidelines were developed to assist clinicians, including primary care physicians and psychiatrists, as well as psychologists, social workers, occupational therapists, and nurses with the diagnosis and treatment of anxiety and related disorders by providing practical, evidence-based recommendations. This guideline document is not focused on any individual type of clinician but rather on assessing the data and making recommendations. Subsequent “user friendly” tools and other initiatives are planned.
The guidelines include panic disorder, agoraphobia, specific phobia, social anxiety disorder (SAD), generalized anxiety disorder (GAD), as well as obsessive-compulsive disorder (OCD), and posttraumatic stress disorder (PTSD). Also included are brief discussions of clinically relevant issues in the management of anxiety and related disorders in children and adolescents, women who are pregnant or lactating, and elderly patients, and patients with comorbid conditions.
Methods
These guidelines are based on a thorough review of the current literature and were developed by a panel of Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE searches of English language citations (1980–2012), using search terms encompassing the specific treatments and specific anxiety and related disorders. These searches were supplemented with data from PsycINFO and manual searches of the bibliographies of efficacy studies, meta-analyses, and review articles. Treatment strategies were rated on strength of evidence for the intervention (Table 1). A clinical recommendation for each intervention was then made, based on global impression of efficacy in clinical trials, effectiveness in clinical practice, and side effects, using a modified version of the periodic health examination guidelines (Table 2).
The guidelines were initiated prior to the introduction of the American Psychiatric Association’s (APA) fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the committee was sensitive to potential changes to the nosology of anxiety and related disorders and its impact on the guidelines. However, it was agreed that, since the evidence for treatment is based on studies using DSM-IV criteria (or earlier), the introduction of the DSM-5 would not fundamentally alter the evidence and recommendations at this time. Whether using DSM-5 diagnostic criteria for the inclusion patients in clinical trials in the future will have an impact on outcomes, remains to be seen.
The panel of Canadian experts in anxiety and related disorders responsible for the development of these guidelines via consensus process included 10 psychiatrists and seven psychologists who were organized into subpanels based on their expertise in particular anxiety or related disorders as well as in treating specific patient populations. Preliminary treatment recommendations and the evidence upon which they had been based were reviewed at a meeting of the panel in December 2012; subsequently, draft guidelines were prepared by the subpanels which were then circulated to the entire group for consensus ratification during 2013. Preliminary recommendations were also presented to the Canadian psychiatric community for input in September 2012 at the Canadian Psychiatric Association annual conference.
These guidelines are presented in 10 sections, the first of which is this introduction. In the following section, the principles of diagnosis and management of anxiety and related disorders are covered. That section provides an overview of the differential diagnoses associated with anxiety and related disorders in general, discusses issues that affect all anxiety disorders, and presents the general advantages and disadvantages of psychological treatment and pharmacotherapy options. In the subsequent six sections (Sections 3 through 8), the specific diagnosis and management of the individual anxiety and related disorders (panic disorder, specific phobia, SAD, OCD, GAD, and PTSD) are reviewed and recommendations are made for psychological and pharmacological treatments. Section 9 discusses issues that may warrant special attention pertaining to anxiety and related disorders in children and adolescents, pregnant or lactating women, and the elderly. The last section of these guidelines addresses clinical issues that may arise when treating patients with anxiety and related disorders who are also diagnosed with comorbid psychiatric conditions such as major depressive disorder (MDD), bipolar disorder, or other psychoses, and attention deficit/hyperactivity disorder (ADHD), or medical comorbidities, such as pain syndromes, cardiovascular disease, and diabetes/metabolic syndrome.
Prevalence and impact
Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence rates as high as 31% and 12-month prevalence rates of about 18%. Rates for individual disorders vary widely. Women generally have higher prevalence rates for most anxiety disorders, compared with men. Anxiety and related disorders are associated with an increased risk of developing a comorbid major depressive disorder.
Anxiety and related disorders put a significant burden on patients and their family members. They are associated with substantial functional impairment, which increases as the severity of anxiety or the number of comorbid anxiety disorders increases. In addition, studies have demonstrated quality of life impairments in patients with various anxiety and related disorders. Anxiety has a considerable economic impact on society as well, being associated with greater use of health care services and decreased work productivity.
Importantly, studies report that about 40% of patients diagnosed with anxiety and related disorder are untreated.
Suicide risk
In large surveys, anxiety and related disorders were independently associated with a significant 1.7-2.5 times increased risk of suicide attempts; however, data are conflicting as to whether the risk is moderated by gender. Increased risk of suicide attempts or completed suicide has been reported for patients with panic disorder, PTSD, and GAD, even in the absence of a comorbid mood disorder. These data indicate that patients with an anxiety disorder warrant explicit evaluation for suicide risk. The presence of a comorbid mood disorder significantly increases the risk of suicidal behavior.
Initial assessment of patients with anxiety
The management of patients presenting with anxiety symptoms should initially follow the flow of the five main components outlined in Table 3.
Screen for anxiety and related symptoms
Anxiety and related disorders are generally characterized by the features of excessive anxiety, fear, worry, and avoidance. While anxiety can be a normal part of everyday life, anxiety disorders are associated with functional impairment; as part of the key diagnostic criteria for anxiety disorders is the requirement that the symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
Asking patients if they are feeling nervous, anxious or on edge, or whether they have uncontrollable worry, can be useful to detect anxiety in patients in whom the clinician suspects an anxiety or related disorder. The DSM-5 suggests the questions shown in Table 4 for the identification of anxiety-related symptoms; items scored as mild or greater may warrant further assessment. If anxiety symptoms are endorsed, they should be explored in more detail by including questions about the onset of the anxiety symptoms, associations with life events or trauma, the nature of the anxiety (i.e., worry, avoidance, or obsession), and the impact they have had on the patient’s current functioning.
Table 5 presents suggested screening questions for individual anxiety and related disorders, from various validated screening tools, some of which are freely available online (e.g., http://www.macanxiety.com/online-anxiety-screening-test).
Conduct differential diagnosis
The differential diagnosis of anxiety and related disorders should consider whether the anxiety is due to another medical or psychiatric condition, is comorbid with another medical or psychiatric condition, or is medication-induced or drug-related.
When a patient presents with excessive or uncontrollable anxiety it is important to identify other potential causes of the symptoms, including direct effects of a substance (e.g., drug abuse or medication) or medical condition (e.g., hyperthyroidism, cardiopulmonary disorders, traumatic brain injury), or another mental disorder. However, since comorbid conditions are common, the presence of some of these other conditions may not preclude the diagnosis of an anxiety or related disorder.
Certain risk factors have been associated with anxiety and related disorders and should increase the clinician’s index of suspicion (Table 6). A family or personal history of mood or anxiety disorders is an important predictor of anxiety symptoms. In addition, family history is associated with a more recurrent course, greater impairment, and greater service use. A personal history of stressful life events is also associated the development of anxiety and related disorders, in particular, childhood abuse.
Women generally have higher prevalence rates across all anxiety and related disorders, compared with men. The median of age of onset is very early for some phobias and for separation anxiety disorder (seven to 14 years), but later for GAD, panic disorder, and PTSD (24-50 years).
Loneliness, low education, and adverse parenting, as well as chronic somatic illnesses, such as cardiovascular disease, diabetes, asthma, and obesity may increase the risk for a lifetime diagnosis of anxiety.
Comorbid medical and psychiatric disorders
Anxiety and related disorders frequently co-occur with other psychiatric disorders. More than half of patients with an anxiety disorder have multiple anxiety disorders, and almost 30% will have three or more comorbid anxiety or related disorders. Anxiety is often comorbid with substance use and mood disorders. An estimated 52% of patients with bipolar disorder, 60% of patients with MDD, and 47% of those with ADHD will have a comorbid anxiety or related disorder. Therefore, anxiety disorders should be considered in these patients.
The high frequency of comorbidity must be considered when diagnosing anxiety and related disorders since this can have important implications for diagnosis and treatment. Anxiety disorders comorbid with other anxiety or depressive disorders are associated with poorer treatment outcomes, greater severity and chronicity, more impaired functioning, increased health service use, and higher treatment costs. The impact tends to increase with an increasing number of comorbid conditions.
Patients with anxiety disorders have a higher prevalence of hypertension and other cardiovascular conditions, gastrointestinal disease, arthritis, thyroid disease, respiratory disease, migraine headaches, and allergic conditions compared to those without anxiety disorders. Comorbid anxiety and related disorders have a significant impact on quality of life (QoL) in patients with medical conditions.
Baseline assessment
Baseline assessment should include a review of systems, prescribed medications, over-the-counter agents, alcohol use, caffeine intake, and illicit drug use, in addition to evaluation of the anxiety symptoms and functioning. Table 7 lists potential investigations that can be considered based on an individual patient’s presentation and specific symptoms (e.g., dizziness or tachycardia). Ideally, a physical examination and baseline laboratory investigations should be performed before pharmacotherapy is initiated, with repeat assessments according to best practice guidelines. Patients with anxiety and related disorders should be monitored initially every one to two weeks and then every four weeks for weight changes and adverse effects of medications, as this is a major factor contributing to discontinuation of medication.
Closer monitoring may be required in children younger than 10 years of age, older or medically ill patients, patients on medications associated with metabolic changes, and those on multiple medications.
Identify specific anxiety or related disorder
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) has been finalized by the American Psychiatric Association (APA). The new DSM-5 provides diagnostic criteria for psychiatric disorders based on scientific reviews of the literature, field trial data, internal evaluations, public comments, and a final review by APA’s Board of Trustees.
The “anxiety disorders” chapter now includes panic disorder, agoraphobia, GAD, selective mutism, separation anxiety disorder, SAD (social phobia), specific phobia, substance/medication-induced anxiety disorder, as well as anxiety disorder due to another medical condition or not elsewhere classified. OCD and PTSD have been moved to separate chapters on obsessive-compulsive and related disorders and trauma- and stressor-related disorders, respectively.
Table 8 provides a brief summary of the key DSM-5 diagnostic features of the anxiety and related disorders that are included in these guidelines. While the DSM-5 is the most up-to-date diagnostic criteria, it is important to note that the evidence for treatment is based on studies using DSM-IV criteria (or earlier) for inclusion of patients. However, most of the diagnostic criteria have not changed substantially (see Sections 3–9 for more information on diagnosis); the exception being agoraphobia, which is now designated as a separate diagnosis.
Specific individual anxiety and related disorders should be diagnosed with the DSM-5 criteria in the sections devoted to each anxiety disorder. An accurate diagnosis is important to help guide treatment.
Psychological and pharmacological treatment
Treatment options for anxiety and related disorders include psychological and pharmacological treatments. All patients should receive education about their disorder, efficacy (including expected time to onset of therapeutic effects) and tolerability of treatment choices, aggravating factors, and signs of relapse. Information on self-help materials such as books or websites may also be helpful.
The choice of psychological or pharmacological treatment depends on factors such as patient preference and motivation, ability of the patient to engage in the treatment, severity of illness, clinicians’ skills and experience, availability of psychological treatments, patient’s prior response to treatment, and the presence of comorbid medical or psychiatric disorders.
A brief overview of psychological and pharmacological treatments is provided below, with more specific recommendations in the individual sections for each anxiety and related disorder.
Overview of psychological treatment
Psychological treatments play an important role in the management of anxiety and related disorders. Regardless of whether formal psychological treatment is undertaken, patients should receive education and be encouraged to face their fears. Meta-analyses have demonstrated the efficacy of psychological treatments in group and individual formats in patients with panic disorder, specific phobia, SAD, OCD, GAD, or PTSD, particularly exposure-based and other cognitive behavioral therapy (CBT) protocols, as well as mindfulness-based cognitive therapy (MBCT). When choosing psychological treatments for individual patients, the forms of therapy that have been most thoroughly evaluated in the particular anxiety or related disorder should be used first.
CBT is not a single approach to treatment, but rather a process that focuses on addressing the factors that caused and maintain the individual patient’s anxiety symptoms. Some of the core components of CBT are shown in Table 9.
CBT can be effectively delivered as individual or group therapy for most anxiety and related disorders. In addition, a variety of self-directed or minimal intervention formats (e.g., bibliotherapy/self-help books, or internet/computer-based programs with or without minimal therapist contact) have demonstrated significant improvements in anxiety symptoms. Meta-analyses have also shown that exposure therapy can be effectively administered in a virtual reality format. These strategies may be particularly useful in cases where real-life exposure is difficult due to inconvenience, expense, or patient reluctance.
Psychotherapy and pharmacotherapy generally demonstrate about equivalent efficacy for the treatment of most anxiety and related disorders. Results with combination therapy vary for the different anxiety disorders, and results have been conflicting (see Sections 3–9 for evidence and references regarding combination therapy). Therefore, current evidence does not support the routine combination of CBT and pharmacotherapy as initial treatment. However, when patients do not benefit from CBT or have a limited response, a trial of pharmacotherapy is advisable. Similarly, patients who show limited benefit from pharmacotherapy may benefit from CBT. All patients being treated with pharmacotherapy should be instructed to gradually face their fears (exposure to decrease avoidance).
Overview of pharmacological treatment
This section provides a general overview of some of the commonly recommended pharmacological agents. Evidence and recommendations for specific medications are described in the individual sections for each of the anxiety and related disorders.
Table 10 shows medications that have Health Canada approved indications for use in different anxiety and related disorders, and dosing suggestions are shown in Additional file 1. Various antidepressants including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), noradrenergic and specific serotonergic antidepressants (NaSSAs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and reversible inhibitors of monoamine oxidase A (RIMAs) have demonstrated some efficacy in the treatment of anxiety and related disorders (see Sections 3–9 for evidence and references). SSRIs and SNRIs are usually preferred as initial treatments, since they are generally safer and better tolerated than TCAs or MAOIs.
Benzodiazepines may be useful as adjunctive therapy early in treatment, particularly for acute anxiety or agitation, to help patients in times of acute crises, or while waiting for onset of adequate efficacy of SSRIs or other antidepressants. Due to concerns about possible dependency, sedation, cognitive impairment, and other side effects, benzodiazepines should usually be restricted to short-term use, and generally dosed regularly rather than as-needed.
Several anticonvulsants and atypical antipsychotics have demonstrated efficacy in some anxiety and related disorders, but for various reasons, including side effects, as well as limited randomized controlled trial (RCT) data and clinical experience, these agents are generally recommended as second-line, third-line, or adjunctive therapies (see Sections 3–9 for evidence and references).
The choice of medication should take into consideration the evidence for its efficacy and safety/tolerability for the treatment of the specific anxiety and related disorder, as well as for any comorbid conditions the patient might have, in both acute and long-term use.
Safety and side effects
Antidepressants: The most common side effects seen with SSRIs and SNRIs include headache, irritability, gastrointestinal complaints, insomnia, sexual dysfunction, weight gain, increased anxiety, drowsiness, and tremor. Patients report that the most common bothersome side effects are sexual dysfunction, drowsiness, fatigue, and weight gain. Most side effects occur early and transiently during the first two weeks of treatment, but others, such as sexual dysfunction and weight gain, may persist for the duration of treatment.
Use of SSRIs or SNRIs has been associated with an increased risk of upper gastrointestinal bleeding, particularly when used in combination with nonsteroidal anti-inflammatory drugs (NSAIDs). SSRI use has also been associated with low bone mineral density, as well as an increased risk of fractures and hyponatremia.
Abrupt discontinuation of SSRIs or SNRIs can lead to a discontinuation syndrome with gastrointestinal, psychiatric, vasomotor, and other symptoms.
Health Canada and the US Food and Drug Administration (FDA) require antidepressants to include a warning regarding an increased risk of suicidal ideation and behavior in children and adolescents. The increased risk of suicidal behavior reported in pediatric patients does not appear to be seen in adults, and may in fact be decreased. Careful monitoring for evidence of self-harming or suicidal thoughts or behaviors is important in both adult and pediatric patients.
SSRIs and SNRIs are generally better tolerated and safer than TCAs and MAOIs, having less anticholinergic effects, toxicity, lethality, and psychomotor or cognitive impairment. MAOIs are generally reserved for second- or third-line treatment because of side effects, drug interactions, and dietary restrictions.
Anxiolytics: The most common side effects associated with benzodiazepines include primarily sedation, fatigue, ataxia, slurred speech, memory impairment, and weakness. Benzodiazepines are associated with withdrawal reactions, rebound, and dependence, with the risk being greater with short- and intermediate-acting compared to long-acting agents. These agents should be used with caution in patients with SUDs. Older patients (generally over 65 years of age) may be at high risk for falls and fractures due to psychomotor impairment associated with benzodiazepines. Cognitive impairment has been reported, some of which may persist after cessation of therapy. In particular, memory impairment has been associated with high-dose or high-potency benzodiazepines, particularly in older people.
Reported side effects of azapirones (buspirone) include dizziness, drowsiness, and nausea.
Atypical antipsychotics: Atypical antipsychotics are associated to varying degrees with weight gain, diabetes, and other metabolic side effects, including alterations in glucose and lipid levels. Metabolic disturbances generally appear to be higher with olanzapine, intermediate with risperidone and quetiapine, and lower with aripiprazole, asenapine, lurasidone, and ziprasidone.
Atypical antipsychotics have varying sedative effects, with quetiapine, clozapine, asenapine, and olanzapine generally causing more sedation than ziprasidone, risperidone, lurasidone, or aripiprazole. Data on cognitive effects are conflicting, with some studies suggesting improvements, while other data suggest greater cognitive dysfunction in patients using, versus those not using, antipsychotics.
Because of the risks of diabetes and weight gain, and the fact that there is limited RCT evidence of the efficacy of these agents in anxiety and related disorders, atypical antipsychotics are generally recommended as second-line, third-line, or adjunctive therapies (see Sections 3–9 for evidence and references).
Anticonvulsants: Anticonvulsants are associated with gastrointestinal side effects, somnolence, weight gain, tremor, as well as dermatologic and hematologic side effects. In addition, several anticonvulsants have a potential risk of serious rash, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis. Regular monitoring of serum medication levels and liver function is required for patients on divalproex.
Follow-up
Anxiety and related disorders are often chronic and a systematic approach to treatment should include patient education, assessment of comorbidities, and evidence-based pharmacological and psychological interventions with adequate monitoring and duration. Pharmacological treatment is often associated with a delay of about two to eight weeks in onset of symptom relief, with full response taking up to 12 weeks or more. Longer-term therapy has been associated with continued symptomatic improvement and the prevention of relapse, and therapy should be continued for at least 12-24 months for most patients.
Medication should be initiated at low doses and titrated to the recommended dosage range at one- to two-week intervals over four to six weeks. Once the therapeutic range has been achieved, improvement is usually seen over the next four to eight weeks. Follow-up should occur at two-week intervals for the first six weeks and monthly thereafter.
For a patient undergoing psychotherapy, the treatment schedule is structured around weekly contact with a therapist for about 12-20 weeks, although shorter protocols and minimal intervention programs have also proven effective (see Sections 3–9 for evidence and references). A follow-up appointment four weeks later and then every two to three months is usually sufficient.
Assessing response to treatment
Therapy should seek to improve symptoms and distress. The optimal goal is full remission of symptoms and return to a premorbid level of functioning. However, goals may need to be individualized for some patients with disorders that have been present since childhood as they may never have had adequate premorbid functioning. A response to therapy is often defined as a percentage reduction in symptoms (usually 25-50%) on an appropriate scale. Remission is often defined as loss of diagnostic status, a pre-specified low score on an appropriate disorder-specific scale, and no functional impairment in fully recovered patients as measured by a scale such as the Sheehan Disability Scale or SF-36.
Objective scales can be used to help assess a patient’s progress. The Clinical Global Impression (CGI) scale is brief, comprehensive, and can easily be used at each appointment to assess improvement. The clinician-rated Hamilton Anxiety Rating Scale (HARS) can assess anxiety symptoms in general and is often used in clinical trials but is less practical in clinical practice. A variety of self-report and clinician-rated scales are available to assess the specific anxiety or related disorder.
Epidemiology
The lifetime and 12-month prevalence of panic disorder have been estimated at 4.7-5.1% and 2.1-2.8%, respectively. The estimated prevalence of panic attacks is considerably greater at 28.3% (lifetime) and 6.4-11.2% (12-month). Youth with panic attacks (which often do not meet diagnostic criteria for panic disorder) will frequently have or develop other psychiatric disorders including mood disorders (bipolar disorder and MDD), other anxiety or related disorders, SUDs, eating disorders, psychotic disorders, and personality disorders. Annually, 8-10% of the general public will have a panic attack without ever developing any identifiable psychopathology. About 40-70% of patients with panic disorder experience nocturnal panic (waking from sleep in a state of panic). Rates of 12-month and lifetime agoraphobia (without panic) are quite low, at 0.8% and 1.4%, respectively.
The risk of panic disorder and agoraphobia is higher in women than men, and patients who are middle-aged, widowed/divorced, and those of low income. In the Canadian Community Health Survey 1.2 (CCHS 1.2) there were no differences in the rates of panic disorder or agoraphobia in urban versus rural settings.
Panic disorder has a negative impact on both psychological and physical functioning, and puts a substantial burden on the patient’s family. Patients with panic disorder have more QoL impairment and dissatisfaction, greater likelihood of suicide attempts, and increased cognitive and emotional dysfunction compared to healthy controls. Panic disorder is also associated with substantial societal costs, both in terms of health care utilization and loss of workplace productivity. In a 2012 survey, panic disorder conferred a substantial rate of work absenteeism (mean: 36.0 days/year).
Comorbidity
Patients with panic disorder, or those experiencing panic attacks, have significantly increased odds of being diagnosed with a comorbid disorder, including another anxiety or related disorder, mood disorder, impulse-control disorder, or SUD. MDD is very common, occurring in an estimated 35-40% of patients with panic disorder. Panic disorder also frequently co-occurs with agoraphobia.
Panic disorder is more prevalent in patients with medical conditions, including thyroid disease, cancer, chronic pain, cardiac disease, irritable bowel syndrome, migraine, as well as allergic and respiratory diseases compared with the general population. The presence of medical comorbidity is associated with greater severity of panic disorder symptoms and disability.
Diagnosis
For a diagnosis of panic disorder, a patient must have had recurrent, unexpected panic attacks (Table 11), followed by at least one month of persistent concern or worry about further attacks or their consequences, or a significant maladaptive behavioral change related to attacks (Table 12).
A panic attack continues to be considered a noncodable event in the DSM-5, with only minor revisions, including removal of the “10-minute” window, changing “hot flushes” to “heat sensations,” and the re-ordering of the list of symptoms to increase clinical utility.
Compared to the DSM-IV-TR, changes to the diagnostic criteria for panic disorder largely consisted of minor phrasing changes to improve clinical utility, with the most substantial change being the title of the disorder. The DSM-5 now lists agoraphobia (anxiety about having a panic attack in certain situations, which are avoided or endured with marked distress) as a separate codable disorder, whereas previously panic disorder could be diagnosed as “panic disorder with agoraphobia” or “panic disorder without agoraphobia”.
For a diagnosis of agoraphobia, a patient must have intense fear about at least two different types of situations, with the fear resulting from thoughts that escape may be difficult or help may be unavailable if panic-like symptoms occur (Table 13). The situations provoke anxiety and are avoided or endured with intense fear or anxiety, or may require that a companion be present. The resultant fear or anxiety is out of proportion to any actual danger from the situation, causes substantial functional impairment, and usually lasts for six months or longer.
While the most up-to-date DSM-5 diagnostic criteria are presented here, the treatment data described within this section are based on studies involving patients meeting DSM-IV panic criteria (or older).
Establishing the context in which panic attacks occur, and whether there is any prior history of recurrent, unexpected panic attacks, is important for accurate diagnosis. Panic attacks frequently occur in other psychiatric disorders (e.g., MDD, PTSD), and medical conditions (e.g., cardiac, respiratory), and the DSM-5 has identified panic attacks as a specifier to be used in the absence of a diagnosable panic disorder. Another disorder may better account for the panic attacks; for example, panic attacks in social situations may be SAD, those related to defined phobic objects or situations may be specific phobia, those related to reminders of traumatic events may be PTSD, and those related to being kidnapped by extraterrestrials may be schizophrenia. Some medical conditions that can be associated with panic symptoms include hyper- or hypothyroidism, hypoglycemia, seizure disorders, and cardiac conditions. Panic attacks may also be associated with intoxication or withdrawal from drugs of abuse, medications such as decongestants, stimulants, or beta-adrenergic agonist inhalers, or caffeine.
Psychological treatment
CBT has been extensively studied, and is an efficacious psychological treatment for panic disorder (Level 1). In fact, CBT was significantly favored over medications for the treatment of panic disorder in a meta-analysis. In a meta-analysis of 42 studies, exposure and combinations of exposure, cognitive restructuring and other CBT techniques had the most consistent evidence of efficacy for the treatment of panic disorder. Strategies that included exposure were the most effective for panic measures. For measures of agoraphobia, combined strategies were more effective than single techniques, which did not result in significant improvements. Factors that improved the effectiveness of treatments were the inclusion of homework and a follow-up program. Another meta-analysis also found that CBT that included interoceptive exposure was superior to relaxation therapy for panic symptoms. CBT can be effectively delivered in both individual and group settings. Conducting exposure in virtual reality appears to be effective when used as part of a CBT protocol.
Minimal intervention formats, such as self-help books (bibliotherapy), treatment via telephone/videoconferencing, and internet-based CBT (ICBT) have been shown to be more effective than wait-list or relaxation controls, as effective as face-to-face CBT, and may be cost-effective options particularly for agoraphobic patients who are unwilling or unable to attend a clinic. When using bibliotherapy, providing information all at one time was as effective as pacing, and therapist support does not appear to be essential. Most ICBT programs have some therapist contact by either telephone or email, and once weekly contact appeared to be as effective as more frequent contact.
CBT panic disorder protocols usually involve 12-14 weekly sessions, but briefer strategies of six to seven sessions have been shown to be as effective. In addition, compressing the duration of therapy by administering 13 sessions over three weeks has also been shown to be as effective as traditional weekly CBT. Patients with higher baseline severity, disability, or comorbidity may have better outcomes with standard CBT. CBT programs sometimes include one or more follow-up or “booster” sessions.
Predictors of decreased response to CBT were severity of panic disorder, strength of blood/injury fears, earlier age of initial onset of panic symptoms, comorbid social anxieties, and degree of agoraphobic avoidance. Changes in symptoms are preceded by changes in beliefs during therapy, and change in beliefs and avoidance behaviors are considered key process variables.
Eye movement desensitization and reprocessing (EMDR) does not appear to offer advantages over the same strategy without the eye movement component for the treatment of panic disorder.
Combined psychological and pharmacological treatment
A meta-analysis of 21 trials found that combination psychotherapy and pharmacotherapy with antidepressants was superior to CBT or pharmacotherapy alone during the acute treatment phase and while medication was continued. After termination of treatment, combined therapy was more effective than pharmacotherapy alone and was as effective as psychotherapy. Prior meta-analyses have reported similar findings, suggesting that CBT alone or CBT combined with pharmacotherapy should be considered as first-line treatment.
A meta-analysis of the combination of psychotherapy and benzodiazepines included only three trials, and found no benefit to combination therapy compared with psychotherapy or medication alone. The follow-up data suggested that the combination might be inferior to behavior therapy alone.
Adding self-administered CBT to SSRI therapy did not result in significant improvements overall, but patients did report a significantly greater rate of decline in fear of bodily sensations compared to medication alone. Early results suggest a benefit of MBCT as an adjunct to pharmacotherapy in relieving anxiety and depressive symptoms in patients with panic disorder.
Providing CBT sessions around the time of medication discontinuation was associated with a lower relapse rate during follow-up among patients treated with antidepressants. In addition, CBT has been shown to be helpful in facilitating benzodiazepine discontinuation.
A cost-effectiveness study found that combined CBT and pharmacotherapy was associated with a robust clinical improvement compared to usual care, with only a moderate increase in costs.
In a RCT, buspirone enhanced the effects of CBT in the short-term, but had no significant benefit over CBT alone during long-term follow-up.
Data on the efficacy of d-cycloserine as an adjunct to CBT are conflicting, with one study suggesting significant benefits at posttreatment and one-month follow-up, while another found an acceleration of symptom reduction in severely ill patients but no significant improvement in outcomes overall compared to CBT plus placebo. Another compound acting at the N-methyl-D-aspartate (NMDA) receptor, Org 25935, demonstrated no benefit over placebo in augmenting CBT for panic disorder.
Long-term effects of psychological treatment
In naturalistic long-term follow-up studies, the benefits of CBT were maintained for up to three years. At two-year follow-up, individual, group, and brief CBT were associated with lower relapse rates compared to the wait-list control. A long-term follow-up study of patients who had become panic-free with exposure therapy found that 93% remained in remission after two years and 62% after 10 years.
A meta-analysis found that at six to 24 months follow-up, remission/response rates with the combination of psychotherapy and antidepressants continued to be superior to antidepressants alone, or to psychotherapy as long as therapy was continued.
Pharmacological treatment
The management of patients with panic disorder should follow the principles discussed in Section 2. Pharmacological interventions that have good evidence for efficacy in treating panic disorder include SSRIs, TCAs, and other antidepressants, as well as benzodiazepines. Treatments that have been investigated for use in panic disorder have been assessed according to the criteria for strength of evidence (Tables 1 and 2) and are summarized in Tables 14 and 15.
First-line agents
SSRIs: Evidence from meta-analyses and RCTs supports the use of the SSRIs citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline (all Level 1), as well as escitalopram and paroxetine controlled-release (CR) (both Level 2) for the treatment of panic disorder. In meta-analyses, SSRIs demonstrated significant improvements in panic symptoms, agoraphobic avoidance, depressive symptomatology, and general anxiety. Effect sizes for SSRIs and TCAs are similar, although dropout rates may be lower with SSRIs.
SNRIs: Venlafaxine extended-release (XR) has been shown to be useful in reducing the severity of panic disorder symptoms in RCTs (Level 1). Two studies found significantly greater rates of panic-free patients compared with placebo while two did not.
Second-line agents
TCAs: There is good evidence from RCTs to support the use of the TCAs clomipramine and imipramine in panic disorder (Level 1). In meta-analyses, TCAs have demonstrated efficacy for the treatment of panic symptoms and agoraphobia. Efficacy is generally equivalent to SSRIs, however, since TCAs tend to be less well tolerated and have higher discontinuation rates than SSRIs, they are recommended as second-line options.
Other antidepressants: Although there is level 1 evidence to support the use of reboxetine, limited experience with this agent in Canada, and its side effect profile, which includes dry mouth, constipation, and insomnia, led to its recommendation as a second-line option. Mirtazapine has demonstrated efficacy for the treatment of panic disorder in several open trials and one small RCT (Level 2). It appears to be as effective as fluoxetine and may be a useful second-line choice.
Benzodiazepines: Alprazolam, clonazepam, lorazepam, and diazepam have demonstrated efficacy for the treatment of panic disorder (Level 1). While it has been suggested that alprazolam may be more effective, a meta-analysis found no evidence that it was superior to other benzodiazepines for the treatment of panic disorder. Although benzodiazepines are second-line options, they may be useful at any time during therapy for the short-term management of acute or severe agitation or anxiety. They may also be useful at the initiation of SSRI treatment to hasten response (Level 1).
Third-line agents
MAOIs and RIMAs: Results with moclobemide for the management of panic disorder have been conflicting (Level 1). In clinical trials, moclobemide demonstrated efficacy similar to that of clomipramine and fluoxetine, but was not superior to placebo. However, significant efficacy in more severely ill patients, suggests it may be useful in treatment-resistant patients. In a RCT, phenelzine was more effective than placebo and as effective as imipramine (Level 2). In a small randomized, uncontrolled trial, tranylcypromine demonstrated efficacy for patients with comorbid panic and social anxiety disorders (Level 3).
Atypical antipsychotics: There is some evidence that atypical antipsychotics may have some benefits in the treatment of patients with refractory panic disorder. In a RCT, risperidone monotherapy was as effective as paroxetine (Level 2). Open-label data also support the use of risperidone, olanzapine, and quetiapine. There are also open-label data supporting the use of some atypical antipsychotics as adjunctive therapy (see below).
Other therapies: The antidepressants duloxetine, milnacipran, and bupropion sustained release (SR) have shown some efficacy in open trials, as have the anticonvulsants divalproex and levetiracetam (all Level 3). In a RCT, gabapentin was superior to placebo in patients who were more severely ill, but not in the overall group (Level 2, negative). These agents are recommended only as third-line options in patients with refractory panic disorder.
Adjunctive therapy
There is good evidence that adjunctive clonazepam (Level 1), and open-label evidence that adjunctive alprazolam orally-disintegrating tablet (ODT) (Level 3), used short-term (<8 weeks including taper) at the initiation of SSRI treatment, can lead to a more rapid response.
In a RCT, pindolol added to fluoxetine therapy in patients with treatment-resistant panic disorder was associated with significant improvement in panic disorder symptoms compared with fluoxetine plus placebo (Level 2). Open-label data also support the use of the atypical antipsychotics aripiprazole, olanzapine, and risperidone (all Level 3), as well as the anticonvulsant divalproex, as adjunctive strategies for patients with treatment-resistant panic disorder.
Not recommended
Buspirone (Level 1, negative), propranolol (Level 2, negative), tiagabine (Level 2, negative), and trazodone (Level 2, negative) have not demonstrated efficacy and are not recommended for the treatment of panic disorder. Carbamazepine (Level 3, negative) also does not appear to be effective in this disorder.
Maintenance pharmacological treatment
In long-term, open, follow-up studies, citalopram, fluoxetine, fluvoxamine, paroxetine, and moclobemide, as well as clomipramine and imipramine demonstrated maintenance of benefits and continued improvements over six months to three years of ongoing treatment. In a RCT, sertraline and imipramine were equally effective over a six month period. However, in another RCT, imipramine was not superior to placebo in the proportion of panic-free patients after eight months of therapy.
Venlafaxine XR and imipramine have been shown to prevent relapse in randomized, placebo-controlled, discontinuation studies. After three months of acute treatment, relapse rates were significantly lower with ongoing venlafaxine XR or imipramine therapy compared with switching to placebo during six to 12 months of follow-up.
Benzodiazepines are generally recommended for short-term use only. However, several trials have demonstrated the benefits of up to two years of alprazolam maintenance therapy. There was no evidence of tolerance, but up to one-third of patients were unable to discontinue therapy. The efficacy of clonazepam was maintained over a three-year course of treatment, and patients who had been asymptomatic for at least one year were able to successfully discontinue the medication, using a slow tapering strategy over four to seven months, and improvement in panic disorder was maintained.
Biological and alternative therapies
Biological therapies: In open-label case series, noninvasive brain stimulation using a radioelectric asymmetric conveyor (REAC) demonstrated efficacy for panic symptoms and agoraphobia (Level 3). A small case series suggested repetitive transcranial magnetic stimulation (rTMS) could improve panic and anxiety in patients with panic disorder with comorbid MDD (Level 4). However, a small RCT found no additional benefit of rTMS compared to sham rTMS as an add-on to SSRI therapy in patients with panic disorder (Level 2, negative).
Alternative therapies: In a RCT, capnometry-assisted respiratory training was as effective as cognitive training in reducing panic symptom severity and panic-related cognitions and improving perceived control (Level 2). However, breathing training did not significantly improve reactivity or recovery after a respiratory challenge in another small trial (Level 2, negative). In a RCT, patients with panic disorder randomized to the exercise groups (plus paroxetine or placebo) had a trend toward better improvement compared to relaxation training, but this was not significant (Level 2, negative). However, in an open cross-over study, acute aerobic exercise was found to reduce anxiety as well as panic attack frequency and intensity in patients with panic disorder compared to a quiet rest condition (Level 3). These therapies may be useful for some patients; however, more data are needed.
Summary
As much as 40% of the general population has experienced a panic attack at some point in their lifetime. However, patients with actual panic disorder experience recurrent, unexpected panic attacks as well as persistent concern or behavioral change around further attacks.
Data support pharmacotherapy, CBT alone, and CBT combined with pharmacotherapy as initial treatments for panic disorder. CBT alone may be insufficient in patients with comorbid moderate-to-severe major depression, or in those with severe, frequent panic attacks, or rapid worsening of agoraphobia, and/or suicidal ideation, as well as in situations where one might consider initial rescue treatment with a benzodiazepine to minimize or stop the panic attacks while waiting the 4-12 weeks for the first-line pharmacotherapy to become effective. Also there are patients who are not motivated to participate in CBT (preferring medication as initial treatment) or are too fearful to engage in any kind of exposure before being treated with a first-line pharmacotherapeutic agent. At the very least, if agoraphobic distress or avoidance persists, these patients need instruction and support to engage in exposure exercises. For panic symptoms, strategies should include exposure; and combined strategies should be considered for patients with agoraphobia. CBT can be effectively delivered in both individual and group settings, as well as via self-help books, virtual reality, and internet-based programs. The benefits of CBT are maintained during follow-up. In addition, data suggest that combination of psychotherapy and pharmacotherapy may be superior to pharmacotherapy alone during follow-up.
Pharmacotherapeutic approaches should begin with a first-line agent. If response to optimal dosing is inadequate or the agent is not tolerated, treatment should be switched to another first-line agent before considering second-line medications. First-line options for the treatment of panic disorder include citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine XR, escitalopram, or paroxetine CR. Second-line choices include the TCAs (clomipramine and imipramine), mirtazapine, reboxetine, or benzodiazepines (alprazolam, clonazepam, lorazepam, and diazepam).
Patients who do not respond to first- or second-line agents are considered to have treatment-refractory illness. In such patients it is important to reassess the diagnosis and consider comorbid medical (e.g., ischemic heart disease) and psychiatric conditions (e.g., SUDs) that may be affecting response to therapy. Third-line agents, adjunctive therapies, as well as biological and alternative therapies may be useful when patients fail to respond to an optimal treatment trial of first- and second-line therapies used alone and in combination.
Epidemiology
A specific phobia is an intense fear of a specific object or situation and is usually associated with avoidance of the feared object. The most prevalent phobia types include animal (e.g., insects, snakes), natural environment (e.g., heights, storms, water), situational (e.g., flying, enclosed spaces), and blood-injection-injury (B-I-I) (e.g., blood, dentists, hospitals). Large US and European epidemiologic surveys report lifetime prevalence estimates of 10-13% and 12-month prevalence rates of 7-9%. Rates among adolescents may be particularly high with lifetime prevalence estimates of 36.5% and 12-month prevalence rates of 27.3% being reported. Specific phobias are more common in women than men. Age of onset is usually in the range of five to 12 years (median: seven years); however, this varies by type of phobia. Animal and B-I-I phobias generally begin in childhood, whereas situational phobias (e.g., driving phobia, claustrophobia) have a later onset, typically during late adolescence or early adulthood.
Specific phobias are associated with significant distress, regardless of the number of feared stimuli reported. Specific phobias have a negative impact on social/occupational functioning and lead to restriction of usual daily activities, which increases with an increasing number of fears.
Comorbidities
Specific phobias tend to co-occur with other specific phobias, with less than 10% of patients having only one fear. The mean number of fears, in one survey, was three. In addition, specific phobias are frequently comorbid with other psychiatric disorders, including SUDs, mood disorders, and other anxiety or related disorders (particularly panic disorder, SAD, and GAD), as well as personality disorders.
Diagnosis
To receive a DSM-5 diagnosis of specific phobia a patient must experience marked (intense) fear or anxiety about a specific object or situation, which is associated with significant distress or functional impairment (Table 16). The object or situation will be actively avoided or endured with intense anxiety. Compared to the DSM-IV-TR criteria for specific phobia, few changes were made in the DSM-5. Of note, recognition that the fear is excessive or unreasonable has been removed and a new criterion stating “the fear or anxiety is out of proportion to danger posed” has been added. Avoidance has been clarified as “actively avoided” to distinguish the avoidance seen in specific phobias from passive avoidance that may occur for other reasons.
While the most up-to-date DSM-5 diagnostic criteria are presented here, it is important to note that most of the treatment data described within this section are based on patients meeting DSM-IV criteria (or older).
Specific phobias are delineated into five types: animal type, natural environment type, B-I-I type, situational type, or other type (Table 17). The fear of contracting an illness has been removed because of high relatedness to OCD and anxiety disorder related to medical condition.
Specific phobias can be difficult to distinguish from panic disorder. It is important to consider the focus of apprehension (e.g., fear of crashing while on an airplane versus fear of having a panic attack on an airplane), the types of panic attacks experienced (e.g., expected versus unexpected), and the range of situations associated with fear and avoidance.
Psychological treatment
Psychosocial interventions, particularly exposure-based treatments, are the treatments of choice and are associated with a high degree of success in providing remission of specific phobias. Both in vivo exposure and virtual reality exposure (VRE) can be effective, with in vivo exposure being shown to be superior to alternative types (e.g., imaginal, virtual reality, etc.) at posttreatment but not at follow-up.
In general, exposure-based therapy has been shown to be more effective if: sessions are grouped closely together; exposure is prolonged, real (not imagined), and provided in multiple different settings; and there is some degree of therapist involvement (not entirely self-directed). While one-session treatments have demonstrated efficacy, a meta-analysis found that a greater number of sessions predicted more favorable outcomes.
There is no evidence that either flooding or gradual exposure is more effective, however, progressive exposures are generally more tolerable to patients. An example of graded exposure in a patient with arachnophobia would be to look at pictures of spiders, hold a rubber spider, look at a live spider in a jar, touch the jar containing the spider, stand two feet from a live spider, and finally touch a live spider. This approach can be used to guide exposure depending on the patient’s symptom severity and tolerance to each level of exposure.
While a meta-analysis of 33 RCTs of psychological approaches found that treatment outcomes were not moderated by type of specific phobia, studies have suggested that certain subtypes may respond more favorably to specific types of treatment (Table 18).
For patients with B-I-I phobias, exposure therapy combined with muscle tension exercises (applied tension) designed to prevent fainting has been shown to be effective. Use of stress-reducing medical devices, such as decorated butterfly needles and syringes, has been shown to significantly reduce needle phobia and stress in both pediatric and adult patients. CBT reduced avoidance of oral injections and decreased anxiety in patients with dental phobias.
Fear of flying has been effectively treated with group CBT. In addition, computer-generated VRE has demonstrated efficacy, which was comparable to standard exposure therapy in several studies, and can have long-term benefits. Bibliotherapy was found to be less effective than VRE or CBT for patients with fear of flying. VRE has also been shown to be effective for patients with a fear of heights, and those with claustrophobia. This approach may also be useful for treating fears for which in vivo exposure may not be practical (e.g., fear of storms).
Arachnophobia has been successfully treated with in vivo and VR exposure, with little difference between the two modalities. A spiderless form of VRE, which presented images that were not spiders, but had some of the characteristics of spiders, was shown to be useful in patients with severe arachnophobia who were reluctant to undergo direct exposure or VRE. An internet-based self-help program was associated with improvement, but was not as effective as one session of in vivo exposure at the post-treatment assessment, although results were similar at follow-up. However, even one session of VRE was associated with greater fear reduction compared to a control group, and may be a useful self-help intervention to reduce fear of spiders. Computer-based self-help has also shown promise for other small-animal phobias (e.g., cockroaches, mice).
Combined psychological and pharmacological treatment
It has been speculated that d-cycloserine, a partial agonist at the NMDA receptor, may improve extinction of fear in patients with phobias undergoing behavioral exposure therapy. In a RCT (n=28), d-cycloserine as an adjunct to VRE resulted in significantly larger reductions of acrophobia symptoms compared with VRE alone. In another study (n=100), adjunctive d-cycloserine did not improve the reduction of spider fears compared to exposure-based therapy alone, however, patients had heightened, but subclinical, spider fears.
In two RCTs, use of adjunctive cortisol, a glucocorticoid, significantly enhanced the benefits of exposure therapy compared with placebo in patients with acrophobia (n=40) and arachnophobia (n=20), with evidence suggesting that cortisol may facilitate the extinction of phobic fear at follow-up.
Enhanced emotional memory may be stimulated through elevated noradrenaline levels, and data suggest that yohimbine hydrochloride, a noradrenaline agonist, can facilitate fear extinction. In RCTs, there were no significant VRE-enhancing effects with adjunctive yohimbine compared with placebo in patients with fear of flying (n=48) or claustrophobia (n=24). However, in the claustrophobia study, patients treated with yohimbine showed greater improvements in outcomes at the one-week follow-up.
In contrast, naltrexone was found to render one-session exposure therapy less effective compared with placebo or no treatment in 15 patients with specific phobias (animals).
Long-term effects of psychological treatment
Long-term treatment of specific phobia is rare. As discussed above, CBT and exposure therapies have demonstrated sustained benefits at long-term follow-up assessments.
Pharmacological treatment
There is a minimal role for pharmacotherapy in the treatment of specific phobias, largely due to the lack of research on medications in this condition, and the success of exposure-based therapies.
Antidepressants have been investigated in two small RCTs. In a small RCT, paroxetine was significantly more effective than placebo in resolving anxiety in patients with specific phobias (n=11). Similarly, escitalopram was associated with a strong treatment effect in a small RCT (n=12); however, the trial was under-powered to show statistically significant superiority over placebo on the primary outcome. In addition, cases of successful treatment of flying phobias with fluoxetine, and storm phobia with fluvoxamine, have been reported.
Benzodiazepines have usually been assessed as adjuncts to exposure therapy, and these studies have found no additional benefit with medication. Benzodiazepines are often used in clinical practice to provide acute symptom relief when it is necessary for a patient with a specific phobia to face a feared situation (e.g., dental procedure, magnetic resonance imaging [MRI], unexpected flight). Nasal midazolam has proven useful in facilitating MRI in claustrophobic patients.
Summary
Specific phobia is quite common, particularly among adolescents. Patients with specific phobia exhibit an intense fear or anxiety about a specific object or situation which is associated with significant distress or functional impairment. The most prevalent phobia types include animal, natural environment, situational, and B-I-I.
Exposure-based techniques, including virtual exposure, are highly effective, and are the foundation of treatment for specific phobias. Pharmacotherapy is generally unproven, and thus not a recommended treatment for most cases.
Epidemiology
SAD is one of the most common anxiety disorders, with lifetime prevalence estimates ranging from 8-12% among the international general population. It is more common in women than men, and higher rates have been reported in developed (6.1%) versus developing (2.1%) countries. SAD has an early age of onset, typically during adolescence (mean 12 years), and tends to have a chronic and unremitting course. Factors such as low educational achievement, low socioeconomic status, being single or separated, and having comorbid MDD have been associated with a higher prevalence of SAD in epidemiological studies.
SAD is associated with significant impairments including problems with educational and occupational performance, family functioning, and an overall reduced QoL. SAD also confers a substantial economic burden upon afflicted individuals and society in terms of work days missed and health care costs. Canadians with SAD were twice as likely to report at least one disability day in the past two weeks, compared to those without SAD.
Psychiatric comorbidity
SAD is associated with significant comorbidity, with up to 72% of patients reporting criteria for another psychiatric disorder. The highest rates of comorbidity have been found with MDD and other anxiety or related disorders. Avoidant personality disorder, body dysmorphic disorder, SUD, ADHD, and schizophrenia also commonly occur with SAD.
Diagnosis
SAD is characterized by a persistent fear that in social and performance situations the individual will say or do something that will lead to humiliation, embarrassment, or negative evaluation by others (Table 19). Social situations are actively avoided or endured with distress, and the individual recognizes the fears as excessive or unreasonable. The avoidance or anxiety induced by these fears incurs significant functional impairment and distress. Compared to the DSM-IV-TR, changes to the diagnostic criteria for SAD in the DSM-5 have been minimal, largely consisting of minor phrasing changes to improve clinical utility. The criterion that the “person recognizes that the fear is excessive or unreasonable” has been changed to “out of proportion to the actual threat posed by the social situation.” Since patients with SAD are often unable to recognize that their fear may be excessive the clinician may be in a better position to judge this.
The DSM-IV-TR criteria excluded social fears/avoidance associated with and secondary to medical conditions, however, the DSM-5 recognizes that SAD may be secondary to a medical condition. Some patients experience excessive social anxiety about their medical symptoms (e.g., stuttering, tremulousness from Parkinson’s disease, obesity, disfigurement from burns or injury), and may experience disability due to their social anxiety.
In addition, the “generalized” subtype specifier included in DSM-IV-TR has been removed, while the “performance only” specifier has been added for DSM-5. This change was made because there was little supporting evidence for the generalized specifier, and the evidence that SAD symptoms fall along a continuum of severity characterized by the number of fears. The “performance only” specifier appears to represent a subset of SAD patients typically experiencing impairment from performance fears primarily related to their professional lives.
While the most up-to-date DSM-5 diagnostic criteria are presented here, it is important to note that all of the treatment data described within this section are based on patients meeting DSM-IV criteria (or older).
Psychological treatment
Psychological treatment, in the form of CBT, is considered to be the gold-standard nonpharmacological treatment in SAD. Cognitive techniques involved in CBT for SAD include restructuring and challenging of maladaptive thoughts, while the behavioral component is typically in the form of exposure therapy. The efficacy of CBT compared with placebo, treatment-as-usual, or wait-list conditions, is supported by many RCTs as well as meta-analytic evidence. Although results vary, several studies of acute SAD treatment have also found a similar efficacy between CBT and pharmacotherapy. Some reports suggest that after treatment discontinuation, gains achieved with CBT may persist longer than those achieved with pharmacotherapy. CBT for SAD can be administered in group or individual formats. Although some studies have reported that individual CBT is superior to group CBT, meta-analyses have failed to find significant differences in efficacy between the two modalities.
The treatment literature has also examined the efficacy of the individual components of CBT. There is evidence to support the effectiveness of exposure therapy alone, however the efficacy of exposure alone compared with CBT is equivocal in the current treatment literature.
There are several variants of CBT that have been examined in the literature. For example, videotaped feedback was not shown to enhance the effects of exposure-based treatment. However, CBT with VRE was found to be more effective than wait-list control and as effective as CBT with imaginal or in vivo exposure according to two meta-analyses.
A form of CBT focused on interpersonal behavior found similar improvements in social anxiety compared to standard CBT but also increased relationship satisfaction and social approach behaviors. Evidence to support interpersonal therapy (IPT) in SAD is conflicting; while some results have been negative, it is likely that IPT is more effective than wait-list control, but less effective than traditional CBT.
Similarly, while less effective than traditional CBT, mindfulness-based therapy (MBT) has been associated with improvements in symptoms of SAD. In addition, small studies of attentional bias training suggest there may be some benefit associated with training patients to disengage from negative social cues, but data are conflicting.
ICBT is a newer treatment that may increase the availability of CBT for anxiety and mood disorders in the future. Studies have evaluated this treatment in comparison to individual and group CBT. ICBT has demonstrated efficacy in RCTs of SAD, significantly improving social anxiety symptoms compared to wait-list control conditions. Most ICBT programs include minimal therapist contact via email or telephone. Many programs involve a component of interaction with other participants through the use of internet discussion groups. However, it remains unclear whether the therapist component is necessary, and studies comparing guided with unguided ICBT have yielded conflicting results. In one RCT, clinician-assisted ICBT was more effective than a self-guided ICBT, and the self-guided ICBT was not significantly better than the wait-list condition. Similarly, a self-help program augmented with minimal therapist contact was more useful than a pure self-help strategy. However, several other RCTs have found that unguided ICBT self-help was as effective as ICBT with therapist involvement. A few ICBT programs included face-to-face in vivo exposure sessions, but one RCT found that adding this component did not significantly improve outcomes versus ICBT with self-directed exposure. In addition, several RCTs have shown ICBT (with minimal therapist contact) to be as effective as face-to-face CBT, while being more cost-effective. As with other RCTs, research on ICBT has involved pre-screening of participants in-person or by telephone, with posttreatment and follow-up assessments by telephone or through self-report measures. Little is known about the effectiveness of self-administered treatments (ICBT or self-help books) used with no pre-screening or planned follow-up contacts.
Combined psychological and pharmacological treatments
When used in combination, pharmacotherapy has not been shown to add to the benefits of CBT in some studies, while one study found the combination of phenelzine and CBT superior to either modality alone. D-cycloserine has also been found to enhance treatment outcomes when used during exposure exercises as an adjunct to exposure alone. In addition, a study of psychodynamic group therapy with or without the addition of clonazepam also found combination treatment to be superior to clonazepam treatment alone.
Long-term effects of psychological treatment
The benefits of CBT have been found to be maintained at six to 12 month follow-up visits, with sustained improvement being reported at five years posttreatment. Long-term assessments post-ICBT have shown sustained improvement at one to five years follow-up. Long-term benefits with psychotherapy appear to be more enduring than those of pharmacotherapy after treatment discontinuation.
Pharmacological treatment
The management of patients with SAD should follow the principles discussed in Section 2. Pharmacological interventions that have good evidence for efficacy in treating SAD include SSRIs, SNRIs, anticonvulsants, and benzodiazepines. Treatments that have been investigated for use in SAD have been assessed according to the criteria for strength of evidence (Tables 1 and 2) and are summarized in Tables 20 and 21.
First-line agents
Antidepressants: Meta-analyses demonstrate that SSRIs and SNRIs are significantly more effective than placebo and RIMAs for the treatment of SAD. There is level 1, RCT evidence supporting the use of the SSRIs escitalopram, fluvoxamine, fluvoxamine CR, paroxetine, and sertraline, as well as the SNRI venlafaxine XR, for the first-line treatment of SAD. There is also good evidence for the efficacy of paroxetine CR (Level 2).
Pregabalin: Pregabalin has also demonstrated efficacy versus placebo for the treatment of SAD in RCTs at higher (600 mg/day) but not lower dose levels (150-300 mg/day) (Level 1). Although there is Level 1 evidence for pregabalin, it is not clear how its efficacy compares to that of SSRIs. In addition, SSRIs may have a broader spectrum of efficacy for common comorbid conditions.
Second-line agents
Benzodiazepines: In RCTs, the benzodiazepines clonazepam (Level 1), alprazolam, and bromazepam (both Level 2) have demonstrated efficacy in the treatment of SAD.
Although, a meta-analysis found benzodiazepines to be as effective as SSRIs, these agents are recommended as second-line options because of the lack of effect on common comorbidities and the potential for abuse/dependence in individuals with a history of SUDs.
Antidepressants: In RCTs, citalopram was found to be significantly more effective than placebo, and as effective as moclobemide (Level 2). Although there is limited evidence for citalopram in SAD, it is likely as effective as the other SSRIs.
The efficacy of phenelzine has been established in multiple RCTs (Level 1); however, this agent is recommended as a second-line option because of concerns regarding dietary restrictions, drug interactions, and the potential for hypertensive crisis.
Anticonvulsants: Gabapentin was significantly more effective than placebo in a RCT, and as effective as tiagabine in a small cross-over study (Level 2).
Third-line agents
Antidepressants: Results with fluoxetine have been mixed (Level 1, conflicting). A large RCT found that fluoxetine was more effective than placebo and as effective as CBT. However, in two other small RCTs, fluoxetine alone or when added to self-exposure showed no benefit over placebo, with or without self-exposure. These negative trials with fluoxetine suggest it may be less effective than other SSRIs.
Similarly, results with moclobemide have also been mixed (Level 1, conflicting), with some RCTs demonstrating significantly higher response rates with moclobemide compared with placebo (Level 1), while others have not. Moclobemide was found to be superior to CBT early in treatment; however, after six months CBT was found to be superior.
Data from two small RCTs assessing mirtazapine were also mixed (Level 1, conflicting), with one showing significant improvements over placebo and the other showing no differences.
In a dose-finding study in which patients treated with open-label duloxetine 60 mg/day were randomized to continue or double their dose, both doses improved symptoms, but there was no significant advantage to the higher dose (Level 2).
Small open-label trials have also suggested that bupropion SR and clomipramine (both Level 3) may be effective in patients with SAD.
Anticonvulsants: Open-label studies have demonstrated some efficacy with divalproex, topiramate, and tiagabine (all Level 3). In addition, tiagabine was comparable to gabapentin in a small RCT, crossover study in eight adults.
Other treatments: Olanzapine was effective in a small RCT (Level 2), and selegiline demonstrated efficacy in a small, open-label trial (Level 3). In a RCT, atomoxetine significantly improved SAD symptoms compared with placebo; however, in a another small RCT, atomoxetine showed no significant difference in outcomes compared with placebo (Level 1, conflicting).
All of these agents are recommended as third-line options, and may be useful in refractory patients after first- and second-line monotherapies and adjuncts have been unsuccessful.
Adjunctive therapy
Adjunctive strategies have generally been studied in patients who have had an inadequate response to antidepressant therapy and can be considered for patients with treatment-resistant SAD.
Third-line adjunctive therapies: Open-label studies and case series have suggested that patients with refractory SAD may benefit from adjunctive therapy with aripiprazole, risperidone, buspirone, or paroxetine (all Level 3).
Not recommended adjunctive or combination therapies: In RCTs, clonazepam combined with paroxetine and pindolol augmentation of paroxetine (both Level 2, negative) were not significantly superior to placebo in augmenting the effects of SSRI treatment for SAD.
Not recommended
In RCTs there was no evidence of benefits with the beta-blockers atenolol (Level 1, negative) or propranolol (Level 2, negative), or for the following treatments: buspirone, levetiracetam (both Level 1, negative), or quetiapine (Level 2, negative). These agents are not recommended for SAD. Imipramine and pergolide (both Level 3, negative) also do not appear to be effective in this disorder.
Maintenance pharmacological treatment
Long-term therapy has been evaluated in relapse prevention and naturalistic follow-up studies. Relapse-prevention studies are those in which responders to medication are randomized to continued active treatment or placebo. A meta-analysis of four relapse prevention studies included 760 patients with SAD and found a highly significant reduction in relapse rates with continued SSRI treatment compared with placebo over three to six months. The relative risk (RR) for relapse was 0.39 (95% CI 0.30–0.49) and number needed to treat (NNT) was 3.57 (95% CI 2.94–4.76). The anticonvulsant pregabalin has also demonstrated reductions in relapse rates over six months.
In RCTs, escitalopram, fluvoxamine CR, and venlafaxine XR have demonstrated continued improvement compared with placebo over approximately six months. Additional open follow-up data support the long-term efficacy of moclobemide over six to 24 months.
Biological and alternative therapies
Biological therapies: In an open-label study, neuro psycho physical optimization-radio electric asymmetric conveyor (NPPO-REAC) (a brain stimulation technique) was as effective as sertraline for the treatment of SAD (Level 3).
Alternative therapies: St John’s wort failed to demonstrate superiority over placebo, and is not recommended for the treatment of SAD (Level 2, negative).
Summary
SAD is one of the most common anxiety disorders, occurring more often in women than men. SAD has a negative impact on QoL, functional and occupational outcomes, and is often associated with other comorbid disorders, including MDD and other anxiety and related disorders. SAD is characterized by intense fear or anxiety relating to social or performance situations where the individual is exposed to scrutiny by others. These situations are often actively avoided.
CBT and exposure therapy alone are effective first-line options for the treatment of SAD, although limited data suggest that CBT may be more effective in maintaining benefits during follow-up. VRE and internet-based programs have also demonstrated efficacy. The benefits of CBT are maintained over one to five years of follow-up. CBT and pharmacotherapy appear to have similar efficacy for the acute treatment of SAD, but after treatment discontinuation, gains achieved with CBT appear to persist longer than those achieved with pharmacotherapy. In most studies, adding pharmacotherapy has not been shown to increase the benefits of CBT.
Pharmacotherapeutic approaches should begin with a first-line antidepressant such as escitalopram, fluvoxamine, fluvoxamine CR, paroxetine, paroxetine CR, sertraline, or venlafaxine XR, or the anticonvulsant pregabalin. If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first-line agent before considering a second-line medication. Second-line choices include the benzodiazepines alprazolam, bromazepam, and clonazepam, as well as citalopram, gabapentin, and phenelzine. Pregabalin has also been shown to maintain benefits and prevent relapse in a six-month study.
Patients who do not respond to several medication trials and/or CBT are considered to have treatment-refractory illness. In such patients it is important to reassess the diagnosis and consider comorbid medical and psychiatric conditions that may be affecting response to therapy. Third-line agents and adjunctive therapies may be useful when patients fail to respond to optimal treatment trials of first- and second-line therapies used alone and in combination.
Epidemiology
The estimated 12-month prevalence of GAD ranges from 1-4%, and the lifetime prevalence is approximately 6%. GAD is more frequent in Caucasians compared to other groups. The usual age of onset varies and may be bimodal with the median age of onset being approximately 31 years and mean age of onset being 32.7 years. The prevalence of GAD is estimated to be 3% in children and 10.8% in adolescents, with the age of onset for children and adolescents being between ages 10 and 14. Some data suggest that women may be two to three times more likely to suffer from GAD than men, and GAD may be more common in older adults. This disorder is reportedly frequently under-recognized with less than one-third of patients being adequately treated. This is further complicated in children because of the previous designation of Overanxious Disorder of Childhood and its possible differentiation of childhood GAD from GAD in adults.
GAD is associated with functional, occupational, and QoL impairments, as well as substantial economic costs. In addition, in primary care 60-94% of patients with GAD report painful physical symptoms, and these were the main reason for initial presentation to a physician in 72% of cases.
Comorbidity
GAD is associated with high rates of comorbid psychiatric conditions including other anxiety or related disorders and MDD. The risk of medical conditions is also elevated, including pain syndromes, hypertension, as well as cardiovascular and gastric conditions. The presence of comorbid depression increases the severity of illness, functional impairment, and economic costs.
Diagnosis
GAD is characterized by excessive anxiety and worry about multiple events or activities such as school or work difficulties, which is apparent on a majority of days over the previous six months (Table 22). In addition, GAD is associated with restlessness, muscle tension, fatigue, concentration difficulties, irritability, and sleep issues.
The diagnostic criteria for GAD underwent one minor revision in the DSM-5 compared to the DSM-IV-TR, the requirement that the disturbance not occur exclusively during a mood, psychotic, or pervasive developmental disorder was removed. However, it remains important to note that most of the treatment data described within this section are based on patients meeting DSM-IV criteria (or older).
Psychological treatment
Meta-analyses clearly demonstrate that CBT significantly reduces GAD symptoms and is markedly more effective than placebo or wait-list control conditions for GAD (Level 1). Few studies have compared CBT and pharmacotherapy alone in the same trial, but the magnitude of benefits appear to be comparable for both groups. Individual and group therapy appear to be equally effective in terms of anxiety symptom reduction, but individual therapy may lead to earlier improvement in worry and depression symptoms.
The intensity of therapy was assessed in a meta-analysis of 25 studies. Regimens including fewer than eight sessions were as effective as those of eight or more for anxiety symptoms, but the more intense regimens were more effective in improving symptoms of worry and depression compared with fewer sessions.
Several studies have demonstrated the utility of internet-based or computer-based CBT programs. ICBT has been shown to be significantly more effective than wait-list control, with benefits being maintained at long-term follow-up. In addition, a peer-to-peer cognitive self-therapy program was as effective as treatment-as-usual, with a decreased need for therapist contact.
A meta-analysis of five trials found no significant differences between CBT and relaxation therapy. However, more recent studies suggest that applied relaxation has limited efficacy. One RCT found little evidence that patients with GAD can learn to relax in therapy or that a decrease in activation is associated with a reduction in anxiety. Balneotherapy, a relaxation therapy involving spa-related treatments, demonstrated potential advantages over SSRI pharmacotherapy in improving anxiety scores and response rates in patients with GAD in a large RCT; however, while this study may be interesting, concerns pertaining to blinding and potential bias indicate further study is needed.
Several research-based variables have been specifically identified among individuals with GAD in order to generate evidence-based CBT protocols for GAD, including: intolerance of uncertainty, poor problem-solving confidence, as well as positive and negative metacognitive beliefs about the function or utility of worry. Specific psychotherapeutic protocols based upon models of the disorder that target variables underlying GAD have been developed to individualize therapy. Acceptance-based behavior therapy, meta-cognitive therapy, CBT targeting intolerance of uncertainty, and adjunctive MBCT have demonstrated efficacy for the treatment of GAD. Targeting worry and relaxation, as well as looming vulnerability (the tendency to generate and maintain internal scenarios of increasing risk and danger), may also be beneficial.
Psychodynamic therapy may also be of benefit, however the research findings to date are unclear. A RCT found that short-term psychodynamic psychotherapy was as effective as CBT in improving anxiety scores, but CBT was superior on measures of worry and depression. Another study found no significant differences between brief psychodynamic therapy, pharmacotherapy, or the combination.
No significant benefits were found with the addition of interpersonal and emotional processing therapy to CBT when compared with CBT plus supportive listening. However, pretreatment motivational interviewing as an adjunct to CBT was shown to help reduce resistance to therapy, improve homework compliance, and improve worry outcomes — this strategy may be particularly useful in more severe cases.
In clinical practice, the approach may need to be individualized to the problems experienced by the patient.
Psychological and pharmacological treatment
Few data are available on the use of combined psychological and pharmacological treatment. A meta-analysis concluded that combination pharmacotherapy and CBT was more effective than CBT alone at posttreatment but not at six-month follow-up. While large effect sizes were found for GAD, data were available from only two studies, and these compared CBT plus diazepam or buspirone with CBT alone. Compared to pharmacotherapy alone, the few studies that have assessed the benefits of adjunctive psychotherapy have been conflicting. One study suggested benefits of the combination, while two other studies did not. However, adjunctive CBT was shown to facilitate benzodiazepine tapering in patients with GAD.
There is no current evidence to support the routine combination of CBT and pharmacotherapy. However, as in other anxiety and related disorders, when patients do not benefit from CBT or have a limited response, a trial of pharmacotherapy is advisable. Similarly, patients who show limited benefit from pharmacotherapy may benefit from CBT.
Long-term effects of psychological treatment
Long-term follow-up data from a meta-analysis and RCTs suggest that benefits of psychological treatments are maintained at one to three years follow-up after treatment.
Pharmacological treatment
The management of patients with GAD should follow the principles discussed in Section 2. Pharmacological interventions that have good evidence for efficacy in treating GAD include SSRIs, SNRIs, TCAs, benzodiazepines, pregabalin, quetiapine XR, and other therapies. Treatments that have been investigated for use in GAD have been assessed according to the criteria for strength of evidence (Tables 1 and 2) and are summarized in Tables 23 and 24.
First-line agents
Antidepressants (SSRIs & SNRIs): Evidence from RCTs supports the use of SSRIs including escitalopram and sertraline, as well as the SNRIs duloxetine and venlafaxine XR (all Level 1) for the first-line treatment of GAD. Similar evidence exists for paroxetine supporting its use as a first-line option. Paroxetine CR has a similar active ingredient, and although there are less data supporting its use, it is likely interchangeable with paroxetine as a first-line agent (Level 3). In head-to-head comparisons, the efficacy of SSRIs and SNRIs appear to be similar. Some data suggest that escitalopram may be less effective than venlafaxine XR or quetiapine XR. Efficacy of venlafaxine was similar to pregabalin in one RCT, but less effective in another.
Other antidepressants: In two 12-week, double-blind RCTs, agomelatine was found to be more effective than placebo (Level 1), and as effective as escitalopram.
Pregabalin: The anticonvulsant pregabalin was more effective than placebo in RCTs and as effective as benzodiazepines in patients with GAD (Level 1). Pregabalin was more effective than venlafaxine XR in one RCT, but equivalent in another.
Second-line agents
Benzodiazepines: Alprazolam, bromazepam, diazepam, and lorazepam all have demonstrated efficacy for the treatment of GAD (all Level 1). While these agents have level 1 evidence for efficacy, they are recommended as second-line therapy, and usually only for short-term use, because of side effects, dependence, and withdrawal issues.
TCAs and other antidepressants: In RCTs, imipramine was superior to placebo and as effective as benzodiazepines for the treatment of GAD (Level 1). However, because of side effects and potential toxicity in overdose, imipramine is recommended as a second-line option. While there are little data on bupropion XL (Level 2), in a 12-week RCT in patients with GAD it was as effective as escitalopram (a first-line option), supporting its use as a second-line option.
Vortioxetine is a so-called "serotonin modulator" because of its activity in a variety of serotonin receptors. Results from two similar, eight-week, placebo-controlled RCTs with vortioxetine were conflicting, with one trial being positive and the other negative (Level 1, conflicting). The differences in outcomes may be related to differences in recruitment between the two studies, and data suggest that vortioxetine may be useful in GAD.
Quetiapine XR: There is good evidence for the efficacy of quetiapine XR for the management of GAD (Level 1). Two meta-analyses concluded that quetiapine was significantly superior to placebo and equivalent to antidepressants for the treatment of GAD. However, quetiapine was associated with more weight gain and sedation, and higher dropout rates due to adverse events compared with placebo or antidepressants. Due to tolerability and long-term safety concerns with atypical antipsychotics, this treatment is recommended as a second-line option for patients who cannot be provided antidepressants or benzodiazepines.
Other treatments: Buspirone was more effective than placebo and as effective as benzodiazepines in several RCTs (Level 1). There are limited data comparing buspirone to antidepressants, with it being less effective than venlafaxine XR in one study, but as effective as sertraline in another. Limited effectiveness in clinical practice relegates buspirone to a second-line agent.
Hydroxyzine has demonstrated efficacy superior to placebo and similar to benzodiazepines and buspirone in RCTs (Level 1); however, clinical experience with this agent in the treatment of GAD remains limited.
Third-line agents
The following agents are recommended as third-line options because of limited data, side effects, or lack of clinical experience as a primary therapy for the treatment of GAD.
Antidepressants: In open-label studies or case series, the antidepressants citalopram, fluoxetine, paroxetine CR, and mirtazapine have demonstrated efficacy in patients with GAD (all Level 3). In a RCT, trazodone was as effective as diazepam (Level 2).
Other treatments: Divalproex chrono was superior to placebo for the treatment of GAD (Level 2), however this formulation is not widely available.
Adjunctive therapy
Adjunctive strategies have generally been studied in patients who have had an inadequate response to SSRI therapy, and can be considered for patients with treatment-resistant GAD.
Second-line adjunctive therapies: Adjunctive pregabalin demonstrated good efficacy in a large RCT in patients with GAD who had an inadequate response to prior treatments (Level 2).
Third-line adjunctive therapies: A meta-analysis of five RCTs of adjunctive atypical antipsychotics found no significant improvement in response rates but higher discontinuation rates versus placebo in patients with refractory GAD.
Two RCTs suggest that adjunctive risperidone (Level 1, conflicting) may be useful in some patients, but in the larger RCT it demonstrated superiority over placebo only in patients with moderate to severe residual symptoms at baseline. Similarly, data on adjunctive quetiapine have been inconsistent (Level 1, conflicting), with one RCT being negative, while another, unblinded RCT showed some, but limited benefits. Adjunctive olanzapine demonstrated efficacy in a small RCT in patients who remained symptomatic after six weeks of SSRI therapy. Adjunctive treatment with quetiapine XR or aripiprazole (both Level 3) also had some benefit in open trials.
Because of the limited evidence for efficacy and their potential for weight gain and metabolic side effects, atypical antipsychotics should be reserved for highly treatment-refractory cases of GAD, and other than quetiapine XR, used only as an adjunctive treatment.
Not recommended adjunctive therapies: Ziprasidone does not appear to be effective as adjunctive therapy (Level 2, negative).
Not recommended
Propranolol and pexacerfont (both Level 2, negative) have not demonstrated efficacy and are not recommended in the treatment of GAD. While a small randomized, open-label trial suggested that tiagabine was as effective as paroxetine, the results of three placebo-controlled RCTs do not support the efficacy of tiagabine in patients with GAD (Level 1, negative). Memantine also does not appear to be effective in this disorder (Level 4, negative).
Maintenance pharmacological treatment
Long-term therapy has been evaluated in relapse prevention and naturalistic follow-up studies. Relapse-prevention studies are those in which responders to SSRI therapy are randomized to continued active treatment or placebo. A meta-analysis of three relapse prevention studies included 1342 patients with GAD and found a highly significant reduction in relapse rates with continued SSRI treatment compared with placebo over six to 12 months (odds ratio for relapse was 0.20).
In RCT discontinuation studies, duloxetine, escitalopram, paroxetine, and venlafaxine XR have demonstrated significantly lower relapse rates over six to 18 months in the range of 10-20% with active treatment compared to 40-56% with placebo. Pregabalin and quetiapine XR have also demonstrated significantly lower relapse rates over six to 12 months of continued treatment in discontinuation trials.
In long-term RCT studies, escitalopram, paroxetine, and venlafaxine XR have demonstrated continued improvement compared with placebo over approximately six months.
Biological and alternative therapies
In general, these therapies may be useful for some patients; however, more data are needed.
Biological therapies: In a small open trial, rTMS was effective as monotherapy or as an adjunct to SSRIs in patients with GAD (Level 3), and improvements were largely maintained six months after treatment.
Alternative therapies: Several herbal preparations have demonstrated efficacy comparable to lorazepam for the treatment of GAD including silexan (lavender oil) (Level 1) and Galphimia glauca extract (Level 2). Cochrane meta-analyses found two studies of passiflora (passion flower) indicating it was as effective as benzodiazepines (Level 2), and one study of valerian which found no significant differences between placebo, valerian, or diazepam (Level 2, negative). Unfortunately, because these preparations are poorly standardized and have substantial variation in proportion of the active ingredient in different products, they cannot be widely recommended.
A RCT of adjunctive resistance training (weightlifting) or aerobic exercise found significant symptomatic improvements compared to a wait-list condition (Level 2). A systematic review included four studies of acupuncture in GAD or anxiety neurosis, and while all trials reported positive findings, methodological details were lacking and the authors concluded that there was insufficient evidence to determine efficacy (Level 2). Open-label studies suggest that adjunctive meditation and yoga-based treatments may be useful in patients with GAD (Level 3).
Not recommended alternative therapy: In a RCT, there were no significant improvements with bright light therapy compared with placebo (Level 2, negative), and this treatment is not recommended.
Summary
The lifetime prevalence of GAD is approximately 6%, it is more frequent in women than in men, with age of onset reflecting a bimodal distribution (onset in late-teens to early-twenties, and again in the 30s and 40s). GAD is associated with substantial functional impairment and a high prevalence of comorbid psychiatric and medical disorders. According to DSM-5 criteria, GAD is characterized by excessive anxiety and worry about multiple situations and is associated with restlessness, muscle tension, and behavioral changes.
CBT is an effective first-line option for the treatment of GAD and is as effective as pharmacotherapy. Internet-based and computer-based CBT have also demonstrated efficacy. Evidence does not support the routine combination of CBT and pharmacotherapy, but when patients do not benefit from CBT, a trial of pharmacotherapy is advisable, and vice versa.
Pharmacotherapeutic approaches should begin with one of the first-line options including an SSRI such as escitalopram, paroxetine, or sertraline, an SNRI such as duloxetine or venlafaxine XR, or other antidepressant such as agomelatine. The anticonvulsant pregabalin is also a recommended first-line therapy.
If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first-line agent before considering second-line medications. Second-line choices include bupropion XL, buspirone, hydroxyzine, imipramine, quetiapine XR, vortioxetine, as well as the benzodiazepines, alprazolam, bromazepam, diazepam, and lorazepam.
Patients who do not respond to multiple courses of therapy are considered to have treatment-refractory illness. In such patients it is important to reassess the diagnosis and consider comorbid medical and psychiatric conditions that may be affecting response to therapy. Third-line agents, adjunctive therapies, as well as biological and alternative therapies may be useful when patients fail to respond to an optimal treatment trial of first- and second-line therapies used alone and in combination.
Epidemiology
OCD is a relatively uncommon, yet severe, mental disorder, with an estimated lifetime and 12-month prevalence of 1.0-2.3% and 0.7%-1.2% in adults, respectively. Mean age of onset of OCD is ~20 years of age, but symptoms can occur below the age of 10, with few new cases after the early 30s. Rates of treatment-seeking have been estimated to be only about 14-56% of patients, suggesting that OCD may be under-recognized and under-treated. Social isolation, history of physical abuse, and negative emotionality are risk factors for the development of OCD.
OCD is associated with a substantial negative impact on QoL for both patients and their caregivers. Patients experience cognitive, social, and occupational impairments. In addition, up to one-quarter of patients with OCD have attempted suicide. OCD symptoms are associated with increased rates of health care utilization compared to those without OCD symptoms, with health care costs estimated at $10.6 billion/year (2005) in the US.
Comorbidity
About 60-90% of patients with OCD also have a comorbid disorder. Patients with OCD or OCD symptoms have a three-times higher rate of comorbidity compared to those without OCD symptoms. Common comorbidities include mood, anxiety, and somatoform disorders, as well as SUDs, psychotic disorders, and bipolar disorders.
Diagnosis
A diagnosis of OCD requires the presence of obsessions and/or compulsions (Table 25). Obsessions are defined as recurrent, persistent, and intrusive thoughts, images, or urges that cause marked anxiety, and compulsions are defined as repetitive behaviors or mental acts that the patient feels compelled to perform to reduce the obsession-related anxiety. The obsessions or compulsions are time consuming and cause significant impairment in social or occupational functioning.
In the DSM-5, OCD has been moved from the “anxiety disorders” to a new diagnostic category called “obsessive-compulsive and related disorders.” In addition to OCD, this new category also includes diagnostic criteria for body dysmorphic disorder, hoarding disorder, hair-pulling disorder (trichotillomania), and skin picking disorder.
Most of the other modifications to the OCD diagnostic criteria in the DSM-5 were minor wording changes designed to enhance clarity or further operationalize concepts that were considered too vague. In particular, the definitions of obsessions and compulsions were clarified and simplified. The requirement that the patient recognizes that the obsessions or compulsions are “excessive or unreasonable” has been deleted, since these terms are subject to interpretation and patients can have varying levels of insight. As a result, the previous DSM-IV-TR specifier of “poor insight” has been expanded to include: good or fair, poor, and absent insight. Finally, a specifier of "tic-related" OCD has been added.
While the most up-to-date DSM-5 diagnostic criteria are presented here, it is important to note that most of the treatment data described within this section are based on patients meeting DSM-IV criteria (or older).
Psychological treatment
Meta-analyses support the beneficial effects of psychological treatment for OCD, mainly CBT, generally including exposure with response prevention (ERP). CBT is equivalent or superior to pharmacotherapy. Results with CBT were generally similar in comparisons of interventions with an emphasis on ERP and those with an emphasis on cognitive elements. A treatment specifically designed to address fear of contamination with infectious substances, using a cognitive intervention that includes no direct exposure (“danger ideation reduction therapy, DIRT”), was found to be more efficacious than ERP. Cognitive interventions may be important in patients who do not have overt compulsions, which can make ERP more difficult. One meta-analysis found that exposure in vivo combined with imaginal exposure was better than exposure in vivo alone.
Several meta-analyses have demonstrated no significant differences in efficacy between group and individual CBT. However, results of head-to-head trials are conflicting, with some RCTs finding no significant differences in efficacy between group and individual therapy, and others showing individual therapy to be superior. Differences in results may be explained by the fact that in individual therapy the therapist may have the advantage of being more aware of the patient’s dysfunctional beliefs, however, the group therapy setting may offer the advantages of group encouragement, reciprocal support, imitation, and interpersonal learning which may result in an increased motivation and reduced discontinuation of treatment.
An important practical question concerns the intensity and duration of treatment. The intensive ERP program described by Foa’s group involves 15 two-hour sessions scheduled five days a week over three weeks. A similar program administered twice-weekly (a more practical approach for many patients and therapists) was as effective at the end of follow-up as the intensive five-days/week strategy. A step-care approach in which patients received six weeks of low-intensity counseling with ERP bibliotherapy followed by standard ERP for non-responders only was found to be as effective as initial therapy with standard ERP (17 sessions twice weekly), but was significantly less costly.
Other techniques that may be useful include acceptance and commitment therapy (ACT), modular cognitive therapy (CT) addressing OCD beliefs, CT addressing obsessional doubt, organizational training, and mindfulness training. RCTs on the benefits of adding motivational interviewing to CBT have been conflicting, with one showing no additional benefits, while another demonstrated improved symptom reduction and remission rates compared with CBT alone. While EMDR was more effective than an SSRI in a RCT, data are limited and this technique is not generally recommended for patients with OCD.
Data suggest that therapist-guided exposure is better than self-exposure. While both treatment conditions showed significant symptom reduction, therapist-administered ERP was superior to self-administered ERP in improving OCD symptoms and self-reported functional impairment. Other data suggest that ERP delivered by telephone is equivalent to face-to-face ERP. Bibliotherapy in the form of self-help manuals delivered to patients via email has demonstrated significantly greater improvements in OCD symptoms compared with wait-list control groups in two RCTs.
ICBT is an easily accessible treatment that has the potential to reach untreated patients and motivate them for face-to-face psychotherapy if necessary. Several RCTs have demonstrated that ICBT programs are significantly more effective than supportive therapy or relaxation control strategies. ICBT was as effective as therapist-led CBT only when patients completed at least one self-exposure session. ICBT was associated with significantly better outcomes when it included brief, scheduled, therapist-initiated telephone support compared with on-demand phone support.
Family accommodation (i.e., family members taking part in the performance of rituals, avoidance of anxiety-provoking situations, or modification of daily routines to assist a relative with OCD) has been associated with poorer response to both behavioral and pharmacological treatments. Clinicians may want to consider targeting family accommodation in order to improve treatment outcomes for some patients.
Although hoarding disorder is now a separate diagnosis, the limited data available on the treatment of hoarding will be mentioned in this section on OCD. One RCT found that group CBT significantly reduced hoarding and depression symptoms while bibliotherapy alone was associated with very limited improvements. The addition of posttreatment, nonclinician, home assistance did not significantly improve outcomes.
Combined psychological and pharmacological treatment
The combination of psychological and pharmacological treatment has been shown to be superior to medication alone, but not to CBT alone. These findings suggest that if pharmacotherapy is required or preferred, adding CBT to pharmacological treatment of OCD may enhance response rates and reduce relapse rates. Unlike in some anxiety and related disorders, there does not appear to be any contraindication to combining CBT with medications in patients with OCD, and combined treatment may improve relapse prevention.
Adding d-cycloserine may hasten the onset of improvements with ERP, with significant benefits over placebo during the first four or five ERP sessions, but this effect has not been seen in all studies.
Long-term effects of psychological treatment
Follow-up studies suggest that the benefits of CBT are maintained at one to five years of follow-up.
Pharmacological treatment
The management of patients with OCD should follow the principles discussed in Section 2. SSRIs are recommended first-line pharmacological interventions for OCD, while SNRIs, clomipramine, and other antidepressants are recommended second- and third-line treatments. Treatments that have been investigated for use in OCD have been assessed according to the criteria for strength of evidence (Tables 1 and 2) and are summarized in Tables 26 and 27.
First-line agents
SSRIs: Evidence from RCTs and meta-analyses support the use of SSRIs, including escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline (all Level 1), in the treatment of OCD. In meta-analyses, response rates with SSRIs are generally twice those of placebo, at 40-60% with treatment versus <20% with placebo. Pooled response rates are not significantly different between SSRIs. In meta-analyses and head-to-head trials, compared with clomipramine, the SSRIs fluoxetine, fluvoxamine, paroxetine, and sertraline had similar efficacy but better tolerability.
Dimensional analyses have suggested that symmetry/hoarding symptoms may be associated with a poorer response to SSRI therapy, while aggressive/religious/sexual symptoms may predict better outcomes. It has been hypothesized that the symmetry/hoarding symptom dimension may be mediated by the dopamine system and aggressive behaviors by the serotonin system.
Second-line agents
Clomipramine: There is good evidence to support the use of clomipramine in the treatment of OCD (Level 1). Clomipramine has efficacy similar to SSRIs, but SSRIs are generally better tolerated. Side effects and safety are issues with clomipramine and therefore it is recommended as a second-line choice. Common adverse effects include anticholinergic effects such as dry mouth, constipation, and blurred vision, as well as urinary retention, orthostatic hypotension, weight gain, and sedation. The major safety concerns are cardiac arrhythmias, seizures, drug interactions, and toxicity in overdose.
Antidepressants: In RCTs, citalopram was more effective than placebo but less effective than psychotherapy (Level 2). Additional data from augmentation studies support the efficacy of citalopram for the treatment of OCD. However, given that other SSRIs have much stronger evidence, citalopram was designated a second-line option. The only RCT data on the use of mirtazapine in OCD are from a discontinuation study in which continued mirtazapine was associated with continued improvement (Level 2). There is some evidence to support the use of venlafaxine XR for the treatment of OCD (Level 2). In RCTs, venlafaxine XR was more effective than placebo, and as effective as paroxetine and clomipramine. In a double-blind extension of a RCT, paroxetine was more efficacious than venlafaxine in the treatment of non-responders to previous treatment with the alternate antidepressant.
Third-line agents
Intravenous clomipramine: In a RCT, intravenous (IV) clomipramine was more effective than placebo in patients with OCD (Level 2). Initiating therapy with IV then switching to oral therapy does not appear to be associated with greater benefit compared with oral therapy alone.
Other agents: IV citalopram (Level 3), as well as duloxetine, tramadol, and tranylcypromine (all Level 4) have demonstrated some efficacy in open trials or case reports. Results with phenelzine have been inconsistent. In one RCT, phenelzine was not significantly better than placebo, but in another it was as effective as clomipramine (Level 2). In the placebo-controlled trial, post-hoc analysis suggested that phenelzine may be beneficial in patients with symmetry or other atypical obsessions.
These agents are recommended as third-line options, and may be useful in refractory patients after first- and second-line monotherapies and adjuncts have been unsuccessful.
Adjunctive therapy
Adjunctive strategies have generally been studied in patients who have had an inadequate response to SSRI therapy, and can be considered for patients with treatment-resistant OCD. A meta-analysis demonstrated that response rates with adjunctive medication were twice those of placebo, however these were still quite low (31.8% versus 13.6%). Meta-analyses of RCTs found that adding risperidone (and possibly quetiapine) to antidepressants increased efficacy but decreased tolerability, while adjunctive olanzapine did not improve response rates.
First-line adjunctive therapies: In RCTs, adjunctive aripiprazole was significantly more effective than placebo (Level 1), and may be as effective as risperidone. Additional open-label data also support the beneficial effects of adjunctive aripiprazole.
As adjunctive therapy for treatment-resistant OCD, risperidone was more effective than placebo (Level 1) and as effective as olanzapine and aripiprazole overall. Compared with aripiprazole, risperidone may provide greater improvement in obsessions. Risperidone was also as effective as haloperidol for obsessions, but less so for compulsions, however it was better tolerated. More recently an open, randomized study found that while augmentation with ERP was superior to risperidone or pill placebo, risperidone was not significantly more effective than placebo. However, patients in this study had some response to SSRI therapy and may have been less refractory compared to those in other studies. Considering the tolerability concerns of atypical antipsychotics, these data reinforce that this augmentation strategy should be reserved for patients with treatment-resistant OCD.
Second-line adjunctive therapies: RCT evidence demonstrated that adjunctive memantine was superior to placebo (Level 2). Additional open-label data also support this therapy. Another option which may be useful as an adjunctive therapy in those with refractory OCD is the atypical antipsychotic quetiapine (Level 1, conflicting).
Data from small RCTs suggest that topiramate may be a useful adjunctive therapy, but data are conflicting (Level 1). In one RCT, adjunctive topiramate significantly improved Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores compared with placebo, while in another trial, adjunctive topiramate significantly improved compulsions but not obsessions. Additional open-label data support the use of adjunctive topiramate.
Third-line adjunctive therapies: The agents discussed below are recommended as third-line adjunctive options, since some data are available to suggest they may be useful but there is conflicting or inadequate evidence to warrant stronger recommendations. These agents may be useful for some patients, but more data are needed.
Other atypical antipsychotics have been assessed as adjunctive therapies in patients with refractory OCD, including olanzapine (Level 1, conflicting), amisulpride (Level 3), and ziprasidone (Level 4).
There is level 2 evidence to support the use of adjunctive haloperidol in patients with refractory OCD, and although it may be as effective as adjunctive risperidone, it is a third-line choice because it was less well tolerated.
Adjunctive mirtazapine was associated with an earlier onset of response of OCD symptoms compared with citalopram alone, but there was no advantage of the combination over time (Level 2). Some data also support the efficacy of adjunctive citalopram for treatment-resistant OCD (Level 3).
Adjunctive anticonvulsants may be useful for some patients with refractory illness. In a small RCT, adjunctive lamotrigine improved both obsessions and compulsions compared to SSRI therapy (Level 2). Open-label data also suggest that adjunctive pregabalin may be useful (Level 3).
Other agents that have been studied as adjunctive therapy for treatment-resistant OCD include celecoxib, granisetron, IV ketamine, ondansetron, N-acetylcysteine (all Level 2), and riluzole (Level 3). There is little clinical experience with these agents for refractory OCD, therefore they are recommended as third-line adjunctive options only.
Results with pindolol augmentation have been inconsistent, with significant improvements in one small RCT, but not in other randomized or open trials (Level 1, conflicting).
In two randomized, quetiapine-controlled trials, adjunctive clomipramine was not superior to SSRI therapy (Level 2, negative). Clinical experience suggests that some patients may benefit from adjunctive clomipramine; however, plasma levels should be monitored because of the risk of drug interactions with SSRIs.
Not recommended
Clonazepam, clonidine, and desipramine (all Level 2, negative) have not demonstrated efficacy and are not recommended in the treatment of OCD. Bupropion and naltrexone (both Level 3, negative) also do not appear to be effective in this disorder.
Adjunctive buspirone, clonazepam (Level 2, negative), or lithium (Level 1, negative) have not demonstrated efficacy for the treatment of OCD. There is currently no evidence for the efficacy of adjunctive gabapentin (Level 3, negative) or minocycline (Level 4, negative), but there are insufficient data to make recommendations at this time. In a RCT, adjunctive once-weekly oral morphine was effective in patients who had failed six SSRI trials (Level 2), however, morphine is not generally recommended because of its potential for abuse.
Maintenance pharmacological treatment
Long-term therapy has been evaluated in relapse prevention and naturalistic follow-up studies. Relapse-prevention studies are those in which responders to SSRI therapy are randomized to continued active treatment or placebo. A meta-analysis of six relapse prevention studies included 951 patients with OCD and found a highly significant reduction in relapse rates with continued SSRI treatment compared with placebo over six to 12 months (odds ratio for relapse was 0.38). In RCTs, escitalopram, paroxetine, sertraline, and high-dose fluoxetine have demonstrated reductions in relapse rates. In RCT discontinuation studies, mirtazapine and clomipramine have demonstrated continued improvement compared with placebo over approximately six to 12 months. Additional data support the long-term efficacy of fluoxetine, fluvoxamine XR, and sertraline over six to 24 months.
Biological and alternative therapies
Biological therapies: Biological therapies may be useful in patients with OCD who have not responded to CBT and multiple medication trials. Open trials have suggested that rTMS may be a promising adjunctive therapy in patients with treatment-refractory OCD. However, results of sham-controlled trials are conflicting, with some trials finding significant improvements and others concluding that rTMS was ineffective for treatment-resistant OCD (Level 1, conflicting). Some data suggest that rTMS may improve comorbid depressive symptoms in patients with OCD.
Several very small studies have suggested that deep brain stimulation may improve symptoms and functionality in up to two-thirds of patients with highly treatment-refractory OCD (Level 4).
Open trials suggest that capsulotomy (Level 3) or cingulotomy (Level 3) may be effective in reducing symptoms in patients with severe, treatment-refractory OCD, however these treatments are usually considered last resorts.
Alternative therapies: A meta-analysis of meditation therapies found only two small studies and showed that transcendental meditation and Kundalini yoga were likely no more effective than other kinds of relaxation therapies in treating OCD (Level 3, negative). Open studies suggest that adjunctive moderate-intensity aerobic exercise may help improve OCD symptoms (Level 3).
Small RCTs and open trials have suggested that herbal therapies such as milk thistle (Silybum marianum L. Gaertn.) (Level 2), valerian root (Valeriana officinalis L.) (Level 2), and St John’s wort (Hypericum perforatum) (Level 3) may be useful in patients with OCD. Unfortunately, because these preparations are poorly standardized and have substantial variation in the proportion of the active ingredient in different products, they cannot be widely recommended. These therapies may be useful for some patients; however, more data are needed.
Summary
OCD is a relatively rare, yet severe, mental disorder, with an onset in the 20s or earlier. It is characterized by the presence of obsessions (persistent, intrusive thoughts) and/or compulsions (repetitive behaviors the individual feels compelled to perform). OCD is associated with substantial functional impairment and a high prevalence of comorbid disorders.
CBT, and notably ERP, are effective first-line options for the treatment of OCD, being equivalent or superior to pharmacotherapy. CBT can be effectively delivered in both individual and group settings, as well as via self-exposure, self-help books, telephone, and internet-based programs. The benefits of CBT are maintained over one to five years of follow-up. The combination of psychotherapy and pharmacotherapy appears to be superior to pharmacotherapy alone, but not to CBT alone, and data suggest that adding CBT to pharmacological treatment may yield better long-term outcomes.
Pharmacotherapeutic approaches should begin with a first-line SSRI such as escitalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline. If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first-line agent before considering second-line medications. Second-line choices include citalopram, clomipramine, mirtazapine, and venlafaxine XR. OCD can be difficult to treat; therefore, in order to preserve any benefits of a therapy, adjunctive strategies may be important early in treatment.
Patients who do not respond to multiple courses of therapy are considered to have treatment-refractory illness. In such patients it is important to reassess the diagnosis and consider comorbid medical and psychiatric conditions that may be affecting response to therapy. Third-line agents, adjunctive therapies, as well as biological and alternative therapies may be useful when patients fail to respond to optimal treatment trials of first- and second-line therapies used alone and in combination.
Epidemiology
The lifetime prevalence of PTSD in Canada was estimated to be 9.2%, and current (1-month) rates were 2.4%. Over 76% of Canadians reported exposure to a significantly traumatic event. US and European community studies report lifetime prevalence rates of 6.4-6.8% and 12-month rates of 1.1-3.5%. The most common forms of trauma resulting in PTSD included unexpected death of someone close, sexual assault, serious illness or injury to someone close, having a child with serious illness, and being beaten by a partner or caregiver. Onset is generally in the mid to late 20s, and the prevalence is about twice as high among women versus men.
PTSD was associated with significant QoL and functional impairments, which increase with increasing severity of symptoms. In addition, PTSD is associated with high rates of chronic pain, sleep problems, and sexual dysfunction, as well as cognitive dysfunction and alexithymia. The risk of suicide attempts is increased two- to three-fold by the presence of PTSD.
In primary care, PTSD was associated with more and longer hospitalizations as well as a greater use of mental health care. Among Canadian military personnel, greater use of mental health care was associated with cumulative lifetime trauma exposure, index trauma type, PTSD symptom interference, suicidal ideation, female gender, and comorbid MDD.
Comorbidity
An estimated 75% of patients with PTSD have another comorbid psychiatric disorder; and rates are particularly high for other anxiety and related disorders, MDD, oppositional defiant disorder, ADHD, SUD, alcohol dependence, and borderline personality disorder (BPD). Comorbid panic or mood disorders have been associated with greater functional impairment than PTSD alone. Patients with comorbid PTSD and BPD had a poorer QoL, more comorbidity with other psychiatric conditions, and increased odds of a lifetime suicide attempt versus patients with either condition alone.
Diagnosis
By definition PTSD requires exposure to trauma, including actual or threatened death, serious injury, or sexual violation. It is characterized by intrusive and distressing memories or dreams, dissociative reactions, and substantial psychological or physiological distress related to the event (Table 28). A diagnosis of PTSD requires the disturbances to be present for longer than one month; symptoms of >3 days but less than one month may be diagnosed as acute stress disorder (ASD), if the required ASD criteria are met.
Compared to the DSM-IV-TR, changes to the diagnostic criteria for PTSD in the DSM-5 include adjusting the symptom clusters, adding some new symptoms, and re-classifying PTSD as a ‘‘trauma- and stressor-related disorder’’ instead of an anxiety disorder. In addition to PTSD, this new category also includes diagnostic criteria for reactive attachment disorder, disinhibited social engagement disorder, ASD, and adjustment disorders. The DSM-5 diagnostic criteria for PTSD sharpens the definition of “traumatic event,” and there are now four symptom clusters rather than three with the “avoidance” and “numbing of responsiveness” being separated (Table 28). The DSM-5 also eliminated the acute and chronic PTSD specifiers. The PTSD diagnostic criteria apply to adults, adolescents, and children >6 years of age. A subtype has been added for children ≤6 years of age, as well as a dissociative symptoms specifier for patients of all ages.
While the most up-to-date DSM-5 diagnostic criteria are being presented here, it is important to note that the treatment data described within this section are based on patients meeting DSM-IV criteria (or older).
PTSD is frequently comorbid with other psychiatric disorders, including other anxiety and related disorders, MDD, and SUDs, which may complicate diagnosis and management. In addition, patients with PTSD frequently present with somatic symptoms and pain. It is important to ask patients with psychological or somatic symptoms about trauma.
Prevention and early intervention
A number of studies have assessed early intervention with psychological and pharmacological strategies for the prevention of PTSD. Meta-analyses do not support the efficacy of wide spread use of single-session or multiple-session psychological debriefing after trauma in preventing or reducing the intensity of PTSD in individuals who have been exposed to a traumatic event but have not been identified as suffering from any specific psychological difficulties. In fact, these interventions may have an adverse effect on some individuals. These findings pertain to individual debriefings only; there is insufficient evidence to comment on the utility of group debriefings.
Conversely, meta-analyses have demonstrated the benefit of multisession trauma-focused-CBT (TF-CBT) in patients with ASD or PTSD. Therefore, debriefing of all trauma victims is not recommended, rather, screening and treating appropriate individuals is preferred. For the prevention of chronic PTSD in patients with ASD or acute PTSD, brief TF-CBT was more effective than both wait-list and supportive counseling interventions, but there was no evidence of the effectiveness of structured writing compared to minimal intervention.
There are few data on the use of pharmacotherapy for the prevention of PTSD. In a cohort study and a RCT, the early use of benzodiazepines following trauma was not beneficial, and may increase the risk of developing PTSD. Similarly, retrospective data suggested that gabapentin or pregabalin had no effect on PTSD development. Data from cohort studies on the use of the beta-blocker propranolol have been conflicting, but one small RCT did show a significant decrease in the severity of PTSD symptoms and lower likelihood of developing subsequent PTSD. SSRI therapy was significantly more effective than placebo in preventing PTSD symptoms according to parent reports but not child reports in a RCT in children. Cohort studies suggest that the early use of morphine during trauma care may reduce the risk of the subsequent development of PTSD in children and adults.
Psychological treatment
Psychological therapies for PTSD generally include education about the disorder and its treatment, as well as exposure to cues relating to the traumatic event. Psychotherapy has demonstrated significant efficacy, although a meta-analysis suggested it may be less effective than pharmacotherapy in improving PTSD and comorbid depression symptoms.
Meta-analyses of over 30 RCTs of psychological interventions provide evidence of the efficacy of several CBT approaches for the management of chronic PTSD compared with wait-list or usual care control groups. There was evidence that individual TF-CBT, EMDR, stress management, and group TF-CBT were effective, while other nontrauma focused psychological treatments (supportive therapy, nondirective counseling, psychodynamic therapy, and hypnotherapy) did not reduce PTSD symptoms as significantly. Individual TF-CBT and EMDR appeared to be equally effective, but superior to stress management in the treatment of PTSD. Another meta-analysis also found EMDR and TF-CBT were equally effective. However, in a head-to-head RCT, EMDR resulted in faster recovery compared with the more gradual improvement with brief TF-CBT. Cognitive therapy approaches have been used effectively in treating PTSD following sexual or interpersonal violence, civilian trauma, and military trauma.
Cognitive processing therapy (CPT) is an effective protocol that combines cognitive therapy and written accounts; however, an analysis of the components found no differences in outcomes with either component alone or the combined protocol.
Prolonged exposure (PE) is a widely studied CBT approach. A meta-analysis of 13 RCTs concluded that PE therapy was more effective than wait-list or psychological placebo control conditions, and as effective as other active treatments (e.g., CBT, CPT, EMDR). One study found that 30-minute imaginal exposure sessions were as effective as 60-minute sessions. Imaginal appears to be as effective as in vivo exposure.
Data are conflicting as to the benefits of adding cognitive restructuring to exposure therapy; several studies suggest that exposure alone is superior to the combination, however, another large RCT found the combination to be significantly better than imaginal or in vivo exposure alone. When used as an adjunct to exposure therapy, cognitive restructuring may improve non-fear problems like anger and guilt, and may be a useful adjunct in patients in which these emotions predominate. Similarly, the addition of social emotional rehabilitation to exposure therapy did not improve PTSD symptoms but did improve social functioning in male combat veterans with chronic PTSD.
Meta-analyses and systematic reviews reveal two current limitations of CBT for PTSD. The first is that about one-third to one-half of patients experience substantial residual symptoms and functional impairments posttreatment, still report symptoms meeting diagnostic criteria at follow-up, or relapse and require booster sessions. The second issue pertains to external validity. While CBT for PTSD has been shown to be efficacious in RCTs, there is a dearth of effectiveness studies to suggest that CBT can be generalized to many patients commonly found in clinical practice. Many RCTs have excluded patients with complex clinical profiles including childhood abuse histories, current SUDs, personality disorders, suicidality or self-injurious behavior, homelessness, refugees, intimate partner violence, and significant dissociative symptoms among others. In this regard, Bradley et al. found a positive association between the number of exclusion criteria and the strength of effect sizes, such that studies with stricter inclusion criteria tended to report larger treatment effects. Additionally, numerous studies fail to report whether patients experience any adverse effects from psychological treatments, or whether dropout rates (ranging between 0-50%) result from treatment demands.
Dialectical behavior therapy (DBT), which was developed to reduce self-harm behavior in patients with BPD, was shown to be useful in patients with PTSD. When used as a pretreatment, DBT reduced self-harm behaviors allowing over half of patients to become suitable candidates for PTSD treatment.
Another study demonstrated some success with PE treatment of PTSD and comorbid substance abuse. Results of a recent expert clinician survey on best practices suggests that CBT is useful for fear-based PTSD, while this treatment approach may require an additional treatment module targeting affective regulation for patients presenting with a diagnosis of Disorders of Extreme Stress (DESNOS) or complex PTSD.
Internet-based treatments are being increasingly investigated, in part because they can be administered remotely and anonymously to under-served or disaster-stricken areas at a relatively low-cost. RCTs have shown that therapist-assisted ICBT is more effective than wait-list or supportive care control strategies in improving PTSD symptoms, depression, anxiety, and disability. In addition, a strong therapeutic relationship can be established through the internet, which improved the treatment process. VRE therapy has also demonstrated some utility in improving PTSD symptoms. Compared to face-to-face CBT, video-conference CBT was equally effective but telehealth CBT was less effective; however, both were effective compared with pre-treatment.
Combined psychological and pharmacological treatment
Research evaluating combined treatment in PTSD is limited; a meta-analysis found only four small trials. Combination SSRI plus psychotherapy was not superior to psychotherapy alone in two RCTs, but was superior to pharmacotherapy alone in the other two trials. In contrast, a more recent RCT found that combination therapy was superior to psychotherapy alone. The role of combining psychotherapy and medication requires further study.
Adjunctive propranolol with trauma reactivation therapy was found to help prevent reconsolidation of the traumatic memory and thus decreased physiological responses and PTSD symptoms during subsequent follow-up in randomized and open trials. Two RCTs have found that use of d-cycloserine did not enhance the overall treatment effects of exposure therapy, and may in fact decrease response to psychotherapy.
Long-term effects of psychological treatment
Open follow-up data of psychological treatments suggest that benefits are maintained at six- to 18-month assessments after treatment. Longer-term follow-up of patients treated with EMDR showed that benefits were maintained at three years, with the majority of patients who had initially remitted being at full working capacity. Very long-term follow-up showed that improvements in PTSD and related symptoms achieved with CPT and PE were maintained over an extended five to 10 year period.
Pharmacological treatment
The management of patients with PTSD should follow the principles discussed in Section 2. Pharmacological interventions that have good evidence for efficacy in treating PTSD include fluoxetine, paroxetine, sertraline, and venlafaxine XR. Treatments that have been investigated for use in PTSD have been assessed according to the criteria for strength of evidence (Tables 1 and 2) and are summarized in Tables 29 and 30.
First-line agents
Antidepressants (SSRIs & SNRIs): Evidence from meta-analyses and RCTs supports the use of the SSRI paroxetine and the SNRI venlafaxine XR (both Level 1) for the first-line treatment of PTSD. Data with fluoxetine are mixed, with both positive and negative RCTs (Level 1, conflicting). Similarly, RCTs with sertraline have yielded both positive and negative results (Level 1, conflicting). However, there appear to be sufficient data from the larger RCTs to suggest that these agents can be effective first-line options. Conflicting results may be related to the types of traumas, symptom clusters, and comorbidities included in the various studies.
Second-line agents
Antidepressants: The efficacy of mirtazapine was demonstrated in one small RCT (Level 2) and three open trials. In a randomized, open-label trial, response rates were significantly higher with mirtazapine than sertraline.
Fluvoxamine demonstrated efficacy for PTSD in open trials, and in a RCT was as effective as reboxetine (Level 2).
Phenelzine was more effective than placebo in two RCTs, but not significantly different from placebo in a RCT crossover study (Level 1, conflicting). Caution is needed when using MAOIs because of the dietary restrictions and potential for drug interactions.
Third-line agents
The following agents are recommended as third-line options because of limited data, side effects, or lack of clinical experience as a primary therapy for the treatment of PTSD.
Antidepressants: In small RCTs, imipramine (Level 1) and amitriptyline (Level 2) demonstrated some efficacy in patients with PTSD. Data with desipramine are mixed, with one RCT showing significant benefit, which were comparable to paroxetine, and the other showing improvements in depression only. While RCTs with the TCAs suggest some benefit with these agents, it appears to be limited.
Reboxetine and fluvoxamine were equally effective in a small RCT (both Level 2), and open-label studies suggest that bupropion SR, duloxetine, escitalopram, moclobemide, and tianeptine (all Level 3) may be useful in PTSD.
Anticonvulsants: Data on topiramate are mixed, with one RCT finding significant benefits over placebo, while the other did not (Level 1, conflicting). There are also limited data suggesting efficacy of other anticonvulsants, including lamotrigine (Level 2) and carbamazepine (Level 3).
Atypical antipsychotics: Some data suggest that the atypical antipsychotics, risperidone (Level 2), aripiprazole (Level 3), and quetiapine (Level 3) may be a useful alternative to SSRIs for some patients with PTSD. A meta-analysis of seven RCTs using atypical antipsychotics, either as monotherapy or adjunctively, concluded that these agents may be beneficial in the treatment of PTSD, particularly for the symptom of “intrusion”.
Other therapies: Small, open case series have suggested benefits with trazodone, buspirone, and memantine (all Level 4).
Adjunctive therapies
Adjunctive strategies have generally been studied in patients who have had an inadequate response to adequate antidepressant therapy, and can be considered for patients with treatment-resistant PTSD.
Second-line adjunctive therapies: In a RCT, adjunctive eszopiclone was significantly more effective than placebo in improving PTSD and sleep symptoms (Level 2). There is RCT evidence for the use of adjunctive atypical antipsychotics, including risperidone (Level 1, conflicting) and olanzapine (Level 2), for patients with treatment-resistant PTSD. While a number of small RCTs demonstrated benefits with adjunctive risperidone, a large, six-month trial in approximately 250 patients failed to show improvements in PTSD symptoms compared with placebo.
Third-line adjunctive therapies: Open-label trials and case series suggest that adjunctive quetiapine or aripiprazole (both Level 3) are useful in patients with refractory PTSD.
Similarly, there are some data suggesting adjunctive anticonvulsants including: gabapentin, levetiracetam, pregabalin, or tiagabine (all Level 4), as well as the alpha-adrenergic agonist clonidine (Level 3), can improve symptoms in patients with treatment-resistant PTSD.
Not recommended adjunctive therapies: Small RCTs failed to show the superiority of adjunctive therapy with guanfacine (Level 1, negative), bupropion SR (Level 2, negative), or zolpidem (Level 2, negative). While case series suggested that adjunctive topiramate may be effective in treatment-resistant PTSD, a RCT failed to show superiority over placebo (Level 2, negative).
Treatments for specific PTSD-associated symptoms
Several agents have been used to target particular symptoms associated with PTSD. Prazosin has demonstrated significant efficacy for reducing trauma nightmares and improving sleep quality in patients with PTSD compared with placebo (Level 1). Some open-label data suggest that naltrexone may help reduce flashbacks (Level 3), and fluphenazine may improve trauma re-experiencing symptoms (Level 3).
Cyproheptadine was not effective for nightmares or sleep problems in patients with PTSD and may actually exacerbate sleep disturbance (Level 2, negative).
Not recommended
In general, data do not currently support the use of divalproex (Level 1, negative), alprazolam, citalopram, olanzapine, tiagabine (all Level 2, negative), or clonazepam (Level 3, negative).
Maintenance pharmacological treatment
Long-term therapy has been evaluated in relapse-prevention and naturalistic follow-up studies. Relapse-prevention studies are those in which responders to SSRI therapy are randomized to continued active treatment or placebo. A meta-analysis of three relapse-prevention studies included 272 patients with PTSD, and found a highly significant reduction in relapse rates with continued SSRI treatment compared with placebo over approximately six months (odds ratio for relapse was 0.25).
In RCT discontinuation studies, fluoxetine and sertraline have demonstrated significantly lower relapse rates over six months in the range of 5-22% with active treatment compared to 16-50% with placebo. However, in a small discontinuation RCT, tiagabine was not superior to placebo in preventing relapse.
Open follow-up studies with paroxetine and sertraline have demonstrated sustained and continued improvement over six to 12 months of continued SSRI therapy.
Biological and alternative therapies
In general, these therapies may be useful for some patients; however, more data are needed.
Biological therapies: In RCTs, rTMS was effective as monotherapy or as an adjunct to SSRIs in patients with PTSD (Level 1), and at least some improvements were maintained at two to three months after treatment. Open prospective and retrospective data suggest that adjunctive electroconvulsive therapy may be helpful in patients with refractory PTSD (Level 3).
Alternative therapies: In a RCT, acupuncture was more effective than a wait-list control and as effective as group CBT (Level 2). Adjunctive use of symptom-oriented hypnotherapy or mantra repetition (both Level 2) improved PTSD symptoms in small trials; and in a small case series, patients with PTSD benefited from transcendental meditation (Level 4).
Summary
The lifetime prevalence of PTSD is around 6-9%; it is more frequent in women than in men, with an onset generally in the mid to late 20s. PTSD is associated with high rates of functional impairment, somatic complaints, suicide risk, and comorbid psychiatric disorders. A diagnosis of PTSD requires evidence of exposure to trauma, and is characterized by intrusive and dissociative symptoms.
Evidence does not support the wide spread use of early intervention with psychological strategies for the prevention of PTSD. Debriefing of all trauma victims is not recommended, rather, screening and treating appropriate individuals is preferred. In general, there is little evidence supporting the use of pharmacotherapy for the prevention of PTSD, with most studies suggesting no preventive benefits.
CBT is an effective first-line option for the treatment of PTSD. Effective approaches include TF-CBT, EMDR, PE, and stress management therapy. ICBT and VRE have also demonstrated efficacy. Benefits are maintained during long-term follow-up of up to one to 10 years after treatment. Research evaluating combined psychological and pharmacological treatments in PTSD is limited, and this requires further study.
Pharmacotherapeutic approaches should begin with one of the first-line options which include SSRIs such as fluoxetine, paroxetine, or sertraline, or the SNRI venlafaxine XR. If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first- or second-line agent, or a second-line agent should be added. Patients with PTSD may make few gains during treatment, and it is important to preserve even small gains achieved with initial therapy. Therefore, augmentation with second- or third-line agents may be important early in treatment.
Patients who do not respond to multiple courses of therapy are considered to have treatment-refractory illness. In such patients it is important to reassess the diagnosis and consider comorbid medical and psychiatric conditions that may be affecting response to therapy. Third-line agents, adjunctive therapies, as well as biological and alternative therapies may be useful when patients fail to respond to an optimal treatment trial of first- and second-line therapies used alone and in combination.
Epidemiology
Women have been found to be at higher risk for anxiety and related disorders than men. Anxiety disorders during the perinatal period are increasingly gaining research attention. Although further investigation is needed, data from a large national survey suggest the overall prevalence of anxiety and related disorders is unchanged in women during pregnancy; however, other data have found an increased risk for individual disorders, such as GAD. Similarly, some data suggest that anxiety disorders are also not more prevalent during the postpartum period, but other studies suggest higher rates of OCD and GAD during this period. In addition, PTSD can develop as a result of pregnancy complications that are experienced as traumatic.
Anxiety and related disorders during pregnancy or postpartum may have a negative impact on the pregnancy, the child, or the mother. While studies report that maternal anxiety disorders are associated with adverse pregnancy outcomes such as a shorter gestational age, premature delivery, or elective cesarean delivery, a meta-analysis found no relationship between anxiety symptoms per se and adverse perinatal outcomes. Anxiety symptoms during pregnancy have been associated with depressive symptoms, substance use, and anemia, as well as decreased use of prenatal vitamins.
Parenting may also be affected by maternal anxiety and related disorders. Mothers with anxiety disorders have been found to be less promoting of psychological autonomy than those mothers without anxiety. Maternal anxiety has been found to be predictive of child cognitive development, associated with behavioral/emotional problems in childhood, and maternal anxiety and related disorders have been found to be related to subsequent development of an anxiety disorder in the child.
Treatment issues
Psychosocial treatments, with CBT specifically, have strong empirical support for the treatment of anxiety and related disorders, but evidence of their efficacy in perinatal women with anxiety disorders is lacking. Cohort studies have shown beneficial effects of group CBT in pregnant women with B-I-I phobia, and individual CBT in women with OCD in the postnatal period. Arch et al. argued that although exposure-based CBT or behavioral therapy may have been avoided in the past because of concerns of potential harm, they likely can be viable, safe alternatives in pregnancy. The lack of data on the use of structured psychosocial interventions for anxiety and related disorders during the perinatal period is a significant gap in the literature.
It is important to consider the risks and benefits of pharmacotherapy during pregnancy and while breastfeeding during the postpartum period. Risks to the fetus and newborn should be weighed against that of the potential harm of untreated anxiety and related disorders, an area that is gaining increasingly more research attention. Treatment decisions should attempt to optimize outcomes for both mother and baby.
Detailed recommendations on the use of psychiatric medications during pregnancy and lactation are available from the American Congress of Obstetricians and Gynecologists (ACOG) Practice Bulletin. Although it is over five years old, risks associated with various psychotropic medications are summarized. The FDA pregnancy risk category system has been criticized as being insufficient and is currently under the process of revision. The Canadian Hospital for Sick Children Motherisk website (http://www.Motherisk.org) is also a useful resource.
Antidepressants: There appears to be little evidence of an association between maternal antidepressant use and increased risks of congenital malformations in general, and major congenital malformations in infants. The exception is a statistically increased risk of cardiac defects with antidepressants, and with paroxetine specifically, although the clinical significance of this has been questioned. There have been reports of increased rates of spontaneous abortion following antidepressant use during pregnancy; in the most recent meta-analysis, this was not supported using data from studies with higher study quality but found by others who included all studies. In terms of delivery outcomes, a recent meta-analysis found a statistically increased risk for preterm birth, lower gestational age, birth weight, and APGAR scores – but the effects were small, generally in the normal range, and of questionable clinical significance. However, data support an increased risk for poor neonatal adaptation syndrome (PNAS), while findings of increased risk for persistent pulmonary hypertension in the antenatally exposed infant have not been consistent. Systematic reviews suggest that overall prenatal exposure to antidepressants does not appear to be associated with changes in long-term neurocognitive or behavioral development in children and that illness itself appears to play a role in negative outcomes (although this study examined the effects of maternal depression). Two reports link prenatal antidepressant use to childhood autism spectrum disorders and two others link bupropion exposure to childhood ADHD. These studies have limitations and further research is required.
In terms of breastfeeding, potential risks of antidepressant use during lactation must be weighed against the recognized benefits for the infant. Antidepressants are excreted into breast milk and although data are limited, the majority are found in very low amounts with few isolated instances of adverse signs. If antidepressant treatment is indicated, sertraline or paroxetine is preferred. Long-term data on potential neurobehavioral effects are lacking. Clinicians can consult LactMed at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT for the latest information available.
Benzodiazepines: The data on benzodiazepines remain more limited. A recent meta-analysis did not find an increased risk of major malformations or cardiac defects following prenatal benzodiazepine exposure, but concluded the significant increase in risk of oral cleft remains based on data derived from case-control studies, although another meta-analysis reported the absolute risk is small (<1%). A case-control study published in 2002 examining exposure to five benzodiazepines (including clonazepam) and not included in the above meta-analyses, with over 60,000 infants, did not find an association with various congenital malformations or oral clefts. Although there are a lack of meta-analytic data, neonatal withdrawal or toxicity syndrome has been described with antenatal benzodiazepine exposure and close monitoring of the infant has been recommended. The neurobehavioral effects on the child over the long-term due to antenatal exposure have been topics of debate and remain uncertain. Benzodiazepines are excreted into breast milk at low levels generally. A recent study with 124 mothers documented low levels of adverse effects (sedation in particular) and supported the initiation of breastfeeding. Caution may be advised regardless however in infants who poorly metabolize benzodiazepines.
Atypical antipsychotics: Data on the use of antipsychotics during pregnancy continue to be limited. Thus far, there does not appear to be an increased risk for malformations although inconsistent data have been reported with some suggesting the data are inconclusive. These drugs have been found to be associated with both increased and decreased birth weight as well as increased risk for preterm birth. The second-generation antipsychotics can increase the risk of complications given the risk of metabolic syndrome, and thus diabetes, in the mother. Monitoring has been recommended. Both the FDA and Health Canada have issued safety alerts advising of the potential risk for abnormal muscle movements and withdrawal symptoms in infants exposed to antipsychotic medications during the 3rd trimester of pregnancy. Data on breastfeeding are more limited, but levels in breast milk have typically been shown to be low although adverse effects have been reported.
Summary
The management of anxiety and related disorders in women who are pregnant or lactating requires careful consideration of both the potential risks of any treatment option as well as risks of an untreated anxiety disorder. Antidepressants are generally associated with low teratogenic risk and adverse delivery outcomes. Patients should be counseled about PNAS and its management. Less is known about the risk of benzodiazepine and atypical antipsychotic exposure during pregnancy as the data are more limited. Treatment must be individualized and decisions should be made with the most up-to-date information with the best course of action decided upon with the patient. Poorly or untreated psychiatric illness carries its own risks, both in the short- and long-term.
Epidemiology
Anxiety and related disorders were the most common psychiatric disorders noted in the National Comorbidity Survey-Adolescent supplement (NCS-A) (age 13-18 years), with a lifetime and 12-month prevalence of 31.9% and 24.9%, respectively. Prevalence rates for individual anxiety and related disorders are shown in Table 31.
Specific phobias are very common in children. However, although most adolescents reported at least one fear (77%), lifetime prevalence rates are in the range of 10-35%. A study including children as young as five years of age found lower rates of diagnosed specific phobias (1%). B-I-I and animal fears are the most common types reported in pediatric populations. The prevalence of OCD is only 0.25% in children, but is 1-2% in adolescents, which is comparable to the rate seen in adults.
In the adolescent population, anxiety and related disorders were found to have the earliest median age of onset (six years), compared to other psychiatric disorders (11-15 years). Similarly, in the adult population, the median age of onset was earliest for anxiety and related disorders (11 years) compared to other psychiatric disorders (20-30 years). Separation anxiety disorder and the phobias (seven to 14 years) have much earlier median ages of onset compared to OCD, GAD, panic disorder, or PTSD (20-30 years).
Anxiety and related disorders can have a substantial long-term impact, putting children at elevated risk for MDD, other anxiety disorders, and SUD in adulthood. Anxiety and related disorders among younger patients are associated with high rates of comorbid psychiatric conditions, SUD, sleep problems, somatic symptoms, and suicidality, as well as problems with cognition/attention, academic performance, and peer relationships.
Diagnostic issues
Diagnostic evaluation of pediatric patients should be based on DSM-5 criteria, but use developmentally appropriate language, and consider collateral information from parents and teachers. Children may express anxiety through crying, tantrums, freezing, or clinging, as well as through play. The DSM-5 provides some modifications to adult criteria to assist in the diagnosis of anxiety and related disorders in children (Table 32). In particular, a separate subtype for patients ≤6 years of age has been added to the criteria for PTSD to make it more developmentally sensitive to young children.
Prevention strategies
Psychoeducational programs for children and adolescents aimed at preventing the development of an anxiety or related disorder have shown small, but significant effects. Both universal (administered to all children within target population) and indicated prevention programs (administered to children demonstrating highly anxious symptoms) demonstrate benefits, but indicated programs are associated with larger effect sizes than universal programs.
Both psychological and pharmacological strategies have been assessed for the prevention of PTSD. An early psychological intervention with children involved in road traffic accidents failed to result in any significant benefits over a control group.
In a RCT in burn victims, sertraline was more effective in preventing PTSD symptoms than placebo according to parent report but not child report. Data do not support the use of propranolol in preventing PTSD or ASD in pediatric injury patients.
Psychological treatment
Psychological therapies for children often need to be adapted to suit the chronological and developmental ages of young patients and to include parental involvement. Meta-analyses support the efficacy of CBT for the treatment of anxiety and related disorders in children and adolescents. A meta-analysis of 24 clinical trials showed that almost 70% of youths who received CBT no longer met diagnostic criteria for their anxiety disorder compared to only 13% of wait-list controls. Meta-analyses and RCTs have confirmed the efficacy of CBT in children with SAD, panic disorder, OCD, PTSD, school refusal, and separation anxiety disorder.
CBT has demonstrated efficacy in both group and individual formats, as well as in computer- or internet-based formats.
One commonly used pediatric CBT protocol is the “Coping Cat” program, which has demonstrated efficacy in RCTs and in long-term follow-up studies. In a RCT, Coping Cat CBT was as effective as pharmacotherapy with an SSRI, but less effective than combination therapy.
Additional specific psychological approaches that have demonstrated efficacy in treating anxiety in children and adolescents include: attention bias modification (ABM), MBCT, and social effectiveness therapy (SET) for SAD; ERP, family-based CBT, and meta-cognitive therapy for OCD; cognitive behavioral writing therapy (CBWT), spiritual-hypnosis assisted therapy (SHAT), emotion regulation therapy, exposure therapy, and EMDR for PTSD; and exposure therapy for specific phobias.
Approaches that include parental or family involvement may have some additional benefit over strategies that include children only, especially when parents suffer from an anxiety or related disorder themselves. Parental training only has also demonstrated beneficial effects on children with an anxiety disorder.
The presence of comorbidities may have a negative impact on the efficacy of CBT in pediatric patients. However, integrated CBT protocols designed to target both conditions have demonstrated efficacy in youths with anxiety and related disorders and comorbid ADHD, aggression, or comorbid SUD.
Long-term follow-up studies have shown sustained benefits of CBT over two to seven years posttreatment.
Pharmacological treatment
Complete treatment recommendations for the management of anxiety and related disorders in youths are beyond the scope of these guidelines and the reader is referred to specific guidelines for the assessment and treatment of children and adolescents with anxiety disorders, such as those developed by the American Academy of Child and Adolescent Psychiatry (AACAP).
For children and adolescents, psychological treatments are generally preferred over pharmacotherapy, or if warranted combination therapy may be an option. RCTs comparing combined pharmacological and psychological treatments in younger patients with anxiety have demonstrated efficacy equal or superior to either treatment alone. In the pediatric population, safety concerns associated with antidepressants (see “Safety Issues”) should be weighed against the potential benefits of therapy. Medication may be warranted in children and adolescents with severe impairment or those who are unlikely to respond to CBT due to cognitive or other issues. A “start low and go slow” approach is advised when using medications in this patient population.
The strength of evidence for pharmacotherapeutic agents in the treatment of pediatric patients is shown in Table 33. When pharmacotherapy is felt to be warranted, SSRIs are generally preferred for children and adolescents with anxiety and related disorders.
Antidepressants: SSRIs and TCAs have been well studied in pediatric patients with anxiety and related disorders (Table 33), although these agents should be used with caution in youths as discussed in the section on safety issues below. Most of the data in pediatric patients are in those with OCD or SAD.
There is good evidence for the efficacy of SSRIs in children and adolescents with OCD, including fluoxetine (Level 1), citalopram (Level 2), fluvoxamine (Level 2), paroxetine (Level 2), and sertraline (Level 2), as well as for the TCA clomipramine (Level 1).
Similarly, there is good evidence for the efficacy of SSRIs in SAD, including fluoxetine (Level 1), fluvoxamine (Level 2), paroxetine (Level 2), escitalopram (Level 3), and sertraline (Level 3), as well as for the SNRI venlafaxine XR (Level 2), and some evidence for mirtazapine (Level 3).
There is level 2 evidence for the efficacy of fluoxetine and fluvoxamine in separation anxiety disorder, and for fluoxetine, fluvoxamine, and sertraline in GAD. In school-refusing children and adolescents, a small case-series suggested benefit with citalopram (Level 4), and a RCT demonstrated that imipramine as an adjunct to CBT was more effective than CBT alone (Level 2).
In pediatric PTSD, sertraline alone or as an adjunct to CBT was not more effective than placebo or CBT (both Level 2, negative) and cannot be recommended at this time.
Benzodiazepines: There are little data demonstrating the efficacy of benzodiazepines in children and adolescents with anxiety and related disorders (Table 33). In fact, the few RCTs have demonstrated no significant improvements in anxiety symptoms with alprazolam over placebo in overanxious or avoidant disorders (Level 2, negative) or school-refusal (Level 2, negative), or with clonazepam in separation anxiety disorder (Level 2, negative). Benzodiazepines have limited utility in youths, although they may be useful for short-term therapy in specific situations where there is a need to achieve rapid reduction in severe anxiety symptoms to allow exposure-related psychotherapy (e.g., panic disorder, school refusal behavior).
Other treatments: In open trials in pediatric patients with treatment-resistant OCD, the atypical antipsychotic aripiprazole (Level 3) and the glutamate antagonist riluzole (Level 4) have demonstrated some efficacy.
Combination psychological and pharmacological therapies
The combination of sertraline and CBT was significantly superior to both monotherapies in a large RCT in pediatric patients with separation anxiety disorder, GAD, or SAD. In pediatric patients with OCD, the addition of CBT in those with a partial response to SSRIs resulted in significantly greater response rates compared with the SSRI alone, while the addition of d-cycloserine to CBT was not superior to placebo.
Alternative therapies
There is currently little evidence supporting the efficacy of exercise in reducing anxiety symptoms in pediatric populations, although some open data suggest it may have a small beneficial effect in pediatric PTSD.
Safety issues
An important consideration when using antidepressant medications in children and adolescents is the potential for an increased risk of suicidality. Clinicians should be aware of the potential activating side effects of SSRIs (insomnia, agitation, tremor, and anxiety), especially in young children. Regulatory bodies in many countries have issued black-box warnings about suicidal ideation/suicide attempts with the use of antidepressants in patients younger than 19 years. However, in a comprehensive analysis, the pooled absolute risk difference for suicidal thinking or behavior between SSRI- and placebo-treated youth with anxiety and related disorders was non-significant (0.5-0.7%), and lower than the risk for youth treated for MDD (0.9%). Anxiety and related disorders also increase the risk of suicidality — nearly eight times for suicidal ideation and six times for suicide attempts compared with not having an anxiety disorder. Therefore, risks and benefits of treatment should be discussed with both children and their parents.
The most common antidepressant adverse events are generally activation and vomiting in children, and somnolence in adolescents. More conservative dosing strategies may be needed especially in younger children or those with low body weight.
Summary
The management of anxiety and related disorders in children and adolescents can be challenging. Diagnostic evaluation of pediatric patients should use developmentally appropriate language and consider collateral information from parents and teachers. Children may express anxiety through crying, tantrums, freezing, or clinging, as well as through play. For children and adolescents, psychological therapies are generally preferred over pharmacotherapy, or if warranted combination therapy may be an option. Psychological therapies often need to be adapted to suit the chronological and developmental ages of young patients and to include parental involvement. When pharmacotherapy is warranted, SSRIs are generally preferred, although antidepressants should be used with caution in pediatric patients.
Epidemiology
The lifetime and 12-month prevalence of any anxiety or related disorder among those age 65 or older is estimated to be 13.6% and 7.0%, respectively, compared with 27.8% and 17.8% in the overall adult population. Including subthreshold anxiety increases the 12-month prevalence from about 6% to over 26% in older adults. The prevalence rates of anxiety and related disorders have generally been shown to decline with age, and as in younger age groups, the prevalence is higher in women than in men. The decline in prevalence may be related to age biases in the assessment of anxiety and the masking effect of other risk factors that increase with aging. Under-diagnosis is common, with one study finding that only 34% of older patients with GAD had previously had anxiety symptoms documented.
Among older adults (≥55 years) with mood or anxiety and related disorders, 60-70% do not use mental health care services, although use is higher among those with comorbid disorders. Older adults with anxiety and related disorders have higher rates of sleep disturbances and greater impairment in cognitive functioning compared to those without anxiety disorder. In addition, anxiety negatively impacts physical functioning and mobility, and health related QoL.
Comorbidities
Depression is among the most common comorbid disorders among older adults with anxiety and related disorders, and is associated with poorer outcomes of both disorders. Approximately 80% of adults ≥65 years of age have at least one chronic medical condition, and this may be even higher among those with anxiety disorders. Older patients with anxiety and related disorders report higher rates of diabetes, gastrointestinal conditions, and dementia.
Chronic urinary incontinence, hearing impairment, hypertension, respiratory disease, and poor sleep were associated with elevated rates of anxiety symptoms or disorders. Comorbid anxiety in patients with medical illnesses, particularly cardiovascular disease, has been associated with an increased risk of mortality. Furthermore, the relationship between anxiety and related disorders in the elderly and cognitive impairment remains largely neglected.
Diagnostic issues
The recognition and accurate diagnosis of anxiety and related disorders in older patients can be challenging. Modifications to the DSM-5 diagnostic criteria may assist clinicians in more accurately recognizing and diagnosing anxiety and related disorders in the elderly.
Older patients with anxiety often present differently than younger patients. Avoidance and excessive anxiety may be difficult to detect in older patients. Older adults may describe symptoms differently; for example, they may discuss concerns rather than worries. They are less likely to attribute symptoms to anxiety and related disorders, but rather may attribute them to physical illness and they may have difficulty remembering symptoms. Obtaining information from collateral sources may be useful. Assessing impact on work or social functioning may also be complicated by changes in responsibilities associated with aging (e.g., retirement). It may be helpful to ask about activities relevant to older adults, such as visiting grandchildren. Similarly, avoidance may be harder to detect because of limitations in physical mobility or visual problems, leading to a decline in activities outside the home.
Chronic medical illness or the use of medications can also complicate the diagnosis of anxiety and related disorders. Determining which came first, the physical illness or the anxiety symptoms can be helpful. However, when a medical illness is chronic, this precludes the likelihood that the anxiety would resolve when the medical condition resolves.
Late-onset anxiety and related disorders are relatively unusual, therefore older patients with new onset anxiety should be investigated for potential causative factors (e.g., physical illness, medication side effects).
Psychological treatment
Relaxation training, CBT, supportive therapy, and CT have support for the treatment of anxiety symptoms and disorders in older patients. Meta-analyses suggest the efficacy of psychological treatment is similar to that of pharmacotherapy for the treatment of anxiety and related disorders in older patients.
In meta-analyses, CBT was an effective option in reducing anxiety symptoms among older patients compared to wait-list or active controls. Some data suggest that CBT may be less effective for anxiety and related disorders in older patients than in working-age adults. Older patients may benefit from the inclusion of learning- and memory-aids with standard CBT. In RCTs in older patients, CBT demonstrated efficacy for the treatment of GAD and panic disorder. Exposure therapy, with or without CBT, demonstrated efficacy in case-controlled studies in patients with PTSD or specific phobias. CBT may also be effectively delivered via telephone, although improvements may not be long lasting.
In a case-control study, regular physical exercise reduced the risk of developing anxiety disorders among older adults.
Pharmacological treatment
Data suggest that pharmacotherapy including antidepressants or anticonvulsants is likely as effective in older adults as it is in younger patients. Most of the studies in older patients include those ≥60 or 65 years and have been conducted in patients with GAD or panic disorder.
The most robust data in elderly patients with GAD are from a large RCT (n=273), which demonstrated significant improvements and good tolerability with pregabalin compared with placebo. Pregabalin was also effective as adjunctive therapy in an open trial in older patients with comorbid GAD and depression.
Pooled analyses of subsets of older patients from multiple RCTs demonstrate that duloxetine and venlafaxine were effective for the treatment of GAD. Citalopram was effective in an eight-week RCT and in an open study over six months of treatment. Some data suggest that escitalopram may be useful in older patients with GAD; although in one RCT, response rates were not significantly different than placebo in the intention-to-treat analysis. Sertraline was more effective than CBT, particularly at a one-year follow-up assessment, and was as effective as buspirone in older adults with GAD.
In older patients with panic disorder, paroxetine was as effective as CBT and more effective than a wait-list control, and results were sustained at a six-month follow-up. Escitalopram and citalopram were equally effective in a small, open trial. A small, open trial also showed fluvoxamine to be effective in older patients with GAD, panic disorder, or OCD. Data in patients with MDD, suggest that mirtazapine may have beneficial anxiolytic effects in the elderly.
Data show that 45-60% of older patients (>55 years) with anxiety and related disorders are prescribed a benzodiazepine, which is higher than the rate of antidepressant use. The very high use of these agents is a cause for concern since they are not a preferred long-term treatment strategy and elderly patients may be more sensitive to their negative effects.
Safety issues
The elderly maybe more susceptible to adverse drug events and drug-drug interactions (DDIs) due to gradual age-related physiologic changes that affect the pharmacokinetic and pharmacodynamic properties of many medications. Factors which may alter drug metabolism and plasma concentrations among elderly patients include frailty, reduced homoeostatic mechanisms, and psychosocial issues. Age-related changes in body composition can result in increases or decreases of drug volume distribution, and hepatic or renal dysfunction can impair drug metabolism and drug clearance. All of these changes are highly variable in elderly patients, further complicating use of medications in this population. A review of the literature found that almost half of available antidepressants are associated with age-related clearance changes and identified at least 45 medications that could interact with specific antidepressants.
DDIs may be more common in older adults because of the greater number of concomitant medication they may be taking to treat multiple comorbid conditions. In one study of US community-dwelling older adults, almost 30% used at least five prescription medications, 80% used at least one prescription medication, and almost half used over-the-counter and dietary supplements.
Psychotropic medications have been associated with an increased risk of fractures. In a meta-analysis, the RR of fractures was 1.34 for benzodiazepines, 1.60 for antidepressants, 1.54 for anticonvulsants, and 1.59 for antipsychotics. In a prospective cohort study (The Rotterdam Study) of subjects over 55 years of age, the risk of non-vertebral fractures was 2.35 for current SSRI use versus non-use. The increased risk for hip fracture associated with benzodiazepines was further increased with increasing dose and the use of concomitant interacting drugs. There does not appear to be any difference between atypical antipsychotic agents in the increased risk of falls or fractures.
An increased mortality risk has been associated with the use antipsychotics in older patients with dementia, which appears to be greater with conventional compared to atypical antipsychotics.
Antidepressants are frequently used to treat symptoms of anxiety in older adults who suffer from comorbid medical conditions such as heart disease. In a meta-analysis of SSRIs versus placebo or no antidepressant therapy in patients with coronary heart disease (CHD) and depression, SSRIs were associated with lower rates of all-cause mortality and readmissions for CHD, indicating that treatment may improve CHD prognosis. Clinicians should weigh the risks associated with antidepressants against the potential benefits when making prescribing decisions.
Summary
While onset of anxiety and related disorders in late-life is uncommon, they do persist into older age and can have substantial impact on QoL and functionality. Older patients can present differently compared to younger patients, and diagnosis can be complicated by communication barriers, changes in role functioning, memory difficulties, and comorbid medical conditions.
Few treatment studies are conducted in older patients; however, data suggest that psychological treatment and pharmacotherapy appear to be similarly effective in older patients. Using pharmacotherapy in elderly patients can be challenging, and should consider patient factors such as body mass, hepatic and renal function, comorbid conditions, and use of concomitant medications.
Overview
Anxiety and related disorders often present together with other psychiatric or medical conditions. About 60-80% of patients with an anxiety disorder have at least one other comorbid psychiatric condition, which most commonly include another anxiety or related disorder, MDD, bipolar disorder, ADHD, and SUD. The presence of comorbid disorders has a negative impact on most aspects of care. Patients with psychiatric comorbidities have more severe symptoms, poorer treatment outcomes for both disorders, greater functional impairment, poorer QoL, and an increased risk of suicide.
Medical conditions and pain disorders are also common comorbidities in patients with anxiety and related disorders. Medical conditions frequently reported in patients with anxiety and related disorders include cardiovascular disease, gastrointestinal disease, arthritis, respiratory disease, thyroid disease, migraine, and allergic conditions. Patients with both anxiety disorders and medical conditions experience elevated disability, including more psychiatric comorbidity and depressive symptoms, as well as poorer interpersonal and physical functioning. Patients with chronically painful conditions such as arthritis, back pain, or migraine are at a two- to four-fold higher risk of having an anxiety or related disorder, particularly panic disorder or PTSD.
The high probability of comorbid disorders should be considered when diagnosing and treating patients with anxiety and related disorders. In patients with comorbid psychiatric conditions, such as another anxiety disorder or mood disorder, consider therapies that are effective for both disorders. Benzodiazepines should be prescribed with additional caution in patients with comorbid SUDs. In patients with comorbid medical conditions, the clinician must weigh the benefits and risks of medication for the anxiety or related disorder, but should also consider the impact of untreated anxiety.
Q. What is the prevalence and impact of comorbid MDD and anxiety/related disorders?
MDD is very common in patients with anxiety, being reported in 20-36% of patients; and conversely, about 60% of patients with MDD will have a comorbid anxiety or related disorder. In patients with anxiety, comorbid depression has been associated with more severe symptoms, lower likelihood of remission, greater functional impairment, an increased risk of suicide, and a greater risk of having another comorbid anxiety disorder. Similarly, in patients with MDD, comorbid anxiety and related disorders were associated with poorer treatment outcomes including higher recurrence rates, poorer QoL, and an increased risk of suicide.
Q. What pharmacological treatment may be useful for patients with an anxiety/related disorder and comorbid MDD?
Guidelines generally recommend antidepressants (most commonly SSRIs and SNRIs) as first-line treatments in patients with both anxiety and depressive symptoms. SSRIs and SNRIs in patients with anxiety and related disorders, including panic disorder, GAD, OCD, or PTSD, with comorbid MDD have been shown to be effective in improving both disorders. Among the atypical antipsychotics, quetiapine has been found to have efficacy as monotherapy in both MDD and GAD, as well as MDD with anxiety, while case series suggest that aripiprazole augmentation of antidepressants, and risperidone monotherapy may also reduce comorbid depressive and anxiety symptoms.
Q. What is the prevalence and impact of comorbid bipolar disorder or psychoses with anxiety/related disorders?
Among patients with anxiety and related disorders, almost 14% also met criteria for bipolar I or II disorder. However, among patients with bipolar disorder the rates of comorbid anxiety disorders are very high compared to the general population, and the DSM-5 notes anxiety disorders as the most common comorbidities in patients with bipolar disorder. In epidemiological surveys, the lifetime comorbidity rates for any anxiety or related disorder among patients with bipolar disorder was 52% in Canada and 60-75% in the US. In a clinic population, the rate of anxiety and related disorders was 22% in patients with bipolar disorder, compared to 17% in patients with schizophrenia, and 30% in those with schizoaffective disorder. A meta-analysis of prevalence studies found that the rates of various anxiety disorders in patients with schizophrenia and related psychotic disorders ranged from 10-15%.
Comorbid anxiety and related disorders in patients with bipolar disorder were associated with a greater risk of MDD and drug use disorders, a poorer bipolar course, lower QoL, and lower psychosocial functioning. Data are conflicting on the impact of anxiety and related disorders on suicidal tendencies in patients with bipolar disorder, with some analyses finding an increased risk, but not all. Similar findings have been reported in patients with schizophrenia, where comorbid anxiety and related disorders have been associated with more past SUDs, lower social adjustment and overall QoL, and greater suicidality.
Q. What pharmacological treatment may be useful for patients with an anxiety/related disorder and comorbid bipolar disorder or psychoses?
The management of patients with anxiety and related disorders and comorbid bipolar disorder, schizophrenia, or other psychosis should consider therapies that are effective for both disorders. Atypical antipsychotics are recommended treatments for bipolar disorder and schizophrenia, while the long-term use of antidepressants may destabilize patients with bipolar I disorder.
Data in patients with a diagnosed anxiety or related disorder and comorbid bipolar disorder or psychosis are limited. In a RCT, risperidone monotherapy was shown to be no more effective than placebo for patients with bipolar and comorbid panic disorder or GAD. However, in a single-blind trial, olanzapine or lamotrigine when added to lithium demonstrated improvements in anxiety disorder symptoms in patients with remitted bipolar disorder; and in an open trial, switching to aripiprazole significantly improved social anxiety and psychosis in patients with SAD and schizophrenia. In addition, atypical antipsychotics have demonstrated efficacy in RCTs in patients with anxiety and related disorders (see specific disorder sections for evidence), and data show that these agents can significantly reduce anxiety symptoms in patients with bipolar disorder. Taken together, these data suggest these agents may be useful in comorbid patients.
Anticonvulsants have also demonstrated efficacy in the treatment of some anxiety and related disorders (see specific disorder sections for evidence) and are often used for the treatment of bipolar disorder. In patients with bipolar disorder, adjunctive valproate and gabapentin have demonstrated efficacy for the treatment of panic disorder and resulted in reductions in anxiety symptoms.
Q. What is the prevalence of comorbid ADHD and anxiety/related disorders?
It is estimated that the lifetime rate of ADHD in children is 6-9%, with 70% persistence into adolescence and 50-60% into adulthood. In a community-based survey, the estimated prevalence of current self-reported adult ADHD was 4.4%. While ADHD has long been known to persist into adulthood, it has only recently become the focus of widespread clinical attention.
Of adults identified with ADHD in the National Comorbidity Survey-Replication (NCS-R), only one in 10 had received treatment within the previous year. Of these individuals, it is estimated that approximately 47% meet criteria for an anxiety or related disorder within 12 months of assessment, with the most common being SAD (29.3%), followed by specific phobia (22.7%), PTSD (11.9%), panic disorder (8.9%), and GAD (8.0%). Patients with an anxiety or related disorder were reportedly four times more likely to meet criteria for ADHD than the general population. Similar results were found in a Canadian survey of patients in an anxiety disorders clinic, where the rate of adult ADHD was 28%.
Q. What factors should be considered when treating patients with an anxiety/related disorder and comorbid ADHD?
When managing a patient with ADHD, it may be important to differentiate ADHD with anxious symptoms from comorbid ADHD and anxiety/related disorders. This can be challenging, as anxiety symptoms are frequently related to a sense of being overwhelmed or to compensatory skills in patients with ADHD. Stimulants may play a larger role in managing ADHD in patients with anxiety symptoms; however, in an open trial, atomoxetine improved ADHD and comorbid symptoms of depression and anxiety.
Treatment of patients with comorbid ADHD and an anxiety or related disorder may be more complicated. Generally, in patients with comorbid anxiety disorders and ADHD the diagnostic and treatment priority should be determined by the relative severity of symptoms and risks of each disorder. There are limited data on the role of stimulants in patients with ADHD and an anxiety disorder. In a RCT, atomoxetine significantly improved ADHD and SAD symptoms compared with placebo. In separate open trials, adjunctive atomoxetine and adjunctive extended release mixed amphetamine salts significantly improved anxiety symptoms in patients with ADHD and GAD refractory to antidepressants alone.
Q. What is the prevalence and impact of comorbid medical conditions and anxiety/related disorders?
Medical conditions are also common comorbidities that must be considered when prescribing medication for patients with anxiety and related disorders. Medical conditions are reported in over 60% of patients with anxiety and related disorders including cardiovascular diseases, gastrointestinal diseases, arthritis, respiratory diseases such as asthma, thyroid disease, migraine headaches, back pain, and allergic conditions. Comorbidities are particularly common among patients with GAD, panic disorder, and PTSD.
Patients with anxiety and related disorders and medical conditions experience more psychiatric comorbidity, depressive symptoms, and more severe anxiety disorder symptoms, as well as poorer interpersonal and physical functioning.
Q. What factors should be considered when treating patients with an anxiety/related disorder and comorbid chronic pain?
Chronically painful conditions (i.e., arthritis, back pain, and migraine) are commonly associated with anxiety. Patients with anxiety and related disorders are twice as likely to have painful physical symptoms compared to of those without, 45-60% versus 28%. About 60-70% of patients with anxiety disorders report migraine headaches.
For the management of anxiety and related disorders in patients with pain it may be helpful to consider treatments that have demonstrated efficacy in both anxiety disorders as well as pain. While there are few data available, duloxetine has demonstrated efficacy for both GAD and pain symptoms in RCTs. TCAs, and to a lesser extent SSRIs, have been shown to reduce headache attacks in patients with migraine, and provide moderate relief of neuropathic pain.
Q. What factors should be considered when treating patients with an anxiety/related disorder and comorbid cardiovascular disease?
Although panic attacks can sometimes be mistaken for cardiovascular symptoms, it is important to be aware that patients with anxiety and related disorders do have a two- to three-times greater risk of cardiovascular disease compared to the general population. In addition, anxiety disorders have been associated with increased risk of cardiovascular hospitalization rates and mortality risk. In patients with cardiovascular or cerebrovascular comorbidity, it is important to consider the impact of treatments used for anxiety on heart rate, blood pressure, and lipid measures.
Q. What factors should be considered when treating patients with an anxiety/related disorder and comorbid diabetes and metabolic syndrome?
Patients with anxiety symptoms have an elevated risk of type 2 diabetes. While glycemic measures do not appear to be affected by anxiety symptoms, some treatments, particularly some atypical antipsychotics, alter glucose parameters, lipid levels, and cause weight gain. Some antidepressants, including amitriptyline, mirtazapine, and paroxetine have also been associated with weight gain.
Additional authors
Martin M. Antony1, Stéphane Bouchard2, Alain Brunet3, Martine Flament4, Sophie Grigoriadis5, Sandra Mendlowitz6, Kieron O’Connor7, Kiran Rabheru4, Peggy M.A. Richter5, Melisa Robichaud8, John R. Walker9
1Department of Psychology, Ryerson University, Toronto, M5B 2K3, Canada; 2Department of Psychoeducation and Psychology, University of Québec in Outaouais, Gatineau, J9A 1L8, Canada; 3Department of Psychiatry, McGill University, Montreal, H3A 1A1, Canada; 4Department of Psychiatry, University of Ottawa, Ottawa, K1Z 7K4, Canada; 5Department of Psychiatry, University of Toronto, Toronto, M5S 1A1, Canada; 6Department of Child Psychiatry, University of Toronto, Toronto, M5S 1A1, Canada; 7Department of Psychiatry, University of Montreal, Montreal, H3C 3J7, Canada; 8Departments of Psychiatry and Psychology, University of British Columbia, Vancouver, V6T 2A1, Canada; 9Department of Clinical Health Psychology, University of Manitoba, Winnipeg, R3E 3N4, Canada
Email: Martin M. Antony - mantony@psych.ryerson.ca; Stéphane Bouchard - stephane.bouchard@uqo.ca; Alain Brunet - alain.brunet@mcgill.ca; Martine Flament - martine.flament@theroyal.ca; Sophie Grigoriadis - sophie.grigoriaidis@sunnybrook.ca; Sandra Mendlowitz - sandra.mendlowitz@sickkids.on.ca; Kieron O’Connor - kieron.oconnor@umontreal.ca; Kiran Rabheru - kiranrabheru@hotmail.com; Peggy M.A. Richter - peggy.richter@sunnybrook.ca; Melisa Robichaud - robichau@mail.ubc.ca; John R. Walker - jwalker@cc.umanitoba.ca
Additional contributors to the comorbidity section
Gordon Asmundson10, Larry J. Klassen11, Raymond W. Lam12, Roger S. McIntyre13, Isaac Szpindel14
10Department of Psychology, University of Regina, Regina, S4S 0A2, Canada; 11Department of Psychiatry, Faculty of Medicine, University of Manitoba, Winnipeg, R3T 2N2, Canada; 12Department of Psychiatry, University of British Columbia, Vancouver, V6T 2A1, Canada; 13Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, M5S 1A1, Canada; 14Attention and Learning Related Disorders, START Clinic, Toronto, M4W 2N4, Canada
Email: Gordon Asmundson - gordon.asmundson@uregina.ca; Larry J. Klassen - larryjklassen@hotmail.com; Raymond W. Lam - r.lam@ubc.ca; Roger S. McIntyre - roger.mcintyre@uhn.ca; Isaac Szpindel - iszpindel@startclinic.ca
List of abbreviations used
AACAP: American Academy of Child and Adolescent Psychiatry; ABM: attention bias modification; ACOG: American Congress of Obstetricians and Gynecologists; ADHD: attention-deficit/hyperactivity disorder; APA: American Psychiatric Association; ASD: acute stress disorder; B-I-I: blood-injection-injury; BPD: borderline personality disorder; CBT: cognitive behavioral therapy; CBWT: cognitive behavioral writing therapy; CCHS: Canadian Community Health Survey; CHD: coronary heart disease; CPT: cognitive processing therapy; CR: controlled release; DBT: dialectical behavioral therapy; DDI: drug-drug interactions; DIRT: danger ideation reduction therapy; DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition; EMDR: eye movement desensitization and reprocessing; ERP: exposure with response prevention; FDA: Food and Drug Administration; GAD: generalized anxiety disorder; HARS: Hamilton Anxiety Rating Scale; HDL: high-density lipoprotein; ICBT: internet-based CBT; IPT: interpersonal therapy; IV: intravenous; LDL: low-density lipoprotein; MAOI: monoamine oxidase inhibitor; MBCT: mindfulness-based cognitive therapy; MBT: mindfulness-based therapy; MDD: major depressive disorder; Mini-SPIN: Mini-Social Phobia Inventory; MRI: magnetic resonance imaging; N/A: not available; NaSSA: noradrenergic and specific serotonergic antidepressant; NCS-A: National Comorbidity Survey – Adolescent supplement; NCS-R: National Comorbidity Survey – Replication; NMDA: N-methyl-D-aspartate; NNT: number needed to treat; NPPO-REAC: neuro psycho physical optimization-radio electric asymmetric conveyor; NSAID: nonsteroidal anti-inflammatory drug; OCD: obsessive-compulsive disorder; ODT: orally disintegrating tablet; PNAS: poor neonatal adaptation syndrome; PTSD: posttraumatic stress disorder; QoL: quality of life; RCT: randomized controlled trial; REAC: radioelectric asymmetric conveyor; RIMA: reversible inhibitors of monoamine oxidase A; RR: relative risk; rTMS: repetitive transcranial magnetic stimulation; SAD: social anxiety disorder; SET: social effectiveness therapy; SHAT: spiritual-hypnosis assisted therapy; SNRI: serotonin–norepinephrine reuptake inhibitor; SR: sustained release; SSRI: selective serotonin reuptake inhibitor; SUD: substance use disorder; TC: total cholesterol; TCA: tricyclic antidepressant; TF-CBT: trauma-focused-CBT; TG: triglycerides; vLDL: very-low-density lipoprotein; VRE: virtual reality exposure; XL: extended release; XR: extended release; Y-BOCS: Yale-Brown Obsessive Compulsive Scale.
Competing interests
Unrestricted educational grants for the development of these guidelines were provided by Astra Zeneca Canada, Eli-Lilly Canada, Janssen Inc., Lundbeck Canada, Pfizer Canada, Purdue Canada, Servier Canada Inc., Shire Canada, and Valeant Canada. None of the members received payment for participating in the development of these guidelines.
The following authors do not have any competing interests to declare: AB, GA, JRW, KO, MMA, MF, LK, MR, SM.
Advisory board/speaker's bureau: Astra Zeneca (KK, KR, MK, P. Bleau, P. Blier, RWL, RSM), Biovail (RWL), Boehringer Ingelheim (MK), BMS (KK, KR, MK, P. Bleau, P. Blier, PC, RWL, RSM), Canadian Institutes of Health Research (CIHR) (RWL), Canadian Network for Mood and Anxiety Treatments (CANMAT) (RWL), Canadian Psychiatric Association (CPA) Foundation (RWL), Eli Lilly Canada (MK, P. Bleau, P. Blier, PC, SG, RWL, RSM, IS), France Foundation (RSM), GlaxoSmithKline (MK, P. Blier, RSM, SG), Janssen Ortho (KK, MK, P. Blier, PC, RSM), Labopharm (P. Blier), Litebook Company (RWL), Lundbeck (KK, KR, MK, P. Bleau, P. Blier, PC, RWL, RSM, SG), Lundbeck Institute (RWL), Organon (MK, RSM), Merck (P. Blier, RSM), Mochida (RWL), Otsuka (KK), Pfizer (P. Bleau, P. Blier, PC, RWL, RSM, SG), Pierre Fabre (P. Blier), Purdue (IS), Servier (P. Blier, RWL, SG), Shire (MK, RSM, IS), Solvay (MK), St. Jude's Medical (RWL), Sunovion (KK, P. Blier), Takeda (P. Blier, RWL), UBC Institute of Mental Health/Coast Capital Savings (RWL), Valeant (P. Blier, IS), Wyeth (P. Bleau, MK, SG)
Consultation fees: AstraZeneca (MK), BMS (MK), Boehringer Ingelheim (MK), Clinique et Développement In Virtuo Inc. (SB), Eli Lilly Canada (MK, SG), GlaxoSmithKline (MK, SG), Janssen Ortho (MK), Lundbeck (MK, PR, SG), Organon (MK), Pfizer (SG), Servier (SG), Shire (MK), Solvay (MK), Wyeth (MK, SG)
Educational support: Astra Zeneca (RSM), BMS (RSM), CME Outfitters (RSM), Eli Lilly Canada (RSM, IS), France Foundation (RSM), I3CME (RSM), Merck (RSM), Optum Health (RSM), Pfizer (RSM), Physicians' Postgraduate Press (RSM), Shire (IS)
Research grants/clinical trial funding: AstraZeneca (KK, MK, P. Bleau, RSM, RWL), Biovail (RWL), BMS (KK, P. Bleau, RWL), Canadian Foundation for Innovation (MK), Canadian Institutes of Health Research (CIHR) (MK, RWL, SG), Canadian Network for Mood and Anxiety Treatments (CANMAT) (RWL), Canadian Psychiatric Association (CPA) Foundation (MK, RWL), Centre for Addiction and Mental Health Foundation (MK), CR Younger Foundation (SG), Eli Lilly Canada (MK, P. Bleau, PR, RSM, RWL), Genuine Health (MK), GlaxoSmithKline (MK), Janssen Ortho (MK, RSM), Litebook Company (RWL), Lundbeck (KK, MK, P. Bleau, RSM, RWL), Lundbeck Institute (RWL), Mochida (RWL), National Alliance for Research on Schizophrenia and Depression (NARSAD) (RSM), National Institutes of Mental Health (NIMH) (RSM), Ontario Ministry of Health (SG), Ontario Mental Health Foundation (SG), Organon (MK), Pfizer (P. Bleau, RSM, RWL), Roche (PR), Servier (RWL), Sick Kids Foundation (MK), Solvay (MK), St. Jude's Medical (RWL), Shire (MK, RSM), Stanley Medical Research Institute (RSM), Takeda (RWL), UBC Institute of Mental Health/Coast Capital Savings (RWL), Wyeth (MK, P. Bleau)
Unrestricted grants: Astra Zeneca Canada (MK), Eli Lilly Canada (MK), Janssen Inc. (MK), Lundbeck Canada (MK), Pfizer (MK), Purdue Pharma (MK), Servier Canada (MK), Shire Canada (MK), Valeant Canada (MK)
Reimbursements, fees, funding, or salary: In the past five years, MVA received reimbursements, fees, funding, or salary from: Astra Zeneca, Biovail, Canadian Foundation for Innovation (CFI), Cephalon, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Hamilton Academic Health Sciences Organization (HAHSO) Innovation Grant (AFP Innovation Grant), Janssen Ortho, Labo Pharm, Lundbeck, National Institutes of Health (NIH), Novartis, Pfizer Inc., Servier, Shire, Sunovion, Valeant, Wyeth-Ayerst
Stock/share ownership: Clinique et Développement In Virtuo Inc. (SB)
Authors’ contributions
We thank all co-authors for their considerable expertise in generating these guidelines. Authors who were members of the executive committee (MK, PB, PB, PC, KK, MVA) took part in teleconferences and a meeting in December 2012 to reach consensus on the strength of evidence and treatment recommendations. Draft guidelines were then developed by the core committee and revised by all co-authors. The entire content was subsequently circulated to all members of the Canadian Anxiety Guidelines Initiative Group for additional comments and approval during 2013. GA, LJK, RWL, RSM, and IS provided additional reviews of the comorbidity section. The final manuscript was then circulated to external reviewers (MP, DS, LDM) and revisions were made based on input from the core committee.
References 1448
- 1.
Kessler RC Angermeyer M Anthony JC R DG Demyttenaere K Gasquet I G DG Gluzman S Gureje O Haro JM Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey InitiativeWorld Psychiatry2007 6168176
Not in our library
- 2.
Kessler RC Berglund P Demler O Jin R Merikangas KR Walters EE Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey ReplicationArch Gen Psychiatry2005 62593602
Not in our library10.1001/archpsyc.62.6.593 (opens in a new tab)
- 3.
Kessler RC Chiu WT Demler O Merikangas KR Walters EE Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey ReplicationArch Gen Psychiatry2005 62617627
Not in our library10.1001/archpsyc.62.6.617 (opens in a new tab)
- 4.
Somers JM Goldner EM Waraich P Hsu L Prevalence and incidence studies of anxiety disorders: a systematic review of the literatureCan J Psychiatry2006 51100113
Not in our library10.1177/070674370605100206 (opens in a new tab)
- 5.
Martin-Merino E Ruigomez A Wallander MA Johansson S Garcia-Rodriguez LA Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary careFam Pract2010 27916
Not in our library10.1093/fampra/cmp071 (opens in a new tab)
- 6.
Vermani M Marcus M Katzman MA Rates of detection of mood and anxiety disorders in primary care: a descriptive, cross-sectional studyPrim Care Companion CNS Disord2011 13doi 10.4088/PCC.4010m01013
Not in our library10.4088/pcc.10m01013 (opens in a new tab)
- 7.
Kroenke K Spitzer RL Williams JB Monahan PO Lowe B Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detectionAnn Intern Med2007 146317325
Not in our library10.7326/0003-4819-146-5-200703060-00004 (opens in a new tab)
- 8.
Weisberg RB Dyck I Culpepper L Keller MB Psychiatric treatment in primary care patients with anxiety disorders: a comparison of care received from primary care providers and psychiatristsAm J Psychiatry2007 164276282
Not in our library10.1176/appi.ajp.164.2.276 (opens in a new tab)
- 9.
McLean CP Asnaani A Litz BT Hofmann SG Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illnessJ Psychiatr Res2011 4510271035
Not in our library10.1016/j.jpsychires.2011.03.006 (opens in a new tab)
- 10.
Stein M Fuetsch M Muller N Hofler M Lieb R Wittchen H Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adultsArch Gen Psychiatry2001 58251256
Not in our library10.1001/archpsyc.58.3.251 (opens in a new tab)
- 11.
Pine DS Cohen P Gurley D Brook J Ma Y The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disordersArch Gen Psychiatry1998 555664
Not in our library10.1001/archpsyc.55.1.56 (opens in a new tab)
- 12.
Wittchen HU Kessler RC Pfister H Lieb M Why do people with anxiety disorders become depressed? A prospective-longitudinal community studyActa Psychiatr Scand Suppl2000 1423
Not in our library
- 13.
Senaratne R Van Ameringen M Mancini C Patterson B The burden of anxiety disorders on the familyJ Nerv Ment Dis2010 198876880
Not in our library10.1097/nmd.0b013e3181fe7450 (opens in a new tab)
- 14.
Erickson SR Guthrie S Vanetten-Lee M Himle J Hoffman J Santos SF Janeck AS Zivin K Abelson JL Severity of anxiety and work-related outcomes of patients with anxiety disordersDepress Anxiety2009 2611651171
Not in our library10.1002/da.20624 (opens in a new tab)
- 15.
Sherbourne CD Sullivan G Craske MG Roy-Byrne P Golinelli D Rose RD Chavira DA Bystritsky A Stein MB Functioning and disability levels in primary care out-patients with one or more anxiety disordersPsychol Med2010 4020592068
Not in our library10.1017/s0033291710000176 (opens in a new tab)
- 16.
Comer JS Blanco C Hasin DS Liu SM Grant BF Turner JB Olfson M Health-related quality of life across the anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions (NESARC)J Clin Psychiatry2011 724350
Not in our library10.4088/jcp.09m05094blu (opens in a new tab)
- 17.
Barrera TL Norton PJ Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorderJ Anxiety Disord2009 2310861090
Not in our library10.1016/j.janxdis.2009.07.011 (opens in a new tab)
- 18.
Wittchen HU Generalized anxiety disorder: prevalence, burden, and cost to societyDepress Anxiety2002 16162171
Not in our library10.1002/da.10065 (opens in a new tab)
- 19.
Waghorn G Chant D White P Whiteford H Disability, employment and work performance among people with ICD-10 anxiety disordersAust N Z J Psychiatry2005 395566
Not in our library10.1080/j.1440-1614.2005.01510.x (opens in a new tab)
- 20.
Nepon J Belik SL Bolton J Sareen J The relationship between anxiety disorders and suicide attempts: findings from the National Epidemiologic Survey on Alcohol and Related ConditionsDepress Anxiety2010 27791798
Not in our library10.1002/da.20674 (opens in a new tab)
- 21.
Bolton JM Cox BJ Afifi TO Enns MW Bienvenu OJ Sareen J Anxiety disorders and risk for suicide attempts: findings from the Baltimore Epidemiologic Catchment area follow-up studyDepress Anxiety2008 25477481
Not in our library10.1002/da.20314 (opens in a new tab)
- 22.
Sareen J Cox BJ Afifi TO de Graaf R Asmundson GJ ten Have M Stein MB Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adultsArch Gen Psychiatry2005 6212491257
Not in our library10.1001/archpsyc.62.11.1249 (opens in a new tab)
- 23.
Cougle JR Keough ME Riccardi CJ Sachs-Ericsson N Anxiety disorders and suicidality in the National Comorbidity Survey-ReplicationJ Psychiatr Res2009 43825829
Not in our library10.1016/j.jpsychires.2008.12.004 (opens in a new tab)
- 24.
Pfeiffer PN Ganoczy D Ilgen M Zivin K Valenstein M Comorbid anxiety as a suicide risk factor among depressed veteransDepress Anxiety2009 26752757
Not in our library10.1002/da.20583 (opens in a new tab)
- 25.
Schaffer A Levitt A Bagby R Kennedy S Levitan R Joffe R Suicidal ideation in major depression: sex differences and impact of comorbid anxietyCan J Psychiatry2000 45822826
Not in our library10.1177/070674370004500906 (opens in a new tab)
- 26.
American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders (DSM-5)2013 FifthWashington, DC: American Psychiatric Association
Not in our library
- 27.
Van Ameringen M Pollack M Generalized Anxiety Disorder (Oxford Psychiatry Library)2010 New York, NY: Oxford University Press
Not in our library
- 28.
Connor K Kobak K Churchill L Katzelnick D Davidson J Mini-SPIN: A brief screening assessment for generalized social anxiety disorderDepress Anxiety2001 14137140
Not in our library10.1002/da.1055 (opens in a new tab)
- 29.
Mancini C Van Ameringen M Pipe B Oakman J Development and validation of self-report psychiatric screening tool: MACSCREEN [poster]Anxiety Disorders Association of America 23rd Annual Conference; March 27-30; Toronto, Canada2003
Not in our library
- 30.
Van Ameringen M Mancini C Simpson W Patterson B Potential use of Internet-based screening for anxiety disorders: a pilot studyDepress Anxiety2010 2710061010
Not in our library10.1002/da.20723 (opens in a new tab)
- 31.
Ballenger J Davidson J Lecrubier Y Nutt D Borkovec T Rickels K Stein D Wittchen H Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and AnxietyJ Clin Psychiatry2001 62Suppl 115358
Not in our library
- 32.
Swinson R Antony M Bleau P Chokka P Craven M Fallu A Kjernisted K Lanius R Manassis K McIntosh D Clinical practice guidelines. Management of anxiety disordersCan J Psychiatry2006 519S91S
Not in our library
- 33.
Milne BJ Caspi A Harrington H Poulton R Rutter M Moffitt TE Predictive value of family history on severity of illness: the case for depression, anxiety, alcohol dependence, and drug dependenceArch Gen Psychiatry2009 66738747
Not in our library10.1001/archgenpsychiatry.2009.55 (opens in a new tab)
- 34.
Batelaan NM Smit F de Graaf R van Balkom AJ Vollebergh WA Beekman AT Identifying target groups for the prevention of anxiety disorders in the general populationActa Psychiatr Scand2010 1225665
Not in our library10.1111/j.1600-0447.2009.01488.x (opens in a new tab)
- 35.
Karsten J Hartman CA Smit JH Zitman FG Beekman AT Cuijpers P van der Does AJ Ormel J Nolen WA Penninx BW Psychiatric history and subthreshold symptoms as predictors of the occurrence of depressive or anxiety disorder within 2 yearsBr J Psychiatry2011 198206212
Not in our library10.1192/bjp.bp.110.080572 (opens in a new tab)
- 36.
McLaughlin KA Hatzenbuehler ML Stressful life events, anxiety sensitivity, and internalizing symptoms in adolescentsJ Abnorm Psychol2009 118659669
Not in our library10.1037/a0016499 (opens in a new tab)
- 37.
Chu DA Williams LM Harris AW Bryant RA Gatt JM Early life trauma predicts self-reported levels of depressive and anxiety symptoms in nonclinical community adults: Relative contributions of early life stressor types and adult trauma exposureJ Psychiatr Res2013 472332
Not in our library10.1016/j.jpsychires.2012.08.006 (opens in a new tab)
- 38.
Flensborg-Madsen T Tolstrup J Sorensen HJ Mortensen EL Social and psychological predictors of onset of anxiety disorders: results from a large prospective cohort studySoc Psychiatry Psychiatr Epidemiol2012 47711721
Not in our library10.1007/s00127-011-0373-9 (opens in a new tab)
- 39.
Heider D Matschinger H Bernert S Alonso J Brugha TS Bruffaerts R de Girolamo G Dietrich S Angermeyer MC Adverse parenting as a risk factor in the occurrence of anxiety disorders: a study in six European countriesSoc Psychiatry Psychiatr Epidemiol2008 43266272
Not in our library10.1007/s00127-007-0302-0 (opens in a new tab)
- 40.
Strine TW Mokdad AH Balluz LS Gonzalez O Crider R Berry JT Kroenke K Depression and anxiety in the United States: findings from the 2006 Behavioral Risk Factor Surveillance SystemPsychiatr Serv2008 5913831390
Not in our library10.1176/ps.2008.59.12.1383 (opens in a new tab)
- 41.
Kagan J Snidman N Early childhood predictors of adult anxiety disordersBiol Psychiatry1999 4615361541
Not in our library10.1016/s0006-3223(99)00137-7 (opens in a new tab)
- 42.
Muris P van Brakel AM Arntz A Schouten E Behavioral inhibition as a risk factor for the development of childhood anxiety disorders: A longitudinal studyJ Child Fam Stud2011 20157170
Not in our library10.1007/s10826-010-9365-8 (opens in a new tab)
- 43.
Schaffer A Cairney J Cheung A Veldhuizen S Levitt A Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristicsCan J Psychiatry2006 51916
Not in our library10.1177/070674370605100104 (opens in a new tab)
- 44.
Kessler RC Berglund P Demler O Jin R Koretz D Merikangas KR Rush AJ Walters EE Wang PS The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)JAMA2003 28930953105
Not in our library10.1001/jama.289.23.3095 (opens in a new tab)
- 45.
Kessler RC Adler L Barkley R Biederman J Conners CK Demler O Faraone SV Greenhill LL Howes MJ Secnik K The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey ReplicationAm J Psychiatry2006 163716723
Not in our library10.1176/appi.ajp.163.4.716 (opens in a new tab)
- 46.
Klein Hofmeijer-Sevink M Batelaan NM van Megen HJ Penninx BW Cath DC van den Hout MA van Balkom AJ Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA)J Affect Disord2012 137106112
Not in our library10.1016/j.jad.2011.12.008 (opens in a new tab)
- 47.
Bruce S Machan J Dyck I Keller M Infrequency of "pure" GAD: impact of psychiatric comorbidity on clinical courseDepress Anxiety2001 14219225
Not in our library10.1002/da.1070 (opens in a new tab)
- 48.
Shankman S Klein D The impact of comorbid anxiety disorders on the course of dysthymic disorder: a 5-year prospective longitudinal studyJ Affect Disord2002 70211217
Not in our library10.1016/s0165-0327(01)00302-0 (opens in a new tab)
- 49.
Boylan K Bieling P Marriott M Begin H Young L MacQueen G Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorderJ Clin Psychiatry2004 6511061113
Not in our library10.4088/jcp.v65n0813 (opens in a new tab)
- 50.
Mackenzie CS Reynolds K Cairney J Streiner DL Sareen J Disorder-specific mental health service use for mood and anxiety disorders: associations with age, sex, and psychiatric comorbidityDepress Anxiety2012 29234242
Not in our library10.1002/da.20911 (opens in a new tab)
- 51.
McLaughlin T Geissler E Wan G Comorbidities and associated treatment charges in patients with anxiety disordersPharmacotherapy2003 2312511256
Not in our library10.1592/phco.23.12.1251.32700 (opens in a new tab)
- 52.
Sareen J Jacobi F Cox BJ Belik SL Clara I Stein MB Disability and poor quality of life associated with comorbid anxiety disorders and physical conditionsArch Intern Med2006 16621092116
Not in our library10.1001/archinte.166.19.2109 (opens in a new tab)
- 53.
Yatham LN Kennedy SH Schaffer A Parikh SV Beaulieu S O'Donovan C MacQueen G McIntyre RS Sharma V Ravindran A Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009Bipolar Disord2009 11225255
Not in our library10.1111/j.1399-5618.2009.00672.x (opens in a new tab)
- 54.
van Balkom AJ Bakker A Spinhoven P Blaauw BM Smeenk S Ruesink B A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatmentsJ Nerv Ment Dis1997 185510516
Not in our library10.1097/00005053-199708000-00006 (opens in a new tab)
- 55.
Siev J Chambless DL Specificity of treatment effects: cognitive therapy and relaxation for generalized anxiety and panic disordersJ Consult Clin Psychol2007 75513522
Not in our library10.1037/0022-006x.75.4.513 (opens in a new tab)
- 56.
Sanchez-Meca J Rosa-Alcazar AI Marin-Martinez F Gomez-Conesa A Psychological treatment of panic disorder with or without agoraphobia: a meta-analysisClin Psychol Rev2010 303750
Not in our library10.1016/j.cpr.2009.08.011 (opens in a new tab)
- 57.
Wolitzky-Taylor KB Horowitz JD Powers MB Telch MJ Psychological approaches in the treatment of specific phobias: a meta-analysisClin Psychol Rev2008 2810211037
Not in our library10.1016/j.cpr.2008.02.007 (opens in a new tab)
- 58.
Fedoroff I Taylor S Psychological and pharmacological treatments of social phobia: a meta-analysisJ Clin Psychopharmacol2001 21311324
Not in our library10.1097/00004714-200106000-00011 (opens in a new tab)
- 59.
Acarturk C Cuijpers P van Straten A de Graaf R Psychological treatment of social anxiety disorder: a meta-analysisPsychol Med2009 39241254
Not in our library10.1017/s0033291708003590 (opens in a new tab)
- 60.
Rosa-Alcazar AI Sanchez-Meca J Gomez-Conesa A Marin-Martinez F Psychological treatment of obsessive-compulsive disorder: a meta-analysisClin Psychol Rev2008 2813101325
Not in our library10.1016/j.cpr.2008.07.001 (opens in a new tab)
- 61.
Jonsson H Hougaard E Group cognitive behavioural therapy for obsessive-compulsive disorder: a systematic review and meta-analysisActa Psychiatr Scand2009 11998106
Not in our library10.1111/j.1600-0447.2008.01270.x (opens in a new tab)
- 62.
Gava I Barbui C Aguglia E Carlino D Churchill R De Vanna M McGuire HF Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD)Cochrane Database Syst Rev2007 CD005333
Not in our library10.1002/14651858.cd005333.pub2 (opens in a new tab)
- 63.
Ougrin D Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysisBMC Psychiatry2011 11200
Not in our library10.1186/1471-244x-11-200 (opens in a new tab)
- 64.
Borkovec T Ruscio A Psychotherapy for generalized anxiety disorderJ Clin Psychiatry2001 62Suppl 113742discussion 43-35
Not in our library
- 65.
Hunot V Churchill R Silva de Lima M Teixeira V Psychological therapies for generalised anxiety disorderCochrane Database Syst Rev2007 CD001848
Not in our library10.1002/14651858.cd001848.pub4 (opens in a new tab)
- 66.
Bisson J Andrew M Psychological treatment of post-traumatic stress disorder (PTSD)Cochrane Database Syst Rev2007 CD003388
Not in our library10.1002/14651858.cd003388.pub3 (opens in a new tab)
- 67.
Bisson JI Ehlers A Matthews R Pilling S Richards D Turner S Psychological treatments for chronic post-traumatic stress disorder. Systematic review and meta-analysisBr J Psychiatry2007 19097104
Not in our library10.1192/bjp.bp.106.021402 (opens in a new tab)
- 68.
Seidler GH Wagner FE Comparing the efficacy of EMDR and trauma-focused cognitive-behavioral therapy in the treatment of PTSD: a meta-analytic studyPsychol Med2006 3615151522
Not in our library10.1017/s0033291706007963 (opens in a new tab)
- 69.
Powers MB Halpern JM Ferenschak MP Gillihan SJ Foa EB A meta-analytic review of prolonged exposure for posttraumatic stress disorderClin Psychol Rev2010 30635641
Not in our library10.1016/j.cpr.2010.04.007 (opens in a new tab)
- 70.
Hofmann SG Smits JA Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trialsJ Clin Psychiatry2008 69621632
Not in our library10.4088/jcp.v69n0415 (opens in a new tab)
- 71.
Roshanaei-Moghaddam B Pauly MC Atkins DC Baldwin SA Stein MB Roy-Byrne P Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety?Depress Anxiety2011 28560567
Not in our library10.1002/da.20829 (opens in a new tab)
- 72.
Hofmann SG Sawyer AT Witt AA Oh D The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic reviewJ Consult Clin Psychol2010 78169183
Not in our library10.1037/a0018555 (opens in a new tab)
- 73.
Boschen MJ Oei TP A cognitive behavioral case formulation framework for treatment planning in anxiety disordersDepress Anxiety2008 25811823
Not in our library10.1002/da.20301 (opens in a new tab)
- 74.
Coull G Morris PG The clinical effectiveness of CBT-based guided self-help interventions for anxiety and depressive disorders: a systematic reviewPsychol Med2011 4122392252
Not in our library10.1017/s0033291711000900 (opens in a new tab)
- 75.
Lewis C Pearce J Bisson JI Efficacy, cost-effectiveness and acceptability of self-help interventions for anxiety disorders: systematic reviewBr J Psychiatry2012 2001521
Not in our library10.1192/bjp.bp.110.084756 (opens in a new tab)
- 76.
Lucock M Padgett K Noble R Westley A Atha C Horsefield C Leach C Controlled clinical trial of a self-help for anxiety intervention for patients waiting for psychological therapyBehav Cog Psychother2008 36541551
Not in our library
- 77.
Craske MG Rose RD Lang A Welch SS Campbell-Sills L Sullivan G Sherbourne C Bystritsky A Stein MB Roy-Byrne PP Computer-assisted delivery of cognitive behavioral therapy for anxiety disorders in primary-care settingsDepress Anxiety2009 26235242
Not in our library10.1002/da.20542 (opens in a new tab)
- 78.
Cavanagh K Seccombe N Lidbetter N The implementation of computerized cognitive behavioural therapies in a service user-led, third sector self help clinicBehav Cogn Psychother2011 39427442
Not in our library10.1017/s1352465810000858 (opens in a new tab)
- 79.
Titov N Andrews G Johnston L Robinson E Spence J Transdiagnostic Internet treatment for anxiety disorders: a randomized controlled trialBehav Res Ther2010 48890899
Not in our library10.1016/j.brat.2010.05.014 (opens in a new tab)
- 80.
Opris D Pintea S Garcia-Palacios A Botella C Szamoskozi S David D Virtual reality exposure therapy in anxiety disorders: a quantitative meta-analysisDepress Anxiety2012 298593
Not in our library10.1002/da.20910 (opens in a new tab)
- 81.
Powers MB Emmelkamp PM Virtual reality exposure therapy for anxiety disorders: a meta-analysisJ Anxiety Disord2008 22561569
Not in our library10.1016/j.janxdis.2007.04.006 (opens in a new tab)
- 82.
Bandelow B Seidler-Brandler U Becker A Wedekind D Ruther E Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disordersWorld J Biol Psychiatry2007 8175187
Not in our library10.1080/15622970601110273 (opens in a new tab)
- 83.
Hofmann SG Sawyer AT Korte KJ Smits JA Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? a meta-analytic reviewInt J Cogn Ther2009 2160175
Not in our library10.1521/ijct.2009.2.2.160 (opens in a new tab)
- 84.
Drug product databasehttp://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp
Not in our library
- 85.
Practice guideline for the treatment of patients with panic disorderhttp://psychiatryonline.org/content.aspx?bookid=28§ionid=1680635
Not in our library
- 86.
Brambilla P Cipriani A Hotopf M Barbui C Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial dataPharmacopsychiatry2005 386977
Not in our library10.1055/s-2005-837806 (opens in a new tab)
- 87.
Hu X Bull S Hunkeler E Ming E Lee J Fireman B Markson L Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimateJ Clin Psychiatry2004 65959965
Not in our library10.4088/jcp.v65n0712 (opens in a new tab)
- 88.
Cascade E Kalali AH Kennedy SH Real-world data on SSRI antidepressant side effectsPsychiatry (Edgmont)2009 61618
Not in our library
- 89.
Hirschfeld R Long-term side effects of SSRIs: sexual dysfunction and weight gainJ Clin Psychiatry2003 64Suppl 182024
Not in our library
- 90.
Dall M Schaffalitzky de Muckadell OB Lassen AT Hansen JM Hallas J An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleedingClin Gastroenterol Hepatol2009 713141321
Not in our library10.1016/j.cgh.2009.08.019 (opens in a new tab)
- 91.
de Abajo FJ Garcia-Rodriguez LA Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agentsArch Gen Psychiatry2008 65795803
Not in our library10.1001/archpsyc.65.7.795 (opens in a new tab)
- 92.
Haney EM Chan BK Diem SJ Ensrud KE Cauley JA Barrett-Connor E Orwoll E Bliziotes MM Association of low bone mineral density with selective serotonin reuptake inhibitor use by older menArch Intern Med2007 16712461251
Not in our library10.1001/archinte.167.12.1246 (opens in a new tab)
- 93.
Williams LJ Henry MJ Berk M Dodd S Jacka FN Kotowicz MA Nicholson GC Pasco JA Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depressionInt Clin Psychopharmacol2008 238487
Not in our library10.1097/yic.0b013e3282f2b3bb (opens in a new tab)
- 94.
Eom CS Lee HK Ye S Park SM Cho KH Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysisJ Bone Miner Res2012 2711861195
Not in our library10.1002/jbmr.1554 (opens in a new tab)
- 95.
Smith JM Clinical implications of treating depressed older adults with SSRIs: possible risk of hyponatremiaJ Gerontol Nurs2010 362227quiz 28-29
Not in our library10.3928/00989134-20100202-04 (opens in a new tab)
- 96.
Shelton RC The nature of the discontinuation syndrome associated with antidepressant drugsJ Clin Psychiatry2006 67Suppl 437
Not in our library
- 97.
Kondro W UK bans, Health Canada warns about antidepressantsCMAJ2004 17123
Not in our library10.1503/cmaj.1040981 (opens in a new tab)
- 98.
Labeling change request letter for antidepressant medicationshttp://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096352.htm
Not in our library
- 99.
Barbui C Esposito E Cipriani A Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studiesCMAJ2009 180291297
Not in our library10.1503/cmaj.081514 (opens in a new tab)
- 100.
Olmer A Iancu I Strous RD Exposure to antidepressant medications and suicide attempts in adult depressed inpatientsJ Nerv Ment Dis2012 200531534
Not in our library10.1097/nmd.0b013e318257c7e7 (opens in a new tab)
- 101.
Degner D Grohmann R Bleich S Ruther E New antidepressant drugs. What side effects and interactions are to be expected?MMW Fortschr Med2000 142353840
Not in our library
- 102.
Chouinard G Issues in the clinical use of benzodiazepines: potency, withdrawal, and reboundJ Clin Psychiatry2004 65Suppl 5712
Not in our library
- 103.
Ciraulo DA Nace EP Benzodiazepine treatment of anxiety or insomnia in substance abuse patientsAm J Addict2000 9276279discussion 280-274
Not in our library10.1080/105504900750047346 (opens in a new tab)
- 104.
Petrovic M Mariman A Warie H Afschrift M Pevernagie D Is there a rationale for prescription of benzodiazepines in the elderly? Review of the literatureActa Clin Belg2003 582736
Not in our library10.1179/acb.2003.58.1.004 (opens in a new tab)
- 105.
Allain H Bentue-Ferrer D Polard E Akwa Y Patat A Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative reviewDrugs Aging2005 22749765
Not in our library10.2165/00002512-200522090-00004 (opens in a new tab)
- 106.
Barker MJ Greenwood KM Jackson M Crowe SF Cognitive effects of long-term benzodiazepine use: a meta-analysisCNS Drugs2004 183748
Not in our library10.2165/00023210-200418010-00004 (opens in a new tab)
- 107.
Barker MJ Greenwood KM Jackson M Crowe SF An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine useJ Int Neuropsychol Soc2005 11281289
Not in our library10.1017/s1355617705050332 (opens in a new tab)
- 108.
Chessick CA Allen MH Thase M Batista Miralha da Cunha AB Kapczinski FF de Lima MS dos Santos Souza JJ Azapirones for generalized anxiety disorderCochrane Database Syst Rev2006 3CD006115
Not in our library10.1002/14651858.cd006115 (opens in a new tab)
- 109.
Baker RA Pikalov A Tran QV Kremenets T Arani RB Doraiswamy PM Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysisPsychopharmacol Bull2009 421131
Not in our library
- 110.
Yatham LN Kennedy SH O'Donovan C Parikh SV MacQueen G McIntyre RS Sharma V Beaulieu S Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007Bipolar Disord2006 8721739
Not in our library10.1111/j.1399-5618.2006.00432.x (opens in a new tab)
- 111.
Yatham LN Kennedy SH O'Donovan C Parikh S MacQueen G McIntyre R Sharma V Silverstone P Alda M Baruch P Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversiesBipolar Disord2005 7Suppl 3569
Not in our library10.1111/j.1399-5618.2005.00219.x (opens in a new tab)
- 112.
Sumiyoshi T Roy A Anil AE Jayathilake K Ertugrul A Meltzer HY A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapineJ Clin Psychopharmacol2004 24345348
Not in our library10.1097/01.jcp.0000126668.67820.00 (opens in a new tab)
- 113.
Citrome LL Holt RI Zachry WM Clewell JD Orth PA Karagianis JL Hoffmann VP Risk of treatment-emergent diabetes mellitus in patients receiving antipsychoticsAnn Pharmacother2007 4115931603
Not in our library10.1345/aph.1k141 (opens in a new tab)
- 114.
Olfson M Marcus SC Corey-Lisle P Tuomari AV Hines P L'Italien GJ Hyperlipidemia following treatment with antipsychotic medicationsAm J Psychiatry2006 16318211825
Not in our library10.1176/ajp.2006.163.10.1821 (opens in a new tab)
- 115.
Depping AM Komossa K Kissling W Leucht S Second-generation antipsychotics for anxiety disordersCochrane Database Syst Rev2010 CD008120
Not in our library10.1002/14651858.cd008120.pub2 (opens in a new tab)
- 116.
LaLonde CD Van Lieshout RJ Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysisJ Clin Psychopharmacol2011 31326333
Not in our library10.1097/jcp.0b013e31821b2b3f (opens in a new tab)
- 117.
Torrent C Martinez-Aran A Daban C Amann B Balanza-Martinez V Del Mar Bonnin C Cruz N Franco C Tabares-Seisdedos R Vieta E Effects of atypical antipsychotics on neurocognition in euthymic bipolar patientsCompr Psychiatry2011 52613622
Not in our library10.1016/j.comppsych.2010.12.009 (opens in a new tab)
- 118.
Correll CU Sheridan EM DelBello MP Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trialsBipolar Disord2010 12116141
Not in our library10.1111/j.1399-5618.2010.00798.x (opens in a new tab)
- 119.
Doyle A Pollack M Establishment of remission criteria for anxiety disordersJ Clin Psychiatry2003 64Suppl 154045
Not in our library
- 120.
Kjernisted KD Bleau P Long-term goals in the management of acute and chronic anxiety disordersCan J Psychiatry2004 4951S63S
Not in our library
- 121.
Kessler RC Chiu WT Jin R Ruscio AM Shear K Walters EE The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey ReplicationArch Gen Psychiatry2006 63415424
Not in our library10.1001/archpsyc.63.4.415 (opens in a new tab)
- 122.
Grant BF Hasin DS Stinson FS Dawson DA Goldstein RB Smith S Huang B Saha TD The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related ConditionsJ Clin Psychiatry2006 67363374
Not in our library10.4088/jcp.v67n0305 (opens in a new tab)
- 123.
Kinley DJ Cox BJ Clara I Goodwin RD Sareen J Panic attacks and their relation to psychological and physical functioning in Canadians: results from a nationally representative sampleCan J Psychiatry2009 54113122
Not in our library10.1177/070674370905400209 (opens in a new tab)
- 124.
Goodwin RD Lieb R Hoefler M Pfister H Bittner A Beesdo K Wittchen HU Panic attack as a risk factor for severe psychopathologyAm J Psychiatry2004 16122072214
Not in our library10.1176/appi.ajp.161.12.2207 (opens in a new tab)
- 125.
Kjernisted K McIntosh D Venlafaxine extended release (XR) in the treatment of panic disorderTher Clin Risk Manag2007 35969
Not in our library10.2147/tcrm.2007.3.1.59 (opens in a new tab)
- 126.
Culpepper L Identifying and treating panic disorder in primary careJ Clin Psychiatry2004 65Suppl 51923
Not in our library
- 127.
Craske MG Tsao JC Assessment and treatment of nocturnal panic attacksSleep Med Rev2005 9173184
Not in our library10.1016/j.smrv.2004.11.003 (opens in a new tab)
- 128.
Romans S Cohen M Forte T Rates of depression and anxiety in urban and rural CanadaSoc Psychiatry Psychiatr Epidemiol2011 46567575
Not in our library10.1007/s00127-010-0222-2 (opens in a new tab)
- 129.
Galderisi S Mancuso F Mucci A Garramone S Zamboli R Maj M Alexithymia and cognitive dysfunctions in patients with panic disorderPsychother Psychosom2008 77182188
Not in our library10.1159/000119738 (opens in a new tab)
- 130.
Deckersbach T Moshier SJ Tuschen-Caffier B Otto MW Memory dysfunction in panic disorder: an investigation of the role of chronic benzodiazepine useDepress Anxiety2011 289991007
Not in our library10.1002/da.20891 (opens in a new tab)
- 131.
Pastucha P Prasko J Grambal A Latalova K Sigmundova Z Sykorova T Tichackova A Panic disorder and dissociation - comparison with healthy controlsNeuro Endocrinol Lett2009 30774778
Not in our library
- 132.
Kessler H Roth J von Wietersheim J Deighton RM Traue HC Emotion recognition patterns in patients with panic disorderDepress Anxiety2007 24223226
Not in our library10.1002/da.20223 (opens in a new tab)
- 133.
Tull MT Roemer L Emotion regulation difficulties associated with the experience of uncued panic attacks: evidence of experiential avoidance, emotional nonacceptance, and decreased emotional clarityBehav Ther2007 38378391
Not in our library10.1016/j.beth.2006.10.006 (opens in a new tab)
- 134.
Batelaan N Smit F de Graaf R van Balkom A Vollebergh W Beekman A Economic costs of full-blown and subthreshold panic disorderJ Affect Disord2007 104127136
Not in our library10.1016/j.jad.2007.03.013 (opens in a new tab)
- 135.
Gros DF Frueh BC Magruder KM Prevalence and features of panic disorder and comparison to posttraumatic stress disorder in VA primary careGen Hosp Psychiatry2011 33482488
Not in our library10.1016/j.genhosppsych.2011.06.005 (opens in a new tab)
- 136.
de Graaf R Tuithof M van Dorsselaer S Ten Have M Comparing the effects on work performance of mental and physical disordersSoc Psychiatry Psychiatr Epidemiol2012 4718731883
Not in our library10.1007/s00127-012-0496-7 (opens in a new tab)
- 137.
Mathew AR Norton PJ Zvolensky MJ Buckner JD Smits JA Smoking behavior and alcohol consumption in individuals with panic attacksJ Cogn Psychother2011 256170
Not in our library10.1891/0889-8391.25.1.61 (opens in a new tab)
- 138.
Bienvenu OJ Onyike CU Stein MB Chen LS Samuels J Nestadt G Eaton WW Agoraphobia in adults: incidence and longitudinal relationship with panicBr J Psychiatry2006 188432438
Not in our library10.1192/bjp.bp.105.010827 (opens in a new tab)
- 139.
Korczak DJ Goldstein BI Levitt AJ Panic disorder, cardiac diagnosis and emergency department utilization in an epidemiologic community sampleGen Hosp Psychiatry2007 29335339
Not in our library10.1016/j.genhosppsych.2007.03.006 (opens in a new tab)
- 140.
Senaratne R Van Ameringen M Mancini C Patterson B Bennett M The prevalence of migraine headaches in an anxiety disorders clinic sampleCNS Neurosci Ther2010 167682
Not in our library10.1111/j.1755-5949.2009.00103.x (opens in a new tab)
- 141.
Yamada K Moriwaki K Oiso H Ishigooka J High prevalence of comorbidity of migraine in outpatients with panic disorder and effectiveness of psychopharmacotherapy for both disorders: a retrospective open label studyPsychiatry Res2011 185145148
Not in our library10.1016/j.psychres.2009.08.004 (opens in a new tab)
- 142.
Marshall EC Zvolensky MJ Sachs-Ericsson N Schmidt NB Bernstein A Panic attacks and physical health problems in a representative sample: singular and interactive associations with psychological problems, and interpersonal and physical disabilityJ Anxiety Disord2008 227887
Not in our library10.1016/j.janxdis.2006.10.016 (opens in a new tab)
- 143.
Craske MG Kircanski K Epstein A Wittchen HU Pine DS Lewis-Fernandez R Hinton D Panic disorder: a review of DSM-IV panic disorder and proposals for DSM-VDepress Anxiety2010 2793112
Not in our library10.1002/da.20654 (opens in a new tab)
- 144.
American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR)2000 FourthWashington, DC: American Psychiatric Association
Not in our library
- 145.
Wittchen HU Gloster AT Beesdo-Baum K Fava GA Craske MG Agoraphobia: a review of the diagnostic classificatory position and criteriaDepress Anxiety2010 27113133
Not in our library10.1002/da.20646 (opens in a new tab)
- 146.
Clum GA Surls R A meta-analysis of treatments for panic disorderJ Consult Clin Psychol1993 61317326
Not in our library10.1037//0022-006x.61.2.317 (opens in a new tab)
- 147.
Gould R Otto M Pollack M A meta-analysis of treatment outcome for panic disorderClin Psychol Psychother1995 15819844
Not in our library
- 148.
Marchand A Roberge P Primiano S Germain V A randomized, controlled clinical trial of standard, group and brief cognitive-behavioral therapy for panic disorder with agoraphobia: a two-year follow-upJ Anxiety Disord2009 2311391147
Not in our library10.1016/j.janxdis.2009.07.019 (opens in a new tab)
- 149.
Roberge P Marchand A Reinharz D Savard P Cognitive-behavioral treatment for panic disorder with agoraphobia: a randomized, controlled trial and cost-effectiveness analysisBehav Modif2008 32333351
Not in our library10.1177/0145445507309025 (opens in a new tab)
- 150.
Meyerbroker K Emmelkamp PM Virtual reality exposure therapy in anxiety disorders: a systematic review of process-and-outcome studiesDepress Anxiety2010 27933944
Not in our library10.1002/da.20734 (opens in a new tab)
- 151.
Botella C García-Palacios A Villa H Baños RM Quero S Alcañiz M Riva G Virtual reality exposure in the treatment of panic disorder and agoraphobia: A controlled studyClin Psychol Psychother2007 14164175
Not in our library
- 152.
Malbos E Rapee RM Kavakli M Isolating the effect of virtual reality based exposure therapy for agoraphobia: a comparative trialStud Health Technol Inform2011 1674550
Not in our library
- 153.
Perez-Ara MA Quero S Botella C Banos R Andreu-Mateu S Garcia-Palacios A Breton-Lopez J Virtual reality interoceptive exposure for the treatment of panic disorder and agoraphobiaStud Health Technol Inform2010 1547781
Not in our library
- 154.
Vincelli F Anolli L Bouchard S Wiederhold BK Zurloni V Riva G Experiential cognitive therapy in the treatment of panic disorders with agoraphobia: a controlled studyCyberpsychol Behav2003 6321328
Not in our library10.1089/109493103322011632 (opens in a new tab)
- 155.
Hecker J Losee M Fritzler B Fink C Self-directed versus therapist-directed cognitive behavioural treatment for panic disorderJ Anxiety Disord1996 10253265
Not in our library
- 156.
Lidren DM Watkins PL Gould RA Clum GA Asterino M Tulloch HL A comparison of bibliotherapy and group therapy in the treatment of panic disorderJ Consult Clin Psychol1994 62865869
Not in our library10.1037//0022-006x.62.4.865 (opens in a new tab)
- 157.
Carlbring P Maurin T Sjomark J Maurin L Westling BE Ekselius L Cuijpers P Andersson G All at once or one at a time? A randomized controlled trial comparing two ways to deliver bibliotherapy for panic disorderCogn Behav Ther2011 40228235
Not in our library10.1080/16506073.2011.553629 (opens in a new tab)
- 158.
Nordin S Carlbring P Cuijpers P Andersson G Expanding the limits of bibliotherapy for panic disorder: randomized trial of self-help without support but with a clear deadlineBehav Ther2010 41267276
Not in our library10.1016/j.beth.2009.06.001 (opens in a new tab)
- 159.
McNamee G O’Sullivan G Lelliott P Marks I Telephone-guided treatment for housebound agoraphobics with panic disorder: exposure versus relaxationBehav Ther1989 20491497
Not in our library
- 160.
Swinson RP Fergus KD Cox BJ Wickwire K Efficacy of telephone-administered behavioral therapy for panic disorder with agoraphobiaBehav Res Ther1995 33465469
Not in our library10.1016/0005-7967(94)00061-n (opens in a new tab)
- 161.
Bouchard S Paquin B Payeur R Allard M Rivard V Fournier T Renaud P Lapierre J Delivering cognitive-behavior therapy for panic disorder with agoraphobia in videoconferenceTelemed J E Health2004 101325
Not in our library10.1089/153056204773644535 (opens in a new tab)
- 162.
Carlbring P Ekselius L Andersson G Treatment of panic disorder via the Internet: a randomized trial of CBT vs. applied relaxationJ Behav Ther Exp Psychiatry2003 34129140
Not in our library10.1016/s0005-7916(03)00026-0 (opens in a new tab)
- 163.
Newman MG Kenardy J Herman S Taylor CB Comparison of palmtop-computer-assisted brief cognitive-behavioral treatment to cognitive-behavioral treatment for panic disorderJ Consult Clin Psychol1997 65178183
Not in our library10.1037//0022-006x.65.1.178 (opens in a new tab)
- 164.
- 165.
Carlbring P Bohman S Brunt S Buhrman M Westling BE Ekselius L Andersson G Remote treatment of panic disorder: a randomized trial of internet-based cognitive behavior therapy supplemented with telephone callsAm J Psychiatry2006 16321192125
Not in our library10.1176/ajp.2006.163.12.2119 (opens in a new tab)
- 166.
Kiropoulos LA Klein B Austin DW Gilson K Pier C Mitchell J Ciechomski L Is internet-based CBT for panic disorder and agoraphobia as effective as face-to-face CBT?J Anxiety Disord2008 2212731284
Not in our library10.1016/j.janxdis.2008.01.008 (opens in a new tab)
- 167.
Wims E Titov N Andrews G Choi I Clinician-assisted Internet-based treatment is effective for panic: a randomized controlled trialAust N Z J Psychiatry2010 44599607
Not in our library10.3109/00048671003614171 (opens in a new tab)
- 168.
Klein B Austin D Pier C Kiropoulos L Shandley K Mitchell J Gilson K Ciechomski L Internet-based treatment for panic disorder: does frequency of therapist contact make a difference?Cogn Behav Ther2009 38100113
Not in our library10.1080/16506070802561132 (opens in a new tab)
- 169.
Ruwaard J Broeksteeg J Schrieken B Emmelkamp P Lange A Web-based therapist-assisted cognitive behavioral treatment of panic symptoms: a randomized controlled trial with a three-year follow-upJ Anxiety Disord2010 24387396
Not in our library10.1016/j.janxdis.2010.01.010 (opens in a new tab)
- 170.
Clark DM Salkovskis PM Hackmann A Wells A Ludgate J Gelder M Brief cognitive therapy for panic disorder: a randomized controlled trialJ Consult Clin Psychol1999 67583589
Not in our library10.1037//0022-006x.67.4.583 (opens in a new tab)
- 171.
Bohni MK Spindler H Arendt M Hougaard E Rosenberg NK A randomized study of massed three-week cognitive behavioural therapy schedule for panic disorderActa Psychiatr Scand2009 120187195
Not in our library10.1111/j.1600-0447.2009.01358.x (opens in a new tab)
- 172.
Dow MG Kenardy JA Johnston DW Newman MG Taylor CB Thomson A Prognostic indices with brief and standard CBT for panic disorder: II. Moderators of outcomePsychol Med2007 3715031509
Not in our library10.1017/s0033291707000682 (opens in a new tab)
- 173.
Craske MG Roy-Byrne P Stein MB Sullivan G Hazlett-Stevens H Bystritsky A Sherbourne C CBT intensity and outcome for panic disorder in a primary care settingBehav Ther2006 37112119
Not in our library10.1016/j.beth.2005.05.003 (opens in a new tab)
- 174.
Haby MM Donnelly M Corry J Vos T Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta-regression of factors that may predict outcomeAust N Z J Psychiatry2006 40919
Not in our library10.1080/j.1440-1614.2006.01736.x (opens in a new tab)
- 175.
Dow MG Kenardy JA Johnston DW Newman MG Taylor CB Thomson A Prognostic indices with brief and standard CBT for panic disorder: I. Predictors of outcomePsychol Med2007 3714931502
Not in our library10.1017/s0033291707000670 (opens in a new tab)
- 176.
Bouchard S Gauthier J Nouwen A Ivers H Vallieres A Simard S Fournier T Temporal relationship between dysfunctional beliefs, self-efficacy and panic apprehension in the treatment of panic disorder with agoraphobiaJ Behav Ther Exp Psychiatry2007 38275292
Not in our library10.1016/j.jbtep.2006.08.002 (opens in a new tab)
- 177.
Feske U Goldstein AJ Eye movement desensitization and reprocessing treatment for panic disorder: a controlled outcome and partial dismantling studyJ Consult Clin Psychol1997 6510261035
Not in our library10.1037//0022-006x.65.6.1026 (opens in a new tab)
- 178.
Goldstein AJ de Beurs E Chambless DL Wilson KA EMDR for panic disorder with agoraphobia: comparison with waiting list and credible attention-placebo control conditionsJ Consult Clin Psychol2000 68947956
Not in our library
- 179.
Furukawa TA Watanabe N Churchill R Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic reviewBr J Psychiatry2006 188305312
Not in our library10.1192/bjp.188.4.305 (opens in a new tab)
- 180.
Furukawa TA Watanabe N Churchill R Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobiaCochrane Database Syst Rev2007 CD004364
Not in our library10.1002/14651858.cd004364.pub2 (opens in a new tab)
- 181.
Mitte K A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobiaJ Affect Disord2005 882745
Not in our library10.1016/j.jad.2005.05.003 (opens in a new tab)
- 182.
Watanabe N Churchill R Furukawa TA Combined psychotherapy plus benzodiazepines for panic disorderCochrane Database Syst Rev2009 CD005335
Not in our library10.1002/14651858.cd005335.pub2 (opens in a new tab)
- 183.
Koszycki D Taljaard M Segal Z Bradwejn J A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorderPsychol Med2011 41373383
Not in our library10.1017/s0033291710000930 (opens in a new tab)
- 184.
Kim YW Lee SH Choi TK Suh SY Kim B Kim CM Cho SJ Kim MJ Yook K Ryu M Effectiveness of mindfulness-based cognitive therapy as an adjuvant to pharmacotherapy in patients with panic disorder or generalized anxiety disorderDepress Anxiety2009 26601606
Not in our library10.1002/da.20552 (opens in a new tab)
- 185.
Kim B Lee SH Kim YW Choi TK Yook K Suh SY Cho SJ Yook KH Effectiveness of a mindfulness-based cognitive therapy program as an adjunct to pharmacotherapy in patients with panic disorderJ Anxiety Disord2010 24590595
Not in our library10.1016/j.janxdis.2010.03.019 (opens in a new tab)
- 186.
Schmidt NB Wollaway-Bickel K Trakowski JH Santiago HT Vasey M Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorderBehav Res Ther2002 406773
Not in our library10.1016/s0005-7967(01)00003-1 (opens in a new tab)
- 187.
Otto MW McHugh RK Simon NM Farach FJ Worthington JJ Pollack MH Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: further evaluationBehav Res Ther2010 48720727
Not in our library10.1016/j.brat.2010.04.002 (opens in a new tab)
- 188.
Bruce T Spiegel D Hegel M Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studiesJ Consult Clin Psychol1999 67151156
Not in our library10.1037//0022-006x.67.1.151 (opens in a new tab)
- 189.
Katon W Russo J Sherbourne C Stein MB Craske M Fan MY Roy-Byrne P Incremental cost-effectiveness of a collaborative care intervention for panic disorderPsychol Med2006 36353363
Not in our library10.1017/s0033291705006896 (opens in a new tab)
- 190.
Cottraux J Note ID Cungi C Legeron P Heim F Chneiweiss L Bernard G Bouvard M A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobiaBr J Psychiatry1995 167635641
Not in our library10.1192/bjp.167.5.635 (opens in a new tab)
- 191.
Otto MW Tolin DF Simon NM Pearlson GD Basden S Meunier SA Hofmann SG Eisenmenger K Krystal JH Pollack MH Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorderBiol Psychiatry2010 67365370
Not in our library10.1016/j.biopsych.2009.07.036 (opens in a new tab)
- 192.
Siegmund A Golfels F Finck C Halisch A Rath D Plag J Strohle A D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trialJ Psychiatr Res2011 4510421047
Not in our library10.1016/j.jpsychires.2011.01.020 (opens in a new tab)
- 193.
Nations KR Smits JA Tolin DF Rothbaum BO Hofmann SG Tart CD Lee A Schipper J Sjogren M Xue D Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trialJ Clin Psychiatry2012 73647653
Not in our library10.4088/jcp.11m07081 (opens in a new tab)
- 194.
Fava GA Rafanelli C Grandi S Conti S Ruini C Mangelli L Belluardo P Long-term outcome of panic disorder with agoraphobia treated by exposurePsychol Med2001 31891898
Not in our library10.1017/s0033291701003592 (opens in a new tab)
- 195.
Bakker A van Balkom A Spinhoven P SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysisActa Psychiatr Scand2002 106163167
Not in our library10.1034/j.1600-0447.2002.02255.x (opens in a new tab)
- 196.
Otto MW Tuby KS Gould RA McLean RY Pollack MH An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorderAm J Psychiatry2001 15819891992
Not in our library10.1176/appi.ajp.158.12.1989 (opens in a new tab)
- 197.
Andrisano C Chiesa A Serretti A Newer antidepressants and panic disorder: a meta-analysisInt Clin Psychopharmacol2013 283345
Not in our library10.1097/yic.0b013e32835a5d2e (opens in a new tab)
- 198.
Stahl SM Gergel I Li D Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry2003 6413221327
Not in our library10.4088/jcp.v64n1107 (opens in a new tab)
- 199.
Wade AG Lepola U Koponen HJ Pedersen V Pedersen T The effect of citalopram in panic disorderBr J Psychiatry1997 170549553
Not in our library10.1192/bjp.170.6.549 (opens in a new tab)
- 200.
Seedat S van Rheede van Oudtshoorn E Muller JE Mohr N Stein DJ Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot studyInt Clin Psychopharmacol2003 18279284
Not in our library10.1097/00004850-200309000-00004 (opens in a new tab)
- 201.
Michelson D Lydiard RB Pollack MH Tamura RN Hoog SL Tepner R Demitrack MA Tollefson GD Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study GroupAm J Psychiatry1998 15515701577
Not in our library10.1176/ajp.155.11.1570 (opens in a new tab)
- 202.
Michelson D Allgulander C Dantendorfer K Knezevic A Maierhofer D Micev V Paunovic V Timotijevic I Sarkar N Skoglund L Pemberton S Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trialBr J Psychiatry2001 179514518
Not in our library10.1192/bjp.179.6.514 (opens in a new tab)
- 203.
- 204.
Tiller JW Bouwer C Behnke K Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study GroupEur Arch Psychiatry Clin Neurosci1999 249Suppl 1S710
Not in our library10.1007/pl00014164 (opens in a new tab)
- 205.
Black DW Wesner R Bowers W Gabel J A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorderArch Gen Psychiatry1993 504450
Not in our library10.1001/archpsyc.1993.01820130046008 (opens in a new tab)
- 206.
Asnis G Hameedi F Goddard A Potkin S Black D Jameel M Desagani K Woods S Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatientsPsychiatry Res2001 103114
Not in our library10.1016/s0165-1781(01)00265-7 (opens in a new tab)
- 207.
Bakish D Hooper CL Filteau MJ Charbonneau Y Fraser G West DL Thibaudeau C Raine D A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobiaPsychopharmacol Bull1996 32135141
Not in our library
- 208.
Den Boer JA Westenberg HG Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserinPsychopharmacology (Berl)1990 1028594
Not in our library10.1007/bf02245749 (opens in a new tab)
- 209.
Hoehn-Saric R McLeod DR Hipsley PA Effect of fluvoxamine on panic disorderJ Clin Psychopharmacol1993 13321326
Not in our library
- 210.
Sharp DM Power KG Simpson RJ Swanson V Anstee JA Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary careBr J Gen Pract1997 47150155
Not in our library
- 211.
Bakker A van Dyck R Spinhoven P van Balkom AJ Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorderJ Clin Psychiatry1999 60831838
Not in our library10.4088/jcp.v60n1205 (opens in a new tab)
- 212.
Ballenger JC Wheadon DE Steiner M Bushnell W Gergel IP Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorderAm J Psychiatry1998 1553642
Not in our library10.1176/ajp.155.1.36 (opens in a new tab)
- 213.
Lecrubier Y Bakker A Dunbar G Judge R A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study InvestigatorsActa Psychiatr Scand1997 95145152
Not in our library10.1111/j.1600-0447.1997.tb00388.x (opens in a new tab)
- 214.
Oehrberg S Christiansen PE Behnke K Borup AL Severin B Soegaard J Calberg H Judge R Ohrstrom JK Manniche PM Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled studyBr J Psychiatry1995 167374379
Not in our library10.1192/bjp.167.3.374 (opens in a new tab)
- 215.
Pollack M Mangano R Entsuah R Tzanis E Simon NM Zhang Y A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorderPsychopharmacology (Berl)2007 194233242
Not in our library10.1007/s00213-007-0821-0 (opens in a new tab)
- 216.
Pollack MH Lepola U Koponen H Simon NM Worthington JJ Emilien G Tzanis E Salinas E Whitaker T Gao B A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorderDepress Anxiety2007 24114
Not in our library10.1002/da.20218 (opens in a new tab)
- 217.
- 218.
Nardi AE Valenca AM Freire RC Mochcovitch MD Amrein R Sardinha A Levitan MN Nascimento I de-Melo-Neto VL King AL Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetineBraz J Med Biol Res2011 44366373
Not in our library10.1590/s0100-879x2011007500020 (opens in a new tab)
- 219.
Bertani A Perna G Migliarese G Di Pasquale D Cucchi M Caldirola D Bellodi L Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind studyPharmacopsychiatry2004 37206210
Not in our library10.1055/s-2004-832593 (opens in a new tab)
- 220.
Londborg PD Wolkow R Smith WT DuBoff E England D Ferguson J Rosenthal M Weise C Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigationBr J Psychiatry1998 1735460
Not in our library10.1192/bjp.173.1.54 (opens in a new tab)
- 221.
Pohl RB Wolkow RM Clary CM Sertraline in the treatment of panic disorder: a double-blind multicenter trialAm J Psychiatry1998 15511891195
Not in our library10.1176/ajp.155.9.1189 (opens in a new tab)
- 222.
Pollack MH Otto MW Worthington JJ Manfro GG Wolkow R Sertraline in the treatment of panic disorder: a flexible-dose multicenter trialArch Gen Psychiatry1998 5510101016
Not in our library10.1001/archpsyc.55.11.1010 (opens in a new tab)
- 223.
Pollack M Rapaport M Clary C Mardekian J Wolkow R Sertraline treatment of panic disorder: response in patients at risk for poor outcomeJ Clin Psychiatry2000 61922927
Not in our library
- 224.
Lepola U Arato M Zhu Y Austin C Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorderJ Clin Psychiatry2003 64654662
Not in our library10.4088/jcp.v64n0606 (opens in a new tab)
- 225.
Sheehan DV Burnham DB Iyengar MK Perera P Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorderJ Clin Psychiatry2005 663440
Not in our library
- 226.
Perna G Dacco S Menotti R Caldirola D Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral conditionNeuropsychiatr Dis Treat2011 7621637
Not in our library10.2147/ndt.s12979 (opens in a new tab)
- 227.
Pollack MH Worthington JJ 3rd Otto MW Maki KM Smoller JW Manfro GG Rudolph R Rosenbaum JF Venlafaxine for panic disorder: results from a double-blind, placebo-controlled studyPsychopharmacol Bull1996 32667670
Not in our library
- 228.
Bradwejn J Ahokas A Stein DJ Salinas E Emilien G Whitaker T Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled studyBr J Psychiatry2005 187352359
Not in our library10.1192/bjp.187.4.352 (opens in a new tab)
- 229.
Liebowitz MR Asnis G Mangano R Tzanis E A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorderJ Clin Psychiatry2009 70550561
Not in our library10.4088/jcp.08m04238 (opens in a new tab)
- 230.
Simon NM Kaufman RE Hoge EA Worthington JJ Herlands NN Owens ME Pollack MH Open-label support for duloxetine for the treatment of panic disorderCNS Neurosci Ther2009 151923
Not in our library10.1111/j.1755-5949.2008.00076.x (opens in a new tab)
- 231.
Blaya C Seganfredo AC Dornelles M Torres M Paludo A Heldt E Manfro GG The efficacy of milnacipran in panic disorder: an open trialInt Clin Psychopharmacol2007 22153158
Not in our library10.1097/yic.0b013e32802c7bf5 (opens in a new tab)
- 232.
Kruger MB Dahl AA The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorderEur Arch Psychiatry Clin Neurosci1999 249Suppl 1S1924
Not in our library10.1007/pl00014163 (opens in a new tab)
- 233.
Modigh K Westberg P Eriksson E Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trialJ Clin Psychopharmacol1992 12251261
Not in our library
- 234.
Cox BJ Endler NS Lee PS Swinson RP A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposureJ Behav Ther Exp Psychiatry1992 23175182
Not in our library10.1016/0005-7916(92)90034-g (opens in a new tab)
- 235.
Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase InvestigatorsBr J Psychiatry1992 160191202discussion 202-195
Not in our library10.1192/bjp.160.2.191 (opens in a new tab)
- 236.
Andersch S Rosenberg NK Kullingsjo H Ottosson JO Bech P Bruun-Hansen J Hanson L Lorentzen K Mellergard M Rasmussen S Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter studyActa Psychiatr Scand Suppl1991 3651827
Not in our library10.1111/j.1600-0447.1991.tb03097.x (opens in a new tab)
- 237.
Taylor CB Hayward C King R Ehlers A Margraf J Maddock R Clark D Roth WT Agras WS Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trialJ Clin Psychopharmacol1990 10112118
Not in our library10.1097/00004714-199004000-00006 (opens in a new tab)
- 238.
Barlow D Gorman J Shear M Woods S Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trialJAMA2000 28325292536
Not in our library10.1001/jama.283.19.2529 (opens in a new tab)
- 239.
Marchand A Coutu MF Dupuis G Fleet R Borgeat F Todorov C Mainguy N Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placeboCogn Behav Ther2008 37146159
Not in our library10.1080/16506070701743120 (opens in a new tab)
- 240.
Sheehan DV Ballenger J Jacobsen G Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptomsArch Gen Psychiatry1980 375159
Not in our library10.1001/archpsyc.1980.01780140053006 (opens in a new tab)
- 241.
Uhlenhuth EH Warner TD Matuzas W Interactive model of therapeutic response in panic disorder: moclobemide, a case in pointJ Clin Psychopharmacol2002 22275284
Not in our library10.1097/00004714-200206000-00008 (opens in a new tab)
- 242.
Loerch B Graf-Morgenstern M Hautzinger M Schlegel S Hain C Sandmann J Benkert O Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobiaBr J Psychiatry1999 174205212
Not in our library10.1192/bjp.174.3.205 (opens in a new tab)
- 243.
Nardi AE Lopes FL Valenca AM Freire RC Nascimento I Veras AB Mezzasalma MA de-Melo-Neto VL Soares-Filho GL King AL Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorderPsychiatry Res2010 175260265
Not in our library10.1016/j.psychres.2008.06.025 (opens in a new tab)
- 244.
Versiani M Cassano G Perugi G Benedetti A Mastalli L Nardi A Savino M Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorderJ Clin Psychiatry2002 633137
Not in our library10.4088/jcp.v63n0107 (opens in a new tab)
- 245.
Boshuisen M Slaap B Vester-Blokland E den Boer J The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in periodInt Clin Psychopharmacol2001 16363368
Not in our library10.1097/00004850-200111000-00008 (opens in a new tab)
- 246.
Sarchiapone M Amore M De Risio S Carli V Faia V Poterzio F Balista C Camardese G Ferrari G Mirtazapine in the treatment of panic disorder: an open-label trialInt Clin Psychopharmacol2003 183538
Not in our library10.1097/00004850-200301000-00006 (opens in a new tab)
- 247.
Sheehan DV Davidson J Manschreck T Van Wyck Fleet J Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobiasJ Clin Psychopharmacol1983 32831
Not in our library
- 248.
Simon NM Emmanuel N Ballenger J Worthington JJ Kinrys G Korbly NB Farach FJ Pollack MH Bupropion sustained release for panic disorderPsychopharmacol Bull2003 376672
Not in our library
- 249.
Boyer W Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysisInt Clin Psychopharmacol1995 104549
Not in our library10.1097/00004850-199503000-00006 (opens in a new tab)
- 250.
Tesar GE Rosenbaum JF Pollack MH Otto MW Sachs GS Herman JB Cohen LS Spier SA Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorderJ Clin Psychiatry1991 526976
Not in our library
- 251.
Schweizer E Pohl R Balon R Fox I Rickels K Yeragani VK Lorazepam vs. alprazolam in the treatment of panic disorderPharmacopsychiatry1990 239093
Not in our library10.1055/s-2007-1014489 (opens in a new tab)
- 252.
Moylan S Staples J Ward SA Rogerson J Stein DJ Berk M The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorderJ Clin Psychopharmacol2011 31647652
Not in our library10.1097/jcp.0b013e31822d0012 (opens in a new tab)
- 253.
Marquez M Arenoso H Caruso N Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disordersActas Esp Psiquiatr2011 398894
Not in our library
- 254.
Sheehan D Raj A Harnett-Sheehan K Soto S Knapp E The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled studyActa Psychiatr Scand1993 88111
Not in our library10.1111/j.1600-0447.1993.tb03405.x (opens in a new tab)
- 255.
Beauclair L Fontaine R Annable L Holobow N Chouinard G Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical responseJ Clin Psychopharmacol1994 14111118
Not in our library
- 256.
Moroz G Rosenbaum JF Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosagesJ Clin Psychiatry1999 60604612
Not in our library10.4088/jcp.v60n0907 (opens in a new tab)
- 257.
Rosenbaum JF Moroz G Bowden CL Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study GroupJ Clin Psychopharmacol1997 17390400
Not in our library10.1097/00004714-199710000-00008 (opens in a new tab)
- 258.
Valenca A Nardi A Nascimento I Mezzasalma M Lopes F Zin W Double-blind clonazepam vs placebo in panic disorder treatmentArq Neuropsiquiatr2000 5810251029
Not in our library10.1590/s0004-282x2000000600008 (opens in a new tab)
- 259.
Charney DS Woods SW Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepamJ Clin Psychiatry1989 50418423
Not in our library
- 260.
de Jonghe F Swinkels J Tuynman-Qua H Jonkers F A comparative study of suriclone, lorazepam and placebo in anxiety disorderPharmacopsychiatry1989 22266271
Not in our library10.1055/s-2007-1014613 (opens in a new tab)
- 261.
Dunner DL Ishiki D Avery DH Wilson LG Hyde TS Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled studyJ Clin Psychiatry1986 47458460
Not in our library
- 262.
Noyes R Jr. Anderson DJ Clancy J Crowe RR Slymen DJ Ghoneim MM Hinrichs JV Diazepam and propranolol in panic disorder and agoraphobiaArch Gen Psychiatry1984 41287292
Not in our library10.1001/archpsyc.1984.01790140077009 (opens in a new tab)
- 263.
Noyes R Jr. Burrows GD Reich JH Judd FK Garvey MJ Norman TR Cook BL Marriott P Diazepam versus alprazolam for the treatment of panic disorderJ Clin Psychiatry1996 57349355
Not in our library
- 264.
Pollack MH Simon NM Worthington JJ Doyle AL Peters P Toshkov F Otto MW Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorderJ Psychopharmacol2003 17276282
Not in our library10.1177/02698811030173009 (opens in a new tab)
- 265.
Goddard AW Brouette T Almai A Jetty P Woods SW Charney D Early coadministration of clonazepam with sertraline for panic disorderArch Gen Psychiatry2001 58681686
Not in our library10.1001/archpsyc.58.7.681 (opens in a new tab)
- 266.
Katzelnick DJ Saidi J Vanelli MR Jefferson JW Harper JM McCrary KE Time to response in panic disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alonePsychiatry (Edgmont)2006 33949
Not in our library
- 267.
Galynker I Khan A Grebchenko Y Ten A Malaya L Yanowitch P Cohen LJ Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression [Letter]J Clin Psychiatry2005 66544
Not in our library10.4088/jcp.v66n0420f (opens in a new tab)
- 268.
Hollifield M Thompson PM Ruiz JE Uhlenhuth EH Potential effectiveness and safety of olanzapine in refractory panic disorderDepress Anxiety2005 213340
Not in our library10.1002/da.20050 (opens in a new tab)
- 269.
Hoge EA Worthington JJ 3rd Kaufman RE Delong HR Pollack MH Simon NM Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorderCNS Spectr2008 13522527
Not in our library10.1017/s109285290001676x (opens in a new tab)
- 270.
Sepede G De Berardis D Gambi F Campanella D La Rovere R D'Amico M Cicconetti A Penna L Peca S Carano A Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trialJ Clin Psychopharmacol2006 264549
Not in our library10.1097/01.jcp.0000195108.01898.17 (opens in a new tab)
- 271.
Simon NM Hoge EA Fischmann D Worthington JJ Christian KM Kinrys G Pollack MH An open-label trial of risperidone augmentation for refractory anxiety disordersJ Clin Psychiatry2006 67381385
Not in our library10.4088/jcp.v67n0307 (opens in a new tab)
- 272.
Baetz M Bowen RC Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapyCan J Psychiatry1998 437377
Not in our library10.1177/070674379804300109 (opens in a new tab)
- 273.
Keck PE Jr. Taylor VE Tugrul KC McElroy SL Bennett JA Valproate treatment of panic disorder and lactate-induced panic attacksBiol Psychiatry1993 33542546
Not in our library10.1016/0006-3223(93)90010-b (opens in a new tab)
- 274.
Woodman CL Noyes R Jr. Panic disorder: treatment with valproateJ Clin Psychiatry1994 55134136
Not in our library
- 275.
Primeau F Fontaine R Beauclair L Valproic acid and panic disorderCan J Psychiatry1990 35248250
Not in our library10.1177/070674379003500309 (opens in a new tab)
- 276.
Papp LA Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose studyJ Clin Psychiatry2006 6715731576
Not in our library10.4088/jcp.v67n1012 (opens in a new tab)
- 277.
Pande AC Pollack MH Crockatt J Greiner M Chouinard G Lydiard RB Taylor CB Dager SR Shiovitz T Placebo-controlled study of gabapentin treatment of panic disorderJ Clin Psychopharmacol2000 20467471
Not in our library10.1097/00004714-200008000-00011 (opens in a new tab)
- 278.
Zwanzger P Eser D Nothdurfter C Baghai TC Moller HJ Padberg F Rupprecht R Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorderPharmacopsychiatry2009 42266269
Not in our library10.1055/s-0029-1241798 (opens in a new tab)
- 279.
Sheehan DV Sheehan KH Raj BA Janavs J An open-label study of tiagabine in panic disorderPsychopharmacol Bull2007 403240
Not in our library
- 280.
Uhde TW Stein MB Post RM Lack of efficacy of carbamazepine in the treatment of panic disorderAm J Psychiatry1988 14511041109
Not in our library10.1176/ajp.145.9.1104 (opens in a new tab)
- 281.
Perugi G Frare F Toni C Tusini G Vannucchi G Akiskal HS Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up studyEur Arch Psychiatry Clin Neurosci2010 260553560
Not in our library10.1007/s00406-010-0109-y (opens in a new tab)
- 282.
Sheehan DV Raj AB Sheehan KH Soto S Is buspirone effective for panic disorder?J Clin Psychopharmacol1990 10311
Not in our library
- 283.
Charney DS Woods SW Goodman WK Rifkin B Kinch M Aiken B Quadrino LM Heninger GR Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodoneJ Clin Psychiatry1986 47580586
Not in our library
- 284.
Munjack DJ Crocker B Cabe D Brown R Usigli R Zulueta A McManus M McDowell D Palmer R Leonard M Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacksJ Clin Psychopharmacol1989 92227
Not in our library
- 285.
Ravaris CL Friedman MJ Hauri PJ McHugo GJ A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatientsJ Clin Psychopharmacol1991 11344350
Not in our library
- 286.
Hirschmann S Dannon PN Iancu I Dolberg OT Zohar J Grunhaus L Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trialJ Clin Psychopharmacol2000 20556559
Not in our library10.1097/00004714-200010000-00011 (opens in a new tab)
- 287.
Lepola UM Wade AG Leinonen EV Koponen HJ Frazer J Sjodin I Penttinen JT Pedersen T Lehto HJ A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorderJ Clin Psychiatry1998 59528534
Not in our library10.4088/jcp.v59n1006 (opens in a new tab)
- 288.
Dannon PN Iancu I Lowengrub K Gonopolsky Y Musin E Grunhaus L Kotler M A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorderClin Neuropharmacol2007 30326334
Not in our library10.1097/wnf.0b013e318064579f (opens in a new tab)
- 289.
Lecrubier Y Judge R Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study InvestigatorsActa Psychiatr Scand1997 95153160
Not in our library10.1111/j.1600-0447.1997.tb00389.x (opens in a new tab)
- 290.
Nardi AE Freire RC Mochcovitch MD Amrein R Levitan MN King AL Valenca AM Veras AB Paes F Sardinha A A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetineJ Clin Psychopharmacol2012 32120126
Not in our library10.1097/jcp.0b013e31823fe4bd (opens in a new tab)
- 291.
Curtis GC Massana J Udina C Ayuso JL Cassano GB Perugi G Maintenance drug therapy of panic disorderJ Psychiatr Res1993 27Suppl 1127142
Not in our library10.1016/0022-3956(93)90023-u (opens in a new tab)
- 292.
Mavissakalian M Perel JM Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobiaArch Gen Psychiatry1992 49318323
Not in our library10.1001/archpsyc.49.4.318 (opens in a new tab)
- 293.
Rickels K Schweizer E Panic disorder: long-term pharmacotherapy and discontinuationJ Clin Psychopharmacol1998 1812S18S
Not in our library10.1097/00004714-199812001-00004 (opens in a new tab)
- 294.
Ferguson JM Khan A Mangano R Entsuah R Tzanis E Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended releaseJ Clin Psychiatry2007 685868
Not in our library10.4088/jcp.v68n0108 (opens in a new tab)
- 295.
Mavissakalian MR Perel JM Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobiaArch Gen Psychiatry1999 56821827
Not in our library10.1001/archpsyc.56.9.821 (opens in a new tab)
- 296.
Nardi AE Freire RC Valenca AM Amrein R de Cerqueira AC Lopes FL Nascimento I Mezzasalma MA Veras AB Sardinha A Tapering clonazepam in patients with panic disorder after at least 3 years of treatmentJ Clin Psychopharmacol2010 30290293
Not in our library10.1097/jcp.0b013e3181dcb2f3 (opens in a new tab)
- 297.
Mannu P Rinaldi S Fontani V Castagna A Margotti ML Noninvasive brain stimulation by radioelectric asymmetric conveyor in the treatment of agoraphobia: open-label, naturalistic studyPatient Prefer Adherence2011 5575580
Not in our library10.2147/ppa.s26594 (opens in a new tab)
- 298.
Mannu P Rinaldi S Fontani V Castagna A Margotti ML Radio electric treatment vs. escitalopram in the treatment of panic disorders associated with major depression: an open-label, naturalistic studyAcupunct Electrother Res2009 34135149
Not in our library10.3727/036012909803861040 (opens in a new tab)
- 299.
Mantovani A Lisanby SH Pieraccini F Ulivelli M Castrogiovanni P Rossi S Repetitive transcranial magnetic stimulation (rTMS) in the treatment of panic disorder (PD) with comorbid major depressionJ Affect Disord2007 102277280
Not in our library10.1016/j.jad.2006.11.027 (opens in a new tab)
- 300.
Prasko J Zalesky R Bares M Horacek J Kopecek M Novak T Paskova B The effect of repetitive transcranial magnetic stimulation (rTMS) add on serotonin reuptake inhibitors in patients with panic disorder: a randomized, double blind sham controlled studyNeuro Endocrinol Lett2007 283338
Not in our library
- 301.
Meuret AE Rosenfield D Seidel A Bhaskara L Hofmann SG Respiratory and cognitive mediators of treatment change in panic disorder: evidence for intervention specificityJ Consult Clin Psychol2010 78691704
Not in our library10.1037/a0019552 (opens in a new tab)
- 302.
Wollburg E Roth WT Kim S Effects of breathing training on voluntary hypo- and hyperventilation in patients with panic disorder and episodic anxietyAppl Psychophysiol Biofeedback2011 368191
Not in our library10.1007/s10484-011-9150-5 (opens in a new tab)
- 303.
Wedekind D Broocks A Weiss N Engel K Neubert K Bandelow B A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorderWorld J Biol Psychiatry2010 11904913
Not in our library10.3109/15622975.2010.489620 (opens in a new tab)
- 304.
Strohle A Graetz B Scheel M Wittmann A Feller C Heinz A Dimeo F The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjectsJ Psychiatr Res2009 4310131017
Not in our library10.1016/j.jpsychires.2009.02.004 (opens in a new tab)
- 305.
Stinson FS Dawson DA Patricia Chou S Smith S Goldstein RB June Ruan W Grant BF The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related ConditionsPsychol Med2007 3710471059
Not in our library10.1017/s0033291707000086 (opens in a new tab)
- 306.
LeBeau RT Glenn D Liao B Wittchen HU Beesdo-Baum K Ollendick T Craske MG Specific phobia: a review of DSM-IV specific phobia and preliminary recommendations for DSM-VDepress Anxiety2010 27148167
Not in our library10.1002/da.20655 (opens in a new tab)
- 307.
Becker ES Rinck M Turke V Kause P Goodwin R Neumer S Margraf J Epidemiology of specific phobia subtypes: findings from the Dresden Mental Health StudyEur Psychiatry2007 226974
Not in our library10.1016/j.eurpsy.2006.09.006 (opens in a new tab)
- 308.
Benjet C Borges G Stein D Mendez E Medina-Mora M Epidemiology of fears and specific phobia in adolescence: results from the Mexican Adolescent Mental Health SurveyJ Clin Psychiatry2012 73152158
Not in our library10.4088/jcp.11m07442 (opens in a new tab)
- 309.
Trumpf J Margraf J Vriends N Meyer AH Becker ES Specific phobia predicts psychopathology in young womenSoc Psychiatry Psychiatr Epidemiol2010 4511611166
Not in our library10.1007/s00127-009-0159-5 (opens in a new tab)
- 310.
Choy Y Fyer AJ Goodwin RD Specific phobia and comorbid depression: a closer look at the National Comorbidity Survey dataCompr Psychiatry2007 48132136
Not in our library10.1016/j.comppsych.2006.10.010 (opens in a new tab)
- 311.
Hood H Antony M Davis T, Ollendick T, Öst L-GEvidence-based assessment and treatment of specific phobias in adults, Chapt.2Intensive one-session treatment of specific phobias2012 New York: Springer1942Autism and Child Psychopathology Series
Not in our library
- 312.
Parsons TD Rizzo AA Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysisJ Behav Ther Exp Psychiatry2008 39250261
Not in our library10.1016/j.jbtep.2007.07.007 (opens in a new tab)
- 313.
Ollendick TH Ost LG Reuterskiold L Costa N Cederlund R Sirbu C Davis TE 3rd Jarrett MA One-session treatment of specific phobias in youth: a randomized clinical trial in the United States and SwedenJ Consult Clin Psychol2009 77504516
Not in our library10.1037/a0015158 (opens in a new tab)
- 314.
Craske MG Kircanski K Zelikowsky M Mystkowski J Chowdhury N Baker A Optimizing inhibitory learning during exposure therapyBehav Res Ther2008 46527
Not in our library10.1016/j.brat.2007.10.003 (opens in a new tab)
- 315.
Öst L-G Fellenius J Sterner U Applied tension, exposure in vivo, and tension-only in the treatment of blood phobiaBehav Res Ther1991 29561574
Not in our library10.1016/0005-7967(91)90006-o (opens in a new tab)
- 316.
Hellstrom K Fellenius J Öst L-G One versus five sessions of applied tension in the treatment of blood phobiaBehav Res Ther1996 34101112
Not in our library10.1016/0005-7967(95)00060-7 (opens in a new tab)
- 317.
Kettwich SC Sibbitt WL Jr. Brandt JR Johnson CR Wong CS Bankhurst AD Needle phobia and stress-reducing medical devices in pediatric and adult chemotherapy patientsJ Pediatr Oncol Nurs2007 242028
Not in our library10.1177/1043454206296023 (opens in a new tab)
- 318.
Vika M Skaret E Raadal M Ost LG Kvale G One- vs. five-session treatment of intra-oral injection phobia: a randomized clinical studyEur J Oral Sci2009 117279285
Not in our library10.1111/j.1600-0722.2009.00628.x (opens in a new tab)
- 319.
Krijn M Emmelkamp PM Olafsson RP Bouwman M van Gerwen LJ Spinhoven P Schuemie MJ van der Mast CA Fear of flying treatment methods: virtual reality exposure vs. cognitive behavioral therapyAviat Space Environ Med2007 78121128
Not in our library
- 320.
Van Gerwen LJ Spinhoven P Van Dyck R Behavioral and cognitive group treatment for fear of flying: a randomized controlled trialJ Behav Ther Exp Psychiatry2006 37358371
Not in our library10.1016/j.jbtep.2006.05.002 (opens in a new tab)
- 321.
Wiederhold BK Jang DP Gevirtz RG Kim SI Kim IY Wiederhold MD The treatment of fear of flying: a controlled study of imaginal and virtual reality graded exposure therapyIEEE Trans Inf Technol Biomed2002 6218223
Not in our library10.1109/titb.2002.802378 (opens in a new tab)
- 322.
Rothbaum BO Hodges L Smith S Lee JH Price L A controlled study of virtual reality exposure therapy for the fear of flyingJ Consult Clin Psychol2000 6810201026
Not in our library10.1037//0022-006x.68.6.1020 (opens in a new tab)
- 323.
Tortella-Feliu M Botella C Llabres J Breton-Lopez JM del Amo AR Banos RM Gelabert JM Virtual reality versus computer-aided exposure treatments for fear of flyingBehav Modif2011 35330
Not in our library10.1177/0145445510390801 (opens in a new tab)
- 324.
Rothbaum BO Anderson P Zimand E Hodges L Lang D Wilson J Virtual reality exposure therapy and standard (in vivo) exposure therapy in the treatment of fear of flyingBehav Ther2006 378090
Not in our library10.1016/j.beth.2005.04.004 (opens in a new tab)
- 325.
Kim S Palin F Anderson P Edwards S Lindner G Rothbaum BO Use of skills learned in CBT for fear of flying: managing flying anxiety after September 11thJ Anxiety Disord2008 22301309
Not in our library10.1016/j.janxdis.2007.02.006 (opens in a new tab)
- 326.
Anderson P Jacobs CH Lindner GK Edwards S Zimand E Hodges L Rothbaum BO Cognitive behavior therapy for fear of flying: sustainability of treatment gains after September 11Behav Ther2006 379197
Not in our library10.1016/j.beth.2005.05.001 (opens in a new tab)
- 327.
Emmelkamp PM Krijn M Hulsbosch AM de Vries S Schuemie MJ van der Mast CA Virtual reality treatment versus exposure in vivo: a comparative evaluation in acrophobiaBehav Res Ther2002 40509516
Not in our library10.1016/s0005-7967(01)00023-7 (opens in a new tab)
- 328.
Rothbaum BO Hodges LF Kooper R Opdyke D Williford JS North M Effectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobiaAm J Psychiatry1995 152626628
Not in our library10.1176/ajp.152.4.626 (opens in a new tab)
- 329.
Krijn M Emmelkamp PM Olafsson RP Schuemie MJ van der Mast CA Do self-statements enhance the effectiveness of virtual reality exposure therapy? A comparative evaluation in acrophobiaCyberpsychol Behav2007 10362370
Not in our library10.1089/cpb.2006.9943 (opens in a new tab)
- 330.
Malbos E Mestre DR Note ID Gellato C Virtual reality and claustrophobia: multiple components therapy involving game editor virtual environments exposureCyberpsychol Behav2008 11695697
Not in our library10.1089/cpb.2007.0246 (opens in a new tab)
- 331.
Michaliszyn D Marchand A Bouchard S Martel MO Poirier-Bisson J A randomized, controlled clinical trial of in virtuo and in vivo exposure for spider phobiaCyberpsychol Behav Soc Netw2010 13689695
Not in our library10.1089/cyber.2009.0277 (opens in a new tab)
- 332.
Bouchard S Cote S St-Jacques J Robillard G Renaud P Effectiveness of virtual reality exposure in the treatment of arachnophobia using 3D gamesTechnol Health Care2006 141927
Not in our library
- 333.
Granado LC Ranvaud R Pelaez JR A spiderless arachnophobia therapy: comparison between placebo and treatment groups and six-month follow-up studyNeural Plast2007 200710241
Not in our library10.1155/2007/10241 (opens in a new tab)
- 334.
Andersson G Waara J Jonsson U Malmaeus F Carlbring P Ost LG Internet-based self-help versus one-session exposure in the treatment of spider phobia: a randomized controlled trialCogn Behav Ther2009 38114120
Not in our library10.1080/16506070902931326 (opens in a new tab)
- 335.
Muller BH Kull S Wilhelm FH Michael T One-session computer-based exposure treatment for spider-fearful individuals--efficacy of a minimal self-help intervention in a randomised controlled trialJ Behav Ther Exp Psychiatry2011 42179184
Not in our library10.1016/j.jbtep.2010.12.001 (opens in a new tab)
- 336.
Botella C Quero S Banos RM Garcia-Palacios A Breton-Lopez J Alcaniz M Fabregat S Telepsychology and self-help: the treatment of phobias using the internetCyberpsychol Behav2008 11659664
Not in our library10.1089/cpb.2008.0012 (opens in a new tab)
- 337.
Botella C Breton-Lopez J Quero S Banos R Garcia-Palacios A Treating cockroach phobia with augmented realityBehav Ther2010 41401413
Not in our library10.1016/j.beth.2009.07.002 (opens in a new tab)
- 338.
Ressler KJ Rothbaum BO Tannenbaum L Anderson P Graap K Zimand E Hodges L Davis M Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fearArch Gen Psychiatry2004 6111361144
Not in our library10.1001/archpsyc.61.11.1136 (opens in a new tab)
- 339.
Guastella AJ Dadds MR Lovibond PF Mitchell P Richardson R A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fearJ Psychiatr Res2007 41466471
Not in our library10.1016/j.jpsychires.2006.05.006 (opens in a new tab)
- 340.
de Quervain DJ Bentz D Michael T Bolt OC Wiederhold BK Margraf J Wilhelm FH Glucocorticoids enhance extinction-based psychotherapyProc Natl Acad Sci U S A2011 10866216625
Not in our library10.1073/pnas.1018214108 (opens in a new tab)
- 341.
Soravia LM Heinrichs M Aerni A Maroni C Schelling G Ehlert U Roozendaal B de Quervain DJ Glucocorticoids reduce phobic fear in humansProc Natl Acad Sci U S A2006 10355855590
Not in our library10.1073/pnas.0509184103 (opens in a new tab)
- 342.
Meyerbroeker K Powers MB van Stegeren A Emmelkamp PM Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trialPsychother Psychosom2012 812937
Not in our library10.1159/000329454 (opens in a new tab)
- 343.
Powers MB Smits JA Otto MW Sanders C Emmelkamp PM Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentationJ Anxiety Disord2009 23350356
Not in our library10.1016/j.janxdis.2009.01.001 (opens in a new tab)
- 344.
Kozak AT Spates CR McChargue DE Bailey KC Schneider KL Liepman MR Naltrexone renders one-session exposure therapy less effective: a controlled pilot studyJ Anxiety Disord2007 21142152
Not in our library10.1016/j.janxdis.2006.03.011 (opens in a new tab)
- 345.
Benjamin J Ben-Zion I Karbofsky E Dannon P Double-blind placebo-controlled pilot study of paroxetine for specific phobiaPsychopharmacology (Berl)2000 149194196
Not in our library10.1007/s002130000372 (opens in a new tab)
- 346.
Alamy S Wei Z Varia I Davidson JR Connor KM Escitalopram in specific phobia: results of a placebo-controlled pilot trialJ Psychopharmacol2008 22157161
Not in our library10.1177/0269881107080796 (opens in a new tab)
- 347.
Abene MV Hamilton JD Resolution of fear of flying with fluoxetine treatmentJ Anxiety Disord1998 12599603
Not in our library10.1016/s0887-6185(98)00036-x (opens in a new tab)
- 348.
Balon R Fluvoxamine for phobia of stormsActa Psychiatr Scand1999 100244245discussion 245-246
Not in our library10.1111/j.1600-0447.1999.tb10852.x (opens in a new tab)
- 349.
Choy Y Fyer AJ Lipsitz JD Treatment of specific phobia in adultsClin Psychol Rev2007 27266286
Not in our library10.1016/j.cpr.2006.10.002 (opens in a new tab)
- 350.
Wilhelm FH Roth WT Acute and delayed effects of alprazolam on flight phobics during exposureBehav Res Ther1997 35831841
Not in our library10.1016/s0005-7967(97)00033-8 (opens in a new tab)
- 351.
Johren P Jackowski J Gangler P Sartory G Thom A Fear reduction in patients with dental treatment phobiaBr J Oral Maxillofac Surg2000 38612616
Not in our library10.1054/bjom.2000.0531 (opens in a new tab)
- 352.
Tschirch FT Suter K Froehlich JM Studler U Nidecker A Eckhardt B Beranek-Chiu J Surber C Weishaupt D Multicenter trial: comparison of two different formulations and application systems of low-dose nasal midazolam for routine magnetic resonance imaging of claustrophobic patientsJ Magn Reson Imaging2008 28866872
Not in our library10.1002/jmri.21552 (opens in a new tab)
- 353.
Tschirch FT Gopfert K Frohlich JM Brunner G Weishaupt D Low-dose intranasal versus oral midazolam for routine body MRI of claustrophobic patientsEur Radiol2007 1714031410
Not in our library10.1007/s00330-006-0457-1 (opens in a new tab)
- 354.
Mather AA Stein MB Sareen J Social anxiety disorder and social fears in the Canadian military: prevalence, comorbidity, impairment, and treatment-seekingJ Psychiatr Res2010 44887893
Not in our library10.1016/j.jpsychires.2010.02.013 (opens in a new tab)
- 355.
Beesdo K Bittner A Pine DS Stein MB Hofler M Lieb R Wittchen HU Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of lifeArch Gen Psychiatry2007 64903912
Not in our library10.1001/archpsyc.64.8.903 (opens in a new tab)
- 356.
Shields M Social anxiety disorder--beyond shynessHealth Rep2004 15Suppl4561
Not in our library
- 357.
Magee W Eaton W Wittchen H McGonagle K Kessler R Agoraphobia, simple phobia, and social phobia in the National Comorbidity SurveyArch Gen Psychiatry1996 53159168
Not in our library10.1001/archpsyc.1996.01830020077009 (opens in a new tab)
- 358.
Stein M Walker J Forde D Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxietyAm J Psychiatry1994 151408412
Not in our library10.1176/ajp.151.3.408 (opens in a new tab)
- 359.
Schneier F Johnson J Hornig C Liebowitz M Weissman M Social phobia. Comorbidity and morbidity in an epidemiologic sampleArch Gen Psychiatry1992 49282288
Not in our library10.1001/archpsyc.1992.01820040034004 (opens in a new tab)
- 360.
Ohayon MM Schatzberg AF Social phobia and depression: prevalence and comorbidityJ Psychosom Res2010 68235243
Not in our library10.1016/j.jpsychores.2009.07.018 (opens in a new tab)
- 361.
Stein DJ Ruscio AM Lee S Petukhova M Alonso J Andrade LH Benjet C Bromet E Demyttenaere K Florescu S Subtyping social anxiety disorder in developed and developing countriesDepress Anxiety2010 27390403
Not in our library10.1002/da.20639 (opens in a new tab)
- 362.
Ramsawh HJ Raffa SD Edelen MO Rende R Keller MB Anxiety in middle adulthood: effects of age and time on the 14-year course of panic disorder, social phobia and generalized anxiety disorderPsychol Med2009 39615624
Not in our library10.1017/s0033291708003954 (opens in a new tab)
- 363.
Ruscio AM Brown TA Chiu WT Sareen J Stein MB Kessler RC Social fears and social phobia in the USA: results from the National Comorbidity Survey ReplicationPsychol Med2008 381528
Not in our library10.1017/s0033291707001699 (opens in a new tab)
- 364.
Acarturk C Smit F de Graaf R van Straten A ten Have M Cuijpers P Incidence of social phobia and identification of its risk indicators: a model for preventionActa Psychiatr Scand2009 1196270
Not in our library10.1111/j.1600-0447.2008.01275.x (opens in a new tab)
- 365.
Kessler R Stein M Berglund P Social phobia subtypes in the National Comorbidity SurveyAm J Psychiatry1998 155613619
Not in our library10.1176/ajp.155.5.613 (opens in a new tab)
- 366.
Wong N Sarver DE Beidel DC Quality of life impairments among adults with social phobia: the impact of subtypeJ Anxiety Disord2012 265057
Not in our library10.1016/j.janxdis.2011.08.012 (opens in a new tab)
- 367.
Aderka IM Hofmann SG Nickerson A Hermesh H Gilboa-Schechtman E Marom S Functional impairment in social anxiety disorderJ Anxiety Disord2012 26393400
Not in our library10.1016/j.janxdis.2012.01.003 (opens in a new tab)
- 368.
Tolman RM Himle J Bybee D Abelson JL Hoffman J Van Etten-Lee M Impact of social anxiety disorder on employment among women receiving welfare benefitsPsychiatr Serv2009 606166
Not in our library10.1176/ps.2009.60.1.61 (opens in a new tab)
- 369.
Moitra E Beard C Weisberg RB Keller MB Occupational impairment and social anxiety disorder in a sample of primary care patientsJ Affect Disord2011 130209212
Not in our library10.1016/j.jad.2010.09.024 (opens in a new tab)
- 370.
Acarturk C Smit F de Graaf R van Straten A Ten Have M Cuijpers P Economic costs of social phobia: a population-based studyJ Affect Disord2009 115421429
Not in our library10.1016/j.jad.2008.10.008 (opens in a new tab)
- 371.
Smit F Cuijpers P Oostenbrink J Batelaan N de Graaf R Beekman A Costs of nine common mental disorders: implications for curative and preventive psychiatryJ Ment Health Policy Econ2006 9193200
Not in our library
- 372.
Filho AS Hetem LA Ferrari MC Trzesniak C Martin-Santos R Borduqui T de Lima F Osorio Loureiro SR Busatto G Filho Zuardi AW Crippa JA Social anxiety disorder: what are we losing with the current diagnostic criteria?Acta Psychiatr Scand2010 121216226
Not in our library10.1111/j.1600-0447.2009.01459.x (opens in a new tab)
- 373.
Cox BJ Turnbull DL Robinson JA Grant BF Stein MB The effect of avoidant personality disorder on the persistence of generalized social anxiety disorder in the general population: results from a longitudinal, nationally representative mental health surveyDepress Anxiety2011 28250255
Not in our library10.1002/da.20787 (opens in a new tab)
- 374.
Kelly MM Walters C Phillips KA Social anxiety and its relationship to functional impairment in body dysmorphic disorderBehav Ther2010 41143153
Not in our library10.1016/j.beth.2009.01.005 (opens in a new tab)
- 375.
Coles ME Phillips KA Menard W Pagano ME Fay C Weisberg RB Stout RL Body dysmorphic disorder and social phobia: cross-sectional and prospective dataDepress Anxiety2006 232633
Not in our library10.1002/da.20132 (opens in a new tab)
- 376.
Book SW Thomas SE Randall PK Randall CL Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorderJ Anxiety Disord2008 22310318
Not in our library10.1016/j.janxdis.2007.03.001 (opens in a new tab)
- 377.
Bernardi S Faraone SV Cortese S Kerridge BT Pallanti S Wang S Blanco C The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)Psychol Med2012 42875887
Not in our library10.1017/s003329171100153x (opens in a new tab)
- 378.
Van Ameringen M Mancini C Simpson W Patterson B Adult attention deficit hyperactivity disorder in an anxiety disorders populationCNS Neurosci Ther2011 17221226
Not in our library10.1111/j.1755-5949.2010.00148.x (opens in a new tab)
- 379.
Stern RG Petti TA Bopp K Tobia A Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper studyJ Clin Psychopharmacol2009 29206209
Not in our library10.1097/jcp.0b013e3181a48e12 (opens in a new tab)
- 380.
Bogels SM Alden L Beidel DC Clark LA Pine DS Stein MB Voncken M Social anxiety disorder: questions and answers for the DSM-VDepress Anxiety2010 27168189
Not in our library10.1002/da.20670 (opens in a new tab)
- 381.
Taylor S Meta-analysis of cognitive-behavioral treatments for social phobiaJ Behav Ther Exp Psychiatry1996 2719
Not in our library10.1016/0005-7916(95)00058-5 (opens in a new tab)
- 382.
Clark DM Ehlers A McManus F Hackmann A Fennell M Campbell H Flower T Davenport C Louis B Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trialJ Consult Clin Psychol2003 7110581067
Not in our library10.1037/0022-006x.71.6.1058 (opens in a new tab)
- 383.
Clark D Agras W The assessment and treatment of performance anxiety in musiciansAm J Psychiatry1991 148598605
Not in our library10.1176/ajp.148.5.598 (opens in a new tab)
- 384.
Heimberg R Liebowitz M Hope D Schneier F Holt C Welkowitz L Juster H Campeas R Bruch M Cloitre M Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcomeArch Gen Psychiatry1998 5511331141
Not in our library10.1001/archpsyc.55.12.1133 (opens in a new tab)
- 385.
Otto M Pollack M Gould R Worthington J McArdle E Rosenbaum J A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobiaJ Anxiety Disord2000 14345358
Not in our library10.1016/s0887-6185(00)00027-x (opens in a new tab)
- 386.
Gelernter C Uhde T Cimbolic P Arnkoff D Vittone B Tancer M Bartko J Cognitive-behavioral and pharmacological treatments of social phobia. A controlled studyArch Gen Psychiatry1991 48938945
Not in our library10.1001/archpsyc.1991.01810340070009 (opens in a new tab)
- 387.
Davidson JR Foa EB Huppert JD Keefe FJ Franklin ME Compton JS Zhao N Connor KM Lynch TR Gadde KM Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobiaArch Gen Psychiatry2004 6110051013
Not in our library10.1001/archpsyc.61.10.1005 (opens in a new tab)
- 388.
Liebowitz M Heimberg R Schneier F Hope D Davies S Holt C Goetz D Juster H Lin S Bruch M Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcomeDepress Anxiety1999 108998
Not in our library
- 389.
Haug T Blomhoff S Hellstrom K Holme I Humble M Madsbu H Wold J Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trialBr J Psychiatry2003 182312318
Not in our library10.1192/bjp.182.4.312 (opens in a new tab)
- 390.
Stangier U Heidenreich T Peitz M Lauterbach W Clark DM Cognitive therapy for social phobia: individual versus group treatmentBehav Res Ther2003 419911007
Not in our library10.1016/s0005-7967(02)00176-6 (opens in a new tab)
- 391.
Mortberg E Clark DM Sundin O Aberg Wistedt A Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trialActa Psychiatr Scand2007 115142154
Not in our library10.1111/j.1600-0447.2006.00839.x (opens in a new tab)
- 392.
Hofmann SG Cognitive mediation of treatment change in social phobiaJ Consult Clin Psychol2004 72393399
Not in our library10.1037/0022-006x.72.3.392 (opens in a new tab)
- 393.
Salaberria K Echeburua E Long-term outcome of cognitive therapy's contribution to self-exposure in vivo to the treatment of generalized social phobiaBehav Modif1998 22262284
Not in our library10.1177/01454455980223003 (opens in a new tab)
- 394.
Clark DM Ehlers A Hackmann A McManus F Fennell M Grey N Waddington L Wild J Cognitive therapy versus exposure and applied relaxation in social phobia: a randomized controlled trialJ Consult Clin Psychol2006 74568578
Not in our library10.1037/0022-006x.74.3.568 (opens in a new tab)
- 395.
Borgeat F Stankovic M Khazaal Y Rouget BW Baumann MC Riquier F O'Connor K Jermann F Zullino D Bondolfi G Does the form or the amount of exposure make a difference in the cognitive-behavioral therapy treatment of social phobia?J Nerv Ment Dis2009 197507513
Not in our library10.1097/nmd.0b013e3181aacc08 (opens in a new tab)
- 396.
Smits JA Powers MB Buxkamper R Telch MJ The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigationBehav Res Ther2006 4417731785
Not in our library10.1016/j.brat.2006.01.001 (opens in a new tab)
- 397.
Alden LE Taylor CT Relational treatment strategies increase social approach behaviors in patients with generalized social anxiety disorderJ Anxiety Disord2011 25309318
Not in our library10.1016/j.janxdis.2010.10.003 (opens in a new tab)
- 398.
Lipsitz JD Gur M Vermes D Petkova E Cheng J Miller N Laino J Liebowitz MR Fyer AJ A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorderDepress Anxiety2008 25542553
Not in our library10.1002/da.20364 (opens in a new tab)
- 399.
Stangier U Schramm E Heidenreich T Berger M Clark DM Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trialArch Gen Psychiatry2011 68692700
Not in our library10.1001/archgenpsychiatry.2011.67 (opens in a new tab)
- 400.
Borge FM Hoffart A Sexton H Clark DM Markowitz JC McManus F Residential cognitive therapy versus residential interpersonal therapy for social phobia: a randomized clinical trialJ Anxiety Disord2008 229911010
Not in our library10.1016/j.janxdis.2007.10.002 (opens in a new tab)
- 401.
Koszycki D Benger M Shlik J Bradwejn J Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorderBehav Res Ther2007 4525182526
Not in our library10.1016/j.brat.2007.04.011 (opens in a new tab)
- 402.
Schmidt NB Richey JA Buckner JD Timpano KR Attention training for generalized social anxiety disorderJ Abnorm Psychol2009 118514
Not in our library10.1037/a0013643 (opens in a new tab)
- 403.
Li S Tan J Qian M Liu X Continual training of attentional bias in social anxietyBehav Res Ther2008 46905912
Not in our library10.1016/j.brat.2008.04.005 (opens in a new tab)
- 404.
Berger T Hohl E Caspar F Internet-based treatment for social phobia: a randomized controlled trialJ Clin Psychol2009 6510211035
Not in our library10.1002/jclp.20603 (opens in a new tab)
- 405.
Carlbring P Gunnarsdottir M Hedensjo L Andersson G Ekselius L Furmark T Treatment of social phobia: randomised trial of internet-delivered cognitive-behavioural therapy with telephone supportBr J Psychiatry2007 190123128
Not in our library10.1192/bjp.bp.105.020107 (opens in a new tab)
- 406.
Titov N Andrews G Choi I Schwencke G Mahoney A Shyness 3: randomized controlled trial of guided versus unguided Internet-based CBT for social phobiaAust N Z J Psychiatry2008 4210301040
Not in our library10.1080/00048670802512107 (opens in a new tab)
- 407.
Titov N Andrews G Schwencke G Shyness 2: treating social phobia online: replication and extensionAust N Z J Psychiatry2008 42595605
Not in our library10.1080/00048670802119820 (opens in a new tab)
- 408.
Titov N Andrews G Schwencke G Drobny J Einstein D Shyness 1: distance treatment of social phobia over the InternetAust N Z J Psychiatry2008 42585594
Not in our library10.1080/00048670802119762 (opens in a new tab)
- 409.
Andersson G Carlbring P Holmstrom A Sparthan E Furmark T Nilsson-Ihrfelt E Buhrman M Ekselius L Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trialJ Consult Clin Psychol2006 74677686
Not in our library10.1037/0022-006x.74.4.677 (opens in a new tab)
- 410.
Furmark T Carlbring P Hedman E Sonnenstein A Clevberger P Bohman B Eriksson A Hallen A Frykman M Holmstrom A Guided and unguided self-help for social anxiety disorder: randomised controlled trialBr J Psychiatry2009 195440447
Not in our library10.1192/bjp.bp.108.060996 (opens in a new tab)
- 411.
Berger T Caspar F Richardson R Kneubuhler B Sutter D Andersson G Internet-based treatment of social phobia: a randomized controlled trial comparing unguided with two types of guided self-helpBehav Res Ther2011 49158169
Not in our library10.1016/j.brat.2010.12.007 (opens in a new tab)
- 412.
Rapee RM Abbott MJ Baillie AJ Gaston JE Treatment of social phobia through pure self-help and therapist-augmented self-helpBr J Psychiatry2007 191246252
Not in our library10.1192/bjp.bp.106.028167 (opens in a new tab)
- 413.
Tillfors M Carlbring P Furmark T Lewenhaupt S Spak M Eriksson A Westling BE Andersson G Treating university students with social phobia and public speaking fears: Internet delivered self-help with or without live group exposure sessionsDepress Anxiety2008 25708717
Not in our library10.1002/da.20416 (opens in a new tab)
- 414.
- 415.
Andrews G Davies M Titov N Effectiveness randomized controlled trial of face to face versus Internet cognitive behaviour therapy for social phobiaAust N Z J Psychiatry2011 45337340
Not in our library10.3109/00048674.2010.538840 (opens in a new tab)
- 416.
Hedman E Andersson E Ljotsson B Andersson G Ruck C Lindefors N Cost-effectiveness of Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: results from a randomized controlled trialBehav Res Ther2011 49729736
Not in our library10.1016/j.brat.2011.07.009 (opens in a new tab)
- 417.
Prasko J Dockery C Horacek J Houbova P Kosova J Klaschka J Paskova B Praskova H Seifertova D Zalesky R Hoschl C Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow upNeuro Endocrinol Lett2006 27473481
Not in our library
- 418.
Blanco C Heimberg RG Schneier FR Fresco DM Chen H Turk CL Vermes D Erwin BA Schmidt AB Juster HR A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorderArch Gen Psychiatry2010 67286295
Not in our library10.1001/archgenpsychiatry.2010.11 (opens in a new tab)
- 419.
Guastella AJ Richardson R Lovibond PF Rapee RM Gaston JE Mitchell P Dadds MR A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorderBiol Psychiatry2008 63544549
Not in our library10.1016/j.biopsych.2007.11.011 (opens in a new tab)
- 420.
Hofmann SG Meuret AE Smits JA Simon NM Pollack MH Eisenmenger K Shiekh M Otto MW Augmentation of exposure therapy with d-cycloserine for social anxiety disorderArch Gen Psychiatry2006 63298304
Not in our library10.1001/archpsyc.63.3.298 (opens in a new tab)
- 421.
Knijnik DZ Blanco C Salum GA Moraes CU Mombach C Almeida E Pereira M Strapasson A Manfro GG Eizirik CL A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorderEur Psychiatry2008 23567574
Not in our library10.1016/j.eurpsy.2008.05.004 (opens in a new tab)
- 422.
Watanabe N Furukawa TA Chen J Kinoshita Y Nakano Y Ogawa S Funayama T Ietsugu T Noda Y Change in quality of life and their predictors in the long-term follow-up after group cognitive behavioral therapy for social anxiety disorder: a prospective cohort studyBMC Psychiatry2010 1081
Not in our library10.1186/1471-244x-10-81 (opens in a new tab)
- 423.
Carlbring P Nordgren LB Furmark T Andersson G Long-term outcome of Internet-delivered cognitive-behavioural therapy for social phobia: a 30-month follow-upBehav Res Ther2009 47848850
Not in our library10.1016/j.brat.2009.06.012 (opens in a new tab)
- 424.
- 425.
Mortberg E Clark DM Bejerot S Intensive group cognitive therapy and individual cognitive therapy for social phobia: sustained improvement at 5-year follow-upJ Anxiety Disord2011 259941000
Not in our library10.1016/j.janxdis.2011.06.007 (opens in a new tab)
- 426.
van der Linden G Stein D van Balkom A The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trialsInt Clin Psychopharmacol2000 15Suppl 2S1523
Not in our library10.1097/00004850-200008002-00004 (opens in a new tab)
- 427.
Canton J Scott KM Glue P Optimal treatment of social phobia: systematic review and meta-analysisNeuropsychiatr Dis Treat2012 8203215
Not in our library10.2147/ndt.s23317 (opens in a new tab)
- 428.
Stein DJ Ipser JC Balkom AJ Pharmacotherapy for social phobiaCochrane Database Syst Rev2004 CD001206
Not in our library10.1002/14651858.cd001206.pub2 (opens in a new tab)
- 429.
Hedges DW Brown BL Shwalb DA Godfrey K Larcher AM The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trialsJ Psychopharmacol2007 21102111
Not in our library10.1177/0269881106065102 (opens in a new tab)
- 430.
Kasper S Stein D Loft H Nil R Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage studyBr J Psychiatry2005 186222226
Not in our library10.1192/bjp.186.3.222 (opens in a new tab)
- 431.
Lader M Stender K Burger V Nil R Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose studyDepress Anxiety2004 19241248
Not in our library10.1002/da.20014 (opens in a new tab)
- 432.
Pallanti S Quercioli L Resistant social anxiety disorder response to escitalopramClin Pract Epidemiol Ment Health2006 235
Not in our library10.1186/1745-0179-2-35 (opens in a new tab)
- 433.
van Vliet I den Boer J Westenberg H Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxaminePsychopharmacology (Berl)1994 115128134
Not in our library10.1007/bf02244762 (opens in a new tab)
- 434.
Stein M Fyer A Davidson J Pollack M Wiita B Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled studyAm J Psychiatry1999 156756760
Not in our library10.1176/ajp.156.5.756 (opens in a new tab)
- 435.
Asakura S Tajima O Koyama T Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled studyInt J Neuropsychopharmacol2007 10263274
Not in our library10.1017/s1461145706006602 (opens in a new tab)
- 436.
Davidson J Yaryura-Tobias J Du Pont R Stallings L Barbato L van dHR Li D Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorderJ Clin Psychopharmacol2004 24118125
Not in our library10.1097/01.jcp.0000106222.36344.96 (opens in a new tab)
- 437.
Westenberg H Stein D Yang H Li D Barbato L A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorderJ Clin Psychopharmacol2004 244955
Not in our library10.1097/01.jcp.0000104906.75206.8b (opens in a new tab)
- 438.
Allgulander C Paroxetine in social anxiety disorder: a randomized placebo-controlled studyActa Psychiatr Scand1999 100193198
Not in our library10.1111/j.1600-0447.1999.tb10845.x (opens in a new tab)
- 439.
Allgulander C Mangano R Zhang J Dahl AA Lepola U Sjodin I Emilien G Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetineHum Psychopharmacol2004 19387396
Not in our library10.1002/hup.602 (opens in a new tab)
- 440.
Baldwin D Bobes J Stein D Scharwachter I Faure M Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study GroupBr J Psychiatry1999 175120126
Not in our library10.1192/bjp.175.2.120 (opens in a new tab)
- 441.
Liebowitz M Gelenberg A Munjack D Venlafaxine extended release vs placebo and paroxetine in social anxiety disorderArch Gen Psychiatry2005 62190198
Not in our library10.1001/archpsyc.62.2.190 (opens in a new tab)
- 442.
Liebowitz M Stein M Tancer M Carpenter D Oakes R Pitts C A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorderJ Clin Psychiatry2002 636674
Not in our library10.4088/jcp.v63n0113 (opens in a new tab)
- 443.
Stein D Berk M Els C Emsley R Gittelson L Wilson D Oakes R Hunter B A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South AfricaS Afr Med J1999 89402406
Not in our library
- 444.
Stein M Liebowitz M Lydiard R Pitts C Bushnell W Gergel I Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trialJAMA1998 280708713
Not in our library10.1001/jama.280.8.708 (opens in a new tab)
- 445.
Katzelnick D Kobak K Greist J Jefferson J Mantle J Serlin R Sertraline for social phobia: a double-blind, placebo-controlled crossover studyAm J Psychiatry1995 15213681371
Not in our library10.1176/ajp.152.9.1368 (opens in a new tab)
- 446.
Liebowitz M De Martinis N Weihs K Londborg P Smith W Chung H Fayyad R Clary C Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled studyJ Clin Psychiatry2003 64785792
Not in our library10.4088/jcp.v64n0708 (opens in a new tab)
- 447.
Van Ameringen M Lane R Walker J Bowen R Chokka P Goldner E Johnston D Lavallee Y Nandy S Pecknold J Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled studyAm J Psychiatry2001 158275281
Not in our library10.1176/appi.ajp.158.2.275 (opens in a new tab)
- 448.
Blomhoff S Haug T Hellstrom K Holme I Humble M Madsbu H Wold J Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobiaBr J Psychiatry2001 1792330
Not in our library10.1192/bjp.179.1.23 (opens in a new tab)
- 449.
Kobak K Greist J Jefferson J Katzelnick D Fluoxetine in social phobia: a double-blind, placebo-controlled pilot studyJ Clin Psychopharmacol2002 22257262
Not in our library10.1097/00004714-200206000-00005 (opens in a new tab)
- 450.
Atmaca M Kuloglu M Tezcan E Unal A Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findingsHum Psychopharmacol2002 17401405
Not in our library10.1002/hup.436 (opens in a new tab)
- 451.
Furmark T Appel L Michelgard A Wahlstedt K Ahs F Zancan S Jacobsson E Flyckt K Grohp M Bergstrom M Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placeboBiol Psychiatry2005 58132142
Not in our library10.1016/j.biopsych.2005.03.029 (opens in a new tab)
- 452.
Lepola U Bergtholdt B St Lambert J Davy KL Ruggiero L Controlled-release paroxetine in the treatment of patients with social anxiety disorderJ Clin Psychiatry2004 65222229
Not in our library10.4088/jcp.v65n0213 (opens in a new tab)
- 453.
Schutters S van Megen H Van Veen J Schruers K Westenberg H Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placeboHum Psychopharmacol Clin Exp2011 267276
Not in our library10.1002/hup.1165 (opens in a new tab)
- 454.
Liebowitz M Mangano R Bradwejn J Asnis G A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorderJ Clin Psychiatry2005 66238247
Not in our library10.4088/jcp.v66n0213 (opens in a new tab)
- 455.
Rickels K Mangano R Khan A A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorderJ Clin Psychopharmacol2004 24488496
Not in our library10.1097/01.jcp.0000138764.31106.60 (opens in a new tab)
- 456.
Stein M Pollack M Bystritsky A Kelsey J Mangano R Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trialPsychopharmacology (Berl)2005 177280288
Not in our library10.1007/s00213-004-1957-9 (opens in a new tab)
- 457.
Simon NM Worthington JJ Moshier SJ Marks EH Hoge EA Brandes M Delong H Pollack MH Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize responseCNS Spectr2010 15367373
Not in our library
- 458.
Gringras M An uncontrolled trial of clomipramine (Anafranil) in the treatment of phobic and obsessional states in general practiceJ Int Med Res1977 5Suppl 5111115
Not in our library
- 459.
Beaumont G A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disordersJ Int Med Res1977 5Suppl 5116123
Not in our library
- 460.
Simpson H Schneier F Campeas R Marshall R Fallon B Davies S Klein D Liebowitz M Imipramine in the treatment of social phobiaJ Clin Psychopharmacol1998 18132135
Not in our library10.1097/00004714-199804000-00005 (opens in a new tab)
- 461.
Liebowitz M Schneier F Campeas R Hollander E Hatterer J Fyer A Gorman J Papp L Davies S Gully R Phenelzine vs atenolol in social phobia. A placebo-controlled comparisonArch Gen Psychiatry1992 49290300
Not in our library10.1001/archpsyc.49.4.290 (opens in a new tab)
- 462.
Versiani M Nardi A Mundim F Alves A Liebowitz M Amrein R Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzineBr J Psychiatry1992 161353360
Not in our library10.1192/bjp.161.3.353 (opens in a new tab)
- 463.
International Multicenter Clinical Trial Group on Moclobemide in Social PhobiaMoclobemide in social phobia. A double-blind, placebo-controlled clinical studyEur Arch Psychiatry Clin Neurosci1997 2477180
Not in our library
- 464.
Stein D Cameron A Amrein R Montgomery S Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorderInt Clin Psychopharmacol2002 17161170
Not in our library10.1097/00004850-200207000-00002 (opens in a new tab)
- 465.
Noyes R Moroz G Davidson J Liebowitz M Davidson A Siegel J Bell J Cain J Curlik S Kent T Moclobemide in social phobia: a controlled dose-response trialJ Clin Psychopharmacol1997 17247254
Not in our library10.1097/00004714-199708000-00002 (opens in a new tab)
- 466.
Schneier F Goetz D Campeas R Fallon B Marshall R Liebowitz M Placebo-controlled trial of moclobemide in social phobiaBr J Psychiatry1998 1727077
Not in our library10.1192/bjp.172.1.70 (opens in a new tab)
- 467.
Schutters SI Van Megen HJ Van Veen JF Denys DA Westenberg HG Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled studyInt Clin Psychopharmacol2010 25302304
Not in our library10.1097/yic.0b013e32833a4d71 (opens in a new tab)
- 468.
Muehlbacher M Nickel MK Nickel C Kettler C Lahmann C Pedrosa Gil F Leiberich PK Rother N Bachler E Fartacek R Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol2005 25580583
Not in our library10.1097/01.jcp.0000186871.04984.8d (opens in a new tab)
- 469.
Emmanuel NP Brawman-Mintzer O Morton WA Book SW Johnson MR Lorberbaum JP Ballenger JC Lydiard RB Bupropion-SR in treatment of social phobiaDepress Anxiety2000 12111113
Not in our library10.1002/1520-6394(2000)12:2<111::aid-da9>3.0.co;2-3 (opens in a new tab)
- 470.
Davidson J Potts N Richichi E Krishnan R Ford S Smith R Wilson W Treatment of social phobia with clonazepam and placeboJ Clin Psychopharmacol1993 13423428
Not in our library
- 471.
Munjack D Baltazar P Bohn P Cabe D Appleton A Clonazepam in the treatment of social phobia: a pilot studyJ Clin Psychiatry1990 51Suppl3540discussion 50-33
Not in our library
- 472.
Versiani M Nardi A Figuera I Marques C Double-blind placebo controlled trial with bromazepam in social phobiaJ Bras Psiquiatr1997 46167171
Not in our library
- 473.
Seedat S Stein M Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorderJ Clin Psychiatry2004 65244248
Not in our library
- 474.
Pande A Feltner D Jefferson J Davidson J Pollack M Stein M Lydiard R Futterer R Robinson P Slomkowski M Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter studyJ Clin Psychopharmacol2004 24141149
Not in our library10.1097/01.jcp.0000117423.05703.e7 (opens in a new tab)
- 475.
Feltner DE Liu-Dumaw M Schweizer E Bielski R Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose studyInt Clin Psychopharmacol2011 26213220
Not in our library10.1097/yic.0b013e32834519bd (opens in a new tab)
- 476.
Pande A Davidson J Jefferson J Janney C Katzelnick D Weisler R Greist J Sutherland S Treatment of social phobia with gabapentin: a placebo-controlled studyJ Clin Psychopharmacol1999 19341348
Not in our library10.1097/00004714-199908000-00010 (opens in a new tab)
- 477.
Urbano MR Spiegel DR Laguerta N Shrader CJ Rowe DF Hategan LF Gabapentin and tiagabine for social anxiety: a randomized, double-blind, crossover study of 8 adults [Letter]Prim Care Companion J Clin Psychiatry2009 11123
Not in our library10.4088/pcc.08l00641 (opens in a new tab)
- 478.
Zhang W Connor KM Davidson JR Levetiracetam in social phobia: a placebo controlled pilot studyJ Psychopharmacol2005 19551553
Not in our library10.1177/0269881105056526 (opens in a new tab)
- 479.
Simon NM Worthington JJ Doyle AC Hoge EA Kinrys G Fischmann D Link N Pollack MH An open-label study of levetiracetam for the treatment of social anxiety disorderJ Clin Psychiatry2004 6512191222
Not in our library10.4088/jcp.v65n0909 (opens in a new tab)
- 480.
Stein MB Ravindran LN Simon NM Liebowitz MR Khan A Brawman-Mintzer O Lydiard RB Pollack MH Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trialJ Clin Psychiatry2010 71627631
Not in our library10.4088/jcp.08m04949gre (opens in a new tab)
- 481.
Kinrys G Pollack MH Simon NM Worthington JJ Nardi AE Versiani M Valproic acid for the treatment of social anxiety disorderInt Clin Psychopharmacol2003 18169172
Not in our library10.1097/01.yic.0000064261.66765.9f (opens in a new tab)
- 482.
Dunlop BW Papp L Garlow SJ Weiss PS Knight BT Ninan PT Tiagabine for social anxiety disorderHum Psychopharmacol2007 22241244
Not in our library10.1002/hup.846 (opens in a new tab)
- 483.
Van Ameringen M Mancini C Pipe B Oakman J Bennett M An open trial of topiramate in the treatment of generalized social phobiaJ Clin Psychiatry2004 6516741678
Not in our library10.4088/jcp.v65n1213 (opens in a new tab)
- 484.
Turner SM Beidel DC Jacob RG Social phobia: a comparison of behavior therapy and atenololJ Consult Clin Psychol1994 62350358
Not in our library10.1037//0022-006x.62.2.350 (opens in a new tab)
- 485.
van Vliet I den Boer J Westenberg H Pian K Clinical effects of buspirone in social phobia: a double-blind placebo-controlled studyJ Clin Psychiatry1997 58164168
Not in our library10.4088/jcp.v58n0405 (opens in a new tab)
- 486.
Ravindran LN Kim DS Letamendi AM Stein MB A randomized controlled trial of atomoxetine in generalized social anxiety disorderJ Clin Psychopharmacol2009 29561564
Not in our library10.1097/jcp.0b013e3181bf6303 (opens in a new tab)
- 487.
Adler LA Liebowitz M Kronenberger W Qiao M Rubin R Hollandbeck M Deldar A Schuh K Durell T Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorderDepress Anxiety2009 26212221
Not in our library10.1002/da.20549 (opens in a new tab)
- 488.
Falloon IR Lloyd GG Harpin RE The treatment of social phobia. Real-life rehearsal with nonprofessional therapistsJ Nerv Ment Dis1981 169180184
Not in our library10.1097/00005053-198103000-00005 (opens in a new tab)
- 489.
Simpson HB Schneier FR Marshall RD Campeas RB Vermes D Silvestre J Davies S Liebowitz MR Low dose selegiline (L-Deprenyl) in social phobiaDepress Anxiety1998 7126129
Not in our library
- 490.
Villarreal G Johnson MR Rubey R Lydiard RB Ballanger JC Treatment of social phobia with the dopamine agonist pergolideDepress Anxiety2000 114547
Not in our library10.1002/(sici)1520-6394(2000)11:1<45::aid-da8>3.0.co;2-8 (opens in a new tab)
- 491.
Van Ameringen M Mancini C Wilson C Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobiaJ Affect Disord1996 39115121
Not in our library10.1016/0165-0327(96)00030-4 (opens in a new tab)
- 492.
Stein M Sareen J Hami S Chao J Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover studyAm J Psychiatry2001 15817251727
Not in our library10.1176/appi.ajp.158.10.1725 (opens in a new tab)
- 493.
Barnett S Kramer M Casat C Connor K Davidson J Efficacy of olanzapine in social anxiety disorder: a pilot studyJ Psychopharmacol2002 16365368
Not in our library10.1177/026988110201600412 (opens in a new tab)
- 494.
Schutters SI van Megen HJ Westenberg HG Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study [Letter]J Clin Psychiatry2005 66540542
Not in our library10.4088/jcp.v66n0420b (opens in a new tab)
- 495.
Vaishnavi S Alamy S Zhang W Connor KM Davidson JR Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled studyProg Neuropsychopharmacol Biol Psychiatry2007 3114641469
Not in our library10.1016/j.pnpbp.2007.06.027 (opens in a new tab)
- 496.
Worthington J Kinrys G Wygant L Pollack M Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patientsInt Clin Psychopharmacol2005 20911
Not in our library10.1097/00004850-200501000-00002 (opens in a new tab)
- 497.
Donovan MR Glue P Kolluri S Emir B Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysisJ Affect Disord2010 123916
Not in our library10.1016/j.jad.2009.06.021 (opens in a new tab)
- 498.
Greist JH Liu-Dumaw M Schweizer E Feltner D Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week studyInt Clin Psychopharmacol2011 26243251
Not in our library10.1097/yic.0b013e3283491fd5 (opens in a new tab)
- 499.
Stein D Westenberg H Yang H Li D Barbato L Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trialInt J Neuropsychopharmacol2003 6317323
Not in our library10.1017/s146114570300364x (opens in a new tab)
- 500.
Versiani M Amrein R Montgomery S Social phobia: long-term treatment outcome and prediction of response--a moclobemide studyInt Clin Psychopharmacol1997 12239254
Not in our library
- 501.
Fontani V Mannu P Castagna A Rinaldi S Social anxiety disorder: radio electric asymmetric conveyor brain stimulation versus sertralinePatient Prefer Adherence2011 5581586
Not in our library10.2147/ppa.s27409 (opens in a new tab)
- 502.
Kobak K Taylor L Warner G Futterer R St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot studyJ Clin Psychopharmacol2005 255158
Not in our library10.1097/01.jcp.0000150227.61501.00 (opens in a new tab)
- 503.
Gwynn RC McQuistion HL McVeigh KH Garg RK Frieden TR Thorpe LE Prevalence, diagnosis, and treatment of depression and generalized anxiety disorder in a diverse urban communityPsychiatr Serv2008 59641647
Not in our library10.1176/ps.2008.59.6.641 (opens in a new tab)
- 504.
Asnaani A Richey JA Dimaite R Hinton DE Hofmann SG A cross-ethnic comparison of lifetime prevalence rates of anxiety disordersJ Nerv Ment Dis2010 198551555
Not in our library10.1097/nmd.0b013e3181ea169f (opens in a new tab)
- 505.
Grant BF Hasin DS Stinson FS Dawson DA June Ruan W Goldstein RB Smith SM Saha TD Huang B Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related ConditionsPsychol Med2005 3517471759
Not in our library10.1017/s0033291705006069 (opens in a new tab)
- 506.
Albano A Chorpita B Barlow D Mash E, Barkley RChildhood anxiety disordersChild psychopathology2003 2New York, NY: Guilford279329
Not in our library
- 507.
Beesdo K Pine DS Lieb R Wittchen HU Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorderArch Gen Psychiatry2010 674757
Not in our library10.1001/archgenpsychiatry.2009.177 (opens in a new tab)
- 508.
Ansseau M Fischler B Dierick M Albert A Leyman S Mignon A Socioeconomic correlates of generalized anxiety disorder and major depression in primary care: the GADIS II study (Generalized Anxiety and Depression Impact Survey II)Depress Anxiety2008 25506513
Not in our library10.1002/da.20306 (opens in a new tab)
- 509.
Byers AL Yaffe K Covinsky KE Friedman MB Bruce ML High occurrence of mood and anxiety disorders among older adults: the National Comorbidity Survey ReplicationArch Gen Psychiatry2010 67489496
Not in our library10.1001/archgenpsychiatry.2010.35 (opens in a new tab)
- 510.
Mackenzie CS Reynolds K Chou KL Pagura J Sareen J Prevalence and correlates of generalized anxiety disorder in a national sample of older adultsAm J Geriatr Psychiatry2011 19305315
Not in our library10.1097/jgp.0b013e318202bc62 (opens in a new tab)
- 511.
Revicki DA Travers K Wyrwich KW Svedsater H Locklear J Mattera MS Sheehan DV Montgomery S Humanistic and economic burden of generalized anxiety disorder in North America and EuropeJ Affect Disord2012 140103112
Not in our library10.1016/j.jad.2011.11.014 (opens in a new tab)
- 512.
Baldwin DS Allgulander C Bandelow B Ferre F Pallanti S An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorderWorld J Biol Psychiatry2012 13510516
Not in our library10.3109/15622975.2011.624548 (opens in a new tab)
- 513.
Weisberg RB Beard C Pagano ME Maki KM Culpepper L Keller MB Impairment and functioning in a sample of primary care patients with generalized anxiety disorder: results from the primary care anxiety projectPrim Care Companion J Clin Psychiatry2010 12doi 10.4088/PCC.4009m00890blu
Not in our library10.4088/pcc.09m00890blu (opens in a new tab)
- 514.
Zhu B Zhao Z Ye W Marciniak MD Swindle R The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorderJ Nerv Ment Dis2009 197136139
Not in our library10.1097/nmd.0b013e3181963486 (opens in a new tab)
- 515.
Romera I Fernandez-Perez S Montejo AL Caballero F Caballero L Arbesu JA Delgado-Cohen H Desaiah D Polavieja P Gilaberte I Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health statusJ Affect Disord2010 127160168
Not in our library10.1016/j.jad.2010.05.009 (opens in a new tab)
- 516.
Garcia-Campayo J Caballero F Perez M Lopez V Pain related factors in newly diagnosed generalized anxiety disorder patientsActas Esp Psiquiatr2012 40177186
Not in our library
- 517.
Beesdo K Hoyer J Jacobi F Low NC Hofler M Wittchen HU Association between generalized anxiety levels and pain in a community sample: evidence for diagnostic specificityJ Anxiety Disord2009 23684693
Not in our library10.1016/j.janxdis.2009.02.007 (opens in a new tab)
- 518.
Martens EJ de Jonge P Na B Cohen BE Lett H Whooley MA Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease:The Heart and Soul StudyArch Gen Psychiatry2010 67750758
Not in our library10.1001/archgenpsychiatry.2010.74 (opens in a new tab)
- 519.
Tyrer P Seivewright H Johnson T The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorderPsychol Med2004 3413851394
Not in our library10.1017/s0033291704002569 (opens in a new tab)
- 520.
Covin R Ouimet AJ Seeds PM Dozois DJ A meta-analysis of CBT for pathological worry among clients with GADJ Anxiety Disord2008 22108116
Not in our library10.1016/j.janxdis.2007.01.002 (opens in a new tab)
- 521.
Linden M Zubraegel D Baer T Franke U Schlattmann P Efficacy of cognitive behaviour therapy in generalized anxiety disorders. Results of a controlled clinical trial (Berlin CBT-GAD Study)Psychother Psychosom2005 743642
Not in our library10.1159/000082025 (opens in a new tab)
- 522.
Borkovec T Newman M Pincus A Lytle R A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problemsJ Consult Clin Psychol2002 70288298
Not in our library
- 523.
Ferrero A Piero A Fassina S Massola T Lanteri A Daga GA Fassino S A 12-month comparison of brief psychodynamic psychotherapy and pharmacotherapy treatment in subjects with generalised anxiety disorders in a community settingEur Psychiatry2007 22530539
Not in our library10.1016/j.eurpsy.2007.07.004 (opens in a new tab)
- 524.
- 525.
Paxling B Almlov J Dahlin M Carlbring P Breitholtz E Eriksson T Andersson G Guided internet-delivered cognitive behavior therapy for generalized anxiety disorder: a randomized controlled trialCogn Behav Ther2011 40159173
Not in our library10.1080/16506073.2011.576699 (opens in a new tab)
- 526.
Gorini A Pallavicini F Algeri D Repetto C Gaggioli A Riva G Virtual reality in the treatment of generalized anxiety disordersStud Health Technol Inform2010 1543943
Not in our library
- 527.
den Boer PC Wiersma D Ten Vaarwerk I Span MM Stant AD Van den Bosch RJ Cognitive self-therapy for chronic depression and anxiety: a multi-centre randomized controlled studyPsychol Med2007 37329339
Not in our library10.1017/s0033291706009214 (opens in a new tab)
- 528.
Wells A Welford M King P Papageorgiou C Wisely J Mendel E A pilot randomized trial of metacognitive therapy vs applied relaxation in the treatment of adults with generalized anxiety disorderBehav Res Ther2010 48429434
Not in our library10.1016/j.brat.2009.11.013 (opens in a new tab)
- 529.
Conrad A Isaac L Roth WT The psychophysiology of generalized anxiety disorder: 2. Effects of applied relaxationPsychophysiology2008 45377388
Not in our library10.1111/j.1469-8986.2007.00644.x (opens in a new tab)
- 530.
Dugas MJ Brillon P Savard P Turcotte J Gaudet A Ladouceur R Leblanc R Gervais NJ A randomized clinical trial of cognitive-behavioral therapy and applied relaxation for adults with generalized anxiety disorderBehav Ther2010 414658
Not in our library10.1016/j.beth.2008.12.004 (opens in a new tab)
- 531.
Dubois O Salamon R Germain C Poirier MF Vaugeois C Banwarth B Mouaffak F Galinowski A Olie JP Balneotherapy versus paroxetine in the treatment of generalized anxiety disorderComplement Ther Med2010 1817
Not in our library10.1016/j.ctim.2009.11.003 (opens in a new tab)
- 532.
Dugas MJ Marchand A Ladouceur R Further validation of a cognitive-behavioral model of generalized anxiety disorder: diagnostic and symptom specificityJ Anxiety Disord2005 19329343
Not in our library10.1016/j.janxdis.2004.02.002 (opens in a new tab)
- 533.
Roemer L Orsillo SM Salters-Pedneault K Efficacy of an acceptance-based behavior therapy for generalized anxiety disorder: evaluation in a randomized controlled trialJ Consult Clin Psychol2008 7610831089
Not in our library10.1037/a0012720 (opens in a new tab)
- 534.
van der Heiden C Muris P van der Molen HT Randomized controlled trial on the effectiveness of metacognitive therapy and intolerance-of-uncertainty therapy for generalized anxiety disorderBehav Res Ther2012 50100109
Not in our library10.1016/j.brat.2011.12.005 (opens in a new tab)
- 535.
Hoyer J Beesdo K Gloster AT Runge J Hofler M Becker ES Worry exposure versus applied relaxation in the treatment of generalized anxiety disorderPsychother Psychosom2009 78106115
Not in our library10.1159/000201936 (opens in a new tab)
- 536.
Riskind JH Williams NL Joiner TE Jr The looming cognitive style: A cognitive vulnerability for anxiety disordersJ Social Clin Psychol2006 25779801
Not in our library
- 537.
Leichsenring F Salzer S Jaeger U Kachele H Kreische R Leweke F Ruger U Winkelbach C Leibing E Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trialAm J Psychiatry2009 166875881
Not in our library10.1176/appi.ajp.2009.09030441 (opens in a new tab)
- 538.
Newman MG Castonguay LG Borkovec TD Fisher AJ Boswell JF Szkodny LE Nordberg SS A randomized controlled trial of cognitive-behavioral therapy for generalized anxiety disorder with integrated techniques from emotion-focused and interpersonal therapiesJ Consult Clin Psychol2011 79171181
Not in our library10.1037/a0022489 (opens in a new tab)
- 539.
Aviram A Westra HA The impact of motivational interviewing on resistance in cognitive behavioural therapy for generalized anxiety disorderPsychother Res2011 21698708
Not in our library10.1080/10503307.2011.610832 (opens in a new tab)
- 540.
Westra HA Arkowitz H Dozois DJ Adding a motivational interviewing pretreatment to cognitive behavioral therapy for generalized anxiety disorder: a preliminary randomized controlled trialJ Anxiety Disord2009 2311061117
Not in our library10.1016/j.janxdis.2009.07.014 (opens in a new tab)
- 541.
Crits-Christoph P Newman MG Rickels K Gallop R Gibbons MB Hamilton JL Ring-Kurtz S Pastva AM Combined medication and cognitive therapy for generalized anxiety disorderJ Anxiety Disord2011 2510871094
Not in our library10.1016/j.janxdis.2011.07.007 (opens in a new tab)
- 542.
Gosselin P Ladouceur R Morin CM Dugas MJ Baillargeon L Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapyJ Consult Clin Psychol2006 74908919
Not in our library10.1037/0022-006x.74.5.908 (opens in a new tab)
- 543.
Salzer S Winkelbach C Leweke F Leibing E Leichsenring F Long-term effects of short-term psychodynamic psychotherapy and cognitive-behavioural therapy in generalized anxiety disorder: 12-month follow-upCan J Psychiatry2011 56503508
Not in our library10.1177/070674371105600809 (opens in a new tab)
- 544.
Davidson J Bose A Korotzer A Zheng H Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose studyDepress Anxiety2004 19234240
Not in our library10.1002/da.10146 (opens in a new tab)
- 545.
Goodman WK Bose A Wang Q Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trialsJ Affect Disord2005 87161167
Not in our library10.1016/j.jad.2004.11.011 (opens in a new tab)
- 546.
Bielski RJ Bose A Chang CC A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorderAnn Clin Psychiatry2005 176569
Not in our library10.1080/10401230590932326 (opens in a new tab)
- 547.
Baldwin DS Huusom AK Maehlum E Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind studyBr J Psychiatry2006 189264272
Not in our library10.1192/bjp.bp.105.012799 (opens in a new tab)
- 548.
Bose A Korotzer A Gommoll C Li D Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorderDepress Anxiety2008 25854861
Not in our library10.1002/da.20355 (opens in a new tab)
- 549.
Bystritsky A Kerwin L Feusner JD Vapnik T A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorderPsychopharmacol Bull2008 414651
Not in our library
- 550.
Lenze EJ Rollman BL Shear MK Dew MA Pollock BG Ciliberti C Costantino M Snyder S Shi P Spitznagel E Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trialJAMA2009 301295303
Not in our library10.1001/jama.2008.977 (opens in a new tab)
- 551.
Merideth C Cutler AJ She F Eriksson H Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled studyInt Clin Psychopharmacol2012 274054
Not in our library10.1097/yic.0b013e32834d9f49 (opens in a new tab)
- 552.
Coric V Feldman HH Oren DA Shekhar A Pultz J Dockens RC Wu X Gentile KA Huang SP Emison E Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorderDepress Anxiety2010 27417425
Not in our library10.1002/da.20695 (opens in a new tab)
- 553.
Kapczinski F Lima MS Souza JS Schmitt R Antidepressants for generalized anxiety disorderCochrane Database Syst Rev2003 CD003592
Not in our library10.1002/14651858.cd003592 (opens in a new tab)
- 554.
Rickels K Zaninelli R McCafferty J Bellew K Iyengar M Sheehan D Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled studyAm J Psychiatry2003 160749756
Not in our library10.1176/appi.ajp.160.4.749 (opens in a new tab)
- 555.
Pollack M Zaninelli R Goddard A McCafferty J Bellew K Burnham D Iyengar M Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trialJ Clin Psychiatry2001 62350357
Not in our library10.4088/jcp.v62n0508 (opens in a new tab)
- 556.
Ball S Kuhn A Wall D Shekhar A Goddard A Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertralineJ Clin Psychiatry2005 669499
Not in our library10.4088/jcp.v66n0113 (opens in a new tab)
- 557.
Bandelow B Chouinard G Bobes J Ahokas A Eggens I Liu S Eriksson H Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled studyInt J Neuropsychopharmacol2010 13305320
Not in our library10.1017/s1461145709990423 (opens in a new tab)
- 558.
Kim TS Pae CU Yoon SJ Bahk WM Jun TY Rhee WI Chae JH Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorderPsychiatry Clin Neurosci2006 60347351
Not in our library10.1111/j.1440-1819.2006.01512.x (opens in a new tab)
- 559.
Allgulander C Dahl A Austin C Morris P Sogaard J Fayyad R Kutcher S Clary C Efficacy of sertraline in a 12-week trial for generalized anxiety disorderAm J Psychiatry2004 16116421649
Not in our library10.1176/appi.ajp.161.9.1642 (opens in a new tab)
- 560.
Brawman-Mintzer O Knapp RG Rynn M Carter RE Rickels K Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry2006 67874881
Not in our library10.4088/jcp.v67n0603 (opens in a new tab)
- 561.
Mokhber N Azarpazhooh MR Khajehdaluee M Velayati A Hopwood M Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorderPsychiatry Clin Neurosci2010 64128133
Not in our library10.1111/j.1440-1819.2009.02055.x (opens in a new tab)
- 562.
Varia I Rauscher F Treatment of generalized anxiety disorder with citalopramInt Clin Psychopharmacol2002 17103107
Not in our library10.1097/00004850-200205000-00002 (opens in a new tab)
- 563.
Simon NM Zalta AK Worthington JJ 3rd Hoge EA Christian KM Stevens JC Pollack MH Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorderDepress Anxiety2006 23373376
Not in our library10.1002/da.20184 (opens in a new tab)
- 564.
Gross PK Nourse R Wasser TE Krulewicz S Effects of paroxetine CR on depressive and anxiety symptoms: in a community sample of adult Hispanic women with major depression or generalized anxiety disorderPsychiatry (Edgmont)2006 36468
Not in our library
- 565.
Simon NM Connor KM LeBeau RT Hoge EA Worthington JJ 3rd Zhang W Davidson JR Pollack MH Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findingsPsychopharmacology (Berl)2008 197675681
Not in our library10.1007/s00213-008-1087-x (opens in a new tab)
- 566.
Rynn M Russell J Erickson J Detke MJ Ball S Dinkel J Rickels K Raskin J Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trialDepress Anxiety2008 25182189
Not in our library10.1002/da.20271 (opens in a new tab)
- 567.
Koponen H Allgulander C Erickson J Dunayevich E Pritchett Y Detke MJ Ball SG Russell JM Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physiciansPrim Care Companion J Clin Psychiatry2007 9100107
Not in our library10.4088/pcc.v09n0203 (opens in a new tab)
- 568.
Wu WY Wang G Ball SG Desaiah D Ang QQ Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in ChinaChin Med J (Engl)2011 12432603268
Not in our library
- 569.
Allgulander C Hartford J Russell J Ball S Erickson J Raskin J Rynn M Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trialsCurr Med Res Opin2007 2312451252
Not in our library10.1185/030079907x182202 (opens in a new tab)
- 570.
Hartford J Kornstein S Liebowitz M Pigott T Russell J Detke M Walker D Ball S Dunayevich E Dinkel J Erickson J Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trialInt Clin Psychopharmacol2007 22167174
Not in our library10.1097/yic.0b013e32807fb1b2 (opens in a new tab)
- 571.
Allgulander C Nutt D Detke M Erickson J Spann M Walker D Ball SG Russell JM A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorderJ Psychopharmacol2008 22417425
Not in our library10.1177/0269881108091588 (opens in a new tab)
- 572.
Davidson J Du Pont R Hedges D Haskins J Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorderJ Clin Psychiatry1999 60528535
Not in our library10.4088/jcp.v60n0805 (opens in a new tab)
- 573.
Nimatoudis I Zissis N Kogeorgos J Theodoropoulou S Vidalis A Kaprinis G Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled studyInt Clin Psychopharmacol2004 19331336
Not in our library10.1097/00004850-200411000-00003 (opens in a new tab)
- 574.
Rickels K Pollack M Sheehan D Haskins J Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorderAm J Psychiatry2000 157968974
Not in our library10.1176/appi.ajp.157.6.968 (opens in a new tab)
- 575.
Katz I Reynolds C Alexopoulos G Hackett D Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trialsJ Am Geriatr Soc2002 501825
Not in our library10.1046/j.1532-5415.2002.50003.x (opens in a new tab)
- 576.
Montgomery SA Tobias K Zornberg GL Kasper S Pande AC Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxineJ Clin Psychiatry2006 67771782
Not in our library10.4088/jcp.v67n0511 (opens in a new tab)
- 577.
Kasper S Herman B Nivoli G Van Ameringen M Petralia A Mandel FS Baldinetti F Bandelow B Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trialInt Clin Psychopharmacol2009 248796
Not in our library10.1097/yic.0b013e32831d7980 (opens in a new tab)
- 578.
Allgulander C Hackett D Salinas E Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging studyBr J Psychiatry2001 1791522
Not in our library10.1192/bjp.179.1.15 (opens in a new tab)
- 579.
Gelenberg A Lydiard R Rudolph R Aguiar L Haskins J Salinas E Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trialJAMA2000 28330823088
Not in our library10.1001/jama.283.23.3082 (opens in a new tab)
- 580.
Lenox-Smith AJ Reynolds A A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary careBr J Gen Pract2003 53772777
Not in our library
- 581.
Hoehn-Saric R McLeod D Zimmerli W Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptomsJ Clin Psychiatry1988 49293301
Not in our library
- 582.
Rocca P Fonzo V Scotta M Zanalda E Ravizza L Paroxetine efficacy in the treatment of generalized anxiety disorderActa Psychiatr Scand1997 95444450
Not in our library10.1111/j.1600-0447.1997.tb09660.x (opens in a new tab)
- 583.
Rickels K Downing R Schweizer E Hassman H Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepamArch Gen Psychiatry1993 50884895
Not in our library10.1001/archpsyc.1993.01820230054005 (opens in a new tab)
- 584.
Stein DJ Ahokas AA de Bodinat C Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol2008 28561566
Not in our library10.1097/jcp.0b013e318184ff5b (opens in a new tab)
- 585.
Stein D Marquez M Hoschl C Ahokas A Oh K-S Jarema M Avedisova A Vavrusova L Olivier V Efficacy and tolerability of agomelatine in generalized anxiety disorder: A randomised double blind placebo controlled trial with escitalopram as active control [poster]28th CINP Congress; Jun 3-7; Stockholm, Sweden2012
Not in our library
- 586.
Rothschild AJ Mahableshwarkar AR Jacobsen P Yan M Sheehan DV Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United StatesEur Neuropsychopharmacol2012 22858866
Not in our library10.1016/j.euroneuro.2012.07.011 (opens in a new tab)
- 587.
Bidzan L Mahableshwarkar AR Jacobsen P Yan M Sheehan DV Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trialEur Neuropsychopharmacol2012 22847857
Not in our library10.1016/j.euroneuro.2012.07.012 (opens in a new tab)
- 588.
Gambi F De Berardis D Campanella D Carano A Sepede G Salini G Mezzano D Cicconetti A Penna L Salerno RM Ferro FM Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label studyJ Psychopharmacol2005 19483487
Not in our library10.1177/0269881105056527 (opens in a new tab)
- 589.
Mitte K Noack P Steil R Hautzinger M A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorderJ Clin Psychopharmacol2005 25141150
Not in our library10.1097/01.jcp.0000155821.74832.f9 (opens in a new tab)
- 590.
Lydiard R Ballenger J Rickels K A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work GroupJ Clin Psychiatry1997 58Suppl 111118
Not in our library
- 591.
Moller H Volz H Reimann I Stoll K Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated groupJ Clin Psychopharmacol2001 215965
Not in our library10.1097/00004714-200102000-00011 (opens in a new tab)
- 592.
Rickels K Pollack MH Feltner DE Lydiard RB Zimbroff DL Bielski RJ Tobias K Brock JD Zornberg GL Pande AC Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolamArch Gen Psychiatry2005 6210221030
Not in our library10.1001/archpsyc.62.9.1022 (opens in a new tab)
- 593.
Lydiard RB Rickels K Herman B Feltner DE Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorderInt J Neuropsychopharmacol2010 13229241
Not in our library10.1017/s1461145709990460 (opens in a new tab)
- 594.
Llorca P Spadone C Sol O Danniau A Bougerol T Corruble E Faruch M Macher J Sermet E Servant D Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind studyJ Clin Psychiatry2002 6310201027
Not in our library10.4088/jcp.v63n1112 (opens in a new tab)
- 595.
Rickels K Schweizer E De Martinis N Mandos L Mercer C Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trialJ Clin Psychopharmacol1997 17272277
Not in our library10.1097/00004714-199708000-00006 (opens in a new tab)
- 596.
Rickels K DeMartinis N Aufdembrinke B A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorderJ Clin Psychopharmacol2000 201218
Not in our library10.1097/00004714-200002000-00004 (opens in a new tab)
- 597.
Feltner D Crockatt J Dubovsky S Cohn C Shrivastava R Targum S Liu-Dumaw M Carter C Pande A A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorderJ Clin Psychopharmacol2003 23240249
Not in our library10.1097/01.jcp.0000084032.22282.ff (opens in a new tab)
- 598.
Laakmann G Schule C Lorkowski G Baghai T Kuhn K Ehrentraut S Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatientsPsychopharmacology (Berl)1998 136357366
Not in our library10.1007/s002130050578 (opens in a new tab)
- 599.
Fresquet A Sust M Lloret A Murphy M Carter F Campbell G Marion-Landais G Efficacy and safety of lesopitron in outpatients with generalized anxiety disorderAnn Pharmacother2000 34147153
Not in our library10.1345/aph.19041 (opens in a new tab)
- 600.
Woelk H Schlafke S A multi-center, double-blind, randomised study of the lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorderPhytomedicine2010 179499
Not in our library10.1016/j.phymed.2009.10.006 (opens in a new tab)
- 601.
Herrera-Arellano A Jimenez-Ferrer E Zamilpa A Morales-Valdez M Garcia-Valencia CE Tortoriello J Efficacy and tolerability of a standardized herbal product from galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepamPlanta Med2007 73713717
Not in our library10.1055/s-2007-981539 (opens in a new tab)
- 602.
Khan A Joyce M Atkinson S Eggens I Baldytcheva I Eriksson H A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorderJ Clin Psychopharmacol2011 31418428
Not in our library10.1097/jcp.0b013e318224864d (opens in a new tab)
- 603.
Stein DJ Bandelow B Merideth C Olausson B Szamosi J Eriksson H Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studiesHum Psychopharmacol2011 26614628
Not in our library10.1002/hup.1256 (opens in a new tab)
- 604.
Katzman MA Vermani M Jacobs L Marcus M Kong B Lessard S Galarraga W Struzik L Gendron A Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trialJ Anxiety Disord2008 2214801486
Not in our library10.1016/j.janxdis.2008.03.002 (opens in a new tab)
- 605.
Altamura AC Serati M Buoli M Dell'Osso B Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled studyInt Clin Psychopharmacol2011 26201205
Not in our library10.1097/yic.0b013e3283457d73 (opens in a new tab)
- 606.
Brawman-Mintzer O Knapp RG Nietert PJ Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled studyJ Clin Psychiatry2005 6613211325
Not in our library10.4088/jcp.v66n1016 (opens in a new tab)
- 607.
Pandina GJ Canuso CM Turkoz I Kujawa M Mahmoud RA Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trialPsychopharmacol Bull2007 404157
Not in our library
- 608.
Pollack MH Simon NM Zalta AK Worthington JJ Hoge EA Mick E Kinrys G Oppenheimer J Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled studyBiol Psychiatry2006 59211215
Not in our library10.1016/j.biopsych.2005.07.005 (opens in a new tab)
- 609.
Menza MA Dobkin RD Marin H An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder [Letter]J Clin Psychopharmacol2007 27207210
Not in our library10.1097/01.jcp.0000248620.34541.bc (opens in a new tab)
- 610.
Gabriel A The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): An open label naturalistic studyClin Ter2011 162113118
Not in our library
- 611.
Lohoff FW Etemad B Mandos LA Gallop R Rickels K Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind studyJ Clin Psychopharmacol2010 30185189
Not in our library10.1097/jcp.0b013e3181d21951 (opens in a new tab)
- 612.
Snyderman SH Rynn MA Rickels K Open-label pilot study of ziprasidone for refractory generalized anxiety disorder [Letter]J Clin Psychopharmacol2005 25497499
Not in our library10.1097/01.jcp.0000177853.15910.de (opens in a new tab)
- 613.
Pohl R Feltner D Fieve R Pande A Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosingJ Clin Psychopharmacol2005 25151158
Not in our library10.1097/01.jcp.0000155820.74832.b0 (opens in a new tab)
- 614.
Aliyev NA Aliyev ZN Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled studyEur Psychiatry2008 23109114
Not in our library10.1016/j.eurpsy.2007.08.001 (opens in a new tab)
- 615.
Pollack MH Tiller J Xie F Trivedi MH Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studiesJ Clin Psychopharmacol2008 28308316
Not in our library10.1097/jcp.0b013e318172b45f (opens in a new tab)
- 616.
Rosenthal M Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive controlJ Clin Psychiatry2003 6412451249
Not in our library10.4088/jcp.v64n1016 (opens in a new tab)
- 617.
Rickels K Shiovitz TM Ramey TS Weaver JJ Knapp LE Miceli JJ Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatmentInt Clin Psychopharmacol2012 27142150
Not in our library10.1097/yic.0b013e328350b133 (opens in a new tab)
- 618.
Pollack M Worthington J Manfro G Otto M Zucker B Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspironeJ Clin Psychiatry1997 58Suppl 111923
Not in our library
- 619.
Lader M Scotto J A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorderPsychopharmacology (Berl)1998 139402406
Not in our library10.1007/s002130050731 (opens in a new tab)
- 620.
Guaiana G Barbui C Cipriani A Hydroxyzine for generalised anxiety disorderCochrane Database Syst Rev2010 CD006815
Not in our library10.1002/14651858.cd006815.pub2 (opens in a new tab)
- 621.
Meibach RC Dunner D Wilson LG Ishiki D Dager SR Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trialJ Clin Psychiatry1987 48355358
Not in our library
- 622.
Feusner JD Kerwin L Saxena S Bystritsky A Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trialPsychopharmacol Bull2009 428193
Not in our library
- 623.
Baldwin DS Nutt DJ On assessing potential efficacy for vortioxetine in generalized anxiety disorderEur Neuropsychopharmacol2012 22841843
Not in our library10.1016/j.euroneuro.2012.07.018 (opens in a new tab)
- 624.
Davidson JR Wittchen HU Llorca PM Erickson J Detke M Ball SG Russell JM Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trialEur Neuropsychopharmacol2008 18673681
Not in our library10.1016/j.euroneuro.2008.05.002 (opens in a new tab)
- 625.
Allgulander C Florea I Huusom AK Prevention of relapse in generalized anxiety disorder by escitalopram treatmentInt J Neuropsychopharmacol2006 9495505
Not in our library10.1017/s1461145705005973 (opens in a new tab)
- 626.
Stocchi F Nordera G Jokinen R Lepola U Hewett K Bryson H Iyengar M Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorderJ Clin Psychiatry2003 64250258
Not in our library10.4088/jcp.v64n0305 (opens in a new tab)
- 627.
Rickels K Etemad B Khalid-Khan S Lohoff FW Rynn MA Gallop RJ Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended releaseArch Gen Psychiatry2010 6712741281
Not in our library10.1001/archgenpsychiatry.2010.170 (opens in a new tab)
- 628.
Feltner D Wittchen HU Kavoussi R Brock J Baldinetti F Pande AC Long-term efficacy of pregabalin in generalized anxiety disorderInt Clin Psychopharmacol2008 231828
Not in our library10.1097/yic.0b013e3282f0f0d7 (opens in a new tab)
- 629.
Katzman MA Brawman-Mintzer O Reyes EB Olausson B Liu S Eriksson H Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trialInt Clin Psychopharmacol2011 261124
Not in our library10.1097/yic.0b013e32833e34d9 (opens in a new tab)
- 630.
Bystritsky A Kaplan JT Feusner JD Kerwin LE Wadekar M Burock M Wu AD Iacoboni M A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorderJ Clin Psychiatry2008 6910921098
Not in our library10.4088/jcp.v69n0708 (opens in a new tab)
- 631.
Bystritsky A Kerwin LE Feusner JD A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder: 6-month follow-up [Letter]J Clin Psychiatry2009 70431432
Not in our library10.4088/jcp.08l04641 (opens in a new tab)
- 632.
Kasper S Gastpar M Muller WE Volz HP Moller HJ Dienel A Schlafke S Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trialInt Clin Psychopharmacol2010 25277287
Not in our library10.1097/yic.0b013e32833b3242 (opens in a new tab)
- 633.
Miyasaka LS Atallah AN Soares BG Passiflora for anxiety disorderCochrane Database Syst Rev2007 CD004518
Not in our library10.1002/14651858.cd004518.pub2 (opens in a new tab)
- 634.
Andreatini R Sartori VA Seabra ML Leite JR Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot studyPhytother Res2002 16650654
Not in our library10.1002/ptr.1027 (opens in a new tab)
- 635.
Miyasaka LS Atallah AN Soares BG Valerian for anxiety disordersCochrane Database Syst Rev2006 CD004515
Not in our library10.1002/14651858.cd004515.pub2 (opens in a new tab)
- 636.
Herring MP Jacob ML Suveg C Dishman RK O'Connor PJ Feasibility of exercise training for the short-term treatment of generalized anxiety disorder: a randomized controlled trialPsychother Psychosom2012 812128
Not in our library10.1159/000327898 (opens in a new tab)
- 637.
Pilkington K Kirkwood G Rampes H Cummings M Richardson J Acupuncture for anxiety and anxiety disorders--a systematic literature reviewAcupunct Med2007 25110
Not in our library10.1136/aim.25.1-2.1 (opens in a new tab)
- 638.
Lu CF Smith LN Gau CH Exploring the zen meditation experiences of patients with generalized anxiety disorder: a focus-group approachJ Nurs Res2012 204352
Not in our library10.1097/jnr.0b013e3182466e83 (opens in a new tab)
- 639.
- 640.
Youngstedt SD Kline CE Ginsberg JP Zielinski MR Hardin JW Bright light treatment for high-anxious young adults: a randomized controlled pilot studyDepress Anxiety2011 28324332
Not in our library10.1002/da.20784 (opens in a new tab)
- 641.
Ruscio AM Stein DJ Chiu WT Kessler RC The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey ReplicationMol Psychiatry2010 155363
Not in our library10.1038/mp.2008.94 (opens in a new tab)
- 642.
Adam Y Meinlschmidt G Gloster AT Lieb R Obsessive-compulsive disorder in the community: 12-month prevalence, comorbidity and impairmentSoc Psychiatry Psychiatr Epidemiol2012 47339349
Not in our library10.1007/s00127-010-0337-5 (opens in a new tab)
- 643.
Rosario-Campos MC Leckman JF Mercadante MT Shavitt RG Prado HS Sada P Zamignani D Miguel EC Adults with early-onset obsessive-compulsive disorderAm J Psychiatry2001 15818991903
Not in our library10.1176/appi.ajp.158.11.1899 (opens in a new tab)
- 644.
Veldhuis J Dieleman JP Wohlfarth T Storosum JG van Den Brink W Sturkenboom MC Denys D Incidence and prevalence of "diagnosed OCD" in a primary care, treatment seeking, populationInt J Psychiatry Clin Pract2012 168592
Not in our library10.3109/13651501.2011.617454 (opens in a new tab)
- 645.
Torres AR Prince MJ Bebbington PE Bhugra D Brugha TS Farrell M Jenkins R Lewis G Meltzer H Singleton N Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000Am J Psychiatry2006 16319781985
Not in our library10.1176/ajp.2006.163.11.1978 (opens in a new tab)
- 646.
Grisham JR Fullana MA Mataix-Cols D Moffitt TE Caspi A Poulton R Risk factors prospectively associated with adult obsessive-compulsive symptom dimensions and obsessive-compulsive disorderPsychol Med2011 112
Not in our library10.1017/s0033291711000894 (opens in a new tab)
- 647.
Hauschildt M Jelinek L Randjbar S Hottenrott B Moritz S Generic and illness-specific quality of life in obsessive-compulsive disorderBehav Cogn Psychother2010 38417436
Not in our library10.1017/s1352465810000275 (opens in a new tab)
- 648.
Eisen JL Mancebo MA Pinto A Coles ME Pagano ME Stout R Rasmussen SA Impact of obsessive-compulsive disorder on quality of lifeCompr Psychiatry2006 47270275
Not in our library10.1016/j.comppsych.2005.11.006 (opens in a new tab)
- 649.
Vikas A Avasthi A Sharan P Psychosocial impact of obsessive-compulsive disorder on patients and their caregivers: a comparative study with depressive disorderInt J Soc Psychiatry2011 574556
Not in our library10.1177/0020764009347333 (opens in a new tab)
- 650.
Rampacher F Lennertz L Vogeley A Schulze-Rauschenbach S Kathmann N Falkai P Wagner M ation processing in patients with OCD compared to patients with unipolar depresEvidence for specific cognitive deficits in visual informsionProg Neuropsychopharmacol Biol Psychiatry2010 34984991
Not in our library10.1016/j.pnpbp.2010.05.008 (opens in a new tab)
- 651.
Aigner M Sachs G Bruckmuller E Winklbaur B Zitterl W Kryspin-Exner I Gur R Katschnig H Cognitive and emotion recognition deficits in obsessive-compulsive disorderPsychiatry Res2007 149121128
Not in our library10.1016/j.psychres.2005.12.006 (opens in a new tab)
- 652.
Torres AR Ramos-Cerqueira AT Ferrao YA Fontenelle LF do Rosario MC Miguel EC Suicidality in obsessive-compulsive disorder: prevalence and relation to symptom dimensions and comorbid conditionsJ Clin Psychiatry2011 721726quiz 119-120
Not in our library10.4088/jcp.09m05651blu (opens in a new tab)
- 653.
Eaton WW Martins SS Nestadt G Bienvenu OJ Clarke D Alexandre P The burden of mental disordersEpidemiol Rev2008 30114
Not in our library10.1093/epirev/mxn011 (opens in a new tab)
- 654.
Leckman JF Denys D Simpson HB Mataix-Cols D Hollander E Saxena S Miguel EC Rauch SL Goodman WK Phillips KA Stein DJ Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-VDepress Anxiety2010 27507527
Not in our library10.1002/da.20669 (opens in a new tab)
- 655.
Abramowitz JS Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative reviewJ Consult Clin Psychol1997 654452
Not in our library10.1037//0022-006x.65.1.44 (opens in a new tab)
- 656.
Eddy K Dutra L Bradley R Westen D A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorderClin Psychol Rev2004 2410111030
Not in our library10.1016/j.cpr.2004.08.004 (opens in a new tab)
- 657.
- 658.
Foa E Liebowitz M Kozak M Davies S Campeas R Franklin M Huppert J Kjernisted K Rowan V Schmidt A Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorderAm J Psychiatry2005 162151161
Not in our library10.1176/appi.ajp.162.1.151 (opens in a new tab)
- 659.
Sousa MB Isolan LR Oliveira RR Manfro GG Cordioli AV A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorderJ Clin Psychiatry2006 6711331139
Not in our library10.4088/jcp.v67n0717 (opens in a new tab)
- 660.
Belotto-Silva C Diniz JB Malavazzi DM Valerio C Fossaluza V Borcato S Seixas AA Morelli D Miguel EC Shavitt RG Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trialJ Anxiety Disord2012 262531
Not in our library10.1016/j.janxdis.2011.08.008 (opens in a new tab)
- 661.
Jones MK Menzies RG Danger ideation reduction therapy (DIRT) for obsessive-compulsive washers. A controlled trialBehav Res Ther1998 36959970
Not in our library10.1016/s0005-7967(98)00057-6 (opens in a new tab)
- 662.
Krochmalik A Jones MK Menzies RG Kirkby K The superiority of danger ideation reduction therapy (DIRT) over exposure and response prevention (ERP) in treating compulsive washingBehaviour Change2004 21251268
Not in our library
- 663.
Jonsson H Hougaard E Bennedsen BE Randomized comparative study of group versus individual cognitive behavioural therapy for obsessive compulsive disorderActa Psychiatr Scand2011 123387397
Not in our library10.1111/j.1600-0447.2010.01613.x (opens in a new tab)
- 664.
Jaurrieta N Jimenez-Murcia S Alonso P Granero R Segalas C Labad J Menchon JM Individual versus group cognitive behavioral treatment for obsessive-compulsive disorder: follow upPsychiatry Clin Neurosci2008 62697704
Not in our library10.1111/j.1440-1819.2008.01873.x (opens in a new tab)
- 665.
O'Connor K Freeston MH Gareau D Careau Y Dufour MJ Aardema F Todorov C Group versus individual treatment in obsessions without compulsionsClin Psychol Psychother2005 128796
Not in our library
- 666.
Belloch A Cabedo E Carrio C Fernandez-Alvarez H Garcia F Larsson C Group versus individual cognitive treatment for obsessive-compulsive disorder: changes in non-OCD symptoms and cognitions at post-treatment and one-year follow-upPsychiatry Res2011 187174179
Not in our library10.1016/j.psychres.2010.10.015 (opens in a new tab)
- 667.
Cabedo E Belloch A Carrio C Larsson C Fernandez-Alvarez H Garcia F Group versus individual cognitive treatment for obsessive-compulsive disorder: changes in severity at post-treatment and one-year follow-upBehav Cogn Psychother2010 38227232
Not in our library10.1017/s135246580999066x (opens in a new tab)
- 668.
Kozak M Foa E Mastery of obsessive–compulsive disorder: A cognitive–behavioral approach1997 San Antonio, TX: The Psychological Corporation
Not in our library
- 669.
Abramowitz JS Foa EB Franklin ME Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessionsJ Consult Clin Psychol2003 71394398
Not in our library10.1037/0022-006x.71.2.394 (opens in a new tab)
- 670.
Tolin DF Diefenbach GJ Gilliam CM Stepped care versus standard cognitive-behavioral therapy for obsessive-compulsive disorder: a preliminary study of efficacy and costsDepress Anxiety2011 28314323
Not in our library10.1002/da.20804 (opens in a new tab)
- 671.
Twohig MP Hayes SC Plumb JC Pruitt LD Collins AB Hazlett-Stevens H Woidneck MR A randomized clinical trial of acceptance and commitment therapy versus progressive relaxation training for obsessive-compulsive disorderJ Consult Clin Psychol2010 78705716
Not in our library10.1037/a0020508 (opens in a new tab)
- 672.
Wilhelm S Steketee G Fama JM Buhlmann U Teachman BA Golan E Modular cognitive therapy for obsessive-compulsive disorder: a wait-list controlled trialJ Cogn Psychother2009 23294305
Not in our library10.1891/0889-8391.23.4.294 (opens in a new tab)
- 673.
Freeston MH Ladouceur R Gagnon F Thibodeau N Rheaume J Letarte H Bujold A Cognitive-behavioral treatment of obsessive thoughts: a controlled studyJ Consult Clin Psychol1997 65405413
Not in our library10.1037//0022-006x.65.3.405 (opens in a new tab)
- 674.
O'Connor KP Aardema F Bouthillier D Fournier S Guay S Robillard S Pelissier MC Landry P Todorov C Tremblay M Pitre D Evaluation of an inference-based approach to treating obsessive-compulsive disorderCogn Behav Ther2005 34148163
Not in our library10.1080/16506070510041211 (opens in a new tab)
- 675.
Park HS Shin YW Ha TH Shin MS Kim YY Lee YH Kwon JS Effect of cognitive training focusing on organizational strategies in patients with obsessive-compulsive disorderPsychiatry Clin Neurosci2006 60718726
Not in our library10.1111/j.1440-1819.2006.01587.x (opens in a new tab)
- 676.
Buhlmann U Deckersbach T Engelhard I Cook LM Rauch SL Kathmann N Wilhelm S Savage CR Cognitive retraining for organizational impairment in obsessive-compulsive disorderPsychiatry Res2006 144109116
Not in our library10.1016/j.psychres.2005.10.012 (opens in a new tab)
- 677.
Hanstede M Gidron Y Nyklicek I The effects of a mindfulness intervention on obsessive-compulsive symptoms in a non-clinical student populationJ Nerv Ment Dis2008 196776779
Not in our library10.1097/nmd.0b013e31818786b8 (opens in a new tab)
- 678.
Simpson HB Zuckoff AM Maher MJ Page JR Franklin ME Foa EB Schmidt AB Wang Y Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive-compulsive disorderBehav Res Ther2010 48941948
Not in our library10.1016/j.brat.2010.05.026 (opens in a new tab)
- 679.
Meyer E Souza F Heldt E Knapp P Cordioli A Shavitt RG Leukefeld C A randomized clinical trial to examine enhancing cognitive-behavioral group therapy for obsessive-compulsive disorder with motivational interviewing and thought mappingBehav Cogn Psychother2010 38319336
Not in our library10.1017/s1352465810000111 (opens in a new tab)
- 680.
Nazari H Momeni N Jariani M Tarrahi MJ Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorderInt J Psychiatry Clin Pract2011 15270274
Not in our library10.3109/13651501.2011.590210 (opens in a new tab)
- 681.
Tolin DF Hannan S Maltby N Diefenbach GJ Worhunsky P Brady RE A randomized controlled trial of self-directed versus therapist-directed cognitive-behavioral therapy for obsessive-compulsive disorder patients with prior medication trialsBehav Ther2007 38179191
Not in our library10.1016/j.beth.2006.07.001 (opens in a new tab)
- 682.
Lovell K Cox D Haddock G Jones C Raines D Garvey R Roberts C Hadley S Telephone administered cognitive behaviour therapy for treatment of obsessive compulsive disorder: randomised controlled non-inferiority trialBMJ2006 333883
Not in our library10.1136/bmj.38940.355602.80 (opens in a new tab)
- 683.
Moritz S Jelinek L Hauschildt M Naber D How to treat the untreated: effectiveness of a self-help metacognitive training program (myMCT) for obsessive-compulsive disorderDialogues Clin Neurosci2010 12209220
Not in our library10.31887/dcns.2010.12.2/smoritz (opens in a new tab)
- 684.
Moritz S Jelinek L Further evidence for the efficacy of association splitting as a self-help technique for reducing obsessive thoughtsDepress Anxiety2011 28574581
Not in our library10.1002/da.20843 (opens in a new tab)
- 685.
Andersson E Enander J Andren P Hedman E Ljotsson B Hursti T Bergstrom J Kaldo V Lindefors N Andersson G Ruck C Internet-based cognitive behaviour therapy for obsessive-compulsive disorder: a randomized controlled trialPsychol Med2012 111
Not in our library10.1017/s0033291712000244 (opens in a new tab)
- 686.
Tumur I Kaltenthaler E Ferriter M Beverley C Parry G Computerised cognitive behaviour therapy for obsessive-compulsive disorder: a systematic reviewPsychother Psychosom2007 76196202
Not in our library10.1159/000101497 (opens in a new tab)
- 687.
Greist JH Marks IM Baer L Kobak KA Wenzel KW Hirsch MJ Mantle JM Clary CM Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a controlJ Clin Psychiatry2002 63138145
Not in our library10.4088/jcp.v63n0209 (opens in a new tab)
- 688.
Kenwright M Marks I Graham C Franses A Mataix-Cols D Brief scheduled phone support from a clinician to enhance computer-aided self-help for obsessive-compulsive disorder: randomized controlled trialJ Clin Psychol2005 6114991508
Not in our library10.1002/jclp.20204 (opens in a new tab)
- 689.
Lebowitz ER Panza KE Su J Bloch MH Family accommodation in obsessive-compulsive disorderExpert Rev Neurother2012 12229238
Not in our library10.1586/ern.11.200 (opens in a new tab)
- 690.
Rachman S Elliott CM Shafran R Radomsky AS Separating hoarding from OCDBehav Res Ther2009 47520522
Not in our library10.1016/j.brat.2009.02.014 (opens in a new tab)
- 691.
Muroff J Steketee G Bratiotis C Ross A Group cognitive and behavioral therapy and bibliotherapy for hoarding: a pilot trialDepress Anxiety2012 29597604
Not in our library10.1002/da.21923 (opens in a new tab)
- 692.
Foa EB Franklin ME Moser J Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?Biol Psychiatry2002 52987997
Not in our library10.1016/s0006-3223(02)01552-4 (opens in a new tab)
- 693.
Simpson HB Foa EB Liebowitz MR Ledley DR Huppert JD Cahill S Vermes D Schmidt AB Hembree E Franklin M A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorderAm J Psychiatry2008 165621630
Not in our library10.1176/appi.ajp.2007.07091440 (opens in a new tab)
- 694.
Simpson HB Liebowitz MR Foa EB Kozak MJ Schmidt AB Rowan V Petkova E Kjernisted K Huppert JD Franklin ME Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorderDepress Anxiety2004 19225233
Not in our library10.1002/da.20003 (opens in a new tab)
- 695.
van Oppen P van Balkom AJ de Haan E van Dyck R Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-upJ Clin Psychiatry2005 6614151422
Not in our library10.4088/jcp.v66n1111 (opens in a new tab)
- 696.
O'Connor KP Aardema F Robillard S Guay S Pelissier MC Todorov C Borgeat F Leblanc V Grenier S Doucet P Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorderActa Psychiatr Scand2006 113408419
Not in our library10.1111/j.1600-0447.2006.00767.x (opens in a new tab)
- 697.
Kordon A Kahl KG Broocks A Voderholzer U Rasche-Rauchle H Hohagen F Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-upEur Arch Psychiatry Clin Neurosci2005 2554850
Not in our library10.1007/s00406-004-0533-y (opens in a new tab)
- 698.
Chasson GS Buhlmann U Tolin DF Rao SR Reese HE Rowley T Welsh KS Wilhelm S Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserineBehav Res Ther2010 48675679
Not in our library10.1016/j.brat.2010.03.007 (opens in a new tab)
- 699.
Kushner MG Kim SW Donahue C Thuras P Adson D Kotlyar M McCabe J Peterson J Foa EB D-cycloserine augmented exposure therapy for obsessive-compulsive disorderBiol Psychiatry2007 62835838
Not in our library10.1016/j.biopsych.2006.12.020 (opens in a new tab)
- 700.
Wilhelm S Buhlmann U Tolin DF Meunier SA Pearlson GD Reese HE Cannistraro P Jenike MA Rauch SL Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorderAm J Psychiatry2008 165335341quiz 409
Not in our library10.1176/appi.ajp.2007.07050776 (opens in a new tab)
- 701.
Storch EA Merlo LJ Bengtson M Murphy TK Lewis MH Yang MC Jacob ML Larson M Hirsh A Fernandez M D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorderInt Clin Psychopharmacol2007 22230237
Not in our library10.1097/yic.0b013e32819f8480 (opens in a new tab)
- 702.
Braga DT Manfro GG Niederauer K Cordioli AV Full remission and relapse of obsessive-compulsive symptoms after cognitive-behavioral group therapy: a two-year follow-upRev Bras Psiquiatr2010 32164168
Not in our library10.1590/s1516-44462010000200012 (opens in a new tab)
- 703.
Whittal ML Robichaud M Thordarson DS McLean PD Group and individual treatment of obsessive-compulsive disorder using cognitive therapy and exposure plus response prevention: a 2-year follow-up of two randomized trialsJ Consult Clin Psychol2008 7610031014
Not in our library10.1037/a0013076 (opens in a new tab)
- 704.
Anand N Sudhir PM Math SB Thennarasu K Janardhan Reddy YC Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up studyJ Anxiety Disord2011 25939945
Not in our library10.1016/j.janxdis.2011.05.007 (opens in a new tab)
- 705.
Stein DJ Andersen EW Tonnoir B Fineberg N Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week studyCurr Med Res Opin2007 23701711
Not in our library10.1185/030079907x178838 (opens in a new tab)
- 706.
Khan MN Hotiana UA Ahmad S Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trialJ Ayub Med Coll Abbottabad2007 195863
Not in our library
- 707.
Shim G Park HY Jang JH Kim E Hwang JY Kim SN Jang GE Kwon JS What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label studyInt Clin Psychopharmacol2011 26284290
Not in our library10.1097/yic.0b013e32834a5c09 (opens in a new tab)
- 708.
Dougherty DD Jameson M Deckersbach T Loh R Thompson-Hollands J Jenike M Keuthen NJ Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorderInt Clin Psychopharmacol2009 24306311
Not in our library10.1097/yic.0b013e32833119d8 (opens in a new tab)
- 709.
Rabinowitz I Baruch Y Barak Y High-dose escitalopram for the treatment of obsessive-compulsive disorderInt Clin Psychopharmacol2008 234953
Not in our library10.1097/yic.0b013e3282f0f0c5 (opens in a new tab)
- 710.
Bergeron R Ravindran A Chaput Y Goldner E Swinson R van AM Austin C Hadrava V Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment studyJ Clin Psychopharmacol2002 22148154
Not in our library10.1097/00004714-200204000-00007 (opens in a new tab)
- 711.
Piccinelli M Pini S Bellantuono C Wilkinson G Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic reviewBr J Psychiatry1995 166424443
Not in our library10.1192/bjp.166.4.424 (opens in a new tab)
- 712.
Zitterl W Meszaros K Hornik K Twaroch T Dossenbach M Zitterl-Eglseer K Zapotoczky HG Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorderWien Klin Wochenschr1999 111439442
Not in our library
- 713.
Greist JH Jefferson JW Kobak KA Katzelnick DJ Serlin RC Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysisArch Gen Psychiatry1995 525360
Not in our library10.1001/archpsyc.1995.03950130053006 (opens in a new tab)
- 714.
Ackerman DL Greenland S Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorderJ Clin Psychopharmacol2002 22309317
Not in our library10.1097/00004714-200206000-00012 (opens in a new tab)
- 715.
Sayyah M Boostani H Pakseresht S Malayeri A Comparison of silybum marianum (L.) gaertn. with fluoxetine in the treatment of obsessive-compulsive disorderProg Neuropsychopharmacol Biol Psychiatry2010 34362365
Not in our library10.1016/j.pnpbp.2009.12.016 (opens in a new tab)
- 716.
Lopez-Ibor JJ Jr. Saiz J Cottraux J Note I Vinas R Bourgeois M Hernandez M Gomez-Perez JC Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorderEur Neuropsychopharmacol1996 6111118
Not in our library10.1016/0924-977x(95)00071-v (opens in a new tab)
- 717.
Mundo E Maina G Uslenghi C Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorderInt Clin Psychopharmacol2000 156976
Not in our library10.1097/00004850-200015020-00002 (opens in a new tab)
- 718.
Mundo E Rouillon F Figuera M Stigler M Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramineHum Psychopharmacol2001 16461468
Not in our library10.1002/hup.317 (opens in a new tab)
- 719.
Hollander E Koran LM Goodman WK Greist JH Ninan PT Yang H Li D Barbato LM A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorderJ Clin Psychiatry2003 64640647
Not in our library10.4088/jcp.v64n0604 (opens in a new tab)
- 720.
Zohar J Judge R Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study InvestigatorsBr J Psychiatry1996 169468474
Not in our library10.1192/bjp.169.4.468 (opens in a new tab)
- 721.
Denys D van der Wee N van Megen HJ Westenberg HG A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorderJ Clin Psychopharmacol2003 23568575
Not in our library10.1097/01.jcp.0000095342.32154.54 (opens in a new tab)
- 722.
Hollander E Allen A Steiner M Wheadon DE Oakes R Burnham DB Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetineJ Clin Psychiatry2003 6411131121
Not in our library10.4088/jcp.v64n0919 (opens in a new tab)
- 723.
Hoehn-Saric R Ninan P Black D Stahl S Greist J Lydiard B McElroy S Zajecka J Chapman D Clary C Harrison W Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disordersArch Gen Psychiatry2000 577682
Not in our library10.1001/archpsyc.57.1.76 (opens in a new tab)
- 724.
Bisserbe J Lane R Flament M A double-blind comparison of sertraline and clomipramine in outpatients with obsessive compulsive disorderEur Psychiatry1997 128293
Not in our library10.1016/s0924-9338(97)89646-0 (opens in a new tab)
- 725.
Ninan PT Koran LM Kiev A Davidson JR Rasmussen SA Zajecka JM Robinson DG Crits-Christoph P Mandel FS Austin C High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trialJ Clin Psychiatry2006 671522
Not in our library10.4088/jcp.v67n0103 (opens in a new tab)
- 726.
Montgomery S Kasper S Stein D Bang Hedegaard K Lemming O Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorderInt Clin Psychopharmacol2001 167586
Not in our library10.1097/00004850-200103000-00002 (opens in a new tab)
- 727.
Pallanti S Quercioli L Bruscoli M Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot studyJ Clin Psychiatry2004 6513941399
Not in our library10.4088/jcp.v65n1015 (opens in a new tab)
- 728.
Vulink NC Denys D Fluitman SB Meinardi JC Westenberg HG Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patientsJ Clin Psychiatry2009 7010011008
Not in our library10.4088/jcp.08m04269 (opens in a new tab)
- 729.
Pallanti S Quercioli L Koran LM Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trialJ Clin Psychiatry2002 63796801
Not in our library
- 730.
Marazziti D Golia F Consoli G Presta S Pfanner C Carlini M Mungai F Catena Dell'osso M Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patientsCNS Spectr2008 13971976
Not in our library10.1017/s1092852900014024 (opens in a new tab)
- 731.
Albert U Aguglia E Maina G Bogetto F Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled studyJ Clin Psychiatry2002 6310041009
Not in our library10.4088/jcp.v63n1108 (opens in a new tab)
- 732.
Yaryura-Tobias JA Neziroglu FA Venlafaxine in obsessive-compulsive disorder [Letter]Arch Gen Psychiatry1996 53653654
Not in our library10.1001/archpsyc.1996.01830070103016 (opens in a new tab)
- 733.
Denys D van Megen HJ van der Wee N Westenberg HG A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorderJ Clin Psychiatry2004 653743
Not in our library10.4088/jcp.v65n0106 (opens in a new tab)
- 734.
Dell'osso B Mundo E Marazziti D Altamura AC Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case seriesJ Psychopharmacol2008 22210213
Not in our library10.1177/0269881107079865 (opens in a new tab)
- 735.
Blay S Black DW A case of obsessive-compulsive disorder responding to duloxetinePrim Care Companion J Clin Psychiatry2007 9234235
Not in our library10.4088/pcc.v09n0311c (opens in a new tab)
- 736.
Yeh YW Chen CH Kuo SC Wang SC Chen CK Feng HM High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remissionClin Neuropharmacol2009 32174176
Not in our library10.1097/wnf.0b013e31817f8cef (opens in a new tab)
- 737.
Vallejo J Olivares J Marcos T Bulbena A Menchon JM Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trialBr J Psychiatry1992 161665670
Not in our library10.1192/bjp.161.5.665 (opens in a new tab)
- 738.
Jenike MA Baer L Minichiello WE Rauch SL Buttolph ML Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorderAm J Psychiatry1997 15412611264
Not in our library10.1176/ajp.154.9.1261 (opens in a new tab)
- 739.
Joffe R Swinson R Tranylcypromine in primary obsessive-compulsive disorderJ Anxiety Disord1990 4365367
Not in our library
- 740.
Stein DJ Spadaccini E Hollander E Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorderInt Clin Psychopharmacol1995 101118
Not in our library10.1097/00004850-199503000-00002 (opens in a new tab)
- 741.
Kobak KA Greist JH Jefferson JW Katzelnick DJ Henk HJ Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysisPsychopharmacology (Berl)1998 136205216
Not in our library10.1007/s002130050558 (opens in a new tab)
- 742.
Fallon BA Liebowitz MR Campeas R Schneier FR Marshall R Davies S Goetz D Klein DF Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled studyArch Gen Psychiatry1998 55918924
Not in our library10.1001/archpsyc.55.10.918 (opens in a new tab)
- 743.
Koran LM Sallee FR Pallanti S Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorderAm J Psychiatry1997 154396401
Not in our library10.1176/ajp.154.3.396 (opens in a new tab)
- 744.
Koran LM Aboujaoude E Ward H Shapira NA Sallee FR Gamel N Elliott M Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorderJ Clin Psychopharmacol2006 267983
Not in our library10.1097/01.jcp.0000195112.24769.b3 (opens in a new tab)
- 745.
Goodman WK Price LH Delgado PL Palumbo J Krystal JH Nagy LM Rasmussen SA Heninger GR Charney DS Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramineArch Gen Psychiatry1990 47577585
Not in our library10.1001/archpsyc.1990.01810180077011 (opens in a new tab)
- 746.
Diniz JB Shavitt RG Pereira CA Hounie AG Pimentel I Koran LM Dainesi SM Miguel EC Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trialJ Psychopharmacol2010 24297307
Not in our library10.1177/0269881108099423 (opens in a new tab)
- 747.
Diniz JB Shavitt RG Fossaluza V Koran L Pereira CA Miguel EC A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorderJ Clin Psychopharmacol2011 31763768
Not in our library10.1097/jcp.0b013e3182367aee (opens in a new tab)
- 748.
Koran L Gamel N Choung H Smith E Aboujaoude E Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuationJ Clin Psychiatry2005 66515520
Not in our library
- 749.
Vulink NC Denys D Westenberg HG Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose studyJ Clin Psychiatry2005 66228230
Not in our library10.4088/jcp.v66n0211 (opens in a new tab)
- 750.
Muscatello MR Bruno A Pandolfo G Mico U Scimeca G Romeo VM Santoro V Settineri S Spina E Zoccali RA Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled studyJ Clin Psychopharmacol2011 31174179
Not in our library10.1097/jcp.0b013e31820e3db6 (opens in a new tab)
- 751.
Pessina E Albert U Bogetto F Maina G Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary studyInt Clin Psychopharmacol2009 24265269
Not in our library10.1097/yic.0b013e32832e9b91 (opens in a new tab)
- 752.
Ak M Bulut SD Bozkurt A Ozsahin A Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label studyAdv Ther2011 28341348
Not in our library10.1007/s12325-011-0011-7 (opens in a new tab)
- 753.
Delle Chiaie R Scarciglia P Pasquini M Caredda M Biondi M Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot studyClin Pract Epidemiol Ment Health2011 7107111
Not in our library10.2174/1745017901107010107 (opens in a new tab)
- 754.
Sayyah M Boostani H Ghaffari SM Hoseini A Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial)Depress Anxiety2012 29850854
Not in our library10.1002/da.21996 (opens in a new tab)
- 755.
Selvi Y Atli A Aydin A Besiroglu L Ozdemir P Ozdemir O The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised studyHum Psychopharmacol2011 265157
Not in our library10.1002/hup.1169 (opens in a new tab)
- 756.
McDougle C Epperson C Pelton G Wasylink S Price L A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorderArch Gen Psychiatry2000 57794801
Not in our library10.1001/archpsyc.57.8.794 (opens in a new tab)
- 757.
Hollander E Baldini Rossi N Sood E Pallanti S Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled studyInt J Neuropsychopharmacol2003 6397401
Not in our library10.1017/s1461145703003730 (opens in a new tab)
- 758.
Li X May RS Tolbert LC Jackson WT Flournoy JM Baxter LR Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover studyJ Clin Psychiatry2005 66736743
Not in our library10.4088/jcp.v66n0610 (opens in a new tab)
- 759.
Erzegovesi S Guglielmo E Siliprandi F Bellodi L Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled studyEur Neuropsychopharmacol2005 156974
Not in our library10.1016/j.euroneuro.2004.04.004 (opens in a new tab)
- 760.
Maina G Pessina E Albert U Bogetto F 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorderEur Neuropsychopharmacol2008 18364372
Not in our library10.1016/j.euroneuro.2008.01.001 (opens in a new tab)
- 761.
Simpson HB Foa EB Liebowitz MR Huppert JD Cahill S Maher MJ McLean CP Bender J Jr. Marcus SM Williams MT Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trialJAMA Psychiatry2013 7011901199
Not in our library10.1001/jamapsychiatry.2013.1932 (opens in a new tab)
- 762.
Bystritsky A Ackerman DL Rosen RM Vapnik T Gorbis E Maidment KM Saxena S Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trialJ Clin Psychiatry2004 65565568
Not in our library10.4088/jcp.v65n0418 (opens in a new tab)
- 763.
Shapira NA Ward HE Mandoki M Murphy TK Yang MC Blier P Goodman WK A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorderBiol Psychiatry2004 55553555
Not in our library10.1016/j.biopsych.2003.11.010 (opens in a new tab)
- 764.
Fineberg NA Sivakumaran T Roberts A Gale T Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment studyInt Clin Psychopharmacol2005 20223226
Not in our library10.1097/00004850-200507000-00005 (opens in a new tab)
- 765.
Carey PD Vythilingum B Seedat S Muller JE van Ameringen M Stein DJ Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled studyBMC Psychiatry2005 55
Not in our library10.1186/1471-244x-5-5 (opens in a new tab)
- 766.
Denys D de Geus F van Megen H Westenberg H A double blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitorsJ Clin Psychiatry2004 6510401048
Not in our library10.4088/jcp.v65n0803 (opens in a new tab)
- 767.
Savas HA Yumru M Ozen ME Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative studyClin Drug Investig2008 28439442
Not in our library10.2165/00044011-200828070-00005 (opens in a new tab)
- 768.
Kordon A Wahl K Koch N Zurowski B Anlauf M Vielhaber K Kahl KG Broocks A Voderholzer U Hohagen F Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled studyJ Clin Psychopharmacol2008 28550554
Not in our library10.1097/jcp.0b013e318185e735 (opens in a new tab)
- 769.
McDougle CJ Goodman WK Leckman JF Lee NC Heninger GR Price LH Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without ticsArch Gen Psychiatry1994 51302308
Not in our library10.1001/archpsyc.1994.03950040046006 (opens in a new tab)
- 770.
Metin O Yazici K Tot S Yazici AE Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trialHum Psychopharmacol2003 18463467
Not in our library10.1002/hup.512 (opens in a new tab)
- 771.
Hollander E Kaplan A Stahl SM A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorderWorld J Biol Psychiatry2003 43034
Not in our library10.3109/15622970309167908 (opens in a new tab)
- 772.
Crockett BA Churchill E Davidson JR A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorderAnn Clin Psychiatry2004 16127132
Not in our library10.1080/10401230490486972 (opens in a new tab)
- 773.
Hewlett WA Vinogradov S Agras WS Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorderJ Clin Psychopharmacol1992 12420430
Not in our library
- 774.
Dannon P Sasson Y Hirschmann S Iancu I Grunhaus L Zohar J Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trialEur Neuropsychopharmacol2000 10165169
Not in our library10.1016/s0924-977x(00)00065-1 (opens in a new tab)
- 775.
Mundo E Guglielmo E Bellodi L Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled studyInt Clin Psychopharmacol1998 13219224
Not in our library10.1097/00004850-199809000-00005 (opens in a new tab)
- 776.
Blier P Bergeron R Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findingsInt Clin Psychopharmacol1996 113744
Not in our library10.1097/00004850-199603000-00005 (opens in a new tab)
- 777.
Sayyah M Boostani H Pakseresht S Malayeri A A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorderPsychiatry Res2011 189403406
Not in our library10.1016/j.psychres.2011.01.019 (opens in a new tab)
- 778.
Askari N Moin M Sanati M Tajdini M Hosseini SM Modabbernia A Najand B Salimi S Tabrizi M Ashrafi M Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trialCNS Drugs2012 26883892
Not in our library10.2165/11635850-000000000-00000 (opens in a new tab)
- 779.
Rodriguez CI Kegeles LS Levinson A Feng T Marcus SM Vermes D Flood P Simpson HB Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-conceptNeuropsychopharmacology2013 3824752483
Not in our library10.1038/npp.2013.150 (opens in a new tab)
- 780.
Bloch MH Wasylink S Landeros-Weisenberger A Panza KE Billingslea E Leckman JF Krystal JH Bhagwagar Z Sanacora G Pittenger C Effects of ketamine in treatment-refractory obsessive-compulsive disorderBiol Psychiatry2012 72964970
Not in our library10.1016/j.biopsych.2012.05.028 (opens in a new tab)
- 781.
Aboujaoude E Barry JJ Gamel N Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trialJ Clin Psychopharmacol2009 295155
Not in our library10.1097/jcp.0b013e318192e9a4 (opens in a new tab)
- 782.
Stewart SE Jenike EA Hezel DM Stack DE Dodman NH Shuster L Jenike MA A single-blinded case-control study of memantine in severe obsessive-compulsive disorderJ Clin Psychopharmacol2010 303439
Not in our library10.1097/jcp.0b013e3181c856de (opens in a new tab)
- 783.
Ghaleiha A Entezari N Modabbernia A Najand B Askari N Tabrizi M Ashrafi M Hajiaghaee R Akhondzadeh S Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled studyJ Psychiatr Res2013 47175180
Not in our library10.1016/j.jpsychires.2012.09.015 (opens in a new tab)
- 784.
Pallanti S Bernardi S Antonini S Singh N Hollander E Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective studyCNS Drugs2009 2310471055
Not in our library10.2165/11530240-000000000-00000 (opens in a new tab)
- 785.
Soltani F Sayyah M Feizy F Malayeri A Siahpoosh A Motlagh I A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorderHum Psychopharmacol2010 25509513
Not in our library10.1002/hup.1145 (opens in a new tab)
- 786.
Afshar H Roohafza H Mohammad-Beigi H Haghighi M Jahangard L Shokouh P Sadeghi M Hafezian H N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trialJ Clin Psychopharmacol2012 32797803
Not in our library10.1097/jcp.0b013e318272677d (opens in a new tab)
- 787.
Van Ameringen M Patterson B Simpson W Turna J N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case seriesJ Obsess Compul Rel Dis2013 24852
Not in our library
- 788.
Coric V Taskiran S Pittenger C Wasylink S Mathalon DH Valentine G Saksa J Wu YT Gueorguieva R Sanacora G Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trialBiol Psychiatry2005 58424428
Not in our library10.1016/j.biopsych.2005.04.043 (opens in a new tab)
- 789.
Pittenger C Kelmendi B Wasylink S Bloch MH Coric V Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-upJ Clin Psychopharmacol2008 28363367
Not in our library10.1097/jcp.0b013e3181727548 (opens in a new tab)
- 790.
McDougle CJ Price LH Goodman WK Charney DS Heninger GR A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacyJ Clin Psychopharmacol1991 11175184
Not in our library
- 791.
Pigott TA Pato MT L'Heureux F Hill JL Grover GN Bernstein SE Murphy DL A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorderJ Clin Psychopharmacol1991 11242248
Not in our library
- 792.
Jenike MA Baer L Buttolph L Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorderJ Clin Psychiatry1991 521314
Not in our library
- 793.
Pigott TA L'Heureux F Hill JL Bihari K Bernstein SE Murphy DL A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorderJ Clin Psychopharmacol1992 121118
Not in our library10.1097/00001573-199202000-00003 (opens in a new tab)
- 794.
Rodriguez CI Bender J Jr. Marcus SM Snape M Rynn M Simpson HB Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial [Letter]J Clin Psychiatry2010 7112471249
Not in our library10.4088/jcp.09l05805blu (opens in a new tab)
- 795.
Rubio G Jimenez-Arriero MA Martinez-Gras I Manzanares J Palomo T The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorderJ Clin Psychopharmacol2006 26341344
Not in our library10.1097/01.jcp.0000220524.44905.9f (opens in a new tab)
- 796.
Berlin HA Koran LM Jenike MA Shapira NA Chaplin W Pallanti S Hollander E Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorderJ Clin Psychiatry2011 72716721
Not in our library10.4088/jcp.09m05266gre (opens in a new tab)
- 797.
Mowla A Khajeian AM Sahraian A Chohedri AH Kashkoli F Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trialCNS Spectr2010 15613617
Not in our library10.1017/s1092852912000065 (opens in a new tab)
- 798.
Van Ameringen M Mancini C Patterson B Bennett M Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case seriesDepress Anxiety2006 2315
Not in our library10.1002/da.20118 (opens in a new tab)
- 799.
Bruno A Mico U Pandolfo G Mallamace D Abenavoli E Di Nardo F D'Arrigo C Spina E Zoccali RA Muscatello MR Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled studyJ Psychopharmacol2012 2614561462
Not in our library10.1177/0269881111431751 (opens in a new tab)
- 800.
Kumar TC Khanna S Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorderAust N Z J Psychiatry2000 34527528
Not in our library10.1080/j.1440-1614.2000.0751c.x (opens in a new tab)
- 801.
Di Nicola M Tedeschi D Martinotti G De Vita O Monetta M Pozzi G Janiri L Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case seriesJ Clin Psychopharmacol2011 31675677
Not in our library10.1097/jcp.0b013e31822c29a8 (opens in a new tab)
- 802.
Oulis P Mourikis I Konstantakopoulos G Pregabalin augmentation in treatment-resistant obsessive-compulsive disorderInt Clin Psychopharmacol2011 26221224
Not in our library10.1097/yic.0b013e3283466657 (opens in a new tab)
- 803.
Onder E Tural U Gokbakan M Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?Eur Arch Psychiatry Clin Neurosci2008 258319323
Not in our library10.1007/s00406-007-0798-z (opens in a new tab)
- 804.
Cora-Locatelli G Greenberg BD Martin J Murphy DL Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [Letter]J Clin Psychiatry1998 59480481
Not in our library10.4088/jcp.v59n0907d (opens in a new tab)
- 805.
Goldsmith TB Shapira NA Keck PE Jr. Rapid remission of OCD with tramadol hydrochloride [Letter]Am J Psychiatry1999 156660661
Not in our library10.1176/ajp.156.4.660a (opens in a new tab)
- 806.
Shapira NA Keck PE Jr. Goldsmith TD McConville BJ Eis M McElroy SL Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorderDepress Anxiety1997 6170173
Not in our library
- 807.
Amiaz R Fostick L Gershon A Zohar J Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over studyEur Neuropsychopharmacol2008 18455461
Not in our library10.1016/j.euroneuro.2008.01.006 (opens in a new tab)
- 808.
Koran LM Aboujaoude E Bullock KD Franz B Gamel N Elliott M Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorderJ Clin Psychiatry2005 66353359
Not in our library10.4088/jcp.v66n0312 (opens in a new tab)
- 809.
Soomro GM Altman D Rajagopal S Oakley-Browne M Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)Cochrane Database Syst Rev2008 CD001765
Not in our library10.1002/14651858.cd001765.pub3 (opens in a new tab)
- 810.
Stein DJ Andersen EW Overo KF Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placeboRev Bras Psiquiatr2007 29303307
Not in our library10.1590/s1516-44462007000400003 (opens in a new tab)
- 811.
Stein DJ Carey PD Lochner C Seedat S Fineberg N Andersen EW Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapyCNS Spectr2008 13492498
Not in our library10.1017/s1092852900016722 (opens in a new tab)
- 812.
Landeros-Weisenberger A Bloch MH Kelmendi B Wegner R Nudel J Dombrowski P Pittenger C Krystal JH Goodman WK Leckman JF Coric V Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorderJ Affect Disord2010 121175179
Not in our library10.1016/j.jad.2009.06.010 (opens in a new tab)
- 813.
Koran LM Hanna GL Hollander E Nestadt G Simpson HB Practice guideline for the treatment of patients with obsessive-compulsive disorderAm J Psychiatry2007 164553
Not in our library
- 814.
Decloedt EH Stein DJ Current trends in drug treatment of obsessive-compulsive disorderNeuropsychiatr Dis Treat2010 6233242
Not in our library10.2147/ndt.s3149 (opens in a new tab)
- 815.
Ipser JC Carey P Dhansay Y Fakier N Seedat S Stein DJ Pharmacotherapy augmentation strategies in treatment-resistant anxiety disordersCochrane Database Syst Rev2006 CD005473
Not in our library10.1002/14651858.cd005473.pub2 (opens in a new tab)
- 816.
Bloch MH Landeros-Weisenberger A Kelmendi B Coric V Bracken MB Leckman JF A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorderMol Psychiatry2006 11622632
Not in our library10.1038/sj.mp.4001823 (opens in a new tab)
- 817.
Komossa K Depping AM Meyer M Kissling W Leucht S Second-generation antipsychotics for obsessive compulsive disorderCochrane Database Syst Rev2010 CD008141
Not in our library10.1002/14651858.cd008141.pub2 (opens in a new tab)
- 818.
Fineberg NA Tonnoir B Lemming O Stein DJ Escitalopram prevents relapse of obsessive-compulsive disorderEur Neuropsychopharmacol2007 17430439
Not in our library10.1016/j.euroneuro.2006.11.005 (opens in a new tab)
- 819.
Koran LM Hackett E Rubin A Wolkow R Robinson D Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorderAm J Psychiatry2002 1598895
Not in our library10.1176/appi.ajp.159.1.88 (opens in a new tab)
- 820.
Romano S Goodman W Tamura R Gonzales J Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placeboJ Clin Psychopharmacol2001 214652
Not in our library10.1097/00004714-200102000-00009 (opens in a new tab)
- 821.
Katz RJ DeVeaugh-Geiss J Landau P Clomipramine in obsessive-compulsive disorderBiol Psychiatry1990 28401414
Not in our library10.1016/0006-3223(90)90408-t (opens in a new tab)
- 822.
Rasmussen S Hackett E DuBoff E Greist J Halaris A Koran LM Liebowitz M Lydiard RB McElroy S Mendels J O'Connor K A 2-year study of sertraline in the treatment of obsessive-compulsive disorderInt Clin Psychopharmacol1997 12309316
Not in our library10.1097/00004850-199711000-00003 (opens in a new tab)
- 823.
Ravizza L Barzega G Bellino S Bogetto F Maina G Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs)Psychopharmacol Bull1996 32167173
Not in our library
- 824.
Koran LM Bromberg D Hornfeldt CS Shepski JC Wang S Hollander E Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorderCompr Psychiatry2010 51373379
Not in our library10.1016/j.comppsych.2009.10.001 (opens in a new tab)
- 825.
Mantovani A Lisanby SH Pieraccini F Ulivelli M Castrogiovanni P Rossi S Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS)Int J Neuropsychopharmacol2006 995100
Not in our library10.1017/s1461145705005729 (opens in a new tab)
- 826.
Kumar N Chadda RK Augmentation effect of repetitive transcranial magnetic stimulation over the supplementary motor cortex in treatment refractory patients with obsessive compulsive disorderIndian J Psychiatry2011 53340342
Not in our library10.4103/0019-5545.91909 (opens in a new tab)
- 827.
Mantovani A Simpson HB Fallon BA Rossi S Lisanby SH Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorderInt J Neuropsychopharmacol2010 13217227
Not in our library10.1017/s1461145709990435 (opens in a new tab)
- 828.
Ruffini C Locatelli M Lucca A Benedetti F Insacco C Smeraldi E Augmentation effect of repetitive transcranial magnetic stimulation over the orbitofrontal cortex in drug-resistant obsessive-compulsive disorder patients: a controlled investigationPrim Care Companion J Clin Psychiatry2009 11226230
Not in our library10.4088/pcc.08m00663 (opens in a new tab)
- 829.
Sachdev PS Loo CK Mitchell PB McFarquhar TF Malhi GS Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigationPsychol Med2007 3716451649
Not in our library10.1017/s0033291707001092 (opens in a new tab)
- 830.
Sarkhel S Sinha VK Praharaj SK Adjunctive high-frequency right prefrontal repetitive transcranial magnetic stimulation (rTMS) was not effective in obsessive-compulsive disorder but improved secondary depressionJ Anxiety Disord2010 24535539
Not in our library10.1016/j.janxdis.2010.03.011 (opens in a new tab)
- 831.
Prasko J Paskova B Zalesky R Novak T Kopecek M Bares M Horacek J The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled studyNeuro Endocrinol Lett2006 27327332
Not in our library
- 832.
Greenberg BD Gabriels LA Malone DA Jr. Rezai AR Friehs GM Okun MS Shapira NA Foote KD Cosyns PR Kubu CS Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experienceMol Psychiatry2010 156479
Not in our library10.1038/mp.2008.55 (opens in a new tab)
- 833.
Goodman WK Foote KD Greenberg BD Ricciuti N Bauer R Ward H Shapira NA Wu SS Hill CL Rasmussen SA Okun MS Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset designBiol Psychiatry2010 67535542
Not in our library10.1016/j.biopsych.2009.11.028 (opens in a new tab)
- 834.
Abelson JL Curtis GC Sagher O Albucher RC Harrigan M Taylor SF Martis B Giordani B Deep brain stimulation for refractory obsessive-compulsive disorderBiol Psychiatry2005 57510516
Not in our library10.1016/j.biopsych.2004.11.042 (opens in a new tab)
- 835.
Liu K Zhang H Liu C Guan Y Lang L Cheng Y Sun B Wang H Zuo C Pan L Stereotactic treatment of refractory obsessive compulsive disorder by bilateral capsulotomy with 3 years follow-upJ Clin Neurosci2008 15622629
Not in our library10.1016/j.jocn.2007.07.086 (opens in a new tab)
- 836.
Ruck C Karlsson A Steele JD Edman G Meyerson BA Ericson K Nyman H Asberg M Svanborg P Capsulotomy for obsessive-compulsive disorder: long-term follow-up of 25 patientsArch Gen Psychiatry2008 65914921
Not in our library10.1001/archpsyc.65.8.914 (opens in a new tab)
- 837.
Lopes AC Greenberg BD Noren G Canteras MM Busatto GF de Mathis ME Taub A D'Alcante CC Hoexter MQ Gouvea FS Treatment of resistant obsessive-compulsive disorder with ventral capsular/ventral striatal gamma capsulotomy: a pilot prospective studyJ Neuropsychiatry Clin Neurosci2009 21381392
Not in our library10.1176/jnp.2009.21.4.381 (opens in a new tab)
- 838.
Csigo K Harsanyi A Demeter G Rajkai C Nemeth A Racsmany M Long-term follow-up of patients with obsessive-compulsive disorder treated by anterior capsulotomy: a neuropsychological studyJ Affect Disord2010 126198205
Not in our library10.1016/j.jad.2010.02.127 (opens in a new tab)
- 839.
Ruck C Larsson KJ Mataix-Cols D Predictors of medium and long-term outcome following capsulotomy for obsessive-compulsive disorder: one site may not fit allEur Neuropsychopharmacol2012 22406414
Not in our library10.1016/j.euroneuro.2011.11.003 (opens in a new tab)
- 840.
Jung HH Kim CH Chang JH Park YG Chung SS Chang JW Bilateral anterior cingulotomy for refractory obsessive-compulsive disorder: Long-term follow-up resultsStereotact Funct Neurosurg2006 84184189
Not in our library10.1159/000095031 (opens in a new tab)
- 841.
Dougherty DD Baer L Cosgrove GR Cassem EH Price BH Nierenberg AA Jenike MA Rauch SL Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorderAm J Psychiatry2002 159269275
Not in our library10.1176/appi.ajp.159.2.269 (opens in a new tab)
- 842.
Kim CH Chang JW Koo MS Kim JW Suh HS Park IH Lee HS Anterior cingulotomy for refractory obsessive-compulsive disorderActa Psychiatr Scand2003 107283290
Not in our library10.1034/j.1600-0447.2003.00087.x (opens in a new tab)
- 843.
Krisanaprakornkit T Krisanaprakornkit W Piyavhatkul N Laopaiboon M Meditation therapy for anxiety disordersCochrane Database Syst Rev2006 CD004998
Not in our library10.1002/14651858.cd004998.pub2 (opens in a new tab)
- 844.
Abrantes AM Strong DR Cohn A Cameron AY Greenberg BD Mancebo MC Brown RA Acute changes in obsessions and compulsions following moderate-intensity aerobic exercise among patients with obsessive-compulsive disorderJ Anxiety Disord2009 23923927
Not in our library10.1016/j.janxdis.2009.06.008 (opens in a new tab)
- 845.
Brown RA Abrantes AM Strong DR Mancebo MC Menard J Rasmussen SA Greenberg BD A pilot study of moderate-intensity aerobic exercise for obsessive compulsive disorderJ Nerv Ment Dis2007 195514520
Not in our library10.1097/01.nmd.0000253730.31610.6c (opens in a new tab)
- 846.
Pakseresht S Boostani H Sayyah M Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind studyJ Complement Integr Med2011 810.2202/1553-3840.1465
Not in our library10.2202/1553-3840.1465 (opens in a new tab)
- 847.
Taylor LH Kobak KA An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorderJ Clin Psychiatry2000 61575578
Not in our library10.4088/jcp.v61n0806 (opens in a new tab)
- 848.
Van Ameringen M Mancini C Patterson B Boyle MH Post-traumatic stress disorder in CanadaCNS Neurosci Ther2008 14171181
Not in our library10.1111/j.1755-5949.2008.00049.x (opens in a new tab)
- 849.
Pietrzak RH Goldstein RB Southwick SM Grant BF Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related ConditionsJ Anxiety Disord2011 25456465
Not in our library10.1016/j.janxdis.2010.11.010 (opens in a new tab)
- 850.
Darves-Bornoz JM Alonso J de Girolamo G de Graaf R Haro JM Kovess-Masfety V Lepine JP Nachbaur G Negre-Pages L Vilagut G Gasquet I Main traumatic events in Europe: PTSD in the European study of the epidemiology of mental disorders surveyJ Trauma Stress2008 21455462
Not in our library10.1002/jts.20357 (opens in a new tab)
- 851.
Stein MB Walker JR Hazen AL Forde DR Full and partial posttraumatic stress disorder: findings from a community surveyAm J Psychiatry1997 15411141119
Not in our library10.1176/ajp.154.8.1114 (opens in a new tab)
- 852.
Bravo-Mehmedbasic A Kucukalic A Kulenovic AD Suljic E Impact of chronic posttraumatic stress disorder on the quality of life of war survivorsPsychiatr Danub2010 22430435
Not in our library
- 853.
Pietrzak RH Goldstein MB Malley JC Johnson DC Southwick SM Subsyndromal posttraumatic stress disorder is associated with health and psychosocial difficulties in veterans of Operations Enduring Freedom and Iraqi FreedomDepress Anxiety2009 26739744
Not in our library10.1002/da.20574 (opens in a new tab)
- 854.
Westphal M Olfson M Gameroff MJ Wickramaratne P Pilowsky DJ Neugebauer R Lantigua R Shea S Neria Y Functional impairment in adults with past posttraumatic stress disorder: findings from primary careDepress Anxiety2011 28686695
Not in our library10.1002/da.20842 (opens in a new tab)
- 855.
Rona RJ Jones M Iversen A Hull L Greenberg N Fear NT Hotopf M Wessely S The impact of posttraumatic stress disorder on impairment in the UK military at the time of the Iraq warJ Psychiatr Res2009 43649655
Not in our library10.1016/j.jpsychires.2008.09.006 (opens in a new tab)
- 856.
Asmundson GJ Wright KD Stein MB Pain and PTSD symptoms in female veteransEur J Pain2004 8345350
Not in our library10.1016/j.ejpain.2003.10.008 (opens in a new tab)
- 857.
Poundja J Fikretoglu D Guay S Brunet A Validation of the French version of the brief pain inventory in Canadian veterans suffering from traumatic stressJ Pain Symptom Manage2007 33720726
Not in our library10.1016/j.jpainsymman.2006.09.031 (opens in a new tab)
- 858.
Villano CL Rosenblum A Magura S Fong C Cleland C Betzler TF Prevalence and correlates of posttraumatic stress disorder and chronic severe pain in psychiatric outpatientsJ Rehabil Res Dev2007 44167178
Not in our library10.1682/jrrd.2006.05.0052 (opens in a new tab)
- 859.
Lowe B Kroenke K Spitzer RL Williams JB Mussell M Rose M Wingenfeld K Sauer N Spitzer C Trauma exposure and posttraumatic stress disorder in primary care patients: cross-sectional criterion standard studyJ Clin Psychiatry2011 72304312
Not in our library10.4088/jcp.09m05290blu (opens in a new tab)
- 860.
Babson K Feldner M Badour C Trainor C Blumenthal H Sachs-Ericsson N Schmidt N Posttraumatic stress and sleep: differential relations across types of symptoms and sleep problemsJ Anxiety Disord2011 25706713
Not in our library10.1016/j.janxdis.2011.03.007 (opens in a new tab)
- 861.
Hirsch KA Sexual dysfunction in male Operation Enduring Freedom/Operation Iraqi Freedom patients with severe post-traumatic stress disorderMil Med2009 174520522
Not in our library10.7205/milmed-d-03-3508 (opens in a new tab)
- 862.
Lagarde G Doyon J Brunet A Memory and executive dysfunctions associated with acute posttraumatic stress disorderPsychiatry Res2010 177144149
Not in our library10.1016/j.psychres.2009.02.002 (opens in a new tab)
- 863.
Reinhard MJ Wolf G Cozolino L Using the MMPI to assess reported cognitive disturbances and somatization as a core feature of complex PTSDJ Trauma Dissociation2010 115772
Not in our library10.1080/15299730903318475 (opens in a new tab)
- 864.
Frewen PA Dozois DJ Neufeld RW Lanius RA Meta-analysis of alexithymia in posttraumatic stress disorderJ Trauma Stress2008 21243246
Not in our library10.1002/jts.20320 (opens in a new tab)
- 865.
Sareen J Houlahan T Cox BJ Asmundson GJ Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity SurveyJ Nerv Ment Dis2005 193450454
Not in our library10.1097/01.nmd.0000168263.89652.6b (opens in a new tab)
- 866.
Kartha A Brower V Saitz R Samet JH Keane TM Liebschutz J The impact of trauma exposure and post-traumatic stress disorder on healthcare utilization among primary care patientsMed Care2008 46388393
Not in our library10.1097/mlr.0b013e31815dc5d2 (opens in a new tab)
- 867.
Fikretoglu D Brunet A Guay S Pedlar D Mental health treatment seeking by military members with posttraumatic stress disorder: findings on rates, characteristics, and predictors from a nationally representative Canadian military sampleCan J Psychiatry2007 52103110
Not in our library10.1177/070674370705200208 (opens in a new tab)
- 868.
Sareen J Belik SL Stein MB Asmundson GJ Correlates of perceived need for mental health care among active military personnelPsychiatr Serv2010 615057
Not in our library10.1176/ps.2010.61.1.50 (opens in a new tab)
- 869.
Nacasch N Fostick L Zohar J High prevalence of obsessive-compulsive disorder among posttraumatic stress disorder patientsEur Neuropsychopharmacol2011 21876879
Not in our library10.1016/j.euroneuro.2011.03.007 (opens in a new tab)
- 870.
Cougle JR Feldner MT Keough ME Hawkins KA Fitch KE Comorbid panic attacks among individuals with posttraumatic stress disorder: associations with traumatic event exposure history, symptoms, and impairmentJ Anxiety Disord2010 24183188
Not in our library10.1016/j.janxdis.2009.10.006 (opens in a new tab)
- 871.
Ginzburg K Ein-Dor T Solomon Z Comorbidity of posttraumatic stress disorder, anxiety and depression: a 20-year longitudinal study of war veteransJ Affect Disord2010 123249257
Not in our library10.1016/j.jad.2009.08.006 (opens in a new tab)
- 872.
Post LM Zoellner LA Youngstrom E Feeny NC Understanding the relationship between co-occurring PTSD and MDD: symptom severity and affectJ Anxiety Disord2011 2511231130
Not in our library10.1016/j.janxdis.2011.08.003 (opens in a new tab)
- 873.
Fetzner MG McMillan KA Sareen J Asmundson GJ What is the association between traumatic life events and alcohol abuse/dependence in people with and without PTSD? Findings from a nationally representative sampleDepress Anxiety2011 28632638
Not in our library10.1002/da.20852 (opens in a new tab)
- 874.
Pagura J Stein MB Bolton JM Cox BJ Grant B Sareen J Comorbidity of borderline personality disorder and posttraumatic stress disorder in the U.S. populationJ Psychiatr Res2010 4411901198
Not in our library10.1016/j.jpsychires.2010.04.016 (opens in a new tab)
- 875.
Friedman MJ Resick PA Bryant RA Brewin CR Considering PTSD for DSM-5Depress Anxiety2011 28750769
Not in our library10.1002/da.20767 (opens in a new tab)
- 876.
Rose S Bisson J Churchill R Wessely S Psychological debriefing for preventing post traumatic stress disorder (PTSD)Cochrane Database Syst Rev2002 CD000560
Not in our library10.1002/14651858.cd000560 (opens in a new tab)
- 877.
van Emmerik AA Kamphuis JH Hulsbosch AM Emmelkamp PM Single session debriefing after psychological trauma: a meta-analysisLancet2002 360766771
Not in our library10.1016/s0140-6736(02)09897-5 (opens in a new tab)
- 878.
Roberts NP Kitchiner NJ Kenardy J Bisson J Multiple session early psychological interventions for the prevention of post-traumatic stress disorderCochrane Database Syst Rev2009 CD006869
Not in our library10.1002/14651858.cd006869.pub2 (opens in a new tab)
- 879.
Kornor H Winje D Ekeberg O Weisaeth L Kirkehei I Johansen K Steiro A Early trauma-focused cognitive-behavioural therapy to prevent chronic post-traumatic stress disorder and related symptoms: a systematic review and meta-analysisBMC Psychiatry2008 881
Not in our library10.1186/1471-244x-8-81 (opens in a new tab)
- 880.
Roberts NP Kitchiner NJ Kenardy J Bisson JI Early psychological interventions to treat acute traumatic stress symptomsCochrane Database Syst Rev2010 CD007944
Not in our library10.1002/14651858.cd007944.pub2 (opens in a new tab)
- 881.
Gelpin E Bonne O Peri T Brandes D Shalev A Treatment of recent trauma survivors with benzodiazepines: a prospective studyJ Clin Psychiatry1996 57390394
Not in our library
- 882.
Mellman TA Bustamante V David D Fins AI Hypnotic medication in the aftermath of trauma [letter]J Clin Psychiatry2002 6311831184
Not in our library10.4088/jcp.v63n1214h (opens in a new tab)
- 883.
Fowler M Garza TH Slater TM Maani CV McGhee LL The relationship between gabapentin and pregabalin and posttraumatic stress disorder in burned servicemembersJ Burn Care Res2012 33612618
Not in our library10.1097/bcr.0b013e31823dc710 (opens in a new tab)
- 884.
Vaiva G Ducrocq F Jezequel K Averland B Lestavel P Brunet A Marmar C Immediate treatment with propranolol decreases posttraumatic stress disorder two months after traumaBiol Psychiatry2003 54947949
Not in our library10.1016/s0006-3223(03)00412-8 (opens in a new tab)
- 885.
Tarsitani L De Santis V Mistretta M Parmigiani G Zampetti G Roselli V Vitale D Tritapepe L Biondi M Picardi A Treatment with beta-blockers and incidence of post-traumatic stress disorder after cardiac surgery: a prospective observational studyJ Cardiothorac Vasc Anesth2011 26265269
Not in our library10.1053/j.jvca.2011.09.011 (opens in a new tab)
- 886.
Sharp S Thomas C Rosenberg L Rosenberg M Meyer W 3rd Propranolol does not reduce risk for acute stress disorder in pediatric burn traumaJ Trauma2010 68193197
Not in our library10.1097/ta.0b013e3181a8b326 (opens in a new tab)
- 887.
Pastrana Jimenez JI Catalina Romero C Garcia Dieguez N Lopez-Ibor Alino JJ Pharmacological treatment of acute stress disorder with propranolol and hypnoticsActas Esp Psiquiatr2007 35351358
Not in our library
- 888.
McGhee LL Maani CV Garza TH Desocio PA Gaylord KM Black IH The effect of propranolol on posttraumatic stress disorder in burned service membersJ Burn Care Res2009 309297
Not in our library10.1097/bcr.0b013e3181921f51 (opens in a new tab)
- 889.
Pitman R Sanders K Zusman R Healy A Cheema F Lasko N Cahill L Orr S Pilot study of secondary prevention of posttraumatic stress disorder with propranololBiol Psychiatry2002 51189192
Not in our library10.1016/s0006-3223(01)01279-3 (opens in a new tab)
- 890.
Stoddard FJ Jr. Luthra R Sorrentino EA Saxe GN Drake J Chang Y Levine JB Chedekel DS Sheridan RL A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned childrenJ Child Adolesc Psychopharmacol2011 21469477
Not in our library10.1089/cap.2010.0133 (opens in a new tab)
- 891.
Bryant RA Creamer M O'Donnell M Silove D McFarlane AC A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorderBiol Psychiatry2009 65438440
Not in our library10.1016/j.biopsych.2008.10.032 (opens in a new tab)
- 892.
Stoddard FJ Jr. Sorrentino EA Ceranoglu TA Saxe G Murphy JM Drake JE Ronfeldt H White GW Kagan J Snidman N Preliminary evidence for the effects of morphine on posttraumatic stress disorder symptoms in one- to four-year-olds with burnsJ Burn Care Res2009 30836843
Not in our library10.1097/bcr.0b013e3181b48102 (opens in a new tab)
- 893.
Saxe G Geary M Bedard K Bosquet M Miller A Koenen K Stoddard F Moulton S Separation anxiety as a mediator between acute morphine administration and PTSD symptoms in injured childrenAnn N Y Acad Sci2006 10714145
Not in our library10.1196/annals.1364.004 (opens in a new tab)
- 894.
Holbrook TL Galarneau MR Dye JL Quinn K Dougherty AL Morphine use after combat injury in Iraq and post-traumatic stress disorderN Engl J Med2010 362110117
Not in our library10.1056/nejmoa0903326 (opens in a new tab)
- 895.
Stewart CL Wrobel TA Evaluation of the efficacy of pharmacotherapy and psychotherapy in treatment of combat-related post-traumatic stress disorder: a meta-analytic review of outcome studiesMil Med2009 174460469
Not in our library10.7205/milmed-d-04-1507 (opens in a new tab)
- 896.
Nijdam MJ Gersons BP Reitsma JB de Jongh A Olff M Brief eclectic psychotherapy v. eye movement desensitisation and reprocessing therapy for post-traumatic stress disorder: randomised controlled trialBr J Psychiatry2012 200224231
Not in our library10.1192/bjp.bp.111.099234 (opens in a new tab)
- 897.
Resick PA Nishith P Weaver TL Astin MC Feuer CA A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victimsJ Consult Clin Psychol2002 70867879
Not in our library10.1037//0022-006x.70.4.867 (opens in a new tab)
- 898.
Foa EB Dancu CV Hembree EA Jaycox LH Meadows EA Street GP A comparison of exposure therapy, stress inoculation training, and their combination for reducing posttraumatic stress disorder in female assault victimsJ Consult Clin Psychol1999 67194200
Not in our library10.1037//0022-006x.67.2.194 (opens in a new tab)
- 899.
Resick PA Galovski TE O'Brien Uhlmansiek M Scher CD Clum GA Young-Xu Y A randomized clinical trial to dismantle components of cognitive processing therapy for posttraumatic stress disorder in female victims of interpersonal violenceJ Consult Clin Psychol2008 76243258
Not in our library10.1037/0022-006x.76.2.243 (opens in a new tab)
- 900.
Galovski TE Monson C Bruce SE Resick PA Does cognitive-behavioral therapy for PTSD improve perceived health and sleep impairment?J Trauma Stress2009 22197204
Not in our library10.1002/jts.20418 (opens in a new tab)
- 901.
Resick PA Williams LF Suvak MK Monson CM Gradus JL Long-term outcomes of cognitive-behavioral treatments for posttraumatic stress disorder among female rape survivorsJ Consult Clin Psychol2012 80201210
Not in our library10.1037/a0026602 (opens in a new tab)
- 902.
Bryant RA Moulds ML Guthrie RM Dang ST Nixon RD Imaginal exposure alone and imaginal exposure with cognitive restructuring in treatment of posttraumatic stress disorderJ Consult Clin Psychol2003 71706712
Not in our library10.1037/0022-006x.71.4.706 (opens in a new tab)
- 903.
Ehlers A Clark D Hackmann A McManus F Fennell M Herbert C Mayou R A randomized controlled trial of cognitive therapy, a self-help booklet, and repeated assessments as early interventions for posttraumatic stress disorderArch Gen Psychiatry2003 6010241032
Not in our library10.1001/archpsyc.60.10.1024 (opens in a new tab)
- 904.
Zoellner T Rabe S Karl A Maercker A Post-traumatic growth as outcome of a cognitive-behavioural therapy trial for motor vehicle accident survivors with PTSDPsychol Psychother2011 84201213
Not in our library10.1348/147608310x520157 (opens in a new tab)
- 905.
Kemp M Drummond P McDermott B A wait-list controlled pilot study of eye movement desensitization and reprocessing (EMDR) for children with post-traumatic stress disorder (PTSD) symptoms from motor vehicle accidentsClinical child psychology and psychiatry2010 15525
Not in our library10.1177/1359104509339086 (opens in a new tab)
- 906.
Beck JG Coffey SF Foy DW Keane TM Blanchard EB Group cognitive behavior therapy for chronic posttraumatic stress disorder: an initial randomized pilot studyBehav Ther2009 408292
Not in our library10.1016/j.beth.2008.01.003 (opens in a new tab)
- 907.
Basoglu M Salcioglu E Livanou M A randomized controlled study of single-session behavioural treatment of earthquake-related post-traumatic stress disorder using an earthquake simulatorPsychol Med2007 37203213
Not in our library10.1017/s0033291706009123 (opens in a new tab)
- 908.
Hogberg G Pagani M Sundin O Soares J Aberg-Wistedt A Tarnell B Hallstrom T On treatment with eye movement desensitization and reprocessing of chronic post-traumatic stress disorder in public transportation workers--a randomized controlled trialNord J Psychiatry2007 615461
Not in our library10.1080/08039480601129408 (opens in a new tab)
- 909.
Keane TM Zimering RT Caddell JM Implosive (flooding) therapy reduces symptoms of PTSD in Vietnam combat veteransBehav Ther1989 20245260
Not in our library
- 910.
Forbes D Lloyd D Nixon RD Elliott P Varker T Perry D Bryant RA Creamer M A multisite randomized controlled effectiveness trial of cognitive processing therapy for military-related posttraumatic stress disorderJ Anxiety Disord2012 26442452
Not in our library10.1016/j.janxdis.2012.01.006 (opens in a new tab)
- 911.
Alvarez J McLean C Harris AH Rosen CS Ruzek JI Kimerling R The comparative effectiveness of cognitive processing therapy for male veterans treated in a VHA posttraumatic stress disorder residential rehabilitation programJ Consult Clin Psychol2011 79590599
Not in our library10.1037/a0024466 (opens in a new tab)
- 912.
Macdonald A Monson CM Doron-Lamarca S Resick PA Palfai TP Identifying patterns of symptom change during a randomized controlled trial of cognitive processing therapy for military-related posttraumatic stress disorderJ Trauma Stress2011 24268276
Not in our library10.1002/jts.20642 (opens in a new tab)
- 913.
Monson CM Schnurr PP Resick PA Friedman MJ Young-Xu Y Stevens SP Cognitive processing therapy for veterans with military-related posttraumatic stress disorderJ Consult Clin Psychol2006 74898907
Not in our library10.1037/0022-006x.74.5.898 (opens in a new tab)
- 914.
Gros DF Yoder M Tuerk PW Lozano BE Acierno R Exposure therapy for PTSD delivered to veterans via telehealth: predictors of treatment completion and outcome and comparison to treatment delivered in personBehav Ther2011 42276283
Not in our library10.1016/j.beth.2010.07.005 (opens in a new tab)
- 915.
van Minnen A Foa EB The effect of imaginal exposure length on outcome of treatment for PTSDJ Trauma Stress2006 19427438
Not in our library10.1002/jts.20146 (opens in a new tab)
- 916.
Bryant RA Moulds ML Guthrie RM Dang ST Mastrodomenico J Nixon RD Felmingham KL Hopwood S Creamer M A randomized controlled trial of exposure therapy and cognitive restructuring for posttraumatic stress disorderJ Consult Clin Psychol2008 76695703
Not in our library10.1037/a0012616 (opens in a new tab)
- 917.
Foa EB Hembree EA Cahill SP Rauch SA Riggs DS Feeny NC Yadin E Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: outcome at academic and community clinicsJ Consult Clin Psychol2005 73953964
Not in our library10.1037/0022-006x.73.5.953 (opens in a new tab)
- 918.
Paunovic N Öst L-G Cognitive-behavior therapy vs exposure therapy in the treatment of PTSD in refugeesBehav Res Ther2001 3911831197
Not in our library10.1016/s0005-7967(00)00093-0 (opens in a new tab)
- 919.
Moser JS Cahill SP Foa EB Evidence for poorer outcome in patients with severe negative trauma-related cognitions receiving prolonged exposure plus cognitive restructuring: implications for treatment matching in posttraumatic stress disorderJ Nerv Ment Dis2010 1987275
Not in our library10.1097/nmd.0b013e3181c81fac (opens in a new tab)
- 920.
Grunert BK Weis JM Smucker MR Christianson HF Imagery rescripting and reprocessing therapy after failed prolonged exposure for post-traumatic stress disorder following industrial injuryJ Behav Ther Exp Psychiatry2007 38317328
Not in our library10.1016/j.jbtep.2007.10.005 (opens in a new tab)
- 921.
Arntz A Tiesema M Kindt M Treatment of PTSD: a comparison of imaginal exposure with and without imagery rescriptingJ Behav Ther Exp Psychiatry2007 38345370
Not in our library10.1016/j.jbtep.2007.10.006 (opens in a new tab)
- 922.
Beidel DC Frueh BC Uhde TW Wong N Mentrikoski JM Multicomponent behavioral treatment for chronic combat-related posttraumatic stress disorder: a randomized controlled trialJ Anxiety Disord2011 25224231
Not in our library10.1016/j.janxdis.2010.09.006 (opens in a new tab)
- 923.
Bradley R Greene J Russ E Dutra L Westen D A multidimensional meta-analysis of psychotherapy for PTSDAm J Psychiatry2005 162214227
Not in our library10.1176/appi.ajp.162.2.214 (opens in a new tab)
- 924.
Kar N Cognitive behavioral therapy for the treatment of post-traumatic stress disorder: a reviewNeuropsychiatr Dis Treat2011 7167181
Not in our library10.2147/ndt.s10389 (opens in a new tab)
- 925.
Schottenbauer MA Glass CR Arnkoff DB Tendick V Gray SH Nonresponse and dropout rates in outcome studies on PTSD: review and methodological considerationsPsychiatry2008 71134168
Not in our library10.1521/psyc.2008.71.2.134 (opens in a new tab)
- 926.
van der Kolk BA Roth S Pelcovitz D Sunday S Spinazzola J Disorders of extreme stress: The empirical foundation of a complex adaptation to traumaJ Trauma Stress2005 18389399
Not in our library10.1002/jts.20047 (opens in a new tab)
- 927.
Najavits LM Expanding the boundaries of PTSD treatmentJAMA2012 308714716
Not in our library10.1001/2012.jama.10368 (opens in a new tab)
- 928.
Steil R Dyer A Priebe K Kleindienst N Bohus M Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive residential treatment programJ Trauma Stress2011 24102106
Not in our library10.1002/jts.20617 (opens in a new tab)
- 929.
Harned MS Jackson SC Comtois KA Linehan MM Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with borderline personality disorderJ Trauma Stress2010 23421429
Not in our library10.1002/jts.20553 (opens in a new tab)
- 930.
Harned MS Korslund KE Foa EB Linehan MM Treating PTSD in suicidal and self-injuring women with borderline personality disorder: development and preliminary evaluation of a Dialectical Behavior Therapy Prolonged Exposure ProtocolBehav Res Ther2012 50381386
Not in our library10.1016/j.brat.2012.02.011 (opens in a new tab)
- 931.
Mills KL Teesson M Back SE Brady KT Baker AL Hopwood S Sannibale C Barrett EL Merz S Rosenfeld J Ewer PL Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: a randomized controlled trialJAMA2012 308690699
Not in our library10.1001/jama.2012.9071 (opens in a new tab)
- 932.
Cloitre M Courtois CA Charuvastra A Carapezza R Stolbach BC Green BL Treatment of complex PTSD: results of the ISTSS expert clinician survey on best practicesJ Trauma Stress2011 24615627
Not in our library10.1002/jts.20697 (opens in a new tab)
- 933.
Brunet A Ashbaugh A Hebert P Internet use in the aftermath of trauma2010 Amsterdam: NATO Books, IOS Press
Not in our library
- 934.
Spence J Titov N Dear BF Johnston L Solley K Lorian C Wootton B Zou J Schwenke G Randomized controlled trial of Internet-delivered cognitive behavioral therapy for posttraumatic stress disorderDepress Anxiety2011 28541550
Not in our library10.1002/da.20835 (opens in a new tab)
- 935.
Litz BT Engel CC Bryant RA Papa A A randomized, controlled proof-of-concept trial of an internet-based, therapist-assisted self-management treatment for posttraumatic stress disorderAm J Psychiatry2007 16416761683
Not in our library10.1176/appi.ajp.2007.06122057 (opens in a new tab)
- 936.
- 937.
Klein B Mitchell J Abbott J Shandley K Austin D Gilson K Kiropoulos L Cannard G Redman T A therapist-assisted cognitive behavior therapy internet intervention for posttraumatic stress disorder: pre-, post- and 3-month follow-up results from an open trialJ Anxiety Disord2010 24635644
Not in our library10.1016/j.janxdis.2010.04.005 (opens in a new tab)
- 938.
Knaevelsrud C Liedl A Maercker A Posttraumatic growth, optimism and openness as outcomes of a cognitive-behavioural intervention for posttraumatic stress reactionsJ Health Psychol2010 1510301038
Not in our library10.1177/1359105309360073 (opens in a new tab)
- 939.
Lange A van de Ven JP Schrieken B Emmelkamp PM Interapy, treatment of posttraumatic stress through the Internet: a controlled trialJ Behav Ther Exp Psychiatry2001 327390
Not in our library10.1016/s0005-7916(01)00023-4 (opens in a new tab)
- 940.
Lange A Rietdijk D Hudcovicova M van de Ven JP Schrieken B Emmelkamp PM Interapy: a controlled randomized trial of the standardized treatment of posttraumatic stress through the internetJ Consult Clin Psychol2003 71901909
Not in our library10.1037/0022-006x.71.5.901 (opens in a new tab)
- 941.
Rothbaum BO Hodges LF Ready D Graap K Alarcon RD Virtual reality exposure therapy for Vietnam veterans with posttraumatic stress disorderJ Clin Psychiatry2001 62617622
Not in our library10.4088/jcp.v62n0808 (opens in a new tab)
- 942.
Ready DJ Gerardi RJ Backscheider AG Mascaro N Rothbaum BO Comparing virtual reality exposure therapy to present-centered therapy with 11 U.S. Vietnam veterans with PTSDCyberpsychol Behav Soc Netw2010 134954
Not in our library10.1089/cyber.2009.0239 (opens in a new tab)
- 943.
Difede J Cukor J Jayasinghe N Patt I Jedel S Spielman L Giosan C Hoffman HG Virtual reality exposure therapy for the treatment of posttraumatic stress disorder following September 11, 2001J Clin Psychiatry2007 6816391647
Not in our library
- 944.
Germain V Marchand A Bouchard S Drouin MS Guay S Effectiveness of cognitive behavioural therapy administered by videoconference for posttraumatic stress disorderCogn Behav Ther2009 384253
Not in our library10.1080/16506070802473494 (opens in a new tab)
- 945.
Hetrick SE Purcell R Garner B Parslow R Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD)Cochrane Database Syst Rev2010 CD007316
Not in our library10.1002/14651858.cd007316.pub2 (opens in a new tab)
- 946.
Cohen JA Mannarino AP Perel JM Staron V A pilot randomized controlled trial of combined trauma-focused CBT and sertraline for childhood PTSD symptomsJ Am Acad Child Adolesc Psychiatry2007 46811819
Not in our library10.1097/chi.0b013e3180547105 (opens in a new tab)
- 947.
Simon NM Connor KM Lang AJ Rauch S Krulewicz S LeBeau RT Davidson JR Stein MB Otto MW Foa EB Pollack MH Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapyJ Clin Psychiatry2008 69400405
Not in our library10.4088/jcp.v69n0309 (opens in a new tab)
- 948.
Rothbaum BO Cahill SP Foa EB Davidson JR Compton J Connor KM Astin MC Hahn CG Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorderJ Trauma Stress2006 19625638
Not in our library10.1002/jts.20170 (opens in a new tab)
- 949.
Otto M Hinton D Korbly N Chea A Ba P Gershuny B Pollack M Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline aloneBehav Res Ther2003 4112711276
Not in our library10.1016/s0005-7967(03)00032-9 (opens in a new tab)
- 950.
Schneier FR Neria Y Pavlicova M Hembree E Suh EJ Amsel L Marshall RD Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trialAm J Psychiatry2012 1698088
Not in our library10.1176/appi.ajp.2011.11020321 (opens in a new tab)
- 951.
Brunet A Orr SP Tremblay J Robertson K Nader K Pitman RK Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorderJ Psychiatr Res2008 42503506
Not in our library10.1016/j.jpsychires.2007.05.006 (opens in a new tab)
- 952.
Brunet A Poundja J Tremblay J Bui E Thomas E Orr SP Azzoug A Birmes P Pitman RK Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trialsJ Clin Psychopharmacol2011 31547550
Not in our library10.1097/jcp.0b013e318222f360 (opens in a new tab)
- 953.
de Kleine RA Hendriks GJ Kusters WJ Broekman TG van Minnen A A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorderBiol Psychiatry2012 71962968
Not in our library10.1016/j.biopsych.2012.02.033 (opens in a new tab)
- 954.
Litz BT Salters-Pedneault K Steenkamp MM Hermos JA Bryant RA Otto MW Hofmann SG A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorderJ Psychiatr Res2012 4611841190
Not in our library10.1016/j.jpsychires.2012.05.006 (opens in a new tab)
- 955.
Van Etten M Taylor S Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysisClin Psychol Psychother1998 5126144
Not in our library
- 956.
Edmond T Rubin A Assessing the long-term effects of EMDR: results from an 18-month follow-up study with adult female survivors of CSAJ Child Sex Abus2004 136986
Not in our library10.1300/j070v13n01_04 (opens in a new tab)
- 957.
Wilson SA Becker LA Tinker RH Fifteen-month follow-up of eye movement desensitization and reprocessing (EMDR) treatment for posttraumatic stress disorder and psychological traumaJ Consult Clin Psychol1997 6510471056
Not in our library10.1037//0022-006x.65.6.1047 (opens in a new tab)
- 958.
Knaevelsrud C Maercker A Long-term effects of an internet-based treatment for posttraumatic stressCogn Behav Ther2010 397277
Not in our library10.1080/16506070902999935 (opens in a new tab)
- 959.
Hogberg G Pagani M Sundin O Soares J Aberg-Wistedt A Tarnell B Hallstrom T Treatment of post-traumatic stress disorder with eye movement desensitization and reprocessing: outcome is stable in 35-month follow-upPsychiatry Res2008 159101108
Not in our library10.1016/j.psychres.2007.10.019 (opens in a new tab)
- 960.
van der Kolk B Dreyfuss D Michaels M Shera D Berkowitz R Fisler R Saxe G Fluoxetine in posttraumatic stress disorderJ Clin Psychiatry1994 55517522
Not in our library
- 961.
Connor K Sutherland S Tupler L Malik M Davidson J Fluoxetine in post-traumatic stress disorder. Randomised, double-blind studyBr J Psychiatry1999 1751722
Not in our library10.1192/bjp.175.1.17 (opens in a new tab)
- 962.
Martenyi F Brown E Zhang H Prakash A Koke S Fluoxetine versus placebo in posttraumatic stress disorderJ Clin Psychiatry2002 63199206
Not in our library10.4088/jcp.v63n0305 (opens in a new tab)
- 963.
van der Kolk BA Spinazzola J Blaustein ME Hopper JW Hopper EK Korn DL Simpson WB A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenanceJ Clin Psychiatry2007 683746
Not in our library10.4088/jcp.v68n0105 (opens in a new tab)
- 964.
Martenyi F Brown EB Caldwell CD Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled studyJ Clin Psychopharmacol2007 27166170
Not in our library10.1097/jcp.0b013e31803308ce (opens in a new tab)
- 965.
Hertzberg MA Feldman ME Beckham JC Kudler HS Davidson JR Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veteransAnn Clin Psychiatry2000 12101105
Not in our library10.1023/a:1009076231175 (opens in a new tab)
- 966.
Tucker P Zaninelli R Yehuda R Ruggiero L Dillingham K Pitts C Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trialJ Clin Psychiatry2001 62860868
Not in our library10.4088/jcp.v62n1105 (opens in a new tab)
- 967.
Marshall R Beebe K Oldham M Zaninelli R Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled studyAm J Psychiatry2001 15819821988
Not in our library10.1176/appi.ajp.158.12.1982 (opens in a new tab)
- 968.
Stein D Davidson J Seedat S Beebe K Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studiesExpert Opin Pharmacother2003 418291838
Not in our library10.1517/14656566.4.10.1829 (opens in a new tab)
- 969.
Marshall RD Lewis-Fernandez R Blanco C Simpson HB Lin SH Vermes D Garcia W Schneier F Neria Y Sanchez-Lacay A Liebowitz MR A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adultsDepress Anxiety2007 247784
Not in our library10.1002/da.20176 (opens in a new tab)
- 970.
Petrakis IL Ralevski E Desai N Trevisan L Gueorguieva R Rounsaville B Krystal JH Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependenceNeuropsychopharmacology2012 379961004
Not in our library10.1038/npp.2011.283 (opens in a new tab)
- 971.
Davidson J Rothbaum B van der Kolk B Sikes C Farfel G Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorderArch Gen Psychiatry2001 58485492
Not in our library10.1001/archpsyc.58.5.485 (opens in a new tab)
- 972.
Brady K Pearlstein T Asnis G Baker D Rothbaum B Sikes C Farfel G Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trialJAMA2000 28318371844
Not in our library10.1001/jama.283.14.1837 (opens in a new tab)
- 973.
Zohar J Amital D Miodownik C Kotler M Bleich A Lane R Austin C Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorderJ Clin Psychopharmacol2002 22190195
Not in our library10.1097/00004714-200204000-00013 (opens in a new tab)
- 974.
Tucker P Potter-Kimball R Wyatt D Parker D Burgin C Jones D Masters B Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placeboPsychopharmacol Bull2003 37135149
Not in our library
- 975.
Davidson J Rothbaum BO Tucker P Asnis G Benattia I Musgnung JJ Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled studyJ Clin Psychopharmacol2006 26259267
Not in our library10.1097/01.jcp.0000222514.71390.c1 (opens in a new tab)
- 976.
Stein DJ van der Kolk BA Austin C Fayyad R Clary C Efficacy of sertraline in posttraumatic stress disorder secondary to interpersonal trauma or childhood abuseAnn Clin Psychiatry2006 18243249
Not in our library10.1080/10401230600948431 (opens in a new tab)
- 977.
Friedman MJ Marmar CR Baker DG Sikes CR Farfel GM Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs settingJ Clin Psychiatry2007 68711720
Not in our library10.4088/jcp.v68n0508 (opens in a new tab)
- 978.
Panahi Y Moghaddam BR Sahebkar A Nazari MA Beiraghdar F Karami G Saadat AR A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorderPsychol Med2011 4121592166
Not in our library10.1017/s0033291711000201 (opens in a new tab)
- 979.
Marmar C Schoenfeld F Weiss D Metzler T Zatzick D Wu R Smiga S Tecott L Neylan T Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorderJ Clin Psychiatry1996 57Suppl 86670discussion 71-62
Not in our library
- 980.
Escalona R Canive J Calais L Davidson J Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorderDepress Anxiety2002 152933
Not in our library10.1002/da.1082 (opens in a new tab)
- 981.
Tucker P Smith K Marx B Jones D Miranda R Lensgraf J Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorderJ Clin Psychopharmacol2000 20367372
Not in our library10.1097/00004714-200006000-00014 (opens in a new tab)
- 982.
Neylan T Metzler T Schoenfeld F Weiss D Lenoci M Best S Lipsey T Marmar C Fluvoxamine and sleep disturbances in posttraumatic stress disorderJ Trauma Stress2001 14461467
Not in our library10.1023/a:1011100420978 (opens in a new tab)
- 983.
De Boer M Op den Velde W Falger P Hovens J De Groen J Van Duijn H Fluvoxamine treatment for chronic PTSD: a pilot studyPsychother Psychosom1992 57158163
Not in our library10.1159/000288593 (opens in a new tab)
- 984.
Spivak B Strous RD Shaked G Shabash E Kotler M Weizman A Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trialJ Clin Psychopharmacol2006 26152156
Not in our library10.1097/01.jcp.0000203195.65710.f0 (opens in a new tab)
- 985.
Robert S Hamner MB Ulmer HG Lorberbaum JP Durkalski VL Open-label trial of escitalopram in the treatment of posttraumatic stress disorderJ Clin Psychiatry2006 6715221526
Not in our library10.4088/jcp.v67n1005 (opens in a new tab)
- 986.
Seedat S Stein D Emsley R Open trial of citalopram in adults with post-traumatic stress disorderInt J Neuropsychopharmacol2000 3135140
Not in our library10.1017/s1461145700001899 (opens in a new tab)
- 987.
Seedat S Stein D Ziervogel C Middleton T Kaminer D Emsley R Rossouw W Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorderJ Child Adolesc Psychopharmacol2002 123746
Not in our library10.1089/10445460252943551 (opens in a new tab)
- 988.
English BA Jewell M Jewell G Ambrose S Davis LL Treatment of chronic posttraumatic stress disorder in combat veterans with citalopram: an open trialJ Clin Psychopharmacol2006 268488
Not in our library10.1097/01.jcp.0000195043.39853.bc (opens in a new tab)
- 989.
Davidson J Baldwin D Stein DJ Kuper E Benattia I Ahmed S Pedersen R Musgnung J Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trialArch Gen Psychiatry2006 6311581165
Not in our library10.1001/archpsyc.63.10.1158 (opens in a new tab)
- 990.
Walderhaug E Kasserman S Aikins D Vojvoda D Nishimura C Neumeister A Effects of duloxetine in treatment-refractory men with posttraumatic stress disorderPharmacopsychiatry2010 434549
Not in our library10.1055/s-0029-1237694 (opens in a new tab)
- 991.
Villarreal G Canive JM Calais LA Toney G Smith AK Duloxetine in military posttraumatic stress disorderPsychopharmacol Bull2010 432634
Not in our library
- 992.
Frank J Kosten T Giller E Dan E A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorderAm J Psychiatry1988 14512891291
Not in our library10.1176/ajp.145.10.1289 (opens in a new tab)
- 993.
Kosten T Frank J Dan E McDougle C Giller E Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramineJ Nerv Ment Dis1991 179366370
Not in our library10.1097/00005053-199106000-00011 (opens in a new tab)
- 994.
Davidson J Kudler H Smith R Mahorney S Lipper S Hammett E Saunders W Cavenar J Treatment of posttraumatic stress disorder with amitriptyline and placeboArch Gen Psychiatry1990 47259266
Not in our library10.1001/archpsyc.1990.01810150059010 (opens in a new tab)
- 995.
Reist C Kauffmann C Haier R Sangdahl C De ME Chicz-De MA Nelson J A controlled trial of desipramine in 18 men with posttraumatic stress disorderAm J Psychiatry1989 146513516
Not in our library10.1176/ajp.146.4.513 (opens in a new tab)
- 996.
Shestatzky M Greenberg D Lerer B A controlled trial of phenelzine in posttraumatic stress disorderPsychiatry Res1988 24149155
Not in our library10.1016/0165-1781(88)90057-1 (opens in a new tab)
- 997.
Onder E Tural U Aker T A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquakeEur Psychiatry2006 21174179
Not in our library10.1016/j.eurpsy.2005.03.007 (opens in a new tab)
- 998.
Neal L Shapland W Fox C An open trial of moclobemide in the treatment of post-traumatic stress disorderInt Clin Psychopharmacol1997 12231237
Not in our library10.1097/00004850-199707000-00008 (opens in a new tab)
- 999.
Connor K Davidson J Weisler R Ahearn E A pilot study of mirtazapine in post-traumatic stress disorderInt Clin Psychopharmacol1999 142931
Not in our library10.1097/00004850-199901000-00003 (opens in a new tab)
- 1000.
Davidson JR Weisler RH Butterfield MI Casat CD Connor KM Barnett S van Meter S Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trialBiol Psychiatry2003 53188191
Not in our library10.1016/s0006-3223(02)01411-7 (opens in a new tab)
- 1001.
Chung M Min K Jun Y Kim S Kim W Jun E Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trialHum Psychopharmacol2004 19489494
Not in our library10.1002/hup.615 (opens in a new tab)
- 1002.
Alderman CP Condon JT Gilbert AL An open-label study of mirtazapine as treatment for combat-related PTSDAnn Pharmacother2009 4312201226
Not in our library10.1345/aph.1m009 (opens in a new tab)
- 1003.
Canive J Clark R Calais L Qualls C Tuason V Bupropion treatment in veterans with posttraumatic stress disorder: an open studyJ Clin Psychopharmacol1998 18379383
Not in our library10.1097/00004714-199810000-00005 (opens in a new tab)
- 1004.
Franciskovic T Sukovic Z Janovic S Stevanovic A Nemcic-Moro I Roncevic-Grzeta I Letica-Crepulja M Tianeptine in the combined treatment of combat related posttraumatic stress disorderPsychiatr Danub2011 23257263
Not in our library
- 1005.
Becker ME Hertzberg MA Moore SD Dennis MF Bukenya DS Beckham JC A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorderJ Clin Psychopharmacol2007 27193197
Not in our library10.1097/jcp.0b013e318032eaed (opens in a new tab)
- 1006.
Braun P Greenberg D Dasberg H Lerer B Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatmentJ Clin Psychiatry1990 51236238
Not in our library
- 1007.
Cates M Bishop M Davis L Lowe J Woolley T Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorderAnn Pharmacother2004 3813951399
Not in our library10.1345/aph.1e043 (opens in a new tab)
- 1008.
Shalev A Rogel-Fuchs Y Auditory startle reflex in post-traumatic stress disorder patients treated with clonazepamIsr J Psychiatry Relat Sci1992 2916
Not in our library
- 1009.
Tucker P Trautman RP Wyatt DB Thompson J Wu SC Capece JA Rosenthal NR Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry2007 68201206
Not in our library10.4088/jcp.v68n0204 (opens in a new tab)
- 1010.
Yeh MS Mari JJ Costa MC Andreoli SB Bressan RA Mello MF A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSDCNS Neurosci Ther2011 17305310
Not in our library10.1111/j.1755-5949.2010.00188.x (opens in a new tab)
- 1011.
Hertzberg M Butterfield M Feldman M Beckham J Sutherland S Connor K Davidson J A preliminary study of lamotrigine for the treatment of posttraumatic stress disorderBiol Psychiatry1999 4512261229
Not in our library10.1016/s0006-3223(99)00011-6 (opens in a new tab)
- 1012.
Lipper S Davidson J Grady T Edinger J Hammett E Mahorney S Cavenar J Preliminary study of carbamazepine in post-traumatic stress disorderPsychosomatics1986 27849854
Not in our library10.1016/s0033-3182(86)72590-5 (opens in a new tab)
- 1013.
Wolf M Alavi A Mosnaim A Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepineBiol Psychiatry1988 23642644
Not in our library10.1016/0006-3223(88)90011-x (opens in a new tab)
- 1014.
Fesler F Valproate in combat-related posttraumatic stress disorderJ Clin Psychiatry1991 52361364
Not in our library
- 1015.
Clark R Canive J Calais L Qualls C Tuason V Divalproex in posttraumatic stress disorder: an open-label clinical trialJ Trauma Stress1999 12395401
Not in our library10.1023/a:1024797014210 (opens in a new tab)
- 1016.
Davis LL Davidson JR Ward LC Bartolucci A Bowden CL Petty F Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran populationJ Clin Psychopharmacol2008 288488
Not in our library10.1097/jcp.0b013e318160f83b (opens in a new tab)
- 1017.
Hamner MB Faldowski RA Robert S Ulmer HG Horner MD Lorberbaum JP A preliminary controlled trial of divalproex in posttraumatic stress disorderAnn Clin Psychiatry2009 218994
Not in our library
- 1018.
Davidson JR Brady K Mellman TA Stein MB Pollack MH The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorderJ Clin Psychopharmacol2007 278588
Not in our library10.1097/jcp.0b013e31802e5115 (opens in a new tab)
- 1019.
Hamner M Brodrick P Labbate L Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapyAnn Clin Psychiatry2001 13141146
Not in our library10.1023/a:1012281424057 (opens in a new tab)
- 1020.
Malek-Ahmadi P Gabapentin and posttraumatic stress disorderAnn Pharmacother2003 37664666
Not in our library10.1345/aph.1c082 (opens in a new tab)
- 1021.
Kinrys G Wygant LE Pardo TB Melo M Levetiracetam for treatment-refractory posttraumatic stress disorderJ Clin Psychiatry2006 67211214
Not in our library10.4088/jcp.v67n0206 (opens in a new tab)
- 1022.
Pae CU Marks DM Han C Masand PS Patkar AA Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot studyInt Clin Psychopharmacol2009 242933
Not in our library10.1097/yic.0b013e32831feea9 (opens in a new tab)
- 1023.
Schwartz T The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case seriesPsychopharmacol Bull2002 365357
Not in our library
- 1024.
Taylor F Tiagabine for posttraumatic stress disorder: a case series of 7 womenJ Clin Psychiatry2003 6414211425
Not in our library10.4088/jcp.v64n1204 (opens in a new tab)
- 1025.
Berigan T Treatment of posttraumatic stress disorder with tiagabineCan J Psychiatry2002 47788
Not in our library10.1177/070674370204700821 (opens in a new tab)
- 1026.
Berlant J Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorderBMC Psychiatry2004 424
Not in our library10.1186/1471-244x-4-24 (opens in a new tab)
- 1027.
Berlant J van Kammen D Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary reportJ Clin Psychiatry2002 631520
Not in our library10.4088/jcp.v63n0104 (opens in a new tab)
- 1028.
Lindley SE Carlson EB Hill K A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorderJ Clin Psychopharmacol2007 27677681
Not in our library10.1097/jcp.0b013e31815a43ee (opens in a new tab)
- 1029.
Alderman CP McCarthy LC Condon JT Marwood AC Fuller JR Topiramate in combat-related posttraumatic stress disorderAnn Pharmacother2009 43635641
Not in our library10.1345/aph.1l578 (opens in a new tab)
- 1030.
Padala PR Madison J Monnahan M Marcil W Price P Ramaswamy S Din AU Wilson DR Petty F Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in womenInt Clin Psychopharmacol2006 21275280
Not in our library10.1097/00004850-200609000-00005 (opens in a new tab)
- 1031.
Villarreal G Calais LA Canive JM Lundy SL Pickard J Toney G Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trialPsychopharmacol Bull2007 40618
Not in our library
- 1032.
- 1033.
Lambert MT Aripiprazole in the management of post-traumatic stress disorder symptoms in returning global war on terrorism veteransInt Clin Psychopharmacol2006 21185187
Not in our library10.1097/01.yic.0000185021.48279.00 (opens in a new tab)
- 1034.
Kozaric-Kovacic D Pivac N Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic featuresInt J Neuropsychopharmacol2007 10253261
Not in our library10.1017/s1461145706006596 (opens in a new tab)
- 1035.
Byers MG Allison KM Wendel CS Lee JK Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safetyJ Clin Psychopharmacol2010 30225229
Not in our library10.1097/jcp.0b013e3181dac52f (opens in a new tab)
- 1036.
Butterfield MI Becker ME Connor KM Sutherland S Churchill LE Davidson JR Olanzapine in the treatment of post-traumatic stress disorder: a pilot studyInt Clin Psychopharmacol2001 16197203
Not in our library10.1097/00004850-200107000-00003 (opens in a new tab)
- 1037.
Pivac N Kozaric-Kovacic D Muck-Seler D Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorderPsychopharmacology (Berl)2004 175451456
Not in our library10.1007/s00213-004-1849-z (opens in a new tab)
- 1038.
Petty F Brannan S Casada J Davis L Gajewski V Kramer G Stone R Teten A Worchel J Young K Olanzapine treatment for post-traumatic stress disorder: an open-label studyInt Clin Psychopharmacol2001 16331337
Not in our library10.1097/00004850-200111000-00003 (opens in a new tab)
- 1039.
Hamner M Faldowski R Ulmer H Frueh B Huber M Arana G Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptomsInt Clin Psychopharmacol2003 1818
Not in our library10.1097/00004850-200301000-00001 (opens in a new tab)
- 1040.
Monnelly E Ciraulo D Knapp C Keane T Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorderJ Clin Psychopharmacol2003 23193196
Not in our library10.1097/00004714-200304000-00012 (opens in a new tab)
- 1041.
Bartzokis G Lu P Turner J Mintz J Saunders C Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorderBiol Psychiatry2005 57474479
Not in our library10.1016/j.biopsych.2004.11.039 (opens in a new tab)
- 1042.
Reich D Winternitz S Hennen J Watts T Stanculescu C A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in womenJ Clin Psychiatry2004 6516011606
Not in our library10.4088/jcp.v65n1204 (opens in a new tab)
- 1043.
Krystal JH Rosenheck RA Cramer JA Vessicchio JC Jones KM Vertrees JE Horney RA Huang GD Stock C Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trialJAMA2011 306493502
Not in our library10.1001/jama.2011.1080 (opens in a new tab)
- 1044.
Rothbaum BO Killeen TK Davidson JR Brady KT Connor KM Heekin MH Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorderJ Clin Psychiatry2008 69520525
Not in our library10.4088/jcp.v69n0402 (opens in a new tab)
- 1045.
Stein M Kline N Matloff J Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled studyAm J Psychiatry2002 15917771779
Not in our library10.1176/appi.ajp.159.10.1777 (opens in a new tab)
- 1046.
Robert S Hamner MB Durkalski VL Brown MW Ulmer HG An open-label assessment of aripiprazole in the treatment of PTSDPsychopharmacol Bull2009 426980
Not in our library
- 1047.
Richardson JD Fikretoglu D Liu A McIntosh D Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart reviewBMC Psychiatry2011 1186
Not in our library10.1186/1471-244x-11-86 (opens in a new tab)
- 1048.
Sokolski K Denson T Lee R Reist C Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorderMil Med2003 168486489
Not in our library
- 1049.
Hamner M Deitsch S Brodrick P Ulmer H Lorberbaum J Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapyJ Clin Psychopharmacol2003 231520
Not in our library10.1097/00004714-200302000-00003 (opens in a new tab)
- 1050.
Ahearn EP Mussey M Johnson C Krohn A Krahn D Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label studyInt Clin Psychopharmacol2006 212933
Not in our library10.1097/01.yic.0000182116.49887.ae (opens in a new tab)
- 1051.
Duffy J Malloy P Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trialAnn Clin Psychiatry1994 63337
Not in our library10.3109/10401239409148837 (opens in a new tab)
- 1052.
Wells B Chu C Johnson R Nasdahl C Ayubi M Sewell E Statham P Buspirone in the treatment of posttraumatic stress disorderPharmacotherapy1991 11340343
Not in our library
- 1053.
Hertzberg M Feldman M Beckham J Davidson J Trial of trazodone for posttraumatic stress disorder using a multiple baseline group designJ Clin Psychopharmacol1996 16294298
Not in our library10.1097/00004714-199608000-00004 (opens in a new tab)
- 1054.
Battista MA Hierholzer R Khouzam HR Barlow A O'Toole S Pilot trial of memantine in the treatment of posttraumatic stress disorderPsychiatry2007 70167174
Not in our library10.1521/psyc.2007.70.2.167 (opens in a new tab)
- 1055.
Pollack MH Hoge EA Worthington JJ Moshier SJ Wechsler RS Brandes M Simon NM Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry2011 72892897
Not in our library10.4088/jcp.09m05607gry (opens in a new tab)
- 1056.
Kinzie J Leung P Clonidine in Cambodian patients with posttraumatic stress disorderJ Nerv Ment Dis1989 177546550
Not in our library10.1097/00005053-198909000-00005 (opens in a new tab)
- 1057.
Neylan TC Lenoci M Samuelson KW Metzler TJ Henn-Haase C Hierholzer RW Lindley SE Otte C Schoenfeld FB Yesavage JA Marmar CR No improvement of posttraumatic stress disorder symptoms with guanfacine treatmentAm J Psychiatry2006 16321862188
Not in our library10.1176/appi.ajp.163.12.2186 (opens in a new tab)
- 1058.
Davis LL Ward C Rasmusson A Newell JM Frazier E Southwick SM A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veteransPsychopharmacol Bull2008 41818
Not in our library
- 1059.
Abramowitz EG Barak Y Ben-Avi I Knobler HY Hypnotherapy in the treatment of chronic combat-related PTSD patients suffering from insomnia: a randomized, zolpidem-controlled clinical trialInt J Clin Exp Hypn2008 56270280
Not in our library10.1080/00207140802039672 (opens in a new tab)
- 1060.
Stein D Seedat S van dLG Zungu-Dirwayi N Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: a meta-analysis of randomized controlled trialsInt Clin Psychopharmacol2000 15Suppl 2S3139
Not in our library10.1097/00004850-200008002-00006 (opens in a new tab)
- 1061.
Pae CU Lim HK Peindl K Ajwani N Serretti A Patkar AA Lee C The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trialsInt Clin Psychopharmacol2008 2318
Not in our library10.1097/yic.0b013e32825ea324 (opens in a new tab)
- 1062.
Raskind M Peskind E Kanter E Petrie E Radant A Thompson C Dobie D Hoff D Rein R Straits-Troster K Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled studyAm J Psychiatry2003 160371373
Not in our library10.1176/appi.ajp.160.2.371 (opens in a new tab)
- 1063.
Peskind E Bonner L Hoff D Raskind M Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorderJ Geriatr Psychiatry Neurol2003 16165171
Not in our library10.1177/0891988703256050 (opens in a new tab)
- 1064.
Taylor F Raskind M The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorderJ Clin Psychopharmacol2002 228285
Not in our library10.1097/00004714-200202000-00013 (opens in a new tab)
- 1065.
Raskind MA Peskind ER Hoff DJ Hart KL Holmes HA Warren D Shofer J O'Connell J Taylor F Gross C A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorderBiol Psychiatry2007 61928934
Not in our library10.1016/j.biopsych.2006.06.032 (opens in a new tab)
- 1066.
Taylor FB Martin P Thompson C Williams J Mellman TA Gross C Peskind ER Raskind MA Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled studyBiol Psychiatry2008 63629632
Not in our library10.1016/j.biopsych.2007.07.001 (opens in a new tab)
- 1067.
Lubin G Weizman A Shmushkevitz M Valevski A Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary studyHum Psychopharmacol2002 17181185
Not in our library10.1002/hup.395 (opens in a new tab)
- 1068.
Bohus MJ Landwehrmeyer GB Stiglmayr CE Limberger MF Bohme R Schmahl CG Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trialJ Clin Psychiatry1999 60598603
Not in our library10.4088/jcp.v60n0906 (opens in a new tab)
- 1069.
Glover H A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorderIsr J Psychiatry Relat Sci1993 30255263
Not in our library
- 1070.
Bills LJ Kreisler K Treatment of flashbacks with naltrexoneAm J Psychiatry1993 1501430
Not in our library10.1176/ajp.150.9.1430a (opens in a new tab)
- 1071.
Jacobs-Rebhun S Schnurr PP Friedman MJ Peck R Brophy M Fuller D Posttraumatic stress disorder and sleep difficulty [Letter]Am J Psychiatry2000 15715251526
Not in our library10.1176/appi.ajp.157.9.1525 (opens in a new tab)
- 1072.
Davidson J Connor K Hertzberg M Weisler R Wilson W Payne V Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation studyJ Clin Psychopharmacol2005 25166169
Not in our library10.1097/01.jcp.0000155817.21467.6c (opens in a new tab)
- 1073.
Martenyi F Brown E Zhang H Koke S Prakash A Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorderBr J Psychiatry2002 181315320
Not in our library10.1192/bjp.181.4.315 (opens in a new tab)
- 1074.
Davidson J Pearlstein T Londborg P Brady K Rothbaum B Bell J Maddock R Hegel M Farfel G Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled studyAm J Psychiatry2001 15819741981
Not in our library10.1176/appi.ajp.158.12.1974 (opens in a new tab)
- 1075.
Connor KM Davidson JR Weisler RH Zhang W Abraham K Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatmentPsychopharmacology2006 1842125
Not in our library10.1007/s00213-005-0265-3 (opens in a new tab)
- 1076.
Kim Y Asukai N Konishi T Kato H Hirotsune H Maeda M Inoue H Narita H Iwasaki M Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-week, non-comparative open-label study for clinical use experiencePsychiatry Clin Neurosci2008 62646652
Not in our library10.1111/j.1440-1819.2008.01862.x (opens in a new tab)
- 1077.
Londborg P Hegel M Goldstein S Goldstein D Himmelhoch J Maddock R Patterson W Rausch J Farfel G Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatmentJ Clin Psychiatry2001 62325331
Not in our library10.4088/jcp.v62n0503 (opens in a new tab)
- 1078.
Boggio PS Rocha M Oliveira MO Fecteau S Cohen RB Campanha C Ferreira-Santos E Meleiro A Corchs F Zaghi S Noninvasive brain stimulation with high-frequency and low-intensity repetitive transcranial magnetic stimulation treatment for posttraumatic stress disorderJ Clin Psychiatry2010 71992999
Not in our library10.4088/jcp.08m04638blu (opens in a new tab)
- 1079.
Watts BV Landon B Groft A Young-Xu Y A sham controlled study of repetitive transcranial magnetic stimulation for posttraumatic stress disorderBrain Stimul2012 53843
Not in our library10.1016/j.brs.2011.02.002 (opens in a new tab)
- 1080.
Osuch EA Benson BE Luckenbaugh DA Geraci M Post RM McCann U Repetitive TMS combined with exposure therapy for PTSD: a preliminary studyJ Anxiety Disord2009 235459
Not in our library10.1016/j.janxdis.2008.03.015 (opens in a new tab)
- 1081.
Margoob MA Ali Z Andrade C Efficacy of ECT in chronic, severe, antidepressant- and CBT-refractory PTSD: an open, prospective studyBrain Stimul2010 32835
Not in our library10.1016/j.brs.2009.04.005 (opens in a new tab)
- 1082.
Watts BV Electroconvulsive therapy for comorbid major depressive disorder and posttraumatic stress disorderJ ECT2007 239395
Not in our library10.1097/01.yct.0000264369.38033.34 (opens in a new tab)
- 1083.
Hollifield M Sinclair-Lian N Warner TD Hammerschlag R Acupuncture for posttraumatic stress disorder: a randomized controlled pilot trialJ Nerv Ment Dis2007 195504513
Not in our library10.1097/nmd.0b013e31803044f8 (opens in a new tab)
- 1084.
Bormann JE Thorp S Wetherell JL Golshan S A spiritually based group intervention for combat veterans with posttraumatic stress disorder: feasibility studyJ Holist Nurs2008 26109116
Not in our library10.1177/0898010107311276 (opens in a new tab)
- 1085.
Rosenthal JZ Grosswald S Ross R Rosenthal N Effects of transcendental meditation in veterans of Operation Enduring Freedom and Operation Iraqi Freedom with posttraumatic stress disorder: a pilot studyMil Med2011 176626630
Not in our library10.7205/milmed-d-10-00254 (opens in a new tab)
- 1086.
Vesga-Lopez O Blanco C Keyes K Olfson M Grant BF Hasin DS Psychiatric disorders in pregnant and postpartum women in the United StatesArch Gen Psychiatry2008 65805815
Not in our library10.1001/archpsyc.65.7.805 (opens in a new tab)
- 1087.
Sutter-Dallay AL Giaconne-Marcesche V Glatigny-Dallay E Verdoux H Women with anxiety disorders during pregnancy are at increased risk of intense postnatal depressive symptoms: a prospective survey of the MATQUID cohortEur Psychiatry2004 19459463
Not in our library10.1016/j.eurpsy.2004.09.025 (opens in a new tab)
- 1088.
Buist A Gotman N Yonkers KA Generalized anxiety disorder: course and risk factors in pregnancyJ Affect Disord2011 131277283
Not in our library10.1016/j.jad.2011.01.003 (opens in a new tab)
- 1089.
Ross LE McLean LM Anxiety disorders during pregnancy and the postpartum period: A systematic reviewJ Clin Psychiatry2006 6712851298
Not in our library10.4088/jcp.v67n0818 (opens in a new tab)
- 1090.
Zambaldi CF Cantilino A Montenegro AC Paes JA de Albuquerque TL Sougey EB Postpartum obsessive-compulsive disorder: prevalence and clinical characteristicsCompr Psychiatry2009 50503509
Not in our library10.1016/j.comppsych.2008.11.014 (opens in a new tab)
- 1091.
Alcorn KL O'Donovan A Patrick JC Creedy D Devilly GJ A prospective longitudinal study of the prevalence of post-traumatic stress disorder resulting from childbirth eventsPsychol Med2010 4018491859
Not in our library10.1017/s0033291709992224 (opens in a new tab)
- 1092.
Forray A Mayes LC Magriples U Epperson CN Prevalence of post-traumatic stress disorder in pregnant women with prior pregnancy complicationsJ Matern Fetal Neonatal Med2009 22522527
Not in our library10.1080/14767050902801686 (opens in a new tab)
- 1093.
Banhidy F Acs N Puho E Czeizel AE Association between maternal panic disorders and pregnancy complications and delivery outcomesEur J Obstet Gynecol Reprod Biol2006 1244752
Not in our library10.1016/j.ejogrb.2005.04.013 (opens in a new tab)
- 1094.
Lilliecreutz C Sydsjo G Josefsson A Obstetric and perinatal outcomes among women with blood- and injection phobia during pregnancyJ Affect Disord2011 129289295
Not in our library10.1016/j.jad.2010.08.013 (opens in a new tab)
- 1095.
Chen YH Lin HC Lee HC Pregnancy outcomes among women with panic disorder - do panic attacks during pregnancy matter?J Affect Disord2010 120258262
Not in our library10.1016/j.jad.2009.04.025 (opens in a new tab)
- 1096.
Littleton HL Breitkopf CR Berenson AB Correlates of anxiety symptoms during pregnancy and association with perinatal outcomes: a meta-analysisAm J Obstet Gynecol2007 196424432
Not in our library10.1016/j.ajog.2007.03.042 (opens in a new tab)
- 1097.
Rogal SS Poschman K Belanger K Howell HB Smith MV Medina J Yonkers KA Effects of posttraumatic stress disorder on pregnancy outcomesJ Affect Disord2007 102137143
Not in our library10.1016/j.jad.2007.01.003 (opens in a new tab)
- 1098.
Newport DJ Ji S Long Q Knight BT Zach EB Smith EN Morris NJ Stowe ZN Maternal depression and anxiety differentially impact fetal exposures during pregnancyJ Clin Psychiatry2012 73247251
Not in our library10.4088/jcp.10m06783 (opens in a new tab)
- 1099.
Lee AM Lam SK Sze Mun Lau SM Chong CS Chui HW Fong DY Prevalence, course, and risk factors for antenatal anxiety and depressionObstet Gynecol2007 11011021112
Not in our library10.1097/01.aog.0000287065.59491.70 (opens in a new tab)
- 1100.
Challacombe F Salkovskis P A preliminary investigation of the impact of maternal obsessive-compulsive disorder and panic disorder on parenting and childrenJ Anxiety Disord2009 23848857
Not in our library10.1016/j.janxdis.2009.04.002 (opens in a new tab)
- 1101.
Zelkowitz P Na S Wang T Bardin C Papageorgiou A Early maternal anxiety predicts cognitive and behavioural outcomes of VLBW children at 24 months corrected ageActa Paediatr2011 100700704
Not in our library10.1111/j.1651-2227.2010.02128.x (opens in a new tab)
- 1102.
O'Connor T Heron J Glover V Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depressionJ Am Acad Child Adolesc Psychiatry2002 4114701477
Not in our library10.1097/00004583-200212000-00019 (opens in a new tab)
- 1103.
Martini J Knappe S Beesdo-Baum K Lieb R Wittchen HU Anxiety disorders before birth and self-perceived distress during pregnancy: associations with maternal depression and obstetric, neonatal and early childhood outcomesEarly Hum Dev2010 86305310
Not in our library10.1016/j.earlhumdev.2010.04.004 (opens in a new tab)
- 1104.
Seekles W Cuijpers P Kok R Beekman A van Marwijk H van Straten A Psychological treatment of anxiety in primary care: a meta-analysisPsychol Med2012 111
Not in our library10.1017/s0033291712000670 (opens in a new tab)
- 1105.
Lilliecreutz C Josefsson A Sydsjo G An open trial with cognitive behavioral therapy for blood- and injection phobia in pregnant women-a group intervention programArch Womens Ment Health2010 13259265
Not in our library10.1007/s00737-009-0126-x (opens in a new tab)
- 1106.
Challacombe FL Salkovskis PM Intensive cognitive-behavioural treatment for women with postnatal obsessive-compulsive disorder: a consecutive case seriesBehav Res Ther2011 49422426
Not in our library10.1016/j.brat.2011.03.006 (opens in a new tab)
- 1107.
Arch JJ Dimidjian S Chessick C Are exposure-based cognitive behavioral therapies safe during pregnancy?Arch Womens Ment Health2012 15445457
Not in our library10.1007/s00737-012-0308-9 (opens in a new tab)
- 1108.
ACOG Practice BulletinClinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactationObstet Gynecol2008 11110011020
Not in our library10.1097/aog.0b013e31816fd910 (opens in a new tab)
- 1109.
Law R Bozzo P Koren G Einarson A FDA pregnancy risk categories and the CPS: do they help or are they a hindrance?Can Fam Physician2010 56239241
Not in our library
- 1110.
Einarson A Choi J Einarson TR Koren G Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort studyCan J Psychiatry2009 54242246
Not in our library10.1177/070674370905400405 (opens in a new tab)
- 1111.
Malm H Artama M Gissler M Ritvanen A Selective serotonin reuptake inhibitors and risk for major congenital anomaliesObstet Gynecol2011 118111120
Not in our library10.1097/aog.0b013e318220edcc (opens in a new tab)
- 1112.
Bellantuono C Migliarese G Gentile S Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic reviewHum Psychopharmacol2007 22121128
Not in our library10.1002/hup.836 (opens in a new tab)
- 1113.
Grigoriadis S Vonderporten EH Mamisashvili L Roerecke M Rehm J Dennis CL Koren G Steiner M Mousmanis P Cheung A Ross LE Antidepressant exposure during pregnancy and congenital malformations: is there an association? a systematic review and meta-analysis of the best evidenceJ Clin Psychiatry2013 74e293308
Not in our library10.4088/jcp.12r07966 (opens in a new tab)
- 1114.
Reis M Kallen B Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish dataPsychol Med2010 4017231733
Not in our library10.1017/s0033291709992194 (opens in a new tab)
- 1115.
Bar-Oz B Einarson T Einarson A Boskovic R O'Brien L Malm H Berard A Koren G Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factorsClin Ther2007 29918926
Not in our library10.1016/j.clinthera.2007.05.003 (opens in a new tab)
- 1116.
Wurst KE Poole C Ephross SA Olshan AF First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studiesBirth Defects Res A Clin Mol Teratol2010 88159170
Not in our library10.1002/bdra.20627 (opens in a new tab)
- 1117.
Important safety information on Paxil (paroxetine) and increased risk of cardiac defects following exposure during first trimester of pregnancy2005 http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2005/14173a-eng.php
Not in our library
- 1118.
Ross LE Grigoriadis S Mamisashvili L Vonderporten EH Roerecke M Rehm J Dennis CL Koren G Steiner M Mousmanis P Cheung A Selected pregnancy and delivery outcomes after exposure to antidepressant medication: A systematic review and meta-analysisJAMA Psychiatry2013 70436443
Not in our library10.1001/jamapsychiatry.2013.684 (opens in a new tab)
- 1119.
Hemels ME Einarson A Koren G Lanctot KL Einarson TR Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysisAnn Pharmacother2005 39803809
Not in our library10.1345/aph.1e547 (opens in a new tab)
- 1120.
Rahimi R Nikfar S Abdollahi M Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trialsReprod Toxicol2006 22571575
Not in our library10.1016/j.reprotox.2006.03.019 (opens in a new tab)
- 1121.
Grigoriadis S Vonderporten EH Mamisashvili L Eady A Tomlinson G Dennis CL Koren G Steiner M Mousmanis P Cheung A Ross LE The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysisJ Clin Psychiatry2013 74e309320
Not in our library10.4088/jcp.12r07967 (opens in a new tab)
- 1122.
Moses-Kolko EL Bogen D Perel J Bregar A Uhl K Levin B Wisner KL Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applicationsJAMA2005 29323722383
Not in our library10.1001/jama.293.19.2372 (opens in a new tab)
- 1123.
Lattimore KA Donn SM Kaciroti N Kemper AR Neal CR Jr. Vazquez DM Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysisJ Perinatol2005 25595604
Not in our library10.1038/sj.jp.7211352 (opens in a new tab)
- 1124.
Chambers CD Hernandez-Diaz S Van Marter LJ Werler MM Louik C Jones KL Mitchell AA Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newbornN Engl J Med2006 354579587
Not in our library10.1056/nejmoa052744 (opens in a new tab)
- 1125.
Kieler H Artama M Engeland A Ericsson O Furu K Gissler M Nielsen RB Norgaard M Stephansson O Valdimarsdottir U Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countriesBMJ2012 344d8012
Not in our library10.1136/bmj.d8012 (opens in a new tab)
- 1126.
Andrade SE McPhillips H Loren D Raebel MA Lane K Livingston J Boudreau DM Smith DH Davis RL Willy ME Platt R Antidepressant medication use and risk of persistent pulmonary hypertension of the newbornPharmacoepidemiol Drug Saf2009 18246252
Not in our library10.1002/pds.1710 (opens in a new tab)
- 1127.
Wilson KL Zelig CM Harvey JP Cunningham BS Dolinsky BM Napolitano PG Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitorsAm J Perinatol2011 281924
Not in our library10.1055/s-0030-1262507 (opens in a new tab)
- 1128.
Gentile S Neurodevelopmental effects of prenatal exposure to psychotropic medicationsDepress Anxiety2010 27675686
Not in our library10.1002/da.20706 (opens in a new tab)
- 1129.
Gentile S Galbally M Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic reviewJ Affect Disord2011 12819
Not in our library10.1016/j.jad.2010.02.125 (opens in a new tab)
- 1130.
Udechuku A Nguyen T Hill R Szego K Antidepressants in pregnancy: a systematic reviewAust N Z J Psychiatry2010 44978996
Not in our library10.3109/00048674.2010.507543 (opens in a new tab)
- 1131.
Nulman I Koren G Rovet J Barrera M Pulver A Streiner D Feldman B Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depressionAm J Psychiatry2012 16911651174
Not in our library10.1176/appi.ajp.2012.11111721 (opens in a new tab)
- 1132.
Croen LA Grether JK Yoshida CK Odouli R Hendrick V Antidepressant use during pregnancy and childhood autism spectrum disordersArch Gen Psychiatry2011 6811041112
Not in our library10.1001/archgenpsychiatry.2011.73 (opens in a new tab)
- 1133.
Rai D Lee BK Dalman C Golding J Lewis G Magnusson C Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control studyBMJ2013 346f2059
Not in our library10.1136/bmj.f2059 (opens in a new tab)
- 1134.
Figueroa R Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspringJ Dev Behav Pediatr2010 31641648
Not in our library10.1097/dbp.0b013e3181e5ac93 (opens in a new tab)
- 1135.
Froehlich TE Anixt JS Loe IM Chirdkiatgumchai V Kuan L Gilman RC Update on environmental risk factors for attention-deficit/hyperactivity disorderCurrent psychiatry reports2011 13333344
Not in our library10.1007/s11920-011-0221-3 (opens in a new tab)
- 1136.
Berle JO Spigset O Antidepressant use during breastfeedingCurr Womens Health Rev2011 72834
Not in our library10.2174/157340411794474784 (opens in a new tab)
- 1137.
Enato E Moretti M Koren G The fetal safety of benzodiazepines: an updated meta-analysisJ Obstet Gynaecol Can2011 334648
Not in our library10.1016/s1701-2163(16)34772-7 (opens in a new tab)
- 1138.
Altshuler LL Cohen L Szuba MP Burt VK Gitlin M Mintz J Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelinesAm J Psychiatry1996 153592606
Not in our library10.1176/ajp.153.5.592 (opens in a new tab)
- 1139.
Eros E Czeizel AE Rockenbauer M Sorensen HT Olsen J A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancyEur J Obstet Gynecol Reprod Biol2002 101147154
Not in our library10.1016/s0301-2115(01)00545-0 (opens in a new tab)
- 1140.
Kelly LE Poon S Madadi P Koren G Neonatal benzodiazepines exposure during breastfeedingJ Pediatr2012 161448451
Not in our library10.1016/j.jpeds.2012.03.003 (opens in a new tab)
- 1141.
Gentile S Antipsychotic therapy during early and late pregnancy. A systematic reviewSchizophr Bull2010 36518544
Not in our library10.1093/schbul/sbn107 (opens in a new tab)
- 1142.
Einarson A Boskovic R Use and safety of antipsychotic drugs during pregnancyJ Psychiatr Pract2009 15183192
Not in our library10.1097/01.pra.0000351878.45260.94 (opens in a new tab)
- 1143.
Oyebode F Rastogi A Berrisford G Coccia F Psychotropics in pregnancy: safety and other considerationsPharmacol Ther2012 1357177
Not in our library10.1016/j.pharmthera.2012.03.008 (opens in a new tab)
- 1144.
Newham JJ Thomas SH MacRitchie K McElhatton PR McAllister-Williams RH Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison studyBr J Psychiatry2008 192333337
Not in our library10.1192/bjp.bp.107.041541 (opens in a new tab)
- 1145.
Diav-Citrin O Shechtman S Ornoy S Arnon J Schaefer C Garbis H Clementi M Ornoy A Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled studyJ Clin Psychiatry2005 66317322
Not in our library10.4088/jcp.v66n0307 (opens in a new tab)
- 1146.
McKenna K Koren G Tetelbaum M Wilton L Shakir S Diav-Citrin O Levinson A Zipursky RB Einarson A Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative studyJ Clin Psychiatry2005 66444449quiz 546
Not in our library10.4088/jcp.v66n0406 (opens in a new tab)
- 1147.
Lin HC Chen IJ Chen YH Lee HC Wu FJ Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference?Schizophr Res2010 1165560
Not in our library10.1016/j.schres.2009.10.011 (opens in a new tab)
- 1148.
Hironaka M Kotani T Sumigama S Tsuda H Mano Y Hayakawa H Tanaka S Ozaki N Tamakoshi K Kikkawa F Maternal mental disorders and pregnancy outcomes: a clinical study in a Japanese populationJ Obstet Gynaecol Res2011 3712831289
Not in our library10.1111/j.1447-0756.2010.01512.x (opens in a new tab)
- 1149.
Wichman CL Atypical antipsychotic use in pregnancy: a retrospective reviewArch Womens Ment Health2009 125357
Not in our library10.1007/s00737-008-0044-3 (opens in a new tab)
- 1150.
Galbally M Snellen M Lewis AJ A review of the use of psychotropic medication in pregnancyCurr Opin Obstet Gynecol2011 23408414
Not in our library10.1097/gco.0b013e32834b92f3 (opens in a new tab)
- 1151.
Antipsychotic drugs: class labeling change - treatment during pregnancy and potential risk to newbornshttp://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm244175.htm
Not in our library
- 1152.
FDA drug safety communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newbornshttp://www.fda.gov/Drugs/DrugSafety/ucm243903.htm
Not in our library
- 1153.
Antipsychotic drugs: labelling update regarding the risk of abnormal muscle movements and withdrawal symptoms in newborns exposed during pregnancyhttp://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/13616a-eng.php
Not in our library
- 1154.
Gentile S Infant safety with antipsychotic therapy in breast-feeding: a systematic reviewJ Clin Psychiatry2008 69666673
Not in our library10.4088/jcp.v69n0421 (opens in a new tab)
- 1155.
Kessler RC Avenevoli S Costello EJ Georgiades K Green JG Gruber MJ He JP Koretz D McLaughlin KA Petukhova M Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent SupplementArch Gen Psychiatry2012 69372380
Not in our library10.1001/archgenpsychiatry.2011.160 (opens in a new tab)
- 1156.
Merikangas KR He JP Burstein M Swanson SA Avenevoli S Cui L Benjet C Georgiades K Swendsen J Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A)J Am Acad Child Adolesc Psychiatry2010 49980989
Not in our library10.1016/j.jaac.2010.05.017 (opens in a new tab)
- 1157.
Meltzer H Vostanis P Dogra N Doos L Ford T Goodman R Children's specific fearsChild Care Health Dev2009 35781789
Not in our library10.1111/j.1365-2214.2008.00908.x (opens in a new tab)
- 1158.
Heyman I Fombonne E Simmons H Ford T Meltzer H Goodman R Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental healthInt Rev Psychiatry2003 15178184
Not in our library10.1080/0954026021000046146 (opens in a new tab)
- 1159.
Apter A Fallon TJ Jr. King RA Ratzoni G Zohar AH Binder M Weizman A Leckman JF Pauls DL Kron S Cohen DJ Obsessive-compulsive characteristics: from symptoms to syndromeJ Am Acad Child Adolesc Psychiatry1996 35907912
Not in our library10.1097/00004583-199607000-00016 (opens in a new tab)
- 1160.
Flament MF Whitaker A Rapoport JL Davies M Berg CZ Kalikow K Sceery W Shaffer D Obsessive compulsive disorder in adolescence: an epidemiological studyJ Am Acad Child Adolesc Psychiatry1988 27764771
Not in our library10.1097/00004583-198811000-00018 (opens in a new tab)
- 1161.
Albano AM Kendall PC Cognitive behavioural therapy for children and adolescents with anxiety disorders: Clinical research advancesInt Rev Psychiatry2002 14129134
Not in our library
- 1162.
Kendall P Brady E Verduin T Comorbidity in childhood anxiety disorders and treatment outcomeJ Am Acad Child Adolesc Psychiatry2001 40787794
Not in our library10.1097/00004583-200107000-00013 (opens in a new tab)
- 1163.
Verduin T Kendall P Differential occurrence of comorbidity within childhood anxiety disordersJ Clin Child Adolesc Psychol2003 32290295
Not in our library10.1207/s15374424jccp3202_15 (opens in a new tab)
- 1164.
Bernstein GA Bernat DH Davis AA Layne AE Symptom presentation and classroom functioning in a nonclinical sample of children with social phobiaDepress Anxiety2008 25752760
Not in our library10.1002/da.20315 (opens in a new tab)
- 1165.
Layne AE Bernat DH Victor AM Bernstein GA Generalized anxiety disorder in a nonclinical sample of children: symptom presentation and predictors of impairmentJ Anxiety Disord2009 23283289
Not in our library10.1016/j.janxdis.2008.08.003 (opens in a new tab)
- 1166.
Frojd S Ranta K Kaltiala-Heino R Marttunen M Associations of social phobia and general anxiety with alcohol and drug use in a community sample of adolescentsAlcohol Alcohol2011 46192199
Not in our library10.1093/alcalc/agq096 (opens in a new tab)
- 1167.
Low NC Lee SS Johnson JG Williams JB Harris ES The association between anxiety and alcohol versus cannabis abuse disorders among adolescents in primary care settingsFam Pract2008 25321327
Not in our library10.1093/fampra/cmn049 (opens in a new tab)
- 1168.
Reed PL Anthony JC Breslau N Incidence of drug problems in young adults exposed to trauma and posttraumatic stress disorder: do early life experiences and predispositions matter?Arch Gen Psychiatry2007 6414351442
Not in our library10.1001/archpsyc.64.12.1435 (opens in a new tab)
- 1169.
Cornelius JR Kirisci L Reynolds M Clark DB Hayes J Tarter R PTSD contributes to teen and young adult cannabis use disordersAddict Behav2010 359194
Not in our library10.1016/j.addbeh.2009.09.007 (opens in a new tab)
- 1170.
Forbes EE Bertocci MA Gregory AM Ryan ND Axelson DA Birmaher B Dahl RE Objective sleep in pediatric anxiety disorders and major depressive disorderJ Am Acad Child Adolesc Psychiatry2008 47148155
Not in our library10.1097/chi.0b013e31815cd9bc (opens in a new tab)
- 1171.
Alfano CA Ginsburg GS Kingery JN Sleep-related problems among children and adolescents with anxiety disordersJ Am Acad Child Adolesc Psychiatry2007 46224232
Not in our library10.1097/01.chi.0000242233.06011.8e (opens in a new tab)
- 1172.
Alfano CA Kim KL Objective sleep patterns and severity of symptoms in pediatric obsessive compulsive disorder: a pilot investigationJ Anxiety Disord2011 25835839
Not in our library10.1016/j.janxdis.2011.04.004 (opens in a new tab)
- 1173.
Storch EA Murphy TK Lack CW Geffken GR Jacob ML Goodman WK Sleep-related problems in pediatric obsessive-compulsive disorderJ Anxiety Disord2008 22877885
Not in our library10.1016/j.janxdis.2007.09.003 (opens in a new tab)
- 1174.
Ginsburg GS Riddle MA Davies M Somatic symptoms in children and adolescents with anxiety disordersJ Am Acad Child Adolesc Psychiatry2006 4511791187
Not in our library10.1097/01.chi.0000231974.43966.6e (opens in a new tab)
- 1175.
Boden JM Fergusson DM Horwood LJ Anxiety disorders and suicidal behaviours in adolescence and young adulthood: findings from a longitudinal studyPsychol Med2007 37431440
Not in our library10.1017/s0033291706009147 (opens in a new tab)
- 1176.
Andres S Boget T Lazaro L Penades R Morer A Salamero M Castro-Fornieles J Neuropsychological performance in children and adolescents with obsessive-compulsive disorder and influence of clinical variablesBiol Psychiatry2007 61946951
Not in our library10.1016/j.biopsych.2006.07.027 (opens in a new tab)
- 1177.
Jacob ML Morelen D Suveg C Brown Jacobsen AM Whiteside SP Emotional, behavioral, and cognitive factors that differentiate obsessive-compulsive disorder and other anxiety disorders in youthAnxiety Stress Coping2012 25229237
Not in our library10.1080/10615806.2011.571255 (opens in a new tab)
- 1178.
Hughes AA Lourea-Waddell B Kendall PC Somatic complaints in children with anxiety disorders and their unique prediction of poorer academic performanceChild Psychiatry Hum Dev2008 39211220
Not in our library10.1007/s10578-007-0082-5 (opens in a new tab)
- 1179.
Grills-Taquechel AE Fletcher JM Vaughn SR Denton CA Taylor P Anxiety and inattention as predictors of achievement in early elementary school childrenAnxiety Stress Coping2013 26391410
Not in our library10.1080/10615806.2012.691969 (opens in a new tab)
- 1180.
Tillfors M Persson S Willen M Burk WJ Prospective links between social anxiety and adolescent peer relationsJ Adolesc2012 3512551263
Not in our library10.1016/j.adolescence.2012.04.008 (opens in a new tab)
- 1181.
Teubert D Pinquart M A meta-analytic review on the prevention of symptoms of anxiety in children and adolescentsJ Anxiety Disord2011 2510461059
Not in our library
- 1182.
Barrett PM Farrell LJ Ollendick TH Dadds M Long-term outcomes of an Australian universal prevention trial of anxiety and depression symptoms in children and youth: an evaluation of the friends programJ Clin Child Adolesc Psychol2006 35403411
Not in our library10.1207/s15374424jccp3503_5 (opens in a new tab)
- 1183.
Simon E Bogels SM Voncken JM Efficacy of child-focused and parent-focused interventions in a child anxiety prevention studyJ Clin Child Adolesc Psychol2011 40204219
Not in our library10.1080/15374416.2011.546039 (opens in a new tab)
- 1184.
Manassis K Wilansky-Traynor P Farzan N Kleiman V Parker K Sanford M The feelings club: randomized controlled evaluation of school-based CBT for anxious or depressive symptomsDepress Anxiety2010 27945952
Not in our library10.1002/da.20724 (opens in a new tab)
- 1185.
Stallard P Velleman R Salter E Howse I Yule W Taylor G A randomised controlled trial to determine the effectiveness of an early psychological intervention with children involved in road traffic accidentsJ Child Psychol Psychiatry2006 47127134
Not in our library10.1111/j.1469-7610.2005.01459.x (opens in a new tab)
- 1186.
Nugent NR Christopher NC Crow JP Browne L Ostrowski S Delahanty DL The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: a pilot studyJ Trauma Stress2010 23282287
Not in our library10.1002/jts.20517 (opens in a new tab)
- 1187.
Weisz JR Jensen-Doss A Hawley KM Evidence-based youth psychotherapies versus usual clinical care: a meta-analysis of direct comparisonsAm Psychol2006 61671689
Not in our library10.1037/0003-066x.61.7.671 (opens in a new tab)
- 1188.
Chu BC Harrison TL Disorder-specific effects of CBT for anxious and depressed youth: a meta-analysis of candidate mediators of changeClin Child Fam Psychol Rev2007 10352372
Not in our library10.1007/s10567-007-0028-2 (opens in a new tab)
- 1189.
In-Albon T Schneider S Psychotherapy of childhood anxiety disorders: a meta-analysisPsychother Psychosom2007 761524
Not in our library10.1159/000096361 (opens in a new tab)
- 1190.
Silverman WK Pina AA Viswesvaran C Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescentsJ Clin Child Adolesc Psychol2008 37105130
Not in our library10.1080/15374410701817907 (opens in a new tab)
- 1191.
Cartwright-Hatton S Roberts C Chitsabesan P Fothergill C Harrington R Systematic review of the efficacy of cognitive behaviour therapies for childhood and adolescent anxiety disordersBr J Clin Psychol2004 43421436
Not in our library10.1348/0144665042388928 (opens in a new tab)
- 1192.
Baer S Garland E Pilot study of community-based cognitive behavioral group therapy for adolescents with social phobiaJ Am Acad Child Adolesc Psychiatry2005 44258264
Not in our library10.1097/00004583-200503000-00010 (opens in a new tab)
- 1193.
Beidel D Turner S Morris T Behavioral treatment of childhood social phobiaJ Consult Clin Psychol2000 6810721080
Not in our library
- 1194.
Herbert JD Gaudiano BA Rheingold AA Moitra E Myers VH Dalrymple KL Brandsma LL Cognitive behavior therapy for generalized social anxiety disorder in adolescents: a randomized controlled trialJ Anxiety Disord2009 23167177
Not in our library10.1016/j.janxdis.2008.06.004 (opens in a new tab)
- 1195.
Piet J Hougaard E Hecksher MS Rosenberg NK A randomized pilot study of mindfulness-based cognitive therapy and group cognitive-behavioral therapy for young adults with social phobiaScand J Psychol2010 51503410
Not in our library10.1111/j.1467-9450.2009.00801.x (opens in a new tab)
- 1196.
- 1197.
Segool NK Carlson JS Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxietyDepress Anxiety2008 25620631
Not in our library10.1002/da.20410 (opens in a new tab)
- 1198.
Pincus DB May JE Whitton SW Mattis SG Barlow DH Cognitive-behavioral treatment of panic disorder in adolescenceJ Clin Child Adolesc Psychol2010 39638649
Not in our library10.1080/15374416.2010.501288 (opens in a new tab)
- 1199.
Franklin ME Sapyta J Freeman JB Khanna M Compton S Almirall D Moore P Choate-Summers M Garcia A Edson AL Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trialJAMA2011 30612241232
Not in our library10.1001/jama.2011.1344 (opens in a new tab)
- 1200.
Williams TI Salkovskis PM Forrester L Turner S White H Allsopp MA A randomised controlled trial of cognitive behavioural treatment for obsessive compulsive disorder in children and adolescentsEur Child Adolesc Psychiatry2010 19449456
Not in our library10.1007/s00787-009-0077-9 (opens in a new tab)
- 1201.
Bolton D Williams T Perrin S Atkinson L Gallop C Waite P Salkovskis P Randomized controlled trial of full and brief cognitive-behaviour therapy and wait-list for paediatric obsessive-compulsive disorderJ Child Psychol Psychiatry2011 5212691278
Not in our library10.1111/j.1469-7610.2011.02419.x (opens in a new tab)
- 1202.
Turner C Heyman I Futh A Lovell K A pilot study of telephone cognitive-behavioural therapy for obsessive-compulsive disorder in young peopleBehav Cogn Psychother2009 37469474
Not in our library10.1017/s1352465809990178 (opens in a new tab)
- 1203.
O'Kearney RT Anstey KJ von Sanden C Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in children and adolescentsCochrane Database Syst Rev2006 CD004856
Not in our library10.1002/14651858.cd004856.pub2 (opens in a new tab)
- 1204.
Watson HJ Rees CS Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorderJ Child Psychol Psychiatry2008 49489498
Not in our library10.1111/j.1469-7610.2007.01875.x (opens in a new tab)
- 1205.
Smith P Yule W Perrin S Tranah T Dalgleish T Clark DM Cognitive-behavioral therapy for PTSD in children and adolescents: a preliminary randomized controlled trialJ Am Acad Child Adolesc Psychiatry2007 4610511061
Not in our library10.1097/chi.0b013e318067e288 (opens in a new tab)
- 1206.
Nixon RD Sterk J Pearce A A randomized trial of cognitive behaviour therapy and cognitive therapy for children with posttraumatic stress disorder following single-incident traumaJ Abnorm Child Psychol2012 40327337
Not in our library10.1007/s10802-011-9566-7 (opens in a new tab)
- 1207.
Kowalik J Weller J Venter J Drachman D Cognitive behavioral therapy for the treatment of pediatric posttraumatic stress disorder: a review and meta-analysisJ Behav Ther Exp Psychiatry2011 42405413
Not in our library10.1016/j.jbtep.2011.02.002 (opens in a new tab)
- 1208.
King N Tonge B Mullen P Myerson N Heyne D Rollings S Martin R Ollendick T Treating sexually abused children with posttraumatic stress symptoms: a randomized clinical trialJ Am Acad Child Adolesc Psychiatry2000 3913471355
Not in our library10.1097/00004583-200011000-00008 (opens in a new tab)
- 1209.
Cohen J Mannarino A A treatment outcome study for sexually abused preschool children: initial findingsJ Am Acad Child Adolesc Psychiatry1996 354250
Not in our library10.1097/00004583-199601000-00011 (opens in a new tab)
- 1210.
Scheeringa MS Weems CF Cohen JA Amaya-Jackson L Guthrie D Trauma-focused cognitive-behavioral therapy for posttraumatic stress disorder in three-through six year-old children: a randomized clinical trialJ Child Psychol Psychiatry2011 52853860
Not in our library10.1111/j.1469-7610.2010.02354.x (opens in a new tab)
- 1211.
Deblinger E Mannarino AP Cohen JA Steer RA A follow-up study of a multisite, randomized, controlled trial for children with sexual abuse-related PTSD symptomsJ Am Acad Child Adolesc Psychiatry2006 4514741484
Not in our library10.1097/01.chi.0000240839.56114.bb (opens in a new tab)
- 1212.
King N Tonge B Heyne D Pritchard M Rollings S Young D Myerson N Ollendick T Cognitive-behavioral treatment of school-refusing children: a controlled evaluationJ Am Acad Child Adolesc Psychiatry1998 37395403
Not in our library10.1097/00004583-199804000-00017 (opens in a new tab)
- 1213.
Last C Hansen C Franco N Cognitive-behavioral treatment of school phobiaJ Am Acad Child Adolesc Psychiatry1998 37404411
Not in our library10.1097/00004583-199804000-00018 (opens in a new tab)
- 1214.
Pina AA Zerr AA Gonzales NA Ortiz CD Psychosocial interventions for school refusal behavior in children and adolescentsChild Dev Perspect2009 31120
Not in our library10.1111/j.1750-8606.2008.00070.x (opens in a new tab)
- 1215.
Heyne D King NJ Tonge BJ Rollings S Young D Pritchard M Ollendick TH Evaluation of child therapy and caregiver training in the treatment of school refusalJ Am Acad Child Adolesc Psychiatry2002 41687695
Not in our library10.1097/00004583-200206000-00008 (opens in a new tab)
- 1216.
Schneider S Blatter-Meunier J Herren C Adornetto C In-Albon T Lavallee K Disorder-specific cognitive-behavioral therapy for separation anxiety disorder in young children: a randomized waiting-list-controlled trialPsychother Psychosom2011 80206215
Not in our library10.1159/000323444 (opens in a new tab)
- 1217.
Manassis K Mendlowitz S Scapillato D Avery D Fiksenbaum L Freire M Monga S Owens M Group and individual cognitive-behavioral therapy for childhood anxiety disorders: a randomized trialJ Am Acad Child Adolesc Psychiatry2002 4114231430
Not in our library10.1097/00004583-200212000-00013 (opens in a new tab)
- 1218.
O'Leary EM Barrett P Fjermestad KW Cognitive-behavioral family treatment for childhood obsessive-compulsive disorder: a 7-year follow-up studyJ Anxiety Disord2009 23973978
Not in our library10.1016/j.janxdis.2009.06.009 (opens in a new tab)
- 1219.
Richardson T Stallard P Velleman S Computerised cognitive behavioural therapy for the prevention and treatment of depression and anxiety in children and adolescents: a systematic reviewClin Child Fam Psychol Rev2010 13275290
Not in our library10.1007/s10567-010-0069-9 (opens in a new tab)
- 1220.
Storch EA Caporino NE Morgan JR Lewin AB Rojas A Brauer L Larson MJ Murphy TK Preliminary investigation of web-camera delivered cognitive-behavioral therapy for youth with obsessive-compulsive disorderPsychiatry Res2011 189407412
Not in our library10.1016/j.psychres.2011.05.047 (opens in a new tab)
- 1221.
Kendall P Treating anxiety disorders in children: results of a randomized clinical trialJ Consult Clin Psychol1994 62100110
Not in our library10.1037//0022-006x.62.1.100 (opens in a new tab)
- 1222.
Kendall P Flannery-Schroeder E Panichelli-Mindel S Southam-Gerow M Henin A Warman M Therapy for youths with anxiety disorders: a second randomized clinical trialJ Consult Clin Psychol1997 65366380
Not in our library10.1037//0022-006x.65.3.366 (opens in a new tab)
- 1223.
Walkup JT Albano AM Piacentini J Birmaher B Compton SN Sherrill JT Ginsburg GS Rynn MA McCracken J Waslick B Cognitive behavioral therapy, sertraline, or a combination in childhood anxietyN Engl J Med2008 35927532766
Not in our library10.1056/nejmoa0804633 (opens in a new tab)
- 1224.
Ginsburg GS Kendall PC Sakolsky D Compton SN Piacentini J Albano AM Walkup JT Sherrill J Coffey KA Rynn MA Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMSJ Consult Clin Psychol2011 79806813
Not in our library10.1037/a0025933 (opens in a new tab)
- 1225.
Kendall P Safford S Flannery-Schroeder E Webb A Child anxiety treatment: outcomes in adolescence and impact on substance use and depression at 7.4-year follow-upJ Consult Clin Psychol2004 72276287
Not in our library10.1037/0022-006x.72.2.276 (opens in a new tab)
- 1226.
Eldar S Apter A Lotan D Edgar KP Naim R Fox NA Pine DS Bar-Haim Y Attention bias modification treatment for pediatric anxiety disorders: a randomized controlled trialAm J Psychiatry2012 169213230
Not in our library10.1176/appi.ajp.2011.11060886 (opens in a new tab)
- 1227.
Beidel DC Turner SM Sallee FR Ammerman RT Crosby LA Pathak S SET-C versus fluoxetine in the treatment of childhood social phobiaJ Am Acad Child Adolesc Psychiatry2007 4616221632
Not in our library10.1097/chi.0b013e318154bb57 (opens in a new tab)
- 1228.
Beidel DC Turner SM Young BJ Social effectiveness therapy for children: five years laterBehav Ther2006 37416425
Not in our library10.1016/j.beth.2006.06.002 (opens in a new tab)
- 1229.
Simons M Schneider S Herpertz-Dahlmann B Metacognitive therapy versus exposure and response prevention for pediatric obsessive-compulsive disorder. A case series with randomized allocationPsychother Psychosom2006 75257264
Not in our library10.1159/000092897 (opens in a new tab)
- 1230.
Bolton D Perrin S Evaluation of exposure with response-prevention for obsessive compulsive disorder in childhood and adolescenceJ Behav Ther Exp Psychiatry2008 391122
Not in our library10.1016/j.jbtep.2006.11.002 (opens in a new tab)
- 1231.
Storch EA Geffken GR Merlo LJ Mann G Duke D Munson M Adkins J Grabill KM Murphy TK Goodman WK Family-based cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: comparison of intensive and weekly approachesJ Am Acad Child Adolesc Psychiatry2007 46469478
Not in our library10.1097/chi.0b013e31803062e7 (opens in a new tab)
- 1232.
Barrett P Healy-Farrell L March J Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trialJ Am Acad Child Adolesc Psychiatry2004 434662
Not in our library10.1097/00004583-200401000-00014 (opens in a new tab)
- 1233.
Van der Oord S Lucassen S Van Emmerik AA Emmelkamp PM Treatment of post-traumatic stress disorder in children using cognitive behavioural writing therapyClin Psychol Psychother2010 17240249
Not in our library10.1002/cpp.670 (opens in a new tab)
- 1234.
Lesmana CB Suryani LK Jensen GD Tiliopoulos N A spiritual-hypnosis assisted treatment of children with PTSD after the 2002 Bali terrorist attackAm J Clin Hypn2009 522334
Not in our library10.1080/00029157.2009.10401689 (opens in a new tab)
- 1235.
Ford JD Steinberg KL Hawke J Levine J Zhang W Randomized trial comparison of emotion regulation and relational psychotherapies for PTSD with girls involved in delinquencyJ Clin Child Adolesc Psychol2012 412737
Not in our library10.1080/15374416.2012.632343 (opens in a new tab)
- 1236.
Gilboa-Schechtman E Foa EB Shafran N Aderka IM Powers MB Rachamim L Rosenbach L Yadin E Apter A Prolonged exposure versus dynamic therapy for adolescent PTSD: a pilot randomized controlled trialJ Am Acad Child Adolesc Psychiatry2010 4910341042
Not in our library10.1016/j.jaac.2010.07.014 (opens in a new tab)
- 1237.
Ahmad A Sundelin-Wahlsten V Applying EMDR on children with PTSDEur Child Adolesc Psychiatry2008 17127132
Not in our library10.1007/s00787-007-0646-8 (opens in a new tab)
- 1238.
Ahmad A Larsson B Sundelin-Wahlsten V EMDR treatment for children with PTSD: results of a randomized controlled trialNord J Psychiatry2007 61349354
Not in our library10.1080/08039480701643464 (opens in a new tab)
- 1239.
Barrett P Dadds M Rapee R Family treatment of childhood anxiety: a controlled trialJ Consult Clin Psychol1996 64333342
Not in our library10.1037//0022-006x.64.2.333 (opens in a new tab)
- 1240.
Mendlowitz S Manassis K Bradley S Scapillato D Miezitis S Shaw B Cognitive-behavioral group treatments in childhood anxiety disorders: the role of parental involvementJ Am Acad Child Adolesc Psychiatry1999 3812231229
Not in our library10.1097/00004583-199910000-00010 (opens in a new tab)
- 1241.
Shortt A Barrett P Fox T Evaluating the FRIENDS program: a cognitive-behavioral group treatment for anxious children and their parentsJ Clin Child Psychol2001 30525535
Not in our library10.1207/s15374424jccp3004_09 (opens in a new tab)
- 1242.
Nauta M Scholing A Emmelkamp P Minderaa R Cognitive-behavioral therapy for children with anxiety disorders in a clinical setting: no additional effect of a cognitive parent trainingJ Am Acad Child Adolesc Psychiatry2003 4212701278
Not in our library10.1097/01.chi.0000085752.71002.93 (opens in a new tab)
- 1243.
Bogels SM Siqueland L Family cognitive behavioral therapy for children and adolescents with clinical anxiety disordersJ Am Acad Child Adolesc Psychiatry2006 45134141
Not in our library10.1097/01.chi.0000190467.01072.ee (opens in a new tab)
- 1244.
Wood JJ Piacentini JC Southam-Gerow M Chu BC Sigman M Family cognitive behavioral therapy for child anxiety disordersJ Am Acad Child Adolesc Psychiatry2006 45314321
Not in our library10.1097/01.chi.0000196425.88341.b0 (opens in a new tab)
- 1245.
Piacentini J Bergman RL Chang S Langley A Peris T Wood JJ McCracken J Controlled comparison of family cognitive behavioral therapy and psychoeducation/relaxation training for child obsessive-compulsive disorderJ Am Acad Child Adolesc Psychiatry2011 5011491161
Not in our library10.1016/j.jaac.2011.08.003 (opens in a new tab)
- 1246.
Cobham VE Dadds MR Spence SH The role of parental anxiety in the treatment of childhood anxietyJ Consult Clin Psychol1998 66893905
Not in our library10.1037//0022-006x.66.6.893 (opens in a new tab)
- 1247.
Eisen AR Raleigh H Neuhoff CC The unique impact of parent training for separation anxiety disorder in childrenBehav Ther2008 39195206
Not in our library10.1016/j.beth.2007.07.004 (opens in a new tab)
- 1248.
Thienemann M Moore P Tompkins K A parent-only group intervention for children with anxiety disorders: pilot studyJ Am Acad Child Adolesc Psychiatry2006 453746
Not in our library10.1097/01.chi.0000186404.90217.02 (opens in a new tab)
- 1249.
Storch EA Merlo LJ Larson MJ Geffken GR Lehmkuhl HD Jacob ML Murphy TK Goodman WK Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorderJ Am Acad Child Adolesc Psychiatry2008 47583592
Not in our library10.1097/chi.0b013e31816774b1 (opens in a new tab)
- 1250.
Jarrett MA Ollendick TH Treatment of comorbid attention-deficit/hyperactivity disorder and anxiety in children: A multiple baseline design analysisJ Consult Clin Psychol2012 80239244
Not in our library10.1037/a0027123 (opens in a new tab)
- 1251.
Levy K Hunt C Heriot S Treating comorbid anxiety and aggression in childrenJ Am Acad Child Adolesc Psychiatry2007 4611111118
Not in our library10.1097/chi.0b013e318074eb32 (opens in a new tab)
- 1252.
Najavits LM Gallop RJ Weiss RD Seeking safety therapy for adolescent girls with PTSD and substance use disorder: a randomized controlled trialJ Behav Health Serv Res2006 33453463
Not in our library10.1007/s11414-006-9034-2 (opens in a new tab)
- 1253.
Dadds MR Holland DE Laurens KR Mullins M Barrett PM Spence SH Early intervention and prevention of anxiety disorders in children: results at 2-year follow-upJ Consult Clin Psychol1999 67145150
Not in our library10.1037//0022-006x.67.1.145 (opens in a new tab)
- 1254.
Barrett P Duffy A Dadds M Rapee R Cognitive-behavioral treatment of anxiety disorders in children: long-term (6-year) follow-upJ Consult Clin Psychol2001 69135141
Not in our library
- 1255.
Connolly SD Bernstein GA Practice parameter for the assessment and treatment of children and adolescents with anxiety disordersJ Am Acad Child Adolesc Psychiatry2007 46267283
Not in our library10.1097/01.chi.0000246070.23695.06 (opens in a new tab)
- 1256.
Practice parameter on the use of psychotropic medication in children and adolescentsJ Am Acad Child Adolesc Psychiatry2009 48961973
Not in our library10.1097/chi.0b013e3181ae0a08 (opens in a new tab)
- 1257.
Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorderJ Am Acad Child Adolesc Psychiatry2012 5198113
Not in our library10.1016/j.jaac.2011.09.019 (opens in a new tab)
- 1258.
Cohen JA Bukstein O Walter H Benson SR Chrisman A Farchione TR Hamilton J Keable H Kinlan J Schoettle U Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorderJ Am Acad Child Adolesc Psychiatry2010 49414430
Not in our library
- 1259.
Bernstein G Borchardt C Perwien A Crosby R Kushner M Thuras P Last C Imipramine plus cognitive-behavioral therapy in the treatment of school refusalJ Am Acad Child Adolesc Psychiatry2000 39276283
Not in our library10.1097/00004583-200003000-00008 (opens in a new tab)
- 1260.
Reinblatt SP Riddle MA The pharmacological management of childhood anxiety disorders: a reviewPsychopharmacology2007 1916786
Not in our library10.1007/s00213-006-0644-4 (opens in a new tab)
- 1261.
Ipser JC Stein DJ Hawkridge S Hoppe L Pharmacotherapy for anxiety disorders in children and adolescentsCochrane Database Syst Rev2009 CD005170
Not in our library10.1002/14651858.cd005170.pub2 (opens in a new tab)
- 1262.
Uthman OA Abdulmalik J Comparative efficacy and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysisCurr Med Res Opin2010 265359
Not in our library10.1185/03007990903416853 (opens in a new tab)
- 1263.
Geller D Biederman J Stewart S Mullin B Martin A Spencer T Faraone S Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorderAm J Psychiatry2003 16019191928
Not in our library10.1176/appi.ajp.160.11.1919 (opens in a new tab)
- 1264.
Alaghband-Rad J Hakimshooshtary M A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD)Eur Child Adolesc Psychiatry2009 18131135
Not in our library10.1007/s00787-007-0634-z (opens in a new tab)
- 1265.
Coskun M Zoroglu S Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorderJ Child Adolesc Psychopharmacol2009 19297300
Not in our library10.1089/cap.2008.055 (opens in a new tab)
- 1266.
Ercan ES Kandulu R Akyol Ardic U Preschool children with obsessive-compulsive disorder and fluoxetine treatmentEur Child Adolesc Psychiatry2012 21169172
Not in our library10.1007/s00787-012-0244-2 (opens in a new tab)
- 1267.
Geller D Hoog S Heiligenstein J Ricardi R Tamura R Kluszynski S Jacobson J Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trialJ Am Acad Child Adolesc Psychiatry2001 40773779
Not in our library10.1097/00004583-200107000-00011 (opens in a new tab)
- 1268.
Riddle M Scahill L King R Hardin M Anderson G Ort S Smith J Leckman J Cohen D Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorderJ Am Acad Child Adolesc Psychiatry1992 3110621069
Not in our library10.1097/00004583-199211000-00011 (opens in a new tab)
- 1269.
Liebowitz MR Turner SM Piacentini J Beidel DC Clarvit SR Davies SO Graae F Jaffer M Lin SH Sallee FR Fluoxetine in children and adolescents with OCD: a placebo-controlled trialJ Am Acad Child Adolesc Psychiatry2002 4114311438
Not in our library10.1097/00004583-200212000-00014 (opens in a new tab)
- 1270.
Mukaddes NM Abali O Kaynak N Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary reportPsychiatry Clin Neurosci2003 57405408
Not in our library10.1046/j.1440-1819.2003.01139.x (opens in a new tab)
- 1271.
Riddle M Reeve E Yaryura-Tobias J Yang H Claghorn J Gaffney G Greist J Holland D McConville B Pigott T Walkup J Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trialJ Am Acad Child Adolesc Psychiatry2001 40222229
Not in our library10.1097/00004583-200102000-00017 (opens in a new tab)
- 1272.
Geller DA Wagner KD Emslie G Murphy T Carpenter DJ Wetherhold E Perera P Machin A Gardiner C Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trialJ Am Acad Child Adolesc Psychiatry2004 4313871396
Not in our library10.1097/01.chi.0000138356.29099.f1 (opens in a new tab)
- 1273.
March J Biederman J Wolkow R Safferman A Mardekian J Cook E Cutler N Dominguez R Ferguson J Muller B Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trialJAMA1998 28017521756
Not in our library10.1001/jama.280.20.1752 (opens in a new tab)
- 1274.
De Veaugh-Geiss J Moroz G Biederman J Cantwell D Fontaine R Greist J Reichler R Katz R Landau P Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trialJ Am Acad Child Adolesc Psychiatry1992 314549
Not in our library10.1097/00004583-199201000-00008 (opens in a new tab)
- 1275.
Leonard HL Swedo SE Rapoport JL Koby EV Lenane MC Cheslow DL Hamburger SD Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparisonArch Gen Psychiatry1989 4610881092
Not in our library10.1001/archpsyc.1989.01810120030006 (opens in a new tab)
- 1276.
Flament MF Rapoport JL Berg CJ Sceery W Kilts C Mellstrom B Linnoila M Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled studyArch Gen Psychiatry1985 42977983
Not in our library10.1001/archpsyc.1985.01790330057007 (opens in a new tab)
- 1277.
Birmaher B Axelson D Monk K Kalas C Clark D Ehmann M Bridge J Heo J Brent D Fluoxetine for the treatment of childhood anxiety disordersJ Am Acad Child Adolesc Psychiatry2003 42415423
Not in our library10.1097/01.chi.0000037049.04952.9f (opens in a new tab)
- 1278.
Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study GroupN Engl J Med2001 34412791285
Not in our library10.1056/nejm200104263441703 (opens in a new tab)
- 1279.
Wagner K Berard R Stein M Wetherhold E Carpenter D Perera P Gee M Davy K Machin A A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorderArch Gen Psychiatry2004 6111531162
Not in our library10.1001/archpsyc.61.11.1153 (opens in a new tab)
- 1280.
Isolan L Pheula G Salum GA Jr. Oswald S Rohde LA Manfro GG An open-label trial of escitalopram in children and adolescents with social anxiety disorderJ Child Adolesc Psychopharmacol2007 17751760
Not in our library10.1089/cap.2007.0007 (opens in a new tab)
- 1281.
Compton S Grant P Chrisman A Gammon P Brown V March J Sertraline in children and adolescents with social anxiety disorder: an open trialJ Am Acad Child Adolesc Psychiatry2001 40564571
Not in our library10.1097/00004583-200105000-00016 (opens in a new tab)
- 1282.
March JS Entusah AR Rynn M Albano AM Tourian KA A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorderBiol Psychiatry2007 6211491154
Not in our library10.1016/j.biopsych.2007.02.025 (opens in a new tab)
- 1283.
Mrakotsky C Masek B Biederman J Raches D Hsin O Forbes P de Moor C DeMaso DR Gonzalez-Heydrich J Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobiaJ Anxiety Disord2008 228897
Not in our library10.1016/j.janxdis.2007.01.005 (opens in a new tab)
- 1284.
Rynn MA Siqueland L Rickels K Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorderAm J Psychiatry2001 15820082014
Not in our library10.1176/appi.ajp.158.12.2008 (opens in a new tab)
- 1285.
Lepola U Leinonen E Koponen H Citalopram in the treatment of early-onset panic disorder and school phobiaPharmacopsychiatry1996 293032
Not in our library10.1055/s-2007-979539 (opens in a new tab)
- 1286.
Robb AS Cueva JE Sporn J Yang R Vanderburg DG Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trialJ Child Adolesc Psychopharmacol2010 20463471
Not in our library10.1089/cap.2009.0115 (opens in a new tab)
- 1287.
Kutcher SP MacKenzie S Successful clonazepam treatment of adolescents with panic disorderJ Clin Psychopharmacol1988 8299301
Not in our library
- 1288.
Biederman J Clonazepam in the treatment of prepubertal children with panic-like symptomsJ Clin Psychiatry1987 48Suppl3842
Not in our library
- 1289.
Ballenger JC Carek DJ Steele JJ Cornish-McTighe D Three cases of panic disorder with agoraphobia in childrenAm J Psychiatry1989 146922924
Not in our library10.1176/ajp.146.7.922 (opens in a new tab)
- 1290.
Simeon JG Ferguson HB Knott V Roberts N Gauthier B Dubois C Wiggins D Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disordersJ Am Acad Child Adolesc Psychiatry1992 312933
Not in our library10.1097/00004583-199201000-00006 (opens in a new tab)
- 1291.
Bernstein GA Garfinkel BD Borchardt CM Comparative studies of pharmacotherapy for school refusalJ Am Acad Child Adolesc Psychiatry1990 29773781
Not in our library10.1097/00004583-199009000-00016 (opens in a new tab)
- 1292.
Graae F Milner J Rizzotto L Klein RG Clonazepam in childhood anxiety disordersJ Am Acad Child Adolesc Psychiatry1994 33372376
Not in our library10.1097/00004583-199403000-00011 (opens in a new tab)
- 1293.
Masi G Pfanner C Millepiedi S Berloffa S Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorderJ Clin Psychopharmacol2010 30688693
Not in our library10.1097/jcp.0b013e3181fab7b1 (opens in a new tab)
- 1294.
Grant P Lougee L Hirschtritt M Swedo SE An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorderJ Child Adolesc Psychopharmacol2007 17761767
Not in our library10.1089/cap.2007.0021 (opens in a new tab)
- 1295.
Storch EA Murphy TK Goodman WK Geffken GR Lewin AB Henin A Micco JA Sprich S Wilhelm S Bengtson M Geller DA A preliminary study of d-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorderBiol Psychiatry2010 6810731076
Not in our library10.1016/j.biopsych.2010.07.015 (opens in a new tab)
- 1296.
Larun L Nordheim LV Ekeland E Hagen KB Heian F Exercise in prevention and treatment of anxiety and depression among children and young peopleCochrane Database Syst Rev2006 3CD004691
Not in our library10.1002/14651858.cd004691.pub2 (opens in a new tab)
- 1297.
Newman CL Motta RW The effects of aerobic exercise on childhood PTSD, anxiety, and depressionInt J Emerg Ment Health2007 9133158
Not in our library
- 1298.
Diaz AB Motta R The effects of an aerobic exercise program on posttraumatic stress disorder symptom severity in adolescentsInt J Emerg Ment Health2008 104959
Not in our library
- 1299.
Harris E Eng HY Kowatch R Delgado SV Saldana SN Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorderJ Child Adolesc Psychopharmacol2010 20347353
Not in our library10.1089/cap.2009.0126 (opens in a new tab)
- 1300.
Martin A Young C Leckman JF Mukonoweshuro C Rosenheck R Leslie D Age effects on antidepressant-induced manic conversionArch Pediatr Adolesc Med2004 158773780
Not in our library10.1001/archpedi.158.8.773 (opens in a new tab)
- 1301.
Findling RL Nucci G Piergies AA Gomeni R Bartolic EI Fong R Carpenter DJ Leeder JS Gaedigk A Danoff TM Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorderNeuropsychopharmacology2006 3112741285
Not in our library10.1038/sj.npp.1300960 (opens in a new tab)
- 1302.
Bridge JA Iyengar S Salary CB Barbe RP Birmaher B Pincus HA Ren L Brent DA Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trialsJAMA2007 29716831696
Not in our library10.1001/jama.297.15.1683 (opens in a new tab)
- 1303.
Safer DJ Zito JM Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescentsJ Child Adolesc Psychopharmacol2006 16159169
Not in our library10.1089/cap.2006.16.159 (opens in a new tab)
- 1304.
Gum AM King-Kallimanis B Kohn R Prevalence of mood, anxiety, and substance-abuse disorders for older Americans in the National Comorbidity Survey-ReplicationAm J Geriatr Psychiatry2009 17769781
Not in our library10.1097/jgp.0b013e3181ad4f5a (opens in a new tab)
- 1305.
Grenier S Preville M Boyer R O'Connor K Beland SG Potvin O Hudon C Brassard J The impact of DSM-IV symptom and clinical significance criteria on the prevalence estimates of subthreshold and threshold anxiety in the older adult populationAm J Geriatr Psychiatry2011 19316326
Not in our library10.1097/jgp.0b013e3181ff416c (opens in a new tab)
- 1306.
Streiner DL Cairney J Veldhuizen S The epidemiology of psychological problems in the elderlyCan J Psychiatry2006 51185191
Not in our library10.1177/070674370605100309 (opens in a new tab)
- 1307.
Hollingworth SA Burgess PM Whiteford HA Affective and anxiety disorders: prevalence, treatment and antidepressant medication useAust N Z J Psychiatry2010 44513519
Not in our library10.3109/00048670903555138 (opens in a new tab)
- 1308.
Jorm A Does old age reduce the risk of anxiety and depression? A review of epidemiological studies across the adult life spanPsychol Med2000 301122
Not in our library10.1017/s0033291799001452 (opens in a new tab)
- 1309.
Calleo J Stanley MA Greisinger A Wehmanen O Johnson M Novy D Wilson N Kunik M Generalized anxiety disorder in older medical patients: diagnostic recognition, mental health management and service utilizationJ Clin Psychol Med Settings2009 16178185
Not in our library10.1007/s10880-008-9144-5 (opens in a new tab)
- 1310.
Cairney J Corna LM Streiner DL Mental health care use in later life: results from a national survey of CanadiansCan J Psychiatry2010 55157164
Not in our library10.1177/070674371005500307 (opens in a new tab)
- 1311.
Byers AL Arean PA Yaffe K Low use of mental health services among older Americans with mood and anxiety disordersPsychiatr Serv2012 636672
Not in our library10.1176/appi.ps.201100121 (opens in a new tab)
- 1312.
Scott T Mackenzie CS Chipperfield JG Sareen J Mental health service use among Canadian older adults with anxiety disorders and clinically significant anxiety symptomsAging Ment Health2010 14790800
Not in our library10.1080/13607861003713273 (opens in a new tab)
- 1313.
Brenes GA Miller ME Stanley MA Williamson JD Knudson M McCall WV Insomnia in older adults with generalized anxiety disorderAm J Geriatr Psychiatry2009 17465472
Not in our library10.1097/jgp.0b013e3181987747 (opens in a new tab)
- 1314.
Spira AP Stone K Beaudreau SA Ancoli-Israel S Yaffe K Anxiety symptoms and objectively measured sleep quality in older womenAm J Geriatr Psychiatry2009 17136143
Not in our library10.1097/jgp.0b013e3181871345 (opens in a new tab)
- 1315.
Mehta K Simonsick E Penninx B Schulz R Rubin S Satterfield S Yaffe K Prevalence and correlates of anxiety symptoms in well-functioning older adults: findings from the health aging and body composition studyJ Am Geriatr Soc2003 51499504
Not in our library10.1046/j.1532-5415.2003.51158.x (opens in a new tab)
- 1316.
Beaudreau SA O'Hara R The association of anxiety and depressive symptoms with cognitive performance in community-dwelling older adultsPsychol Aging2009 24507512
Not in our library10.1037/a0016035 (opens in a new tab)
- 1317.
Butters MA Bhalla RK Andreescu C Wetherell JL Mantella R Begley AE Lenze EJ Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorderBr J Psychiatry2011 199211218
Not in our library10.1192/bjp.bp.110.090217 (opens in a new tab)
- 1318.
Sinoff G Werner P Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive declineInt J Geriatr Psychiatry2003 18951959
Not in our library10.1002/gps.1004 (opens in a new tab)
- 1319.
Scott Mackin R Lesselyong JA Yaffe K Pattern of cognitive impairment in older veterans with posttraumatic stress disorder evaluated at a memory disorders clinicInt J Geriatr Psychiatry2012 27637642
Not in our library10.1002/gps.2763 (opens in a new tab)
- 1320.
Mehta KM Yaffe K Brenes GA Newman AB Shorr RI Simonsick EM Ayonayon HN Rubin SM Covinsky KE Anxiety symptoms and decline in physical function over 5 years in the health, aging and body composition studyJ Am Geriatr Soc2007 55265270
Not in our library10.1111/j.1532-5415.2007.01041.x (opens in a new tab)
- 1321.
Porensky EK Dew MA Karp JF Skidmore E Rollman BL Shear MK Lenze EJ The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and healthcare utilizationAm J Geriatr Psychiatry2009 17473482
Not in our library10.1097/jgp.0b013e31819b87b2 (opens in a new tab)
- 1322.
Diefenbach GJ Tolin DF Gilliam CM Impairments in life quality among clients in geriatric home care: associations with depressive and anxiety symptomsInt J Geriatr Psychiatry2012 27828835
Not in our library10.1002/gps.2791 (opens in a new tab)
- 1323.
Cairney J Corna LM Veldhuizen S Herrmann N Streiner DL Comorbid depression and anxiety in later life: patterns of association, subjective well-being, and impairmentAm J Geriatr Psychiatry2008 16201208
Not in our library10.1097/jgp.0b013e3181602a4a (opens in a new tab)
- 1324.
King-Kallimanis B Gum AM Kohn R Comorbidity of depressive and anxiety disorders for older Americans in the National Comorbidity Survey-ReplicationAm J Geriatr Psychiatry2009 17782792
Not in our library10.1097/jgp.0b013e3181ad4d17 (opens in a new tab)
- 1325.
Wetherell JL Ayers CR Nuevo R Stein MB Ramsdell J Patterson TL Medical conditions and depressive, anxiety, and somatic symptoms in older adults with and without generalized anxiety disorderAging Ment Health2010 14764768
Not in our library10.1080/13607861003713240 (opens in a new tab)
- 1326.
Schoevers R Deeg D van Tilburg W Beekman A Depression and generalized anxiety disorder: co-occurrence and longitudinal patterns in elderly patientsAm J Geriatr Psychiatry2005 133139
Not in our library10.1176/appi.ajgp.13.1.31 (opens in a new tab)
- 1327.
Wolitzky-Taylor KB Castriotta N Lenze EJ Stanley MA Craske MG Anxiety disorders in older adults: a comprehensive reviewDepress Anxiety2010 27190211
Not in our library10.1002/da.20653 (opens in a new tab)
- 1328.
Qureshi SU Kimbrell T Pyne JM Magruder KM Hudson TJ Petersen NJ Yu HJ Schulz PE Kunik ME Greater prevalence and incidence of dementia in older veterans with posttraumatic stress disorderJ Am Geriatr Soc2010 5816271633
Not in our library10.1111/j.1532-5415.2010.02977.x (opens in a new tab)
- 1329.
Vogele C von Leupoldt A Mental disorders in chronic obstructive pulmonary disease (COPD)Respir Med2008 102764773
Not in our library10.1016/j.rmed.2007.12.006 (opens in a new tab)
- 1330.
Smoller JW Pollack MH Wassertheil-Smoller S Jackson RD Oberman A Wong ND Sheps D Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational StudyArch Gen Psychiatry2007 6411531160
Not in our library10.1001/archpsyc.64.10.1153 (opens in a new tab)
- 1331.
Tully PJ Baker RA Knight JL Anxiety and depression as risk factors for mortality after coronary artery bypass surgeryJ Psychosom Res2008 64285290
Not in our library10.1016/j.jpsychores.2007.09.007 (opens in a new tab)
- 1332.
Bryant C Jackson H Ames D The prevalence of anxiety in older adults: methodological issues and a review of the literatureJ Affect Disord2008 109233250
Not in our library10.1016/j.jad.2007.11.008 (opens in a new tab)
- 1333.
Mohlman J Bryant C Lenze EJ Stanley MA Gum A Flint A Beekman AT Wetherell JL Thorp SR Craske MG Improving recognition of late life anxiety disorders in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: observations and recommendations of the Advisory Committee to the Lifespan Disorders Work GroupInt J Geriatr Psychiatry2012 27549556
Not in our library10.1002/gps.2752 (opens in a new tab)
- 1334.
Brenes GA Knudson M McCall WV Williamson JD Miller ME Stanley MA Age and racial differences in the presentation and treatment of generalized anxiety disorder in primary careJ Anxiety Disord2008 2211281136
Not in our library10.1016/j.janxdis.2007.11.011 (opens in a new tab)
- 1335.
Wetherell JL Petkus AJ McChesney K Stein MB Judd PH Rockwell E Sewell DD Patterson TL Older adults are less accurate than younger adults at identifying symptoms of anxiety and depressionJ Nerv Ment Dis2009 197623626
Not in our library10.1097/nmd.0b013e3181b0c081 (opens in a new tab)
- 1336.
Jeste DV Blazer DG First M Aging-related diagnostic variations: need for diagnostic criteria appropriate for elderly psychiatric patientsBiol Psychiatry2005 58265271
Not in our library10.1016/j.biopsych.2005.02.004 (opens in a new tab)
- 1337.
Ayers CR Sorrell JT Thorp SR Wetherell JL Evidence-based psychological treatments for late-life anxietyPsychol Aging2007 22817
Not in our library10.1037/0882-7974.22.1.8 (opens in a new tab)
- 1338.
Pinquart M Duberstein PR Treatment of anxiety disorders in older adults: a meta-analytic comparison of behavioral and pharmacological interventionsAm J Geriatr Psychiatry2007 15639651
Not in our library10.1097/jgp.0b013e31806841c8 (opens in a new tab)
- 1339.
Goncalves DC Byrne GJ Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysisJ Anxiety Disord2012 26111
Not in our library10.1016/j.janxdis.2011.08.010 (opens in a new tab)
- 1340.
Hendriks GJ Oude Voshaar RC Keijsers GP Hoogduin CA van Balkom AJ Cognitive-behavioural therapy for late-life anxiety disorders: a systematic review and meta-analysisActa Psychiatr Scand2008 117403411
Not in our library10.1111/j.1600-0447.2008.01190.x (opens in a new tab)
- 1341.
Thorp SR Ayers CR Nuevo R Stoddard JA Sorrell JT Wetherell JL Meta-analysis comparing different behavioral treatments for late-life anxietyAm J Geriatr Psychiatry2009 17105115
Not in our library10.1097/jgp.0b013e31818b3f7e (opens in a new tab)
- 1342.
Gould RL Coulson MC Howard RJ Efficacy of cognitive behavioral therapy for anxiety disorders in older people: a meta-analysis and meta-regression of randomized controlled trialsJ Am Geriatr Soc2012 60218229
Not in our library10.1111/j.1532-5415.2011.03824.x (opens in a new tab)
- 1343.
Mohlman J Gorenstein E Kleber M de JM Gorman J Papp L Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigationsAm J Geriatr Psychiatry2003 112432
Not in our library
- 1344.
Stanley M Hopko D Diefenbach G Bourland S Rodriguez H Wagener P Cognitive-behavior therapy for late-life generalized anxiety disorder in primary care: preliminary findingsAm J Geriatr Psychiatry2003 119296
Not in our library
- 1345.
Bradford A Cully J Rhoades H Kunik M Kraus-Schuman C Wilson N Stanley M Early response to psychotherapy and long-term change in worry symptoms in older adults with generalized anxiety disorderAm J Geriatr Psychiatry2011 19347356
Not in our library10.1097/jgp.0b013e3181f18061 (opens in a new tab)
- 1346.
Stanley MA Wilson NL Novy DM Rhoades HM Wagener PD Greisinger AJ Cully JA Kunik ME Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trialJAMA2009 30114601467
Not in our library10.1001/jama.2009.458 (opens in a new tab)
- 1347.
Wetherell J Gatz M Craske M Treatment of generalized anxiety disorder in older adultsJ Consult Clin Psychol2003 713140
Not in our library10.1037//0022-006x.71.1.31 (opens in a new tab)
- 1348.
Hendriks GJ Keijsers GP Kampman M Oude Voshaar RC Verbraak MJ Broekman TG Hoogduin CA A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorderActa Psychiatr Scand2010 1221119
Not in our library10.1111/j.1600-0447.2009.01517.x (opens in a new tab)
- 1349.
Schuurmans J Comijs H Emmelkamp PM Gundy CM Weijnen I van den Hout M van Dyck R A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adultsAm J Geriatr Psychiatry2006 14255263
Not in our library10.1097/01.jgp.0000196629.19634.00 (opens in a new tab)
- 1350.
Thorp SR Stein MB Jeste DV Patterson TL Wetherell JL Prolonged exposure therapy for older veterans with posttraumatic stress disorder: a pilot studyAm J Geriatr Psychiatry2012 20276280
Not in our library10.1097/jgp.0b013e3182435ee9 (opens in a new tab)
- 1351.
Pachana NA Woodward RM Byrne GJ Treatment of specific phobia in older adultsClin Interv Aging2007 2469476
Not in our library
- 1352.
Brenes GA Miller ME Williamson JD McCall WV Knudson M Stanley MA A randomized controlled trial of telephone-delivered cognitive-behavioral therapy for late-life anxiety disordersAm J Geriatr Psychiatry2012 20707716
Not in our library10.1097/jgp.0b013e31822ccd3e (opens in a new tab)
- 1353.
Pasco JA Williams LJ Jacka FN Henry MJ Coulson CE Brennan SL Leslie E Nicholson GC Kotowicz MA Berk M Habitual physical activity and the risk for depressive and anxiety disorders among older men and womenInt Psychogeriatr2011 23292298
Not in our library10.1017/s1041610210001833 (opens in a new tab)
- 1354.
Montgomery S Chatamra K Pauer L Whalen E Baldinetti F Efficacy and safety of pregabalin in elderly people with generalised anxiety disorderBr J Psychiatry2008 193389394
Not in our library10.1192/bjp.bp.107.037788 (opens in a new tab)
- 1355.
Karaiskos D Pappa D Tzavellas E Siarkos K Katirtzoglou E Papadimitriou GN Politis A Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label studyInt J Geriatr Psychiatry2013 28100105
Not in our library10.1002/gps.3800 (opens in a new tab)
- 1356.
Davidson J Allgulander C Pollack MH Hartford J Erickson JS Russell JM Perahia D Wohlreich MM Carlson J Raskin J Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studiesHum Psychopharmacol2008 23519526
Not in our library10.1002/hup.949 (opens in a new tab)
- 1357.
Lenze EJ Mulsant BH Shear MK Dew MA Miller MD Pollock BG Houck P Tracey B Reynolds CF 3rd Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trialAm J Psychiatry2005 162146150
Not in our library10.1176/appi.ajp.162.1.146 (opens in a new tab)
- 1358.
Blank S Lenze EJ Mulsant BH Dew MA Karp JF Shear MK Houck PR Miller MD Pollock BG Tracey B Reynolds CF Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatmentJ Clin Psychiatry2006 67468472
Not in our library10.4088/jcp.v67n0319 (opens in a new tab)
- 1359.
Mohamed S Osatuke K Aslam M Kasckow J Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trialAm J Geriatr Pharmacother2006 4201209
Not in our library10.1016/j.amjopharm.2006.08.001 (opens in a new tab)
- 1360.
Schuurmans J Comijs H Emmelkamp PM Weijnen IJ van den Hout M van Dyck R Long-term effectiveness and prediction of treatment outcome in cognitive behavioral therapy and sertraline for late-life anxiety disordersInt Psychogeriatr2009 2111481159
Not in our library10.1017/s1041610209990536 (opens in a new tab)
- 1361.
Rampello L Alvano A Raffaele R Malaguarnera M Vecchio I New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopramJ Clin Psychopharmacol2006 266770
Not in our library10.1097/01.jcp.0000195383.96383.25 (opens in a new tab)
- 1362.
Wylie M Miller M Shear M Little J Mulsant B Pollock B Reynolds C Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial dataJ Geriatr Psychiatry Neurol2000 134348
Not in our library10.1177/089198870001300107 (opens in a new tab)
- 1363.
Gardner M Malone D Sey M Babington M Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilitiesJ Am Med Dir Assoc2004 5101106
Not in our library10.1097/01.jam.0000110650.51872.91 (opens in a new tab)
- 1364.
Schatzberg A Kremer C Rodrigues H Murphy G Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patientsAm J Geriatr Psychiatry2002 10541550
Not in our library
- 1365.
Benitez CI Smith K Vasile RG Rende R Edelen MO Keller MB Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective studyAm J Geriatr Psychiatry2008 16513
Not in our library10.1097/jgp.0b013e31815aff5c (opens in a new tab)
- 1366.
Uchida H Suzuki T Mamo DC Mulsant BH Kikuchi T Takeuchi H Tomita M Watanabe K Yagi G Kashima H Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in JapanJ Anxiety Disord2009 23477481
Not in our library10.1016/j.janxdis.2008.10.003 (opens in a new tab)
- 1367.
Preville M Vasiliadis HM Bosse C Dionne PA Voyer P Brassard J Pattern of psychotropic drug use among older adults having a depression or an anxiety disorder: results from the longitudinal ESA studyCan J Psychiatry2011 56348357
Not in our library10.1177/070674371105600606 (opens in a new tab)
- 1368.
Mallet L Spinewine A Huang A The challenge of managing drug interactions in elderly peopleLancet2007 370185191
Not in our library10.1016/s0140-6736(07)61092-7 (opens in a new tab)
- 1369.
Hines LE Murphy JE Potentially harmful drug-drug interactions in the elderly: a reviewAm J Geriatr Pharmacother2011 9364377
Not in our library10.1016/j.amjopharm.2011.10.004 (opens in a new tab)
- 1370.
Klotz U Pharmacokinetics and drug metabolism in the elderlyDrug Metab Rev2009 416776
Not in our library10.1080/03602530902722679 (opens in a new tab)
- 1371.
Boyce RD Handler SM Karp JF Hanlon JT Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert informationAm J Geriatr Pharmacother2012 10139150
Not in our library10.1016/j.amjopharm.2012.01.001 (opens in a new tab)
- 1372.
Qato DM Alexander GC Conti RM Johnson M Schumm P Lindau ST Use of prescription and over-the-counter medications and dietary supplements among older adults in the United StatesJAMA2008 30028672878
Not in our library10.1001/jama.2008.892 (opens in a new tab)
- 1373.
Takkouche B Montes-Martinez A Gill SS Etminan M Psychotropic medications and the risk of fracture: a meta-analysisDrug Saf2007 30171184
Not in our library10.2165/00002018-200730020-00006 (opens in a new tab)
- 1374.
Zint K Haefeli WE Glynn RJ Mogun H Avorn J Sturmer T Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adultsPharmacoepidemiol Drug Saf2010 1912481255
Not in our library10.1002/pds.2031 (opens in a new tab)
- 1375.
Ziere G Dieleman JP van der Cammen TJ Hofman A Pols HA Stricker BH Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fracturesJ Clin Psychopharmacol2008 28411417
Not in our library10.1097/jcp.0b013e31817e0ecb (opens in a new tab)
- 1376.
Chatterjee S Chen H Johnson ML Aparasu RR Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort studyAm J Geriatr Pharmacother2012 108394
Not in our library10.1016/j.amjopharm.2011.10.006 (opens in a new tab)
- 1377.
FDA requests boxed warnings on older class of antipsychotic drugshttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116912.htm
Not in our library
- 1378.
Gill SS Bronskill SE Normand SL Anderson GM Sykora K Lam K Bell CM Lee PE Fischer HD Herrmann N Antipsychotic drug use and mortality in older adults with dementiaAnn Intern Med2007 146775786
Not in our library10.7326/0003-4819-146-11-200706050-00006 (opens in a new tab)
- 1379.
Kales HC Kim HM Zivin K Valenstein M Seyfried LS Chiang C Cunningham F Schneider LS Blow FC Risk of mortality among individual antipsychotics in patients with dementiaAm J Psychiatry2012 1697179
Not in our library10.1176/appi.ajp.2011.11030347 (opens in a new tab)
- 1380.
Schneeweiss S Setoguchi S Brookhart A Dormuth C Wang PS Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patientsCMAJ2007 176627632
Not in our library10.1503/cmaj.061250 (opens in a new tab)
- 1381.
Pizzi C Rutjes AW Costa GM Fontana F Mezzetti A Manzoli L Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart diseaseAm J Cardiol2011 107972979
Not in our library10.1016/j.amjcard.2010.11.017 (opens in a new tab)
- 1382.
Meng X D'Arcy C Common and unique risk factors and comorbidity for 12-month mood and anxiety disorders among CanadiansCan J Psychiatry2012 57479487
Not in our library10.1177/070674371205700806 (opens in a new tab)
- 1383.
Goldstein BI Levitt AJ The specific burden of comorbid anxiety disorders and of substance use disorders in bipolar I disorderBipolar Disord2008 106778
Not in our library10.1111/j.1399-5618.2008.00461.x (opens in a new tab)
- 1384.
O'Neil KA Podell JL Benjamin CL Kendall PC Comorbid depressive disorders in anxiety-disordered youth: demographic, clinical, and family characteristicsChild Psychiatry Hum Dev2010 41330341
Not in our library10.1007/s10578-009-0170-9 (opens in a new tab)
- 1385.
Green BL Krupnick JL Chung J Siddique J Krause ED Revicki D Frank L Miranda J Impact of PTSD comorbidity on one-year outcomes in a depression trialJ Clin Psychol2006 62815835
Not in our library10.1002/jclp.20279 (opens in a new tab)
- 1386.
Andreescu C Lenze EJ Dew MA Begley AE Mulsant BH Dombrovski AY Pollock BG Stack J Miller MD Reynolds CF Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled studyBr J Psychiatry2007 190344349
Not in our library10.1192/bjp.bp.106.027169 (opens in a new tab)
- 1387.
Goes FS McCusker MG Bienvenu OJ Mackinnon DF Mondimore FM Schweizer B Depaulo JR Potash JB Co-morbid anxiety disorders in bipolar disorder and major depression: familial aggregation and clinical characteristics of co-morbid panic disorder, social phobia, specific phobia and obsessive-compulsive disorderPsychol Med2012 4214491459
Not in our library10.1017/s0033291711002637 (opens in a new tab)
- 1388.
Otto MW Simon NM Wisniewski SR Miklowitz DJ Kogan JN Reilly-Harrington NA Frank E Nierenberg AA Marangell LB Sagduyu K Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disordersBr J Psychiatry2006 1892025
Not in our library10.1192/bjp.bp.104.007773 (opens in a new tab)
- 1389.
Sala R Goldstein BI Morcillo C Liu SM Castellanos M Blanco C Course of comorbid anxiety disorders among adults with bipolar disorder in the U.S. populationJ Psychiatr Res2012 46865872
Not in our library10.1016/j.jpsychires.2012.03.024 (opens in a new tab)
- 1390.
McWilliams LA Cox BJ Enns MW Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative samplePain2003 106127133
Not in our library10.1016/s0304-3959(03)00301-4 (opens in a new tab)
- 1391.
Mittal D Fortney JC Pyne JM Edlund MJ Wetherell JL Impact of comorbid anxiety disorders on health-related quality of life among patients with major depressive disorderPsychiatr Serv2006 5717311737
Not in our library10.1176/ps.2006.57.12.1731 (opens in a new tab)
- 1392.
Katz C Yaseen ZS Mojtabai R Cohen LJ Galynker II Panic as an independent risk factor for suicide attempt in depressive illness: findings from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC)J Clin Psychiatry2011 7216281635
Not in our library10.4088/jcp.10m06186blu (opens in a new tab)
- 1393.
Brown LA Gaudiano BA Miller IW The impact of panic-agoraphobic comorbidity on suicidality in hospitalized patients with major depressionDepress Anxiety2010 27310315
Not in our library10.1002/da.20609 (opens in a new tab)
- 1394.
Schaffer A McIntosh D Goldstein BI Rector NA McIntyre RS Beaulieu S Swinson R Yatham LN The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disordersAnn Clin Psychiatry2012 24622
Not in our library
- 1395.
Silverstone P Salinas E Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorderJ Clin Psychiatry2001 62523529
Not in our library10.4088/jcp.v62n07a04 (opens in a new tab)
- 1396.
Maneeton N Maneeton B Srisurapanont M Martin SD Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trialsBMC Psychiatry2012 12160
Not in our library10.1186/1471-244x-12-160 (opens in a new tab)
- 1397.
Maher AR Maglione M Bagley S Suttorp M Hu JH Ewing B Wang Z Timmer M Sultzer D Shekelle PG Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysisJAMA2011 30613591369
Not in our library10.1001/jama.2011.1360 (opens in a new tab)
- 1398.
McIntyre A Gendron A Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot studyDepress Anxiety2007 24487494
Not in our library10.1002/da.20275 (opens in a new tab)
- 1399.
Merikangas KR Akiskal HS Angst J Greenberg PE Hirschfeld RM Petukhova M Kessler RC Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replicationArch Gen Psychiatry2007 64543552
Not in our library10.1001/archpsyc.64.5.543 (opens in a new tab)
- 1400.
Young S Pfaff D Lewandowski KE Ravichandran C Cohen BM Ongur D Anxiety disorder comorbidity in bipolar disorder, schizophrenia and schizoaffective disorderPsychopathology2013 46176185
Not in our library10.1159/000339556 (opens in a new tab)
- 1401.
Achim AM Maziade M Raymond E Olivier D Merette C Roy MA How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant associationSchizophr Bull2011 37811821
Not in our library10.1093/schbul/sbp148 (opens in a new tab)
- 1402.
Simon NM Zalta AK Otto MW Ostacher MJ Fischmann D Chow CW Thompson EH Stevens JC Demopulos CM Nierenberg AA Pollack MH The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorderJ Psychiatr Res2007 41255264
Not in our library10.1016/j.jpsychires.2006.08.004 (opens in a new tab)
- 1403.
Nakagawa A Grunebaum MF Sullivan GM Currier D Ellis SP Burke AK Brent DA Mann JJ Oquendo MA Comorbid anxiety in bipolar disorder: does it have an independent effect on suicidality?Bipolar Disord2008 10530538
Not in our library10.1111/j.1399-5618.2008.00590.x (opens in a new tab)
- 1404.
Pallanti S Quercioli L Hollander E Social anxiety in outpatients with schizophrenia: a relevant cause of disabilityAm J Psychiatry2004 1615358
Not in our library10.1176/appi.ajp.161.1.53 (opens in a new tab)
- 1405.
Makara-Studzinska M Wolyniak M Krys K Influence of anxiety and depression on quality of life of people with schizophrenia in the eastern region of polandISRN Psychiatry2012 2012839324
Not in our library10.5402/2012/839324 (opens in a new tab)
- 1406.
Barnes TR Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for PsychopharmacologyJ Psychopharmacol2011 25567620
Not in our library10.1177/0269881110391123 (opens in a new tab)
- 1407.
Sheehan DV McElroy SL Harnett-Sheehan K Keck PE Jr. Janavs J Rogers J Gonzalez R Shivakumar G Suppes T Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxietyJ Affect Disord2009 115376385
Not in our library10.1016/j.jad.2008.10.005 (opens in a new tab)
- 1408.
Maina G Albert U Rosso G Bogetto F Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot studyJ Clin Psychiatry2008 69609616
Not in our library10.4088/jcp.v69n0413 (opens in a new tab)
- 1409.
Hirschfeld RM Weisler RH Raines SR Macfadden W Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry2006 67355362
Not in our library10.4088/jcp.v67n0304 (opens in a new tab)
- 1410.
McElroy SL Weisler RH Chang W Olausson B Paulsson B Brecher M Agambaram V Merideth C Nordenhem A Young AH A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)J Clin Psychiatry2010 71163174
Not in our library10.4088/jcp.08m04942gre (opens in a new tab)
- 1411.
Young AH McElroy SL Bauer M Philips N Chang W Olausson B Paulsson B Brecher M A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)J Clin Psychiatry2010 71150162
Not in our library10.4088/jcp.08m04995gre (opens in a new tab)
- 1412.
Sagman D Lee B Chandresena R Jones B Brunner E A Canadian naturalistic study of a community-based cohort treated for bipolar disorderBMC Psychiatry2010 1024
Not in our library10.1186/1471-244x-10-24 (opens in a new tab)
- 1413.
Tohen M Calabrese J Vieta E Bowden C Gonzalez-Pinto A Lin D Xu W Corya S Effect of comorbid anxiety on treatment response in bipolar depressionJ Affect Disord2007 104137146
Not in our library10.1016/j.jad.2007.03.014 (opens in a new tab)
- 1414.
Perugi G Toni C Frare F Ruffolo G Moretti L Torti C Akiskal HS Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?J Clin Psychopharmacol2002 22584591
Not in our library10.1097/00004714-200212000-00008 (opens in a new tab)
- 1415.
Davis LL Bartolucci A Petty F Divalproex in the treatment of bipolar depression: a placebo-controlled studyJ Affect Disord2005 85259266
Not in our library10.1016/j.jad.2004.09.009 (opens in a new tab)
- 1416.
Vieta E Martinez-Aran A Nieto E Colom F Reinares M Benabarre A Gasto C Adjunctive gabapentin treatment of bipolar disorderEur Psychiatry2000 15433437
Not in our library10.1016/s0924-9338(00)00514-9 (opens in a new tab)
- 1417.
Wender PH Wolf LE Wasserstein J Adults with ADHD. An overviewAnn N Y Acad Sci2001 931116
Not in our library
- 1418.
Dulcan M Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent PsychiatryJ Am Acad Child Adolesc Psychiatry1997 3685S121S
Not in our library10.1097/00004583-199710001-00007 (opens in a new tab)
- 1419.
Mannuzza S Klein RG Bessler A Malloy P LaPadula M Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric statusArch Gen Psychiatry1993 50565576
Not in our library10.1001/archpsyc.1993.01820190067007 (opens in a new tab)
- 1420.
Weiss G Hechtman L Hyperactive children grown up: ADHD in children, adolescents, and adults1993 New York, NY: Guilford Press
Not in our library
- 1421.
Pary R Lewis S Matuschka PR Rudzinskiy P Safi M Lippmann S Attention deficit disorder in adultsAnn Clin Psychiatry2002 14105111
Not in our library10.1023/a:1016807021779 (opens in a new tab)
- 1422.
Wilens TE Biederman J Spencer TJ Attention deficit/hyperactivity disorder across the lifespanAnnu Rev Med2002 53113131
Not in our library10.1146/annurev.med.53.082901.103945 (opens in a new tab)
- 1423.
Wilens TE Faraone SV Biederman J Attention-deficit/hyperactivity disorder in adultsJAMA2004 292619623
Not in our library10.1001/jama.292.5.619 (opens in a new tab)
- 1424.
Garcia SP Guimaraes J Zampieri JF Martinez AL Polanczyk G Rohde LA Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?J Neural Transm2009 116631636
Not in our library10.1007/s00702-009-0211-3 (opens in a new tab)
- 1425.
Blouin B Maddeaux C Stanley Firestone J van Stralen J Predicting response of ADHD symptoms to methylphenidate treatment based on comorbid anxietyJ Atten Disord2010 13414419
Not in our library10.1177/1087054708326269 (opens in a new tab)
- 1426.
Kratochvil CJ Newcorn JH Arnold LE Duesenberg D Emslie GJ Quintana H Sarkis EH Wagner KD Gao H Michelson D Biederman J Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptomsJ Am Acad Child Adolesc Psychiatry2005 44915924
Not in our library10.1097/01.chi.0000169012.81536.38 (opens in a new tab)
- 1427.
Goodman DW Thase ME Recognizing ADHD in adults with comorbid mood disorders: implications for identification and managementPostgrad Med2009 1212030
Not in our library10.3810/pgm.2009.09.2049 (opens in a new tab)
- 1428.
Gabriel A Violato C Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label studyAtten Defic Hyperact Disord2011 3319326
Not in our library10.1007/s12402-011-0063-1 (opens in a new tab)
- 1429.
Gabriel A The mixed amphetamine salt extended release (Adderall XR, Max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety: an open-label studyAtten Defic Hyperact Disord2010 28792
Not in our library10.1007/s12402-010-0025-z (opens in a new tab)
- 1430.
El-Gabalawy R Mackenzie CS Shooshtari S Sareen J Comorbid physical health conditions and anxiety disorders: a population-based exploration of prevalence and health outcomes among older adultsGen Hosp Psychiatry2011 33556564
Not in our library10.1016/j.genhosppsych.2011.07.005 (opens in a new tab)
- 1431.
Vogelzangs N Seldenrijk A Beekman AT van Hout HP de Jonge P Penninx BW Cardiovascular disease in persons with depressive and anxiety disordersJ Affect Disord2010 125241248
Not in our library10.1016/j.jad.2010.02.112 (opens in a new tab)
- 1432.
Huang KL Su TP Chen TJ Chou YH Bai YM Comorbidity of cardiovascular diseases with mood and anxiety disorder: a population based 4-year studyPsychiatry Clin Neurosci2009 63401409
Not in our library10.1111/j.1440-1819.2009.01974.x (opens in a new tab)
- 1433.
Demyttenaere K Bonnewyn A Bruffaerts R De Graaf R Haro JM Alonso J Comorbid painful physical symptoms and anxiety: prevalence, work loss and help-seekingJ Affect Disord2008 109264272
Not in our library10.1016/j.jad.2007.12.231 (opens in a new tab)
- 1434.
Asmundson GJ Katz J Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-artDepress Anxiety2009 26888901
Not in our library10.1002/da.20600 (opens in a new tab)
- 1435.
Hartford JT Endicott J Kornstein SG Allgulander C Wohlreich MM Russell JM Perahia DG Erickson JS Implications of pain in generalized anxiety disorder: efficacy of duloxetinePrim Care Companion J Clin Psychiatry2008 10197204
Not in our library10.4088/pcc.v10n0304 (opens in a new tab)
- 1436.
Beesdo K Hartford J Russell J Spann M Ball S Wittchen HU The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trialsJ Anxiety Disord2009 2310641071
Not in our library10.1016/j.janxdis.2009.07.008 (opens in a new tab)
- 1437.
Russell JM Weisberg R Fava M Hartford JT Erickson JS D'Souza DN Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptomsDepress Anxiety2008 25E111
Not in our library10.1002/da.20337 (opens in a new tab)
- 1438.
Jackson JL Shimeall W Sessums L Dezee KJ Becher D Diemer M Berbano E O'Malley PG Tricyclic antidepressants and headaches: systematic review and meta-analysisBMJ2010 341c5222
Not in our library10.1136/bmj.c5222 (opens in a new tab)
- 1439.
Saarto T Wiffen PJ Antidepressants for neuropathic painCochrane Database Syst Rev2007 CD005454
Not in our library10.1002/14651858.cd005454.pub2 (opens in a new tab)
- 1440.
Denollet J Maas K Knottnerus A Keyzer JJ Pop VJ Anxiety predicted premature all-cause and cardiovascular death in a 10-year follow-up of middle-aged womenJ Clin Epidemiol2009 62452456
Not in our library10.1016/j.jclinepi.2008.08.006 (opens in a new tab)
- 1441.
Chamberlain AM Vickers KS Colligan RC Weston SA Rummans TA Roger VL Associations of preexisting depression and anxiety with hospitalization in patients with cardiovascular diseaseMayo Clin Proc2011 8610561062
Not in our library10.4065/mcp.2011.0148 (opens in a new tab)
- 1442.
Doering LV Moser DK Riegel B McKinley S Davidson P Baker H Meischke H Dracup K Persistent comorbid symptoms of depression and anxiety predict mortality in heart diseaseInt J Cardiol2010 145188192
Not in our library10.1016/j.ijcard.2009.05.025 (opens in a new tab)
- 1443.
McIntyre RS Alsuwaidan M Goldstein BI Taylor VH Schaffer A Beaulieu S Kemp DE The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disordersAnn Clin Psychiatry2012 246981
Not in our library
- 1444.
Ramasubbu R Taylor VH Saaman Z Sockalingham S Li M Patten S Rodin G Schaffer A Beaulieu S McIntyre RS The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditionsAnn Clin Psychiatry2012 2491109
Not in our library
- 1445.
Ramasubbu R Beaulieu S Taylor VH Schaffer A McIntyre RS The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principlesAnn Clin Psychiatry2012 248290
Not in our library
- 1446.
Engum A The role of depression and anxiety in onset of diabetes in a large population-based studyJ Psychosom Res2007 623138
Not in our library10.1016/j.jpsychores.2006.07.009 (opens in a new tab)
- 1447.
Aujla N Davies MJ Skinner TC Gray LJ Webb DR Srinivasan B Khunti K The association between anxiety and measures of glycaemia in a population-based diabetes screening programmeDiabet Med2011 28785788
Not in our library10.1111/j.1464-5491.2011.03245.x (opens in a new tab)
- 1448.
Serretti A Mandelli L Antidepressants and body weight: a comprehensive review and meta-analysisJ Clin Psychiatry2010 7112591272
Not in our library10.4088/jcp.09r05346blu (opens in a new tab)
Cited by papers we hold 14
- Celecoxib versus placebo as an adjunct to treatment-as-usual in children and youth with obsessive–compulsive disorder: protocol for a single-site randomised quadruple-blind phase II study · 2022Not checked
- Treatment Guidelines for PTSD: A Systematic Review · 2021No notice
- Impulsivity Mediates Associations Between Problematic Internet Use, Anxiety, and Depressive Symptoms in Students: A Cross-Sectional COVID-19 Study · 2021Not checked
- Association between anxiety symptoms and atrial fibrillation in a community cohort of Chinese older adults: a case-control study · 2021Not checked
- Correlates of self-reported history of mental health help-seeking: a cross-sectional study among individuals with symptoms of a mental or substance use disorder initiating care for HIV in Cameroon · 2021Not checked
- Factors influencing the implementation of mental health recovery into services: a systematic mixed studies review · 2021Not checked
- Self-Harming and Sense of Agency in Patients With Borderline Personality Disorder · 2020Not checked
- Depression, Anxiety, and Apathy in Mild Cognitive Impairment: Current Perspectives · 2020No notice
- Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options · 2020No notice
- Patterns in Outpatient Benzodiazepine Prescribing in the United States · 2019No notice
- Patterns of benzodiazepines use in primary care adults with anxiety disorders · 2018Not checked
- Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms · 2018No notice
- Instagram use is linked to increased symptoms of orthorexia nervosa · 2017No notice
- Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life · 2017No notice
Questions about this paper
We email you if it is retracted, withdrawn, corrected or flagged.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.